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ABSTRACT 
 
This study assessed implementation status of collaborative TB/HIV services in Addis 
Ababa City Administration aiming to promote better implementation strategies. The 
study employed mixed research methods and was descriptive. The study design 
used both quantitative and qualitative data using structured questionnaires and 
semi-structured interview guides, respectively. The study population for the 
quantitative design included 1,683 TB/HIV patients from 10 conveniently selected 
health facilities: Zewditu and Menelik Hospitals, health centres of Lideta, Yeka, 
Kazanchis, NifaSilk-Lafto-No1, Woreda-7, Kality, Bole and Gulele. All the patients 
who were on their follow-up cares during the data collection period were interviewed. 
Participants for qualitative design were 1,650 TB/HIV patients for short answered 
questions; 8 FGDs among patients; interview of 10 TB/HIV care facility 
coordinators/health workers and one regional TB/HIV care coordinator, all 
purposively selected. Quantitative data was analysed using SPSS 15.0, while 
qualitative data were thematically analysed manually.  
Majority of HIV patients (92.8%) self-reported that they had been screened for TB; of 
which, 11.2% were diagnosed for active TB during their follow-up cares. Whereas, 
87.1% of TB patients had been offered for HIV test; 79.8% tested; 20.2% tested 
positive. Knowledge on TB and HIV diseases, transmission and prevention was 
found to be low. However, participants appreciated the support of the healthcare 
delivery system in improving their health. Collaborative TB/HIV activities brought 
 additional on-the-job training for healthcare workers; improved flow of logistics and 
re-arrangement of infrastructures of facilities. The study revealed that, 
implementation of collaborative TB/HIV activities in Addis Ababa need boosting.  
The study recommends the need for coordinated efforts of all stakeholders for 
improving implementation of collaborative TB/HIV care services, as identified by this 
study. The contribution of this study developed pocket-guide for healthcare workers 
on collaborative TB/HIV care services, which provides guidance in promoting better 
TB/HIV care. 
KEY CONCEPTS: City Administration; CPT; HIV chronic care clinic; IPT; Mixed 
research methodology; TB clinic; TB/HIV collaborative activity. 
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 CHAPTER ONE 
ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
 
The global spread of human immune deficiency virus (HIV), particularly in sub-Saharan 
Africa, has been accompanied by a major increase in the number of new cases of 
tuberculosis (TB) (Global Fund to Fight AIDS, TB, and Malaria [GFATM], 2011). 
According to the 2010 report of the United Nations Programme for AIDS (UNAIDS), TB 
had killed an estimated 1.68 million people, including 0.38 million TB patients who were 
also HIV-positive (UNAIDS, 2011a). According to World Health Organisation (WHO), in 
the same year (2010), 350,000 people were estimated to have died of TB and HIV co-
infection globally, in addition to the 1.1 million people who died from TB alone (WHO, 
2011a). Those people who have HIV infection as well as TB when they die, that is TB 
and HIV co-infection, are internationally reported as having died of HIV infection (WHO, 
2010b). In total, an estimated 1.8 million people died of HIV infection in 2010 (UNAIDS, 
2010a). In addition, there were an estimated 8.8 million new cases of active TB 
worldwide in 2010, of which 1.1 (13%) million were estimated to have been among 
people living with HIV. The proportion of TB and HIV co-infection was highest in Africa, 
accounting for 82% of TB cases among people living with HIV (WHO, 2011a).  
Effective case detection and treatment of TB should therefore be a priority for HIV 
programmes (Njozing, 2006), to prevent, diagnose, and treat TB in people living with 
HIV, their families and the communities (WHO, 2008a). According to the WHO policy on 
collaborative TB/HIV activities (WHO, 2012a), collaborative TB/HIV management is 
essential to ensure that HIV-positive TB patients are identified and treated 
appropriately, and to prevent TB in HIV-positive people. These activities include: 
• Establishing mechanisms for collaboration between TB and HIV programmes  
o Coordinating bodies, Joint TB/HIV planning, monitoring and evaluation, 
HIV surveillance among TB patients  
• For HIV-positive people, intensified TB case-finding (ICF), and for those without 
active TB, isoniaizid (INH) preventive therapy (IPT) and infection control (IC) in 
healthcare and congregate settings  
2 
• For TB patients; HIV testing, care and support, HIV prevention and for those TB 
patients infected with HIV, Cotrimoxazole preventive therapy (CPT) and 
antiretroviral therapy (ART).  
Statistics show that very few countries in sub-Saharan Africa are fully implementing the 
Directly Observed Treatment Short-Course (DOTS) strategy for TB treatment, achieving 
country-wide coverage and global WHO targets of 70% case detection rate and 85% 
cure rate (WHO, 2003). However, these statistics do not take into account the increased 
TB mortality in high HIV prevalent populations to accurately determine the performance 
of a DOTS programme. Collaborative TB and HIV care and prevention rely on full 
implementation of the DOTS strategy as part of wide-ranging HIV care and support 
programmes as well as collaborative TB and HIV programme activities. These activities 
must not only be acceptable, feasible, and affordable but also part of a strengthened 
national health service. The emphasis on collaborative TB and HIV activities should be 
the logical progression of an effective national DOTS programme, as stated in the WHO 
Guideline (WHO, 2003) for the implementation of collaborative TB and HIV programme 
activities. 
According to a baseline study on collaborative TB/HIV activities in Kinshasa, Congo, by 
Amanda, Annelies, Sabue, Marie, Nikki, Frieda, Valentin and Etienne (2008:137), most 
of the surveyed health facilities are providing activities to decrease the burden of 
TB/HIV. Some HIV activities were implemented in 58% of TB clinics and the majority of 
health facilities had at least one healthcare worker (HCW) trained in either HIV 
counselling or testing. Experience from Tanzania regarding collaboration of TB and HIV 
programmes show that TB case detection among people living with HIV (PLHIV) 
increased more than threefold and TB treatment was integrated in home-based care by 
non-governmental organizations [NGOs] (Wandwalo, Kapalata, Tarimo, Corrigan & 
Morkve, 2004:109). 
Regional as well as national research on assessment of the implementation status of all 
activities of collaborative TB/HIV in Ethiopia is limited. However, research on specific 
activities from the collaborative TB/HIV care activities has been carried out at various 
regions of the country. For example, a study by Degu, Aschalew and Bernt (2007:4) on 
acceptance of voluntary counselling and testing for HIV (VCT) among TB patients in 
Southern Ethiopia shows that 73% were willing to be tested and 58% of those willing 
accepted the test. The overall acceptability rate was 35%, with 20.6% HIV-positive. In 
another study in Addis Ababa, a cross-sectional survey of blood samples was made 
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from smear positive pulmonary TB patients for HIV testing. Of the 236 blood samples 
collected, 107(45.3%) were HIV-positive (Demissie, Lindtjørn & Tegbaru, 2000:277). All 
these studies showed a strong link between the two diseases and the need to urgently 
prioritise the strengthening of collaborative activities. A close follow up of the status of 
collaboration nationally and regionally is equally important for programme improvement. 
 
This research work will explore the implementation status of collaborative TB and HIV 
care activities for mutual benefit to enable the general health service to deliver 
interventions to control HIV-related TB and TB-related HIV cases under Addis Ababa 
City administration. The study was facility based, cross sectional, and employed mixed 
method research design. Interview was done on HIV chronic care clinic attendees and 
TB treatment clinic attendees. In addition, in-depth interviews among patients and 
healthcare providers were conducted. This was supplemented with focus group 
discussions among TB/HIV patients and interview of coordinators of collaborative 
TB/HIV activity at regional and health facility levels. 
 
1.2  BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
 
An east African country, Ethiopia is the most populous landlocked country in the world, 
and with a surface area of 1,127,127 square kilometres is bordered by Eritrea to the 
north, Djibouti and Somalia to the east, Kenya and Somalia to the South, and Sudan 
and South Sudan to the West (see Figure 1.1, below). The country is divided into nine 
ethnically based regions (Afar, Amhara, Binshangul-Gumuz, Gambela, Hareri, Oromiya, 
Somali, Tigray, and Southern National Nationalities and Peoples’ Region [SNNPR]) and 
two city administrations (Dire-Dawa and Addis Ababa). There are 817 Woredas 
(districts) across all 11 regional administrations (Figure 1.2, below), each of which is 
further divided into Kebeles, the smallest administrative units. The total population of the 
country for 2012 was estimated at 84,040760 (projected from Summary and Statistical 
Report of the 2007 Population and Housing Census Results, Central Statistical 
Authority of Ethiopia [CSA], 2008:11), with an annual growth rate of 2.6%.  
The major health problems remain largely preventable communicable diseases and 
nutritional disorders. Despite major progress in the last one and half decades, Ethiopia’s 
population still faces a high rate of morbidity and mortality and the health status remains 
relatively poor (Federal Democratic Republic of Ethiopia [FDRE], 2010:3). The most 
recent vital health indicators (2007/08) show a life expectancy of 54 years (53.4 years 
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for male and 55.4 for female), an infant mortality rate of 59/1000, and an under-five 
mortality rate of 88/1000 (FDRE 2012:109).  
Following changes of government in 1991, the health policy was the first of its kind in 
the country and was among a number of political and socio-economic transformation 
measures that were put in place. This was followed by the formulation of four 
consecutive phases of comprehensive health sector development plans (HSDPs), the 
first phase of which was implemented in 1996/97. Both were the result of critical reviews 
and scrutiny of the nature, magnitude and root causes of prevailing and newly emerging 
health problems. The core elements were democratisation and decentralisation of the 
healthcare system, development of its preventive, promotive and curative components, 
assurance of accessibility for all segments of the population and the promotion of 
private sector and NGOs participation in the health sector (FDRE-MOH, 2010). 
The recently implemented business processing re-engineering (BPR) of the health 
sector has introduced a three-tier delivery system characterised by a first level of a 
Woreda/district health system, comprising a primary hospital (with population coverage 
of 60,000-100,000 people), health centres (1 for 15,000-25,000) and their satellite 
health posts (1 for 3,000-5,000), connected by a referral system. A primary hospital, 
health centres, and health posts form a primary healthcare unit with each health centre 
having five satellite health posts. The second level in the tier is a general hospital with 
population coverage of 1-1.5 million people; and the third a specialised hospital that 
covers a population of 3.5-5 million (FDRE-MOH, 2010).  
The Federal Ministry of Health of Ethiopia (FMOH) and the Regional Health Bureaus 
(RHBs) focus more on policy matters and technical support while Woreda health offices 
have basic roles of managing and coordinating the operation of a district health system 
under their jurisdiction (FDRE-MOH, 2010:4). Regions and districts have RHB and 
district health offices respectively for the management of public health services at their 
levels. RHBs and Woreda health offices share decision-making processes, decision 
powers, duties and responsibilities.  
The development of the HSDP IV is based on the main health problems of the country, 
with HSDP  specifically focussing on  TB, HIV, malaria, and nutritional disorders. 
Particularly, interventions to curb the dual burden of TB and HIV have been given 
special attention for the development of the HSDP IV. Ethiopia’s HIV epidemic status is 
generalised and mainly heterogeneous, with marked regional variations. HIV prevalence 
ranges from 0.9% in Southern Ethiopia to 6.5% in the Gambella region, the western part 
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of the country. There is also wide urban - rural variation in HIV prevalence, with urban 
areas estimated to have a prevalence of 4.2% compared to 0.6% in rural areas (FDRE, 
2012). The first case of HIV in Ethiopia was reported in 1984, since when it has become 
a major public health concern, leading the government to declare a public health 
emergency in 2002 (USAID-E, 2012).  
According to the recent Ethiopian HIV/AIDS progress report, the national epidemiologic 
trend of HIV prevalence over the past eight years seemed to be stable. Nevertheless, 
the prevalence appears to be declining in both urban and rural areas. Data from 
antenatal clinics showed that the HIV prevalence among pregnant women had declined 
from 4.9% in 2001 to 2.6% in 2009. However, the report outlined the most at risk 
individuals and segments of the population affected by the epidemic: semi-urban and 
small market town residents, females of younger age groups, HIV discordant couples, 
commercial sex workers, the uniformed and long distance truck drivers (FDRE, 2012).  
In 2011, the estimated adult HIV prevalence in Ethiopia was 1.5 percent (National AIDS 
Resource Centre [NARC-E], 2012a). Although the epidemic is currently stable, HIV 
remains a major development challenge for Ethiopia. Poverty, food shortages, and other 
socio-economic factors amplify its impact. According to a recent report of Ethiopian 
NARC, approximately 789,960 Ethiopians were living with HIV in 2011, with 53,831 
individuals having died as a result of infection with the virus in the same year (NARC-E, 
2012a).  
TB is prevalent in Ethiopia, ranking the country as seventh among the world’s 22 worst 
burdened countries, and one of the top three in Africa (WHO, 2011a). The annual 
incidence rate of all forms of TB cases was estimated at 378 per 100,000 population 
while incidence rate of smear positive cases was 163 per 100,000. The prevalence of all 
forms of TB was estimated at 579 per 100,000 (WHO, 2009b). According to the 
Ethiopian Millennium Development Goals (MDGs) Progress Report (United Nations 
Development Program-Ethiopia [UNDP-E], 2010), the TB case detection rate for the 
country was only 34% and the death 92 per 100,000 people for 2007.  
Ethiopia adopted the Directly Observed Treatment Short course (DOTS) strategy in 
1991, since then, coverage has expanded to 95 percent of the population. The country 
has increased health service coverage to 89.6% in 2009/10 and recent data shows 
significant progress in relation to TB detection (UNDESA Statistics cited in UNDP-E, 
2010). A recent global TB report for Ethiopia (WHO, 2011a) revealed that TB killed an 
estimated 39,000 people in 2010, with annual prevalence of 394 cases per 100,000 and 
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a case detection rate of 72 per 100,000. A report by UNDP-E (2010) outlined challenges 
and feasible recommendations for increasing TB case detection in Ethiopia. Among 
others, training of TB care staff and strengthening coordination of implementing 
agencies were pointed out. Hence, gaps in diagnostic capacity and weak partnership 
coordinating mechanisms, weak planning and implementation capacity at regional level 
and weak diagnostic laboratory services at health facility levels ought to be addressed. 
The current global health policy to deal with the dual burden of TB and HIV is targeting 
the two diseases in one spot, that is tackling HIV should include tackling TB as a major 
killer of PLHIV. Tackling TB should include tackling HIV as the most potent force driving 
the TB epidemic (WHO 2002:16). 
 
Figure 1.1: Map of Africa showing the location 
of Ethiopia (Adapted from Worldatlas [s.a]) 
 
 
Figure 1.2: Map of Ethiopia by regional 
administration (Adapted from Wikipedia 2012) 
1.2.1 Addis Ababa City Administration (the research area) 
 
Addis Ababa is the capital city of Ethiopia, the largest city in the country with an 
estimated total population of 3,755,192, of whom 47.6% are males and 52.4% female 
(projected from 2007 CSA), with a population growth rate of 2.1% (CSA, 2008:9). As 
a chartered city, Addis Ababa has the status of both city and region (City 
Administration), and is the base for the African Union and its predecessor, 
the Organization of African Union (OAU) . It also hosts the headquarters of the United 
Nations Economic Commission for Africa (UNECA) and numerous other continental and 
international organisations. Addis Ababa is therefore often referred to as "the political 
capital of Africa", due to its historical, diplomatic, and political significance for the 
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continent (United Nations Economic Commission for Africa [UNECA] 2012, cited in 
Wikipedia 2012). The city is populated by diverse ethnic and religious people from the 
other regions of Ethiopia, and the country has as many as 80 ethnic groups speaking at 
least 80 different languages belonging to various religious groups. Administratively, the 
city is divided into ten sub-cities and has 116 Woredas/districts (Figure 1.3, below).  
In the City Administration there are 50 hospitals, of which five are regional (under Addis 
Ababa Health Bureau), four federal (under Federal Ministry of Health), one specialised 
central referral (under Addis Ababa University), three other governmental hospitals (two 
defence force and one police), three NGOs and 34 private. In addition, there are 30 
health centres in the city (Federal Ministry of Health of Ethiopia [FMOH], WHO-Ethiopia, 
Central Statistics Agency of Ethiopia [CSA] and the Health Metrics Network [HMN], 
2007).  
The Addis Ababa City Administration health bureau (AACAHB), often called Addis 
Ababa Health Bureau (AAHB), administers five hospitals, one regional laboratory, one 
health science collage, 10 sub-city health offices and 27 health centres. In addition, 
there are more than 464 private clinics, 262 pharmacies and 244 drug shops. More than 
46 NGOs with 51 projects are working in the city on different health activities. The 
potential health services coverage of Addis Ababa in 2010 was not more than 36%, with 
one public health centre to 40,000 populations (AACAHB, 2011). 
According to the single point HIV estimate of 2007, the adult HIV prevalence for Addis 
Ababa for 2011 was estimated at 9.2%, of whom 7.3% were male and 11% female. 
Consequently, women accounted for 59% of the HIV-positive population in the city 
(FMoH, 2007a). The cumulative number of PLHIV enrolled in chronic HIV care clinics at 
of end of 2010 was 99,875. A total of 10,362 active TB cases had been detected in the 
same year in the city, of whom 87.7% (9,084) were tested for HIV. Of these, 25.1% 
(2,277) were found co-infected with HIV (AACAHB, 2011). In 2011/12, a total of 10,362 
TB cases have been diagnosed in the city. Large number of TB cases (1,185. or 11.4%) 
were diagnosed from HIV care and treatment centres in the same year (AACAHB, 
2011). In Addis Ababa, 35 government health facilities and 40 private health facilities 
offer anti-TB treatment, however, case detection for TB in Addis Ababa is 63%, lower 
than the WHO target of 70% (The Integrated Regional Information Networks [IRIN], 
2012).  
According to personal communication with coordinator of AAHB TB/HIV collaborative 
activity, all the health centres and hospitals administered by the City Administration 
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Health Bureau diagnose and treat active tuberculosis cases routinely. The hospitals 
have all TB diagnostic facilities, including Fine Needle Aspiration (FNA) and x-ray, 
whereas the health centres perform sputum microscopy only. This is because of 
resource limitation to avail all diagnostic facilities and trained heath workers at all of the 
health facility levels (Genet, 2011).  
 
Figure 1.3: Map of Addis Ababa City by sub-city (The Research Site). (Adapted from AACAHB, 2011) 
 
In the following sub-sections; sources of the research problem, global and national 
(Ethiopian) background information about TB/HIV collaborative activities implementation 
and statement of the research problem are described. 
 
1.2.2 Source of the research problem 
 
According to the TB/HIV implementation guideline of the Federal Democratic Republic 
of Ethiopia Ministry of Health (FDRE-MOH), the high burden of HIV presents a serious 
threat to the control of TB. The unprecedented size of the epidemic of HIV-related TB 
demands collaborated TB and HIV programmes actions at all levels. The two diseases 
(TB and HIV) have strong ties in high HIV prevalence populations, with TB a leading 
cause of morbidity and mortality, and HIV driving the TB epidemic, particularly in sub-
Saharan Africa (FMoH, 2007b). Evidence shows that there is no decline in growth in the 
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number of deaths due to TB among HIV-positive in most Africa countries (Olalekan, 
Ismail, Khalid & Mubashir 2009:65). 
TB, a chronic bacterial infection, causes more deaths worldwide than any other 
infectious disease. It is spread through the air and usually infects the lungs, although 
other organs are sometimes involved. Some 2 billion people, one-third of the world's 
population, are infected with the TB organism, mycobacterium tuberculosis, though 
most do not develop active TB. However, in people with weakened immune systems, 
especially those infected with the human immunodeficiency virus (HIV, the cause of 
AIDS), TB organisms may overcome the body's defences, multiply, and cause active 
disease. Each year, 8 million people worldwide develop active TB and three million die 
(The foundation for better healthcare [FBHC], 2012). 
People living with HIV, representing over 10% of annual TB cases, are up to 37 times 
more likely to develop TB disease than those who are HIV negative (WHO 2010a). 
However, although HIV increases the likelihood of progression from latent TB infection 
to active TB disease, it is not known whether HIV infection increases the risk of infection 
if exposed to TB bacteria (Centres for Disease Control and Prevention [CDC], 2005). 
Globally, in 2010, TB accounted for nearly one in five deaths among HIV-positive 
people (WHO 2010a). 
Recent reports continue to show up the major public health threat posed by the dual 
epidemics of TB and HIV. According to D'Arminio, Sabin, Phillips, Sterne, May, Justice, 
Dabis, Grabar, Ledergerber, Gill, Reiss and Egger (2005:416), TB is now the most 
frequent life-threatening opportunistic disease among people living with HIV, including 
those receiving ART, and is a leading cause of death, posing a significant threat to the 
gains made in scaling up prevention, care and treatment programmes. The emergence 
of ever more dangerous strains of multidrug-resistant TB strains, including extensively 
drug resistant TB, represents a critical threat to global health and security. 
HIV testing for TB patients is a critical entry point to interventions for both treatment and 
prevention. A major reason for promoting HIV testing in TB patients is to facilitate 
provision of Cotrimoxazole preventive therapy (CPT) and ART to HIV-positive patients 
(FMoH, 2007b). According to a previous global TB report (WHO, 2008b), this seems to 
be working. In absolute terms, the improvement in provision of CPT and ART is much 
more marked. Based on the findings from WHO technical report (WHO, 2008b), in 2006 
alone, 146,586 HIV-positive TB patients were treated with CPT in 46 countries that 
collectively accounted for 75% of the global number of HIV-positive TB cases, and 
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66,601 started ART. However, some studies showed that, there is low acceptability of 
HIV testing among TB patients. For example, a study carried out in Southern Ethiopia 
showed that the low acceptability of HIV counselling and testing among TB patients 
poses a challenge to the scale up of TB/HIV collaborative efforts (Degu et al., 2007:4). 
 
1.2.3 Background to the research problem 
 
Despite the availability for decades of highly efficacious treatment, TB remains a major 
global health problem. In 2010, there were an estimated 8.5-9.2 million cases and 1.2-
1.5 million deaths, including deaths from TB among HIV-positive people (WHO, 2011:3). 
TB is the second leading cause of death from infectious disease worldwide, after HIV, 
which caused an estimated 1.8 million deaths in 2008 (WHO, 2011:3). Many countries 
have seen an increase in TB case fatality rates and up to a fourfold rise in their TB 
caseload, even those few countries with well-organized national TB Programmes 
(WHO/UNAIDS, 2007; WHO/SEARO, 2003). This suggests that TB control will not 
make much headway in HIV prevalent settings unless HIV control is also achieved. 
Data from the recent global AIDS report (WHO, UNAIDS and UNICEF, 2011) showed 
that, globally, an estimated 34 million people were living with HIV at the end of 2010, 
including 3.4 million children less than 15 years. The same report showed, 2.7 million 
new HIV infections in 2010, including 390,000 among children less than 15 years. Of 
the estimated 34 million people living with HIV, about one third were estimated to have 
concomitant latent infection with Mycobacterium tuberculosis. 
In Africa, which suffers the highest rates of both diseases, TB is a leading cause of HIV-
related death. Nelson Mandela said: “We cannot win the battle against AIDS unless we 
also fight TB” (WHO, 2004g). Ethiopia is one of the countries worst affected by the 
TB/HIV co-epidemic, with the WHO Global TB Report (WHO, 2011a:95) estimating that 
15% of HIV tested TB patients in Ethiopia were HIV-positive, while routine data from 
2006/07 estimated that 31% of TB patients were HIV-positive (FMOH, 2008). 
 
1.2.4 TB/HIV collaborative activities in Ethiopia and Addis Ababa 
 
Ethiopia established its TB/HIV Advisory Committee (THAC) in 2004, consisting of 
stakeholders from the TB and HIV programmes. Major partners, including bilateral 
donor organisations, research institutions, academic institutions, and professional 
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associations represented the committee. THAC provides technical and policy guidance 
to the FMOH and other partners (FMoH, 2007b). TB/HIV collaborative activity was 
initiated in Ethiopia in 2004 (Ethiopian HIV Prevention and Control Office (EHAPCO and 
World Bank, 2008) as a pilot project in six hospitals and three health centres (one 
hospital and one health centre from Addis Ababa City Administration). After brief 
supervision of these pilot sites and with the intention of expansion, the collaborative 
activities were expanded to more than 450 health facilities (hospitals and health 
centres) in 2005/06 alone. Key activities during the piloting project at all the sites 
included HIV testing of TB patients, provision CPT for HIV-infected TB patients, referral 
to HIV-related care, TB screening and referral for HIV-infected clients attending VCT 
clinics. These pilot sites had served as an important testing ground for developing 
training materials, reporting formats, referral systems, implementation guidelines, and 
standard operating procedures.  
According to the recent report (EHAPCO and World Bank, 2008), the percentage of TB 
patients who received HIV counselling and testing in Ethiopia had increased to more 
than 80% in most health facilities. TB/HIV patients are referred to HIV care and ART 
units where they get the appropriate treatment for opportunistic infections, prophylaxis, 
and ART, if eligible. Patients seen at HIV care clinics are also screened for TB and 
referred to TB clinics for treatment if diagnosed with active TB. However, the referral 
system was not well developed between the TB care and HIV caregivers and the follow-
up system was not strong. In addition, it was not known what percentages of TB/HIV 
patients who required the services actually received it. The gap between what is 
supposed to happen in service delivery and what is actually happening may be wide 
(EHAPCO and World Bank, 2008). Following the evaluation of the pilot sites, 
collaborative TB/HIV care services are being implemented widely in most of the 
governmental health institutions (FMoH, 2005). 
Collaborative TB/HIV care services started in two health facilities in Addis Ababa (a 
hospital and a health centre) as part of the national pilot sites in 2004, since when the 
number has increased dramatically. According to the 2011 annual performance report of 
Addis Ababa health bureau, PLHIV are receiving a package of care services that 
includes clinical HIV management and psycho-social support, i.e., counselling and 
home-based care across the continuum. During the reporting period (2010/2011), at 
least 50 health facilities from both public and private sectors were accredited to provide 
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full packages of the HIV care services. The cumulative number of PLHIV enrolled in 
chronic HIV care clinics was 99,875 (AACAHB, 2011). 
 
1.2.5 Statement of the research problem 
 
TB is a common, treatable HIV-related disease and a leading killer of PLHIV, 
consequently there is a strong need for close collaboration between HIV and TB 
programmes. This is necessary to implement the WHO’s recommended directly 
observed treatment short course (DOTS) strategy for TB control and to improve care for 
people with HIV and TB. However, analysis of national TB and HIV programmes, and 
emerging experience from collaborative TB/HIV sites shows there are many unexploited 
potential synergies between TB and HIV programme objectives and activities (WHO, 
2003). National as well as sub-national information for the implementation status of 
TB/HIV collaborative activities in Ethiopia is very limited. Therefore, this research project 
will evaluate the programme implementation of collaborative TB and HIV activities at 
public health facilities in Addis Ababa, Ethiopia. 
 
 
1.3 AIM OF THE STUDY 
 
The purpose of this study and objectives are discussed in this section. 
 
1.3.1 Research purpose 
 
The purpose of this study was to provide guidance in promoting the implementation of 
collaborative TB/HIV care activities in Addis Ababa and to increase knowledge of 
healthcare workers in this area of practice.  
 
1.3.2 Research objectives 
 
The research objectives that guided this study are to:  
• determine HIV prevalence among TB patients in Addis Ababa.  
• determine TB prevalence among HIV patients in Addis Ababa. 
• describe implementation status of collaborative TB and HIV care services. 
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• identify how programme implementation impacts on both TB and HIV patients. 
• identify how programme implementation impacts on staff development. 
• describe the programme implementation in relation to infrastructure. 
• recommend to policymakers and practitioners the technical basis to guide the 
implementation of collaborated TB/HIV activities based on findings of this study. 
 
1.4 SIGNIFICANCE OF THE STUDY 
 
Despite the limited information so far, Ethiopia has implemented the TB/HIV 
collaborative activities based on the interim policy since 2005. It is expected that this will 
generate further evidence to build on phased implementation of collaborative TB and 
HIV activities at a country level.  
 
1.5 DEFINITION OF KEY CONCEPTS 
 
The following concepts are used frequently in this study: 
Collaboration: this is to perform interconnected activities in partnership or in joint effort. 
Tuberculosis (TB): is an infectious disease caused by Mycobacterium tuberculosis, a 
rod shaped bacillus called “acid-fast” due to staining characteristics in laboratory. 
Occasionally, the disease can also be caused by Mycobacterium bovis and 
Mycobacterium africanum. 
Human immunodeficiency virus (HIV): a virus that affects the human body’s defence 
cells, resulting in exposure to different opportunistic infections. To date there is no cure 
for HIV. 
TB/HIV collaboration: both TB and HIV care providers collaborate for prevention, care, 
and treatment of patients who have TB and/or HIV through referral linkage and 
teamwork. 
TB/HIV co-infection: infection with both TB and HIV. 
Isoniazid preventative therapy (IPT): Isoniazid preventative therapy can be given to 
individuals with latent or dormant TB infection in order to prevent progression to active 
TB disease. It is very important to make sure the person does not already have active 
TB before beginning IPT therapy. Isoniazid is given daily as self-administered therapy 
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for six to nine months. Since HIV-infected people could develop TB before antiretroviral 
therapy is prescribed, and since there is no evidence against combined use, use of 
antiretroviral drugs does not prohibit the use of Isoniazid preventative therapy (Open 
Society Foundation, 2006). 
Cotrimoxazole preventive therapy (CPT): Cotrimoxazole preventative therapy is 
promoted by WHO and UNAIDS for the prevention of several secondary bacterial and 
parasitic infections in eligible adults and children living with HIV in Africa. TB patients 
are eligible for this therapy (Open Society Foundation, 2006). 
 
1.6 FOUNDATIONS OF THE STUDY 
 
TB and HIV are global public health problems with considerable mutual interaction. 
Globally, TB is a leading killer of PLHIV. HIV is the leading force driving the TB 
epidemic in countries with a high HIV prevalence (WHO, 2003). Given the close 
interaction between the TB and HIV epidemics, the global Stop TB Partnership 
established the TB/HIV Working Group in 2001 to coordinate and promote interventions 
to decrease the burden of HIV-related TB. The Working Group developed a global 
TB/HIV strategic framework (WHO, 2002) and supportive guidelines for implementation 
(WHO 2003) that need to be adapted in each WHO region. Subsequently, an interim 
policy on collaborative TB and HIV activities was developed (WHO, 2004d). These 
materials were adopted nationally by most countries. 
 
1.6.1 Meta-theoretical assumptions 
 
This research, as stated in the design section, combines both qualitative and 
quantitative methods. For the former, grounded theory research was applied, which 
according to Strauss and Corbin (1990) uses a systematic set of procedures to develop 
an inductively derived grounded theory about a phenomenon. A descriptive mode of 
grounded theory provides rich detail about a phenomenon (Burns & Grove, 2007) and 
answers such questions as “What is going on TB/HIV collaborative activity in Addis 
Ababa?”; “How are TB/HIV collaborative activities organised”; “What are the roles of the 
healthcare system in the programme”; “What are the main activities implemented for 
joint TB and HIV care services?”; and “What does a TB or HIV patient benefit in a 
particular healthcare setting?” In this study, randomly selected health facilities will be 
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assessed for the implementation status of collaborative TB/HIV care services at their 
normal service delivery settings. The clinical settings to be assessed include HIV 
chronic care clinics and TB clinics in the study health facilities. In both of these clinics, 
descriptive and explorative assessment will be conducted regarding case detection and 
management of both TB and HIV diseases, and further analysed within the theoretical 
dimensions. 
 
1.6.2 Conceptual framework 
 
According to the WHO interim policy (WHO, 2004d:2), collaborative TB/HIV activities 
are essential to ensure that HIV-positive TB patients are identified and treated 
appropriately, and to prevent TB in them. These activities include establishing 
mechanisms for collaboration between TB and HIV programmes (coordinating bodies, 
joint TB/HIV planning, monitoring and evaluation and HIV surveillance) for HIV-positive 
people; intensified TB case finding; and, for those without active TB, IPT; infection 
control in health-care and congregate settings; HIV testing for TB patients; and, for 
those TB patients infected with HIV, Cotrimoxazole preventive therapy and ART. 
Therefore, the provision of collaborative TB/HIV care services conceptual framework 
was adapted from Kerrie (2010). Figure 1.4 (below) explains the various steps from 
input to impact of collaborative TB/HIV care service implementation.  
The input step uses concepts as listed, from experience and knowledge, resulting in the 
development of strategies, policies and guidelines on collaborative TB/HIV care 
services. Based on this, policy for TB/HIV collaborative activity was developed, 
strategies with indicators were set and a coordinating body (WHO Stop TB partnership) 
established. The activities were planned to be implemented on the existing 
infrastructure and available health facility resources. In the process, human resource in-
service trainings were conducted for service delivery, staff members were given roles 
and responsibilities, necessary commodities were availed (drugs, lab reagents and 
other supplies), protocols were set, guidelines were produced and distributed, and 
infrastructures re-arranged to make the services ready. In addition, advocacy and social 
mobilisation was conducted to gain the support of all stakeholders. After the initial two 
steps the services were ready for the TB and HIV patients, whereby patients start 
consuming the services to see an output. The interventions become available to large 
number of clients, or the majority of health facilities start implementing the services as 
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routine. TB and HIV patients understand the benefit of dual interventions, and patients 
gain improved knowledge and attitude for collaborative TB/HIV care services. 
The fourth involves outcomes, with the majority of TB and HIV patients benefitting from 
each of the packages of care delivered to each of TB and HIV chronic care clinics for 
patients. For example, the majority of PLHIV screened for TB received necessary 
interventions, and the majority of TB patients tested for HIV enrolled on appropriate 
preventive, care and support interventions. An increased number or proportion of 
TB/HIV patients adopted behaviour which reduced their vulnerability to infection, 
morbidity and mortality associated to TB and HIV. 
The last and most important step of the process is to attain sustained change at holistic 
or larger community level, that is impact. In this stage, the concern is with biological 
change and improvement in quality of life of the general community. As the result of 
effective implementation of TB/HIV collaborative activities, the majority of TB and HIV 
patients attain better quality of life and wellbeing, thus becoming productive citizens 
(Figure 1.4). Therefore, this research follows the basic concepts outlined in this 
framework.  
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Figure 1.4: Conceptual framework for Provision of collaborative TB and HIV care services 
(Adapted from Kerrie [2010]). 
 
 
1.7 RESEARCH DESIGN AND METHODOLOGY 
 
Different methodologists at various instances (Burns & Grove, 2007:38; Polit & Beck, 
2008:66; Saunders, Lewis & Thornhill, 2009:136) define research design similarly as the 
detailed map of how a certain study is planned to be conducted with the advantage of 
controlling over certain factors that can interfere with the desired outcomes and for 
overcoming the difficulties encountered during the research processes. On the other 
hand, Creswell and Plano-Clark (2007:58) state that research design is a procedure for 
collecting, analysing, interpreting, and reporting data in a study. According to Mouton 
(2001:56), research methodology is the research process and the kind of tools and 
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procedures used. This study used mixed research methodologies to collect data from 
the participants, and was descriptive.  
Mixed methodology is an approach where both quantitative and qualitative research 
methods are used at the same time or in a series of studies (Creswell, Plano-Clark & 
Garrett, 2008:66). In order to achieve the study objectives and ensure that the research 
process was logical, two different study populations (patients and healthcare providers), 
as well as four different methods of sampling and data collection were used (see Table 
1.1, below). This was done in order to achieve methodological triangulation, which 
ensured the validity and trustworthiness of results (Polit & Beck, 2008:309). A detailed 
discussion about the research design and methodologies is given in Chapter 3. 
 
Table 1.1: Sources of data, methods of data collection, data type and sampling techniques 
Data Source Data collection method  Type of data Sampling 
Patients (TB and HIV) 
Interviewer administered 
questionnaire  
Quantitative  
 
Probability 
Patients (TB and HIV) Interview guide Qualitative  Non-probability 
Patients (TB and HIV) FGD guide Qualitative Non-probability 
TB/HIV care providers Interview guide Qualitative Purposive 
Coordinators of TB/HIV 
care (HF and regional) 
Interview guide  Qualitative  Purposive 
 
1.7.1 Quantitative study 
  
Quantitative research design was used to collect data from exit interviews of both TB 
and HIV patients (clients) from the health facilities. In addition, quantitative data from 
healthcare providers was collected. The data was collected using an interviewer-
administered questionnaire, in which the participants were asked to respond with 
answers in a structured manner. The data was cross-checked for completeness, coded, 
and entered into a computer using the Statistical Package for Social Sciences (SPSS) 
version 15.0. The researcher cleaned and analysed the data, using the same version of 
SPSS (SPSS, 2006). Statistical calculations were made for both descriptive and 
inferential statistics, and the results presented in the form of graphs and tables (see 
Chapter 4).  
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1.7.2 Qualitative study 
 
For triangulation purposes, qualitative research design has been used to collect data 
from both clients (TB and HIV patients) and healthcare providers for the TB/HIV 
collaborative service provision at health facilities and coordinators at health facility and 
regional level for the TB/HIV collaborative activities. The data obtained using qualitative 
methods, mostly expressed in non-numerical terms, although sometimes it was 
transformed into numerical variables. The healthcare providers from the study facilities 
and coordinators of TB/HIV care at facility and regional health bureau were purposively 
selected for inclusion (Chapter 5).  
 
1.7.3 Design validity and reliability of quantitative data 
 
Validity and reliability are two important notions for determining the suitability of the 
research instrument or tool. These are appropriately dealt with to check for suitability of 
the research designs as described in detail in Chapter 3. 
 
1.7.4 Trustworthiness of the data obtained from qualitative sources 
  
The researcher in this study used credibility, transferability, dependability and 
confirmability constructs to ensure trustworthiness of the study findings. The details of 
these four constructs are discussed in Chapter 3. 
 
1.8 ETHICAL CONSIDERATIONS 
 
Based on the scientific principles of research ethics, the researcher followed and fulfilled 
the following ethical standards during the study. 
• Approval was obtained from the Research and Ethics Committee at the 
Department of Health Studies of UNISA and from the Addis Ababa City 
Administration Health Bureau (AACAHB) Ethical Committee (Annexure A and B).  
• A support and permission letter from the AACAHB was obtained addressing all 
study health facilities (Annexure C). 
• In addition, the participants were provided with all the relevant information 
regarding the details of the study and its benefits (Annexure D).  
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• Informed written consent was obtained from each of the study participants who 
participated in the study (Annexure E).  
• Privacy and confidentiality of the study participants was maintained during each 
of the data collection processes.  
• The researcher respected the work of other scholars by proper citation and 
acknowledgement of all sources of information. In addition, the researcher 
reported what the data revealed but not what the researcher wanted to achieve. 
Hence, maximum care has been employed to minimise distortion of data at any 
moment during data collection, entry, and presentation (detailed in Chapter 3). 
 
1.9 SCOPE AND LIMITATIONS OF THE STUDY 
 
The scope of this study may be taken as a baseline for nationwide study as no similar 
study has previously been conducted at national or sub-national level. In addition, the 
country may adopt the TB/HIV collaborative activities towards a more reliable approach 
as it will be possible to compare findings with countries under implementation of the 
TB/HIV collaborative activities. The findings from this study will be used as an input in 
the planning and implementation of TB/HIV collaborative activities, which ultimately 
contribute to better national achievement of the MDGs regarding HIV and TB control. 
As a limitation, the study was carried out in one administration (Addis Ababa), so the 
findings may not be generalised to the whole country. Private health facilities were not 
included, which may introduce recall bias as the study demanded previous health and 
disease conditions. The study did not consider those who died prior to the study while 
they had been enrolled in the care and treatment of TB/HIV collaborative activities, 
which may impose incidence-prevalence bias. However, the study findings are reliable, 
valid, and trustworthy, having used mixed methods and large sample size (Chapter 6).  
 
1.10 STRUCTURE OF THE THESIS 
 
The configuration of the research report is made with seven interlinked chapters. Each 
preceding chapter was procedurally based on the research activities and subsequent 
chapters constructed on the preceding chapters’ foundation to deliver inter-linked 
information with a logical order. The content of each logical chapter is described below: 
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CHAPTER ONE: In this chapter, the Orientation to the Study is described in various 
sections. In essence, this started with introduction of the research topic, TB/HIV 
collaboration, co-existence of the two diseases, co-infection and collaborative activities. 
The research problem, aims and significance of the study, foundations for the study, 
research design and method in brief, scope and expected limitations of the study were 
outlined. In addition, operational definitions of key concepts are described. 
 
CHAPTER TWO: In this chapter, the Literature Review is described under relevant 
sections. The focus is on reviewing available literatures on TB/HIV collaborative 
activities globally, regionally and at local level, for detailed understanding of the existing 
body of knowledge on the research topic. Basic introductory information about TB, HIV 
and collaborative TB/HIV interventions are stated. The concept of collaboration in 
general and in relation to TB/HIV collaborative activities are described. A rationale for 
collaborative TB/HIV activities, the 12 globally recommended TB/HIV collaborative 
activities and relevant literature on TB/HIV co-infection, HIV among TB patients and TB 
among HIV patients are reviewed in detail.  
 
CHAPTER THREE: In this chapter, the Research Design and Methodology employed in 
this particular thesis work is described in detail. The rationale and scope of the study 
are stated briefly to associate relevant research design and method. The design of 
mixed method study, the research methods for quantitative and qualitative parts of the 
research are described in more detail. For both methods, population and sampling, data 
collection procedures, validity, and reliability of the questionnaires and plan for data 
analysis are described. In addition, the general ethical considerations applied for this 
scientific research are described in greater detail.  
 
CHAPTER FOUR: In this chapter, Quantitative Data Presentation, Analysis, 
Description, and Interpretation are discussed in the relevant sections. The findings are 
based on the research questions or objectives of the research set in the preceding 
chapters. Analysis and interpretation on the findings are presented. Findings in this 
research are compared and contrasted with similar scientific research findings found 
elsewhere and objective analysis made of findings to complement the existing body of 
knowledge on the subject matter.  
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CHAPTER FIVE: In this chapter, Qualitative Data Presentation, Analysis, Description, 
and Interpretation are discussed with relevant sections. The findings are presented 
according to the research objectives outlined in Chapter 1. Qualitative findings are 
discussed thematically and triangulated with findings from the quantitative finding. In 
addition, analysis and interpretations are made on findings to complement the existing 
theoretical body of knowledge. 
 
CHAPTER SIX: In this chapter, Conclusions, Limitations, and Recommendations are 
based on the overall activity procedure and findings of the research, the outcome of 
which was to draw key conclusions and make recommendations for promoting better 
implementation strategies of collaborative tuberculosis and human immunodeficiency 
virus activities in the country in general and in the study area (Addis Ababa) in 
particular, through building on the existing body of knowledge. Feasible 
recommendations were based on the findings and stated in this final chapter. 
Conclusions were systematically objective, to summarise information on the overall 
finding. The conclusion focused on key findings only so that the reader can understand 
the research outputs. Finally, presumed limitations during the overall course of the 
research activity were stated.  
 
CHAPTER SEVEN: In this chapter, Contribution of the Research was based on the 
overall activity procedure and findings. The outline of the researcher’s to developing A 
Pocket Guide for Collaborative TB/HIV Care Services for Health Workers in Ethiopia 
was discussed. Specifically, the chapter discussed processes on the compilation of the 
pocket guide; application of the conceptual and theoretical frameworks to its 
development, and objectives and contents.  
 
1.11 CONCLUSION  
 
In this chapter, orientation of the study has been outlined. A brief introduction was given 
to HIV and TB, two diseases that are highly prevalent and the most important public 
health problems for more than three decades, especially in the developing world. The 
association of the two disease has gained national and international attention. 
Background information about the research problem was outlined. The research area, 
Addis Ababa City Administration, was discussed with specific focus on sources of the 
research problem. TB/HIV collaborative activity in Ethiopia and the research area was 
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discussed, with a statement made of the research problem, particularly Ethiopia and the 
research area. The chapter outlined the aims, research purposes, study objectives and 
significance. Terms used were defined operationally, and the foundation of the study 
discussed under two sub-sections, meta-theoretical assumptions and conceptual 
frameworks. 
The research design and methodologies employed were briefly discussed. This study 
utilises mixed methods study design with triangulation. Both quantitative and qualitative 
research methods are employed for data collection. In this chapter, the ethical 
considerations were briefly outlined, with scope and limitations.  
The researcher made use of the tutorial guideline of UNISA and Department of Health 
Studies for setting the computer to correspond with the University and supervisor, to 
follow the scientific writing, literature review, writing the research proposal, guidelines 
for writing the research report and writing an article based on the thesis (UNISA 2010; 
2012). 
 CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
In this chapter, the existing body of knowledge regarding TB, HIV, TB/HIV co-infection, 
concept of collaborative TB/HIV activities and specific TB/HIV collaborative activities 
reviewed, with description of the epidemiological and clinical linkage between TB and 
HIV, and how each disease affects the other in infection, progression to disease. The 
concept of collaborative TB/HIV activities is described with reference to World Health 
Organization (WHO) guidelines. Internationally recommended and nationally adapted 
collaborative TB/HIV activities to decrease the burden of TB/HIV are described, followed 
by studies related to TB/HIV co-infection, HIV prevalence among TB patients and TB 
prevalence among HIV patients along with the responses to this dual problem 
internationally, regionally and nationally.  
 
2.2 TUBERCULOSIS 
 
Tuberculosis is a bacterial disease caused by Mycobacterium tuberculosis (and 
occasionally by Mycobacterium bovis and Mycobacterium africanum). These organisms 
are also known as tubercle bacilli (because they cause lesions called tubercles) or as 
acid-fast bacilli (AFB). TB infection occurs when a person carries the tubercle bacilli 
inside the body, but the bacteria are in small numbers and dormant. Many people have 
tuberculosis infection and are well. TB is a state in which one or more organs of the 
body becomes diseased, as shown by clinical symptoms and signs. This is because the 
tubercle bacilli in the body have started to multiply and become enough to overcome the 
body’s defences (WHO, 2004a:23). 
TB infects about 10 million people worldwide annually, of whom about 8 million of 
develop active TB. Globally, incidence is rising by about 1% per year (WHO, 2005c), 
almost entirely as a result of increases in sub-Saharan Africa (SSA), while in the other 
five regions (the WHO regions are six: the African Region [AFRO: most of the sub-
Saharan countries], the Region of the Americas [AMRO/PAHO], the Eastern 
Mediterranean Region [EMRO], the European Region [EURO], the South-East Asia 
Region [SEARO] and the Western Pacific Region [WPRO]), incidence is stable or 
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falling. According to the WHO estimate, almost 28% of TB in the African region is 
attributable to HIV, one of the chief factors facilitating the increase of TB in the region 
(WHO, 2012c). 
The impact of HIV on TB stems from the fact that a large portion of the world is infected 
with Mycobacterium tuberculosis. The suppression of the immune system by HIV leads 
to activation of the dormant bacilli, and TB follows HIV infection with an average delay 
of seven years (Williams, Granich, Chauhan, Dharmshaktu and Dye, 2005:9619). 
 
2.3 HUMAN IMMUNODEFICIENCY VIRUS 
 
Since the first description of acquired immunodeficiency syndrome (AIDS) in 1981, 
researchers have identified two types of HIV (HIV-1 and HIV-2), the cause of AIDS. 
HIV-1 is the predominant type worldwide, whereas HIV-2 occurs most commonly in 
West Africa, though occasional infections have occurred in East Africa, Europe, Asia 
and Latin America. Both types cause AIDS and the routes of transmission are the same. 
However, HIV-2 is slightly less easy and the progression of HIV-2 infection to AIDS may 
be slower (WHO, 2004a). 
Since the detection and spread of HIV in the last three decades, the number of PLHIV 
worldwide continued to grow. For example, in 2008, an estimated 33.4 million people 
were infected with HIV, a number more than 20% higher than in 2000, and the 
prevalence was roughly threefold higher than in 1990. In the same year (2008), Sub-
Saharan (SSA) accounted for 67% of HIV infections worldwide, 68% of new HIV 
infections among adults and 91% of new HIV infections among children. The region also 
accounted for 72% of the world’s AIDS-related deaths in 2008 (UNAIDS, 2009:7). 
With an estimated 1.1 million people living with HIV, Ethiopia has one of the largest 
populations of HIV-infected people in the world. However, prevalence among the adult 
population is lower than many SSA countries (FDRE, 2010:6). Ethiopia’s HIV epidemic 
pattern is generalised and heterogeneous with marked regional variations. At the 
national level, the epidemiological trend over the past eight years has been stable, 
however, prevalence appears to be declining in urban areas, according to analysis of 
data from antenatal care (ANC) sites that collected it consistently for more than ten 
years. For example, prevalence among pregnant women attending ANCs in Addis 
Ababa has declined from 23% in 1996 to 10% in 2007. Peri-urban and small market 
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town residents and young females are the most at risk and affected segments of the 
population (FDRE, 2010:7). 
 
2.4 TB/HIV CO-INFECTION 
  
Together, TB and HIV form a lethal combination, with HIV weakening the immune 
system and promoting the progression of recent and latent TB infection to active TB 
disease. A person living with HIV who is also infected with TB is 20 times more likely to 
become sick with active TB than someone who is HIV negative (World Bank, 2010:1). In 
many TB/HIV patients in SSA the most common HIV-related illness is TB. However, 
certain clinical features are more common in HIV-positive patients than in HIV-negative 
TB patients (WHO, 2004a). HIV fuels the tuberculosis epidemic in several ways, 
promoting progression to active TB both in people with recently acquired and with late 
M. tuberculosis infections. HIV is the most powerful known risk factor for reactivation of 
latent tuberculosis infection to active disease. HIV-infected people are more susceptible 
to TB infection when they are exposed to M. tuberculosis (WHO, 2005a). 
HIV not only increases the number of TB cases but also alters the clinical course of TB 
disease. As HIV-related immune-suppression increases, the clinical pattern of TB 
disease changes, with increasing numbers of smear-negative pulmonary TB and extra-
pulmonary TB cases. TB is more likely to be disseminated and more difficult to 
diagnose as immune-suppression progresses (WHO, 2005a). Escalating TB case rates 
over the past decade in many countries in SSA and in parts of South East Asia are 
largely attributable to the HIV epidemic. Since the mid-1980s, in many African countries, 
including those with well-organised programmes, annual tuberculosis case notification 
rates have risen up fourfold, reaching peaks of more than 400 cases per 100,000 
population. Up to 70 percent of patients with sputum smear-positive pulmonary TB are 
HIV-positive in some countries in SSA (WHO, 2004c). 
The TB and HIV epidemics are inextricably linked, as TB is the leading infectious 
disease killing PLHIV. Africa is the global epicentre of TB-HIV co-infection, home to 
roughly 80% of TB cases among PLWHA. Since 1990, the number of new annual TB 
cases in Africa has more than tripled, as has the number of deaths per year. It is also 
the only continent in which TB rates are increasing at a dramatic 5% per year, driven by 
HIV, poverty and weak health systems. Africa’s TB burden has become so great that in 
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August 2005, African Ministers of Health and the WHO declared it an emergency health 
problem for the entire continent (RESULTS Educational Fund 2007). 
A study from a population database and survey in South Korea for the burden of TB/HIV 
showed that the number of cases with both was 137 cases per 100,000 population 
(0.07% among 197,562 TB cases) and the newly detected TB/HIV rate was increasing 
annually: from 0.025 in 2001 to 0.095 in 2005, (Chang-Hoon, Ji-young, Dae-Kyu, Mee-
Kyung, Eunjung, Jung-wook, Jinhyun, Heonsook, Hee-Jin, Sung, Hwahyun and Jeong-
Gu, 2010:66). The burden of HIV-associated TB is greatest in SSA, where the TB 
epidemic is primarily driven by HIV. There has been steady progress made in reducing 
the burden of HIV in TB patients with an increasing number tested for HIV and provided 
with CPT and ART. Less progress is being made to reduce the burden of TB in PLHIV 
(Jeremiah, Haileyesus, Reuben & Diane 2008:6). 
TB treatment programmes have been built over many decades, more recently with 
strong HIV service programmes and new treatment being developed. However, often 
they are not working together, with staffing, training and research endeavours 
approaching HIV and TB as two wholly independent problems. This vertical approach, 
amplified by disease-specific funding streams, has served as a barrier to collaboration 
and integration to address TB-HIV co-infection that occurs in a single patient and that 
threatens public health as a co-epidemic (Infectious disease society of America, 2007). 
A dynamic model based on trends in India suggests that, while the incidence of TB has 
been minimally affected by the HIV epidemic, the impact on TB mortality is likely to have 
been much more substantial (Williams, Granich, Chauhan, Dharmshaktu & Dye 
2005:9619). The impact of HIV on TB mortality has also been recognised in Thailand 
and Myanmar, where high case fatality rates have been reported in regions known to 
have high HIV prevalence (Varma, Wiriyakitjar, Nateniyom, Anuwatnonthakate, 
Monkongdee & Sumnapan 2007:586; Siriarayapon, Yanai, Glynn, Yanpaisarn, 
Uthaivoravit 2002:80; Wandee, Supawitkur, Pinta, Ngoentong, Khunkonkapan, 
Kaewkampa Sumanapun, Levine, Sinsomboontong & Mednavyn, 2004: Abstract no. 
B10478). 
In many African countries, the burden of the dual TB-HIV epidemic continues to rise due 
to poor implementation of the collaborative activities. For example, the greatest 
challenge facing post-apartheid South Africa is the control of the concomitant HIV and 
TB epidemics. HIV continues to spread relentlessly, and tuberculosis has been declared 
a national emergency. In 2007, South Africa, with 07% of the world’s population, had 
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17% of the global burden of HIV infection, and one of the world’s worst TB epidemics, 
compounded by rising drug resistance and HIV co-infection (Salim, Gavin, Quarraisha & 
Stephen, 2010:921). Cohorts of 6,440 employees in occupational clinics of Harare, 
Zimbabwe, were followed-up for two years for incidence of TB using a culture-based 
undiagnosed prevalent TB and anonymised HIV test. According to the results, HIV 
prevalence was 19%. For HIV-positive and negative participants, the incidence of 
culture-positive tuberculosis was 25.3 and 1.3 per 1,000 person-years, respectively 
(Elizabeth, Abbas, Yin Bun, Tsitsi, Ethel, Shungu, Anthony, Simba, Gavin, Stanley, 
Richard & Peter, 2010:13).  
 
2.5 CONCEPT OF COLLABORATION 
 
According to Collins English Dictionary (2012), “Collaboration is working together to 
achieve a goal“. Another resource defines it as:  
 ‘a recursive process where two or more people or organizations work together to 
realize shared goals, this is more than the intersection of common goals seen in 
co-operative ventures, but a deep, collective, determination to reach an identical 
objective for example, an intellectual endeavour that is creative in nature by 
sharing knowledge, learning and building consensus’ (Marinez-Moyano, cited in 
Schuman, ed, 2006).  
The following are some examples of successful collaboration efforts in the past: 
Arts:  
Collaboration or joint production by two or more artists is a common style among 
musicians and performance artists. The strong sense of individualism long 
possessed by artists of fine art began to wane around the 1960s, and some 
artists working in units have emerged and become widely known along with the 
development of new media based on the advances in information technology. 
They have changed the concept of art into something that can be engaged in by 
more than individual artists alone (Wikipedia, the Free Encyclopaedia [s.a]a). 
Business:  
Collaboration in business can be found both inter- and intra-organization and 
ranges from the simplicity of a partnership and crowd funding to the complexity of 
a multinational corporation. Collaboration between team members allows for 
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better communication within the organization and throughout the supply chains. It 
is a way of coordinating different ideas from numerous people to generate a wide 
variety of knowledge. The recent improvement in technology has provided the 
world with high speed internet, wireless connection, and web-based collaboration 
tools like blogs, and wikis, and has as such created a "mass collaboration." 
People from all over the world are efficiently able to communicate and share 
ideas through the internet, or even conferences, without any geographical 
barriers (Wikipedia, the Free Encyclopaedia [s.a]a). 
Collaboration in Education:  
‘’G two or more co-equal individual voluntarily bring their knowledge and 
experience together by interacting toward a common goal in the best interest of 
students for the betterment of their education success’’ (Wikipedia, the Free 
Encyclopaedia [s.a]a). 
Music:  
‘’Musical collaboration occurs when musicians in different places or groups work 
on the same album or song. Collaboration between musicians, especially with 
regards to jazz, is often heralded as the epitome of complex collaborative 
practice. Special software has been written to facilitate musical collaboration over 
the Internet. Websites have also been created to enable creative music 
collaboration over the Internet’’ (Wikipedia, the Free Encyclopaedia [s.a]a). 
Medicine:  
‘’In medicine the physician assistant (PA) - physician relationship involves a 
collaborative plan to be on file with each state board of medicine where the PA 
works. This plan formally delineates the scope of practice approved by the 
physician’’ (Wikipedia, the Free Encyclopaedia [s.a] a). 
 
The term collaboration in relation to other synonyms: 
Team work: In healthcare, team work has been defined as:  
‘’...a dynamic process involving two or more healthcare professionals with 
complementary backgrounds and skills, sharing common health goals and 
exercising concerted physical and mental effort in assessing, planning, or 
evaluating patient care’ (Xyrichis and Ream, 2008). Team work is increasingly 
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advocated by healthcare policy makers as a means of assuring quality and safety 
in the delivery of services’’ (Kohn, Corrigan & Donaldson, eds., 2000). 
Partnership:  
...an arrangement where entities and/or individuals agree to cooperate to 
advance their interests’. In the most frequent instance, a partnership is formed 
between one or more businesses in which partners (owners) co-labour to 
achieve and share profits or losses (Wikipedia, the Free Encyclopaedia, 2012a).  
Association:  
may refer to voluntary association, a group of individuals who voluntarily enter 
into an agreement to accomplish a purpose in non-profit organization, alumni 
association, an association of former students of a college or university, 
professional association, an industry trade group is also known as a trade 
association, sports association etc (Wikipedia, the Free Encyclopaedia, 2012b). 
Alliance  
G an agreement or friendship between two or more parties, made in order to 
advance common goals and to secure common interests (Wikipedia, the Free 
Encyclopaedia, [s.a]c.).  
Co-operation: 
is the process of working or acting together, which can be accomplished by both 
intentional and non-intentional agents. In its simplest form, it involves things 
working in harmony, side by side, while in its more complicated forms, it can 
involve something as complex as the inner workings of a human being or even 
the social patterns of a nation. It is the alternative to working separately in 
competition. Cooperation can also be accomplished by computers, which can 
handle shared resources simultaneously, while sharing processor time 
(Wikipedia, the Free Encyclopaedia, [s.a]d). 
Based on these concepts, collaboration of TB and HIV care services implies the joint 
effort of TB control programmes and HIV prevention and control activities to deal with 
the two diseases in one patient. This means that both TB and HIV care providers deliver 
services in collaborative manner in the same health facility. This is because these two 
diseases are usually interdependent or the chance of having both in one patient is 
higher than having them separately. Therefore, addressing two diseases in one patient 
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becomes cost-effective and allows the use of resources efficient for both programmes. 
In addition, patients benefit more in getting the services in one spot from the same 
healthcare system. 
 
2.6 THE CONCEPT OF COLLABORATIVE TB/HIV ACTIVITY 
 
According to the  WHO (2002:17), the HIV epidemic has increased the global TB 
burden and focused attention on the need to strengthen links between TB and HIV 
programmes in order to tackle these public health emergencies more effectively. In 
response to this situation, the WHO has developed an expanded strategy aimed at 
reducing the burden of HIV-related TB through close collaboration between the two 
programmes. The rapid growth of the HIV epidemic in many countries has resulted in an 
equally dramatic rise in the estimated number of new TB cases. HIV-related TB 
continues to increase, even in countries with well-organised national TB control 
programmes that are successfully implementing the WHO DOTS strategy. This 
suggests that where HIV is increasing the TB epidemic, full implementation of the DOTS 
strategy is insufficient to control TB, and control of HIV infection must become an 
important concern for National TB Programmes (NTPs). The high morbidity and 
mortality from TB among people living with HIV makes TB case detection, treatment, 
and prevention a priority for national HIV control programmes (WHO, 2004b). 
TB and HIV infection co-exist in many people worldwide and both programmes need to 
be collaborative to relieve the resultant suffering and improve diagnostic, care and 
prevention services for PLHIV and TB. The unprecedented scale of the epidemic of 
HIV-related TB demands urgent, effective, and coordinated action, not the development 
of an independent programme for TB/HIV but simply closer collaboration between 
existing TB and HIV programmes to exploit synergies, avoid overlap, and fill the gaps in 
service provision (WHO, 2004b). 
 
2.7 RATIONALE FOR COLLABORATIVE TB/HIV ACTIVITY 
 
The HIV pandemic presents a significant challenge to the control of TB and TB is also 
one of the leading causes of morbidity and mortality among PLHIV (FMOH, 2007b). The 
interaction between TB and HIV has implications for the public health approach to TB 
control among HIV-infected people. Both programmes therefore share mutual concerns: 
prevention of HIV should be a priority for TB control; TB care and prevention should be 
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priority concerns of HIV programmes. According to interim policy for collaborative 
TB/HIV activities (WHO, 2004d), there are 12 recommended collaborative activities that 
countries should implement to decrease the burden of their national TB/HIV:  
1. Set up a coordinating body for collaborative TB/HIV activities at all levels 
2. Conduct surveillance of HIV prevalence among TB patients 
3. Carry out joint TB/HIV planning 
4. Conduct monitoring and evaluation 
5. Establish Intensified TB case-finding 
6. Introduce Isoniazid prevention therapy 
7. Ensure TB Infection control in healthcare and congregate settings 
8. Provide HIV testing and counselling for all TB patients 
9. Introduce HIV prevention methods for all TB patients 
10. Introduce Cotrimoxazole preventive therapy for HIV-infected TB patients 
11. Ensure HIV care and support for PLHIV with or without TB infection 
12. Introduce antiretroviral therapy for PLHIV with or without TB infection. 
 
These collaborative activities will be more successful where national HIV and TB control 
strategies are based on international guidelines and are effectively implemented. The 
recommended activities can be implemented by TB and HIV control programmes, 
NGOs, community-based organisations or the private sector generally under the 
coordination of the national TB and HIV programmes. The following sections describe 
these activities under three main categories, namely (WHO, 2004d):  
• Mechanisms for Collaboration of TB/HIV services 
• Activities to decrease the burden of TB among HIV patients  
• Activities to decrease the burden of HIV in TB patients.  
1. Set up a coordinating body for TB/HIV activities 
at all levels 
2. Conduct surveillance of HIV prevalence among 
TB patients 
3. Carry out joint TB/HIV planning 
4. Conduct monitoring and evaluation 
Mechanisms for 
Collaboration 
5. Establish intensified TB case-finding 
6. Introduce Isoniazid prevention therapy  
7. Ensure TB Infection control in healthcare and 
congregate settings 
Activities to decrease 
the burden of TB among 
HIV patients 
8. Provide HIV testing and counselling Activities to decrease 
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9. Introduce HIV prevention methods 
10. Introduce Cotrimoxazole preventive therapy 
11. Ensure HIV care and support  
12. Introduce antiretroviral therapy 
the burden of HIV 
among TB patients 
 
Whereas previous TB and HIV programmes had largely pursued separate courses, they 
need to exploit synergies in supporting health service providers to deliver these 
interventions. The expanded scope of the new strategy for TB control in high HIV 
prevalent populations includes interventions against TB (intensified TB case finding, 
cure and TB preventive therapy) and interventions against HIV (and therefore indirectly 
against TB), e.g., promoting consistent condom use, sexually transmitted infections 
(STIs) treatment, harm reduction of injected drug users (IDU) and highly active 
antiretroviral therapy (HAART) (WHO, 2005a). 
 
2.7.1 Mechanisms for Collaboration 
 
Some countries have responded to the need for national TB Programmes (NTPs) and 
National AIDS Control Programmes (NACPs) collaboration by integrating the two at 
central and sometimes regional and/or district level. The reasons need to be clear in 
order for true programme collaboration to be made. Integration should provide definite 
synergistic benefits such as joint funding, staffing, procurement, and distribution 
mechanisms. In some countries both report to a single director, but in practice they are 
still run entirely separately. In many countries they have such different philosophies, 
structures, operations and funding channels that integration is difficult and counter-
productive (WHO, 2005a:26). Therefore, specific areas that need mechanisms for 
collaboration between TB and HIV programmes are described below. 
 
2.7.1.1 Set up a coordinating body for TB/HIV activities at all levels 
 
HIV programmes and TB control programmes, including their partners in other line 
ministries (prison or military), the private-for-profit sector and civil society organisations 
should work together to provide access to integrated services, preferably at the same 
time and location, for the prevention, diagnosis, treatment and care of TB/HIV. National 
coordinating bodies are needed at all levels of the health system to ensure strong and 
effective collaboration between HIV and TB control programmes and to offer a platform 
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for coordination and synergy among stakeholders (WHO, 2012a). Representation of 
people at risk of or affected by both diseases is essential to ensure effective 
implementation of integrated services and programme success. National AIDS 
commissions, which coordinate the multi-sectoral response to HIV, should also be 
included in national TB/HIV coordination efforts (WHO, 2012a). 
According to the policy (WHO, 2012a), in countries where coordinating bodies already 
exist (such as country coordinating mechanisms for the Global Fund to Fight AIDS, 
Tuberculosis and Malaria), strengthening their role through revised terms of reference 
and its expansion based on performance and achievements may be needed to deliver 
integrated TB and HIV services, preferably at the same time and location. 
The coordinating body for collaborative TB/HIV activities should have clear and 
consensus-based terms of reference. The important areas of responsibility are: 
•  Governance and coordination at national and sub-national levels 
•  Resource mobilisation 
•  Provision of general policy and programme direction for the management of 
activities 
•  Capacity-building including training 
•  Ensuring coherence of communications about TB and HIV  
•  Ensuring the involvement of civil society, nongovernmental and community 
organisations, and individuals.  
Evidence from operational research and descriptive studies has shown that effective 
coordinating bodies that operate at all levels and which include the participation of all 
stakeholders from both HIV and TB control programmes, civil society organisations, 
patients and communities are feasible and ensure broad commitment and ownership 
(WHO, 2004e; Okot-Chono, Mugisha, Adatu, Madraa, Dlodlo & Fujiwara, 2009). 
 
2.7.1.2 Conduct surveillance of HIV prevalence among TB patients 
 
Surveillance is a “system for collecting information needed for advocating, designing, 
planning, and evaluating public health action” (Reider & Dehne, eds., 1999:8). The 
overall objective of any communicable disease surveillance system is to collect, analyse 
and disseminate accurate epidemiological data (Caribbean Epidemiology Centre, pan-
American health organization [PAHO] & WHO, 2002:7). Surveillance should contribute 
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to a better understanding of the magnitude of the problem and provide reliable, timely, 
and cost effective information for action. 
The intention of surveillance is to better understand the magnitude of the  diseases’ 
effects and to evaluate the efficacy of any plans of action. Due to the strong relationship 
between TB and HIV, co-monitoring is necessity for future efficacious intervention. In 
addition, beyond their intrinsic linkage, in many countries the spread of HIV among the 
general population can be sensitively indicated by HIV prevalence in TB patients (WHO, 
2004f). 
As the HIV and TB epidemics have progressed, surveillance has become widely 
recognised as an activity critical to understanding the trends of the epidemics and 
enabling sound strategies to be developed for responding to them (WHO & UNAIDS, 
2001:1). Surveillance of HIV among TB patients is increasingly seen as important, as 
the HIV epidemic has continued to fuel the TB problem and as new solutions have 
emerged to tackle this developing situation (WHO, 2004c). 
Surveillance systems for measuring HIV prevalence among TB patients have a variety 
of specific objectives, which are likely to vary between countries according to the 
different needs and demands existing in the countries (WHO, 2004c). A major challenge 
to any HIV surveillance system is the ethical issues related to HIV testing, which have 
been widely debated in the published literatures and are complex. The main ethical 
problem with regard to surveillance of HIV among TB patients concerns the use of 
unlinked anonymous or ‘blinded’ methods, especially in the context of increased access 
to ART. Unlinked anonymous testing refers to the taking of blood or other specimens for 
other purposes, stripping the left-over part of the specimen and testing it for HIV 
infection without the consent of the individual concerned (WHO & UNAIDS, 2000:10). 
However, surveillance has not been valued enough by health policy makers, so the 
financing and infrastructure necessary to gather and process the data are not available; 
for example, lack of properly trained epidemiology staff. Without appropriate training 
and consistent performance feedback, there is little quality control of the work. 
Specifically, in dealing with these two epidemics, there is a problem linking TB 
information with that of HIV, since much intervention work is carried out by mutually 
exclusive groups (WHO, 2004f). There is often a general lack of understanding among 
senior health policymakers of the importance of surveillance as a planning and 
evaluation tool, which results in low priority for surveillance activities and insufficient 
36 
investment in the infrastructure necessary for an effective surveillance system (Reider & 
Dehne, 1999:22). 
A problem with many of the current HIV surveillance systems among TB patients is that 
they reflect more the access of patients to healthcare services than the true occurrence 
of HIV within the overall TB population. The bias introduced through differential access 
and through patients’ reluctance to be tested for HIV may be a particular problem for 
surveillance systems that rely on data from HIV routinely testing services. Problems 
also often exist around collecting data from the private sector, which is often omitted 
from surveillance systems, leading to under-representation of all those who use these 
services (Sharman, 2000 cited in WHO, 2004g:6). 
There are three main surveillance methods for measuring the prevalence of HIV 
infection among TB patients, presented as follows. 
 
 
2.7.1.2.1 Periodic (special) surveys 
 
Periodic (special) sero-prevalence surveys have been the main surveillance method for 
measuring HIV prevalence among TB patients for many countries around the world 
(Range, Ipuge, Obrien, Egwaga, Mfinanga, Chonde, Mukadi & Borgdorff, 2001, as cited 
in WHO, 2004g; Colvin & Karim, 1998; Van Gorkon & Kibuga, 1999, as cited in WHO, 
2004g). Well-conducted, cross-sectional sero-prevalence surveys can provide TB 
programmes with sufficiently precise point estimates of HIV prevalence among TB 
patients (Nieto & Szklo, 1999; Jekel, Katz & Elmore, 2001, as cited in WHO, 2004g).  
In settings where the prevalence was previously unknown they are useful as part of the 
initial assessment of the situation. These surveys are also useful in resource-poor 
countries with underdeveloped surveillance systems, where HIV prevalence in the 
general population may be high but the institution of more systematic methods of 
surveillance is not possible. Periodic (special) surveys can also be used to corroborate 
other surveillance methods (WHO, 2004c). 
 
2.7.1.2.2 Sentinel surveillance 
 
For surveillance of HIV among TB patients, some countries use the sentinel surveillance 
methods outlined in the WHO guidelines (Slutkin, Chin, Tarantola, Tarantola & Mann, 
1988, as cited in WHO, 2004g). However, very few reports of the results from these 
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methods have appeared in the literature (Jekel, Katz & Elmore, 2001). The sentinel 
surveillance system was developed specifically to collect information on HIV 
prevalence, based on the measurement of HIV infection in pregnant women and other 
groups from whom blood is usually drawn for purposes other than HIV testing 
(UNAIDS/WHO, 2003:7; Sharman, 2000, cited in WHO 2004g). The WHO guideline 
describes sentinel surveillance as the system by which “specific sites and population 
groups are selected; a predetermined number of persons are routinely tested, and 
testing is performed in a regular and consistent way” (UNAIDS & WHO, 2003:47; Nieto 
and Szklo, 1999, as cited in WHO, 2004g). 
 
2.7.1.2.3 Data from routine patient care 
 
In some countries, particularly those where HIV prevalence in the general population is 
high, HIV testing of TB patients for diagnostic purposes is becoming more routine. As 
treatment and care options for HIV infection increase, diagnostic testing of TB patients 
for HIV in an “opt-out” fashion (i.e., routinely testing unless they decline to be tested) will 
be carried out increasingly in such settings (WHO, 2004c). 
The surveillance method chosen will depend on the underlying HIV epidemic state1, the 
overall TB situation, and the availability of resources and experience. Incorporating HIV 
testing with TB prevalence surveys and anti-TB drug resistance surveillance offers an 
opportunity to expand HIV testing and improve knowledge among national TB control 
programmes on the relationship between HIV and drug-resistant TB at the population 
level (WHO, 2009c, 2010g). It also provides critically important individual benefits to 
people living with HIV, including better access to testing, early case detection, and rapid 
initiation of treatment. With the increasing availability of HIV treatment, unlinked 
anonymous testing for HIV is not recommended because results cannot be traced back 
to individuals who need HIV care and treatment (WHO, 2010g). 
All countries with a generalised HIV epidemic state should aim to ensure that HIV 
testing is actively promoted and offered to all TB patients. The data available from these 
initiatives can form the basis of a reliable surveillance system that achieves high 
coverage (>80%) of testing among TB patients (WHO, 2004c). 
 
                                               
1 Generalized epidemic state: HIV prevalence is consistently >1% in pregnant women; concentrated epidemic state: 
HIV prevalence is consistently >5% in at least one defined subpopulation and is <1% in pregnant women in urban 
areas; Low-level epidemic state: HIV prevalence has not consistently exceeded 5% in any defined subpopulation. 
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2.7.1.3 Carry out joint TB/HIV planning 
 
Medium and long-term joint strategic planning to successfully and systematically scale 
up collaborative TB/HIV activities nationwide and deliver integrated TB and HIV 
services, preferably at the same time and location with due consideration to prevention 
of TB transmission should be developed. HIV- and TB-control programmes should 
either devise a joint TB/HIV plan, or introduce TB/HIV components in their national 
plans for prevention, diagnosis, treatment, and care (WHO, 2012a). 
Main areas to be covered during the joint planning include quality assured health 
services; a well-performing health workforce; well-functioning information systems; 
equitable access to essential medicinal products, vaccines and technologies; good 
health financing; and leadership and governance (Lugada, Levin, Abang, Mermin, 
Mugalanzi, Namara, Gupta, Grosskurth, Jaffar, Coutinho & Bunnell, 2010:245). 
The following elements should be outlined during the joint TB/HIV care planning. 
 
2.7.1.3.1 Joint strategic plan 
 
Crucial elements for joint planning include the activities detailed in sections 2.7.1 to 
2.7.3 of this document, as well as resource mobilisation, capacity-building and training, 
TB/HIV communication (advocacy, programme communication, and social mobilisation), 
enhanced community involvement, and operational research (WHO, 2004d). 
 
2.7.1.3.2 Funding 
 
TB and HIV programmes have recently begun to provide coordinated TB-HIV services, 
so evidence for their cost effectiveness is limited; however, collaborative TB/HIV 
activities, which build on well-resourced tuberculosis and HIV strategies, may not 
require much additional financial input. Pilot projects in Malawi, South Africa and 
Zambia, for example, have shown that screening HIV patients for TB can be done for 
little added time and cost, resulting in increased TB case funding (WHO, 2004f). If either 
or both programmes are under-resourced in funds or human capacity, additional 
resources should first be mobilised to strengthen each programme. Joint proposals to 
solicit resources for implementing collaborative TB/HIV activities should be prepared, 
within the framework of the joint coordinating body, building on the comparative 
strengths of both programmes and the specific needs of the country (WHO, 2004d). 
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2.7.1.3.3 Training and capacity building 
 
Joint capacity building for collaborative activities should include training of TB, HIV and 
primary healthcare workers in TB/HIV issues. Ensuring continued competency-based 
education of health-care workers through clinical mentoring, regular supportive 
supervision, and the availability of standard operating procedures and job aids, 
reference materials and up-to-date national guidelines is important. Capacity should 
also be enhanced in the healthcare system, for example in the laboratory, supply 
management, health information, referral and integrated service delivery systems, to 
enable them to cope better with the increasing demands of collaborative TB/HIV 
activities (WHO, 2005c). 
 
2.7.1.3.4 TB/HIV communication, advocacy and social mobilisation 
 
According to WHO Policy on Collaborative TB/HIV activities (WHO, 2012a), advocacy 
targeted at influencing policy, programme implementation, and resource and community 
mobilisation is important to accelerate the implementation of collaborative TB/HIV 
activities at all levels. Two-way communication between the programmes and the 
general public and with affected populations can inform and create awareness about 
both diseases and is crucial for ensuring that patients actively seek out and demand 
services. Effective communication measures focused on communities rather than 
individuals that combine a series of elements from the use of data, science, research, 
policy and advocacy can inform the public, shape perceptions and attitudes, mitigate 
stigma, enhance the protection of human rights, create demand for services, form 
stronger links with health services and systems, improve provider client relationships, 
and monitor and evaluate TB/HIV activities. Joint TB/HIV communication strategies 
should ensure the mainstreaming of HIV components in TB communication and of TB 
components in HIV communication. 
 
2.7.1.3.5 Involving nongovernmental and other civil society organisations and 
communities 
 
Expanding collaborative TB/HIV activities beyond the health sector through meaningful 
involvement with communities, nongovernmental and civil society organisations, and 
individuals in the planning, implementation and monitoring of TB/HIV activities at all 
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levels is crucially important. People at risk of or affected by TB and HIV as well as 
community-based organisations working on advocacy, treatment literacy and 
community mobilisation are key actors in generating the required demand for integrated 
services at all levels of care. Their recognition and support, including financial, is 
therefore critical. Advocacy targeted at influencing policy and sustaining political 
commitment, programme implementation and resource mobilisation is very important to 
accelerate the implementation of collaborative TB/HIV activities (WHO, 2012a). 
Services for TB prevention, diagnosis, treatment, and care can be integrated with those 
for HIV, and vice versa, through community-based organisations such as community-
based TB care or HIV home-based care. Trained home-based care and community 
healthcare workers as well as NGOs have been successful in providing TB and HIV 
services in various countries (Corbett, Bandason, Duong, Dauya, Makamure, 
Churchyard, Williams, Munyati, Butterworth, Mason, Mungofa & Hayes, 2010:1244; 
Datiko & Lindtjorn, 2009:e5443; Lugada and et al., 2010:245; Miti, Mfungwe, Reijer & 
Maher, 2003:92; Wandwalo, Kapalata, Tarimo, Corrigan & Morkve, 2004:109). 
Community-based TB (Okello, Floyd, Adatu, Odeke & Gargioni, 2003:72; Sinanovic, 
Floyd, Dudley, Azevedo, Grant & Maher, 2003:56) and HIV care services (Creese, 
Floyd, Alban & Guinness, 2002:1635) are cost-effective. While implementing 
collaborative TB/HIV activities it is imperative that civil society organisations, including 
nongovernmental and community-based organisations advocate, promote and follow 
national TB and HIV guidelines, including monitoring and evaluation of TB/HIV activities 
using nationally recommended indicators. 
 
2.7.1.3.6 Engaging the private-for-profit sector 
 
The engagement of the private-for-profit sector in implementing collaborative TB/HIV 
activities requires coordination and collaboration among HIV programmes and TB-
control programmes as well as private service providers and their professional 
associations. This collaboration can be either at national, state, regional, provincial or 
district level, depending on the local context. Private-for-profit sector representation 
should be included in TB/HIV coordinating bodies at all levels and should be 
encouraged to initiate and implement collaborative activities in accordance with national 
norms and guidelines (Sinanovic et al., 2003:56). 
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2.7.1.3.7 Addressing the needs of key populations: women, children and people who 
use drugs 
 
Active TB has been diagnosed at rates up to 10 times higher in pregnant women living 
with HIV than those not (Kali, Gray, Violari, Chaisson, McIntyre & Martinson, 2006:379). 
Maternal TB is associated with a 2.5-fold increased risk of vertical transmission of HIV 
infection to the unborn child (Gupta, Bhosale, Kinikar, Gupte, Bharadwaj, Kagal, Joshi, 
Khandekar, Karmarkar, Kulkarni, Sastry, Mave, Suryavanshi, Thakar, Kulkarni, Tripathy, 
Sambarey, Patil, Paranjape, Bollinger, Jamkar and Six Week Extended-Dose 
Nevirapine (SWEN) India Study Team, 2011:358). Similarly, HIV infection is a risk factor 
for active TB disease in infants or children. More severe forms of TB disease and higher 
mortality rates are reported in children living with HIV (Swaminathan & Rekha, 
2010:184). 
Bacille Calmette–Guérin (BCG) is a live vaccine and should not be given to infants or 
children with known HIV infection (Royal College of Physicians of Ireland, 2008). 
However, HIV infection cannot reliably be determined at birth, and the majority of infants 
born to HIV-infected mothers will be HIV-uninfected. BCG should therefore be 
administered to infants born to HIV-infected mothers in HIV-prevalent settings unless 
the infant is confirmed as HIV-infected. National HIV programmes and TB-control 
programmes should ensure that TB prevention, screening, diagnosis and treatment as 
well as HIV prevention, diagnosis, treatment and care services are integrated with those 
for maternal and child health (International Union Against Tuberculosis and Lung 
Disease [IUATLD], 2010) and prevention of HIV vertical transmission. 
 
2.7.1.3.8 Operational research to scale up collaborative TB/HIV activities 
 
Cultural and system-wide differences between HIV and TB care providers and 
operational difficulties for providing effective and appropriate interventions have 
contributed to a lack of progress in expanding collaborative TB/HIV activities. 
Operational research is needed to define how best to provide high-quality integrated TB 
and HIV interventions at facility and community levels in order to inform global and 
national policy and strategy development (Sculier, Getahun & Lienhardt, 2011:S5). 
Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings, 
including for operational research, have been identified and need to be urgently 
answered (WHO, 2011c). 
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2.7.1.4 Conduct monitoring and evaluation 
 
The extent of the joint TB/HIV epidemics and their impact requires effective, coordinated 
and well-managed interventions. Collaborative TB/HIV activities are a new and 
developing area and must be shown to be effective to justify their becoming an integral 
part of national and international responses to the joint TB/HIV epidemics (WHO, 
2004b).  
Monitoring and Evaluation provides the means to assess quality, effectiveness, 
coverage, and delivery of services and will promote a learning culture within 
programmes to ensure continual health improvement. The urgent need for action 
against TB/HIV means that results must be obtained quickly so that effective 
interventions can be scaled up and ineffective interventions withdrawn or adapted 
(WHO, 2004b). 
The following figure demonstrates the specific implementation phases of monitoring and 
evaluation of collaborative TB/HIV care services (described in Chapter 1 under 
Conceptual framework, section 1.6.2). 
 
Figure 2.1: Monitoring and Evaluation Framework (Adapted from WHO, 2004b) 
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2.7.2 Activities to decrease the burden of TB among HIV patients 
 
According to the global fund to fight AIDS, TB and malaria information note, the 
interaction of TB with HIV presents additional challenges to TB control. It is crucial to 
improve and strengthen TB/HIV collaborative activities to reduce the burden of TB in 
PLHIV and reduce the burden of HIV among TB patients (GFATM, 2011). 
HIV has a specific impact on the dynamics of the tuberculosis epidemic, therefore 
controlling TB in high HIV prevalence populations requires measures not only to 
achieve high rates of detection and successful treatment of cases which are handled 
more effectively, but also additional measures (De Cock & Chaisson, 1999:457) beyond 
case finding and treatment. A global report for 2006 revealed that only 0.96% of PLHIV 
had been screened for TB (intensified TB case finding), 12% diagnosed with TB, and 
the coverage for IPT provision among PLHIV was only 0.08% (Mario, 2008). 
The individual-centred, rights-based paradigm of the South African National AIDS Policy 
remains dissonant with the compelling public-health approach of TB control. The 
existence of independent and disconnected TB and HIV services results in a wastage of 
scarce health resources, an increased burden on patients' time and finances, and 
ignores evidence of patients' preference for an integrated service (Rubeshan, Nesri & 
Ellen, 2009:243). 
The following description of interventions considers their efficacy and effectiveness. 
 
2.7.2.1 Establish intensified TB case finding 
 
Community-based studies have reported high rates of undiagnosed TB both among 
people living with HIV and HIV-negative individuals (Ayles, Schaap, Nota, Sismanidis, 
Tembwe, De Haas, Muyoyeta, Beyers and Peter Godfrey-Faussett for the ZAMSTAR 
Study Team, 2009:e5602; Wood, Middelkoop, Myer, Grant, Whitelaw, Lawn, Kaplan, 
Huebner, McIntyre & Bekker, 2007:87). Early identification of signs and symptoms of TB 
followed by diagnosis and prompt initiation of treatment in PLHIV, their household 
contacts, groups at high risk for HIV and people living in congregate settings (e.g., 
prisons, workers’ hostels, police and military barracks) increases the chances of 
survival, improves quality of life and reduces transmission of TB in the clinic and the 
community. Prompt diagnosis and treatment of TB among HIV-negative people is also 
crucial to reducing TB transmission to PLHIV (WHO, 2012a). 
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All people living with HIV should be regularly screened for TB using a clinical symptom-
based algorithm consisting of current cough, fever, weight loss or night sweats at the 
time of initial presentation for HIV care and at every visit to a health facility or contact 
with a healthcare worker thereafter (WHO 2010b; Haileyesus, Wanitchaya, Charles, 
Elizabeth, Helen, Kevin, Alison, Gavin, Michael, Sarita, Stephen, Robin, Gary, Reuben, 
Anand & Jay, 2011).  
Adults and adolescents living with HIV who report any one of the symptoms of current 
cough, fever, weight loss or night sweats may have active TB and should be evaluated 
for TB and other diseases. Screening for TB is important regardless of whether they 
have received or are receiving IPT or ART. Similarly, children living with HIV who have 
any one of the symptoms (poor weight gain, fever or current cough) or contact history 
with a TB case may have TB and should be evaluated for it and other conditions (WHO, 
2012a). 
In people with a positive screen, the diagnostic workup for TB should be carried out in 
accordance with national guidelines and principles of sound clinical practice to identify 
either active TB or an alternative diagnosis. Smear negative pulmonary and extra-
pulmonary TB is common among people living with HIV and associated with poor 
treatment outcomes and excessive early mortality. If smear negative pulmonary TB or 
extra-pulmonary TB is suspected, diagnostic processes should be expedited using all 
available and appropriate investigations, including myco-bacterial culture (WHO, 
2007b).  
In high HIV prevalence settings, where WHO approved molecular tests (e.g., Xpert 
MTB/RIF) available, they should be the primary diagnostic test for TB in people living 
with HIV (WHO, 2011d). Among seriously ill patients in HIV-prevalent settings, empirical 
anti-TB treatment should be initiated in case of negative investigations and no 
improvement to parenteral antibiotics (WHO, 2007b). Patients should be referred to the 
next level of care to confirm diagnosis. If referral is  not possible, anti-TB treatment 
should be completed. 
New TB patients living with HIV should receive a TB regimen containing six months of 
rifampicin (two months of isoniazid, rifampicin, pyrazinamide and ethambutol followed 
by four months of rifampicin and isoniazid, 2HRZE/4RH) on a daily schedule (WHO 
2009f), and should be started on ART regardless of CD4 count as soon as possible 
within the first eight weeks of anti-TB treatment (WHO, 2010c). 
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Tuberculosis control programmes need to support general health service providers in 
ensuring proper case management conditions for patients to complete a course of 
effective anti-TB treatment and avoid the risk of drug resistance (WHO, 2005c). The 
WHO recommends directly observed therapy as one of a range of measures aimed at 
promoting treatment adherence and completion; in addition, only rifampicin-containing 
regimens (NHS, 2011) are recommended for HIV-TB co-infected persons.  
According to the progress report of Federal Democratic Republic of Ethiopia towards 
implementation of the UN Declaration of Commitment on HIV (FDRE 2010:53), a total of 
24,112 HIV-positive people were screened for TB at HIV counselling and testing (HCT) 
centres, chronic HIV and ART clinics, of whom 4,154 (17.2%) were found to have active 
TB and 2,403 (10%) latent TB, and so put on IPT. The proportion of HIV-positive 
patients who were screened for TB increased from 25% in 2007 to 55% in 2009. 
 
2.7.2.2 Introduce Isoniazid preventive therapy 
 
According to the recent report by WHO, Isoniazid is given to individuals with latent 
infection with Mycobacterium tuberculosis in order to prevent progression to active 
disease. Exclusion of active TB is critically important before IPT is started. The absence 
of all of current cough, night sweats, fever, or weight loss can identify a subset of 
adolescents and adults living with HIV who have a very low probability of having TB 
disease that can reliably be initiated on IPT. This screening rule has a negative 
predictive value of 97.7% (95% CI [confidence interval] 97.4–98.0) at 5% TB prevalence 
among people living with HIV. In children, the absence of poor weight gain, fever, and 
current cough can identify children who are unlikely to have TB. Isoniazid is given daily 
as self-administered therapy for at least six months as part of a comprehensive package 
of HIV care for all eligible people living with HIV irrespective of degree of immune-
suppression, ART use, previous TB treatment, and pregnancy. Information about IPT 
should be made available to all people living with HIV. Providing IPT as a core 
component of HIV preventive care should be the responsibility of national HIV 
programmes and HIV service providers (WHO, 2012a). 
Evidence has shown that IPT is as efficacious as, but safer than Rifampicin and 
Pyrazinamide containing regimens used for prevention of latent TB infection (Akolo, 
Adetifa, Shepperd & Volmink, 2010:CD000171). IPT was also found to be effective in 
reducing the incidence of TB and death from TB in HIV-infected patients with a positive 
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tuberculin skin test (TST) (Charalambous, Grant, Innes, Hoffmann, Dowdeswell, 
Pienaar, Fielding & Churchyard, 2010:s13; Durovni, Saraceni, Pacheco, Cavalcante, 
Cohn, King, Moulton, Chaisson, Golub & THRio study group 2011). Evidence from 
Botswana and South Africa suggests an increased benefit with 36 months or longer 
duration of IPT, particularly in people who are TST-positive in settings with higher TB 
prevalence and transmission (Neil, Grace, Lawrence, Reginah, Harry, Malathi, James, 
Glenda & Richard, 2011:11; Samandari, Agizew, Nyirenda, Tedla, Sibanda, Shang, 
Mosimaneotsile, Motsamai, Bozeman, Davis, Talbot, Moeti, Moffat, Kilmarx, Castro & 
Wells, 2011:1588). However, operational challenges for TST represent significant 
impediments to accessing IPT in resource-limited settings, and TST should therefore 
not be a requirement for initiating IPT among people living with HIV. 
ART is a powerful strategy to reduce TB incidence among people living with HIV across 
a broad range of CD4 cell counts. ART reduces the individual risk of TB by 54% to 92% 
(Lawn, Kranzer & Wood, 2009:685) and the population-based risk by 27% to 80% 
(Middelkoop, Bekker, Myer, Johnson, Kloos, Morrow & Wood, 2011:263; Miranda, 
Morgan, Jamal, Laserson, Barreira, Silva, Santos, Wells, Paine & Garrett, 2007:e826) 
among people living with HIV. Studies conducted in Brazil and South Africa showed up 
to 90% reduction in TB risk among HIV-infected patients with a positive TST who 
received both ART and IPT (Golub, Saraceni, Cavalcante, Pacheco, Moulton, King, 
Efron, Moore, Chaisson & Durovni, 2007:1441; 2009:631). ART also reduces TB 
recurrence rates by 50% (Golub, Astemborski, Ahmed, Cronin, Mehta, Kirk, Vlahov and 
Chaisson, 2008:532). Modelling exercises from nine sub-Saharan African countries 
indicated that the most profound reduction in incidence of HIV-related TB is seen when 
ART is initiated as soon as people test HIV-positive (Williams, Granich, De Cock, 
Glaziou, Sharma & Dye, 2010:19485). 
The WHO recommends that all adolescents and adults, including pregnant women with 
HIV infection, and CD4 counts ≤350 cells/mm3 should be started on ART regardless of 
symptoms (WHO, 2006c). According to the recent WHO TB/HIV policy, a systematic 
review including data from randomly controlled trials and large multicentre cohorts was 
conducted and analysed using the GRADE system to explore the role of earlier initiation 
of ART (at CD4 counts >350 cells/mm3) for preventing TB in PLHIV. The policy showed 
that the risk of TB is reduced by half among people living with HIV when ART is initiated 
at CD4 counts >350 cells/mm3. 
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Base on earlier research, IPT for TB can safely be given to people living with HIV 
without TB disease, reducing the risk of developing TB by 33-67% for up to 48 months. 
It is currently recommended for all people living with HIV in areas with a prevalence of 
latent TB infection >30%, and for all people living with HIV with documented latent TB 
infection or exposure to an infectious TB case, regardless of where they live. More 
recently, evidence has shown that the combined use of IPT and ART among PLHIV 
significantly reduces the incidence of TB; and the use of IPT in patients who have 
successfully completed a course of TB therapy has been shown marked reduction in the 
risk of subsequent TB cases (WHO, 2008a). 
A follow-up study in Tanzania for 565 tuberculin skin test (TST) positive cohorts of 
PLHIV for completion of IPT revealed that 493 (87.3%) completed treatment and 72 
(12.7%) did not. Non-completion was physician-initiated in 24 (33.3%, due to active TB 
or side effects), patient initiated in 42 (58.3%, due to self-cessation or loss to follow-up) 
and due to death in 6 (8.3%, unrelated to IPT). HIV-infected subjects provided with 
counselling, monthly follow-up and travel re-imbursement have high rates of IPT 
completion with minimal side effects (Munseri, Talbot, Mtei & Fordham, 2008:1037). 
A cross-sectional facility based study on provision and awareness of IPT among PLHIV 
in Addis Ababa in 2008 revealed that, only 32.0% of apparently TB free PLHIV had 
received IPT (Wesen & Getnet, 2012:2). 
 
2.7.2.3 Ensure control of TB infection 
  
People living with HIV in congregate settings, such as prisons and centres for refugees 
or internally displaced persons, and people who use drugs have a higher risk of and 
incidence of TB and HIV infection (Getahun, Gunneberg, Granich & Nunn, 2010:201). 
TB Infection Control (IC) measures are essential to prevent the spread of M. 
tuberculosis to vulnerable patients, healthcare workers, the community, and those living 
in congregate settings. Fundamentally, TB infection control is about safety, and people 
receiving or offering HIV care should not have to worry about being exposed to or 
infected with M. tuberculosis in the process. In light of the crisis of drug-resistant TB in 
countries with a high burden of HIV, establishing facilities that are safe from TB has 
become an emergency for health services, prisons and other congregate settings in 
general, but especially for HIV programmes (WHO, 2008a). 
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At one time there were over two million people incarcerated in the USA who were 
disproportionately poor and from African American communities, with rates of HIV in 
prisons five times higher than in the general population. The correctional setting 
provides an excellent opportunity to screen for and treat TB and to develop effective 
prevention programmes (Timothy, Nickolas, Lynn, Curt, Landon, Josiah & Charles 
2009:73). 
Low-cost infection control interventions include triaging patients, scheduling new and 
follow-up patients separately; providing well-ventilated and sheltered waiting rooms; and 
encouraging use of personal respirators by patients and staff. A more patient-centred 
approach to TB care may improve recruitment of the active participation of TB patients 
in positive prevention efforts, including maximising personal infection control, limiting 
exposure of social contacts to TB during the intensive phase of treatment, advocating 
Isoniazid prophylaxis within the home, and patient-centred education efforts to reduce 
overall transmission (Rubeshan et al., 2009:243). 
 
2.7.3 Activities to decrease the burden of HIV in TB patients 
 
Since HIV fuels the TB epidemic, interventions to decrease HIV transmission should 
contribute to decreasing the TB burden. Increased condom use, treatment of STIs, 
reduction in the number of sexual partners, safe injection behaviour, and drugs to 
prevent mother-to-child transmission have all been shown to be effective in preventing 
HIV infection in pilot projects, controlled trials, or national programmes in less 
developed countries (Merson, Dayton & O’Reilly, 2000:68).  
The impact of HIV co-infection on TB case fatality is evident in surveillance data. As the 
rate of co-infection rises so does the reported death rate among sputum smear-positive 
patients (Cambodian Ministry of Health, 2006).  
In the following sections, specific activities to decrease the burden of HIV among TB are 
discussed. 
 
2.7.3.1 Provide HIV testing and counselling for TB patients 
 
The vast majority of people living with HIV do not know their HIV status and seek 
healthcare from general service providers. HIV testing and counselling for people with 
diagnosed or presumptive TB offers an entry point for a continuum of prevention, care, 
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support, and treatment for HIV and for TB (WHO, 2012a). Evidence from observational 
studies shows that testing patients with presumptive and diagnosed TB and their 
contacts for HIV yields a high number of new diagnoses of HIV infection, as prevalence 
of HIV is higher than among the general adult poipulation. The yield of HIV-positive 
testing in TB patients varies significantly from 6.3% to 77% (WHO, 2012a).  
Studies in SSA have shown that HIV testing of presumptive TB cases who turn out not 
to have active TB disease also yields high HIV-positive results (Odhiambo, Kizito, 
Njoroge, Wambua, Nganga, Mburu, Mansoer, Marum, Phillips, Chakaya & De Cock, 
2008:63; Srikantiah, Lin, Walusimbi, Okwera, Luzze, Whalen, Boom, Havlir & 
Charlebois, 2007:168). One study in Thailand showed 74% acceptance rate of HIV 
testing among contacts of TB patients and a higher (13.8%) HIV prevalence rate among 
contacts of HIV-positive TB cases than with contacts of HIV negative TB cases (2.5%) 
(Suggaravetsiri, Yanai, Chongsuvivatwong, Naimpasan & Akarasewi, 2003:424). 
Voluntary HIV testing and counselling for sexual or needle-sharing partners, with shared 
disclosure and mutual support, may also improve the uptake of and adherence to ART, 
benefiting both the index individual and their partners regardless of HIV status (WHO, 
2012b). 
Despite the low quality of evidence, the current TB/HIV Policy recommends routine HIV 
testing and counselling to all patients with presumptive and diagnosed TB as benefits of 
testing accrue to the patient, partner, family, and community at large. The testing should 
be readily available and voluntary, with informed consent and confidentiality protected. 
Moreover, TB patients with a new potential HIV exposure or who are at higher risk of 
HIV exposure and with an HIV-negative test result should be re-tested four weeks after 
the time of initial testing (WHO, 2010d). Age-appropriate algorithms should be in place 
for undertaking HIV testing in young children, and HIV testing should be family- and 
child-focused (WHO & UNICEF, 2010h). All people diagnosed with HIV infection should 
be offered HIV prevention, diagnosis, treatment, and care services, including ART. 
These services should be offered by TB control programmes or through effective 
referral to HIV services. 
A baseline evaluation of access to and acceptance of HIV counselling and testing 
among TB patients in Rwanda indicated a nationwide increase from 46% in 2004 to 
81% by the third quarter of 2006. In that quarter, 49% of HIV-infected TB patients had 
initiated Cotrimoxazole preventive therapy and 34% were receiving antiretroviral 
treatment (Michel, Greet, Gaspard, Jules, Simon, Aliou, Alyssa, Jessica, Ruben & 
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Wafaa, 2007:383). In a similar baseline assessment of TB/HIV collaborative activities in 
the Democratic republic of Congo (DRC), 53% out of 92 surveyed clinics offered 
counselling and testing to TB patients; 22 (42%) routinely offered HCT to all patients, 
while others used selective criteria. While most offered onsite counselling (92%) and 
testing (77%), not all 53 clinics had an HCW trained in counselling, and only 31 had 
access to a counselling room (Amanda et al., 2008:137). 
Voluntary counselling and testing for HIV is recommended for persons treated for TB, 
but in some countries there are barriers to implementing routine HIV testing for all TB 
patients. For example, a qualitative study in Indonesia showed very poor knowledge of 
patients and providers regarding HIV. The main barriers perceived by patients were 
burden for accessing VCT and fear of knowing the test results. Stigma caused concern 
among providers but did not play a great role in patients' attitudes towards VCT. The 
main barriers perceived by providers were communication, patients feeling offended, 
stigmatisation and additional burden (Yodi, Riris, Pierre, Marleen & Patrick, 2008:385). 
An epidemiological synthesis in Ethiopia showed that the percentage of TB patients who 
received HIV counselling and testing had increased from 10% to more than 80% in most 
health facilities (EHAPCO/World Bank, 2008:43).  
A study in Southern Ethiopia to assess acceptability of HIV testing among TB patients 
revealed overall acceptability rate of 35%, with the prevalence of HIV among the study 
TB patients at 20.6% (Degu, Aschalew & Bernt, 2007:4). In a recent report in Ethiopia, 
the introduction of provider-initiated counselling and testing in most public health 
facilities among TB patients had increased from 16% in 2007 to 38% in 2009. A total of 
56,040 TB patients were tested for HIV, of whom 11,118 (20%) were found to be HIV-
positive. The co-infection of TB patients had declined from 31% in 2007 (FDRE-MOH 
2010:53) to 20% in 2009. 
 
2.7.3.2 Introduce HIV prevention methods for TB patients 
  
The Stop TB Partnership and WHO’s (2006:126) Global Plan to Stop TB 2006-2015 
acknowledges that as the HIV pandemic continues to spread, “the TB community must 
advocate for all efforts to mitigate the impact of HIV and to promote HIV preventions 
and treatment as a vital component of the TB control strategy.” Prevention of HIV 
includes interventions to (a) prevent sexual transmission, such as male and female 
condoms, male circumcision, HIV testing and counselling, including couples’ counselling 
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and testing, and early ART in line with WHO guidelines; (b) prevent transmission 
through sharing contaminated injecting equipment among injecting drug users; 
combined with (c) behavioural and brief interventions to prevent hazardous alcohol use 
and use of other psycho-stimulants (WHO, 2010f). 
HIV prevention services also include prevention of vertical transmission of HIV, which 
comprises two key approaches (WHO, 2010l). HIV-infected women, including during 
pregnancy, with CD4 counts ≤350 cells/mm3 irrespective of WHO clinical staging or in 
clinical stage 3 or 4 irrespective of the CD4 cell-count, should start lifelong ART for their 
own health, which is also safe and effective in reducing vertical transmission. For HIV-
infected pregnant women who do not need ART for their own health, prophylaxis with 
triple ARV medicines or with zidovudine plus lamivudine to prevent HIV transmission is 
needed and should be continued until one week after all infant exposure to breast milk 
has ended (WHO, 2010l).  
In sub-Saharan African countries with very high HIV prevalence and low male 
circumcision rates, medical male circumcision in HIV-negative men is also 
recommended, combined with HIV testing and counselling and promotion of consistent 
condom use (WHO, 2010f). In healthcare settings, transmission of HIV can be 
prevented through primary prevention measures such as standard precautions, injection 
safety, blood safety, and safe waste disposal, as well as secondary prevention 
measures such as occupational post-exposure prophylaxis (WHO, 2012a). 
Review of the evidence has shown that HIV prevention methods such as voluntary 
counselling and testing, prevention of vertical transmission of HIV and condom 
distribution are cost-effective (Creese et al., 2002:1635; Daniel, Rob, Chika, Jeremy & 
Joshua, 2005:1431). The provision of HIV preventive interventions by TB-control 
programmes or effective referral of patients to HIV programmes has been successfully 
implemented in many countries (Gasana, Vandebriel, Kabanda, Tsiouris, Justman, 
Sahabo, Kamugundu & El-Sadr, 2008:39; Shetty, Granich, Patil, Sawant, Sahu, Wares, 
Chauhan & Joshi, 2008:26). Improved treatment of sexually transmitted infections has 
been shown to reduce HIV incidence in an environment characterised by an emerging 
HIV epidemic (Sangani, Rutherford & Wilkinson, 2004:CD001220). 
Random trials in areas of high HIV prevalence have shown that male circumcision 
reduces the risk of heterosexually acquired HIV in men up to 60% (Newell & 
Barnighausen, 2007:617). Systematic reviews have shown that behavioural 
interventions targeting HIV-positive individuals in resource-limited settings are effective, 
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especially among HIV sero-discordant couples (Kennedy, Medley, Sweat & O'Reilly, 
2010:615). Meta-analysis random controlled trials and community-based studies 
support the use of ART for HIV prevention in HIV sero-discordant heterosexual couples 
(Attia, Egger, Müller, Zwahlen & Low, 2009:1397; Myron, Ying, Marybeth, Theresa, 
Mina, Nagalingeswaran, James, Johnstone, Beatriz, Jose, Sheela, Sanjay, Suwat, 
Breno, Kenneth, Irving, Susan, Estelle, Lei, Joseph, Lisa, Guy, Ian, Joseph, Joel, Diane, 
Susan, Heather, Vanessa, David, Taha, Karin, David, Max & Thomas, 2011:493). 
Among people who inject drugs, comprehensive harm reduction programming, such as 
wide access to sterile injecting equipment, opioid substitution therapy, and outreach 
services to reduce the risk of HIV transmission and other negative health effects of 
injecting drug use, should be implemented (WHO, UNODC & UNAIDS, 2008). 
 
2.7.3.3 Introduce Cotrimoxazole preventive therapy 
 
Cotrimoxazole, a fixed-dose combination of sulfamethoxazole and trimethoprim, is a 
broad-spectrum antimicrobial agent that targets a range of aerobic gram-positive and 
gram-negative organisms, fungi, and protozoa. Providing Cotrimoxazole has been part 
of the standard of care for preventing Pneumocystis jiroveci pneumonia (PCP) (formerly 
Pneumocystis carinii pneumonia) and toxoplasmosis since the early 1990s. Data on the 
effectiveness of Cotrimoxazole in reducing morbidity and mortality among individuals 
living with HIV in resource-limited countries comes from random clinical trials, 
observational cohort studies and programme analyses from several African countries 
(with varying levels of Cotrimoxazole resistance), India and Thailand. There is limited 
data from the Caribbean and Latin America (WHO 2006a). 
Cotrimoxazole preventive therapy is promoted by WHO and UNAIDS for the prevention 
of a range of secondary bacterial and parasitic infections in eligible adults and children 
living with HIV. TB patients living with HIV should receive CPT and it should be 
implemented as an integral component of the HIV chronic care package (WHO, 2012a). 
Evidence from different random controlled trials, including areas of high levels of 
antibiotic resistance, has shown reduced mortality, morbidity, and hospitalisation with no 
significant increase in adverse events among smear-positive TB patients with HIV 
regardless of their CD4 counts (Nunn, Mwaba, Chintu, Mwinga, Darbyshire & Zumla, 
2008:257; Wiktor, Sassan-Morokro, Grant, Abouya, Karon, Maurice, Djomand, Ackah, 
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Domoua, Kadio, Yapi, Combe, Tossou, Roels, Lackritz, Coulibaly, De Cock, Coulibaly & 
Greenberg, 1999:1469). 
Other non-randomised and operational studies showed that CPT is feasible (Chimzizi, 
Harries, Manda, Khonyongwa and Salaniponi, 2004:938; Zachariah, Spielmann, Harries 
& Salaniponi, 2003:65), safe and reduces mortality rates in TB patients (Mwaungulu, 
Floyd, Crampin, Kasimba, Malema, Kanyongoloka, Harries, Glynn & Fine, 2004:354; 
Zachariah et al., 2003:65). Moreover, CPT did not select for sulfadoxine–
pyrimethamine-resistant malaria parasites among HIV-uninfected household members 
of people living with HIV receiving the medicine, but did reduce the number of malaria 
episodes among household members (Malamba, Mermin, Reingold, Lule, Downing, 
Ransom, Kigozi, Hunt, Hubbard, Rosenthal & Dorsey, 2006:375). 
Based on this evidence from various parts of the world, the WHO policy for collaborative 
TB/HIV care services recommends that routine CPT should be administered in all HIV-
infected patients with active TB disease, regardless of their CD4 cell count. Moreover, 
HIV programmes and TB-control programmes should establish a system to provide CPT 
to all eligible people living with HIV who have active TB (WHO, 2012a). 
According to the 2011 global TB report, in Ethiopia, the percentage of identified HIV-
positive TB patients started on CPT in 2010 was 69% (WHO, 2011a:62). 
 
2.7.3.4 Ensure HIV care and support 
 
According to the WHO policy on collaborative TB/HIV care (WHO, 2012a), all PLHIV 
should be provided with a comprehensive package of prevention, diagnosis, treatment, 
and care interventions (continuum of care). These comprehensive packages of care 
start before the need for ART, which include: 
• regular assessment of the clinical and immunological stages of infection  
• prevention of illness 
• care for opportunistic infections 
• preparation for adherence to ART 
• provision of safe water 
• sanitation and hygiene 
• psychosocial support 
• Prevention and management of mental health disorders, including alcohol and 
other substance use. 
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The policy also outlines the need to provide HIV prevention methods for people already 
living with HIV to prevent inadvertent HIV transmission (“positive prevention” or 
“prevention for positives”). 
A continuum of care should also be provided to people living with HIV who are receiving 
or who have completed their anti-tuberculosis treatment through integrated services or 
strengthened referral systems. Evidence has shown that linking TB and HIV prevention, 
diagnosis, treatment and care services may generate synergies, strengthen both 
programmes, and scale up the delivery of these interventions to HIV-infected TB 
patients (Helena, Catherine, Palwasha, Ade, Haileyesus & Alison, 2010). 
Particular attention should be paid to seriously ill patients (e.g., those with multidrug-
resistant and extensively drug-resistant TB). Palliative care, both chronic and terminal 
as needed, should be offered to ensure that patients and their families live out their lives 
with minimal suffering and loss of dignity, even when all available curative treatments 
have been exhausted (WHO, 2010i). 
 
2.7.3.5 Introduce antiretroviral therapy 
 
ART greatly improves the survival and the quality of life of TB patients living with HIV, 
prevents HIV transmission, and should be considered part of HIV and TB treatment and 
prevention. The availability of ART can also encourage people to be tested for HIV. HIV 
and TB control programmes should ensure that TB patients diagnosed with HIV 
infection are offered ART as early as possible. They should work together to guarantee 
ART to all TB patients living with HIV in a decentralised manner (WHO, 2012a). 
Observational studies conducted in both resource-limited and high-income settings 
have shown that ART is associated with significant reductions in mortality risk (between 
54% and 95%) (Lawn et al., 2009:685).  
Evidence from random controlled trials shows that early initiation of ART during anti-TB 
treatment is associated with reduced mortality rates, especially in patients with profound 
immune-suppression (e.g. CD4 < 50 cells cells/mm3). The CAMELIA trial conducted in 
Cambodia, which enrolled 661 HIV-infected TB patients with a median CD4 count of 25 
cells/mm3,showed that mortality was reduced by 34% when ART was initiated two 
weeks rather than eight weeks after the onset of anti-TB treatment (François-Xavier, 
Thim, Didier, Laurence, Claire, Eric, Yoann, Olivier, Sarin, Narom, Chindamony, 
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Khemarin, Chanroeurn, Bunnet, Chhun, Sath, Bertrand, Borann, Sirenda, Marcelo, 
Lawrence, Jean-François & Anne, 2011:1471).  
The STRIDE and SAPIT trials found similar results of reduced deaths and AIDS-related 
events with combined and earlier ART and anti-TB treatment, by 42% and 68% 
respectively, especially among people with a CD4 count less than 50 cells/mm3 (Havlir, 
Kendall, Ive, Kumwenda, Swindells, Qasba, Luetkemeyer, Hogg, Rooney, Wu, 
Hosseinipour, Lalloo, Veloso, Some, Kumarasamy, Padayatchi, Santos, Reid, Hakim, 
Mohapi, Mugyenyi, Sanchez, Lama, Pape, Sanchez, Asmelash, Moko, Sawe, Andersen 
& Sanne, 2011:493; Salim, Kogieleum, Anneke, Nesri, Cheryl, Andrew, Tanuja, 
Santhanalakshmi, Anushka, Niraksha, Gonasagrie, Wafaa, Gerald & Quarraisha 
2011:1492). Based on these three trials, ART should be started as a matter of 
emergency (within two weeks of the onset of anti-TB treatment) in TB patients with a 
CD4 count < 50 cells/mm3 and as early as possible in the remaining cases.  
Caution is needed in PLHIV with TB meningitis as immediate ART was significantly 
associated with more severe adverse events when compared with initiation of ART 2 
months after the start of anti-tuberculosis treatment (M. Estee, Nguyen TB, Tran, 
Nguyen TH, Nguyen HP, Pham, Nguyen TD, Nguyen, Nguyen VV, Nguyen DB, Nguyen 
AT, Phan, Doan, Do, Nguyen TC, Nguyen, Nguyen NH, Nguyen NL, Hoang, Nguyen 
HD, Tran, Nguyen TC, Cameron, Menno, Marcel & Jeremy, 2011:1374). 
Rifampicin reduces drug levels of both non-nucleoside reverse transcriptase inhibitors 
and protease inhibitors through induction of the cytochrome P450 liver enzyme system. 
A random controlled trial in Thailand comparing efavirenz and nevirapine-based ART in 
HIV-infected TB patients receiving rifampicin showed that both standard doses were 
effective in achieving viral load suppression (Manosuthi, Sungkanuparph, Tantanathip, 
Lueangniyomkul, Mankatitham, Prasithsirskul, Burapatarawong, Thongyen, 
Likanonsakul, Thawornwa, Prommool & Ruxrungtham, 2009:1752). However, reports of 
efficacy, safety, and tolerability of efavirenz and nevirapine administered with rifampicin 
varied across observational studies (Boulle, Van Cutsem, Cohen, Hilderbrand, Mathee , 
Abrahams, Goemaere, Coetzee & Maartens, 2008:530; Shipton, Wester, Stock, 
Ndwapi, Gaolathe, Thior, Avalos, Moffat, Mboya, Widenfelt, Essex, Hughes & Shapiro, 
2009:360). 
When rifampicin is given with protease inhibitors, highly variable and mainly sub-
therapeutic plasma concentrations of the protease inhibitor are observed, even in the 
presence of boosted doses of ritonavir (Nijland, L'homme, Rongen, van Uden, van 
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Crevel, Boeree, Aarnoutse, Koopmans & Burger, 2008:931). Rifabutin, listed in the 
WHO Model List of Essential Medicines, is a less potent inducer of the cytochrome 
P450 system which can be used in patients on ART regimens that include a protease 
inhibitor. 
 
2.8 HIV AMONG TB PATIENTS 
 
According to annual global TB report, in 2008 there were an estimated 9.4 million 
incident cases of TB globally, 11.1 million prevalent cases of TB, 1.3 million deaths from 
TB among HIV negative people and an additional 0.52 million TB deaths among HIV-
positive people, classified as HIV deaths in the International Statistical Classification of 
Diseases (WHO, 2009b). The number of notified cases of TB in 2008 was 5.7 million, 
equivalent to 55-67% of all incident cases, with a best estimate of 61% (WHO 2009a). 
Eastern, Southern, Western, and Middle Africa experienced an upward trend in the 
number of reported TB-HIV deaths (Olalekan et al., 2009:65). 
A study on the prevalence of HIV among TB patients in India (Neeraj, Lakbir, Ajay, 
Jotna, Fraser, Suvanand, Rahul & Puneet, 2008: e2970) revealed that HIV prevalence 
ranged widely among 15 surveyed districts, from 1% to 13.8%. Relative to smear-
positive TB, HIV infection was 1.4 times more likely among smear negative patients and 
1.3 times more likely among extra-pulmonary patients (Neeraj, Lakbir, Ajay, Jotna, 
Fraser, Suvanand, Rahul & Puneet, 2008: e2970). 
According to TB diagnosis data abstracted from clinical records of Ugandan TB 
suspects, 238 (42%) were HIV-positive among 565 consented to test. Of the HIV-
infected patients, 37% had received a non-TB diagnosis. HIV sero-prevalence was 
higher in patients with a non-TB diagnosis (49%) than those diagnosed with TB (39%) 
(Srikantiah, et al., 2007:168). 
A study in Thailand to evaluate the potential impact of the new Global Plan to Stop TB 
from 2004 to 2005 showed that 24% of TB cases were known to be HIV-positive in 2005 
alone. The proportion of TB cases with unknown HIV status decreased from 66% in 
2003 to 23% in 2005 (P< 0.01) (Jay, Daranee, Sriprapa, Amornrat, Patama, Surin, 
Somsak, Wanchai, Pricha, Somsak, Norio, Pasakorn, Charles & Jordan, 2007:586). In 
another earlier study in Thailand for the prevalence of HIV among active TB cases and 
their household contacts, 197 (39.5%) index cases were HIV-positive among 499 
pulmonary TB and higher HIV prevalence was found among contacts of HIV-positive TB 
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patients than among household contacts of HIV negative TB index cases (13.8% vs. 
2.5%). The same study revealed that spouses of HIV-positive TB cases had the highest 
HIV prevalence (48.6%). Among the household contacts who were HIV-positive, 9.5% 
had active TB (Suggaravetsiri et al., 2003:424). 
A facility-based study for the TB-HIV co-infection in Southern Ethiopia (Daniel, 
Mohammed, Luelseged, Lopisso & Bernt 2008:266) showed a higher rate of HIV 
infection among TB patients than non-TB patients. Of the 1,308 TB patients enrolled, 
18% were HIV-positive; whereas, of the 4,199 pregnant women attending ANC, only 
3.8% were HIV-positive (Daniel et al., 2008:266). 
A cross-sectional study in 2000 for determination of HIV status among smear positive 
TB patients in Addis Ababa, Ethiopia, revealed that 45.3% were HIV-positive. Among 
the HIV-positives, 61.7% were male and 38.3% female. The TB-HIV co-infection was 
highest in the age group 20-49 and the largest number of TB co-infection (75% of all 
such co-infection) was found in the 20-39 age groups (Demissie et al., 2000:277). 
 
2.9 TB AMONG HIV PATIENTS 
 
It has been well documented that TB is the most common opportunistic infection in 
PLHIV. Different documents globally as well as regionally confirmed this with firm 
grounds (GFATM 2011; WHO 2005a, 2012a). In the last two decades the number of 
new TB cases has tripled in high HIV-prevalence countries, making TB the leading 
cause of death among people living with HIV in Africa and a major cause of death 
elsewhere, accounting for almost 2 million deaths per year globally. It is also the most 
common presenting illness among people living with HIV (GFATM, 2011).  
A secondary analysis of TB-HIV prevalence survey in Harare, Zimbabwe, found one or 
more symptoms of TB in 21.2% of HIV-positive compared with 9.9% of HIV negative 
participants (P <0.001). TB was subsequently diagnosed in 48 HIV+ and 31 HIV− 
participants. In the HIV+ study participants, cough of ≥2 weeks duration, any one TB 
symptom (night sweat, fever or weight loss) and a positive sputum culture had 
sensitivities of 48%, 81% and 65% respectively (Elizabeth et al., 2010:13).  
A study to evaluate screening tests for TB, using sputum bacteriology in HIV-infected 
persons attending a VCT clinic in Addis Ababa, Ethiopia, found out that 7% were 
diagnosed with TB, of whom 16% were asymptomatic but culture-confirmed TB cases. 
Screening for cough (>2 weeks) would have detected only 38% confirmed TB cases; 
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screening for cough or fever, of any duration, have detected 75% cases, with specificity 
of 64%. Negative predictive value of screening for these two symptoms was 97% (Shah, 
Demissie, Lambert, Ahmed, Leulseged, Kebede, Melaku, Mengistu, Lemma, Wells, 
Wuhib & Nelson, 2009:537). 
Despite these figures, delay in the diagnosis of TB results in excess morbidity and 
mortality, particularly among HIV-infected individuals. For example, a cross sectional 
study conducted in Cape Town, South Africa, among patients admitted for TB suspects 
in a secondary level hospital revealed that provider delay was double that of patient 
delay. Patients had a median of three contacts with formal healthcare services before 
referral (Graeme, Hennie, Chelsea, Douglas & Gary 2008:72). In settings of endemic 
TB and escalating HIV incidence, targeted latent TB infection screening and treatment 
among high risk groups may be highly cost-effective. A study in Mexico over 20 years 
estimated that it would prevent 78 cases of active TB and 55 TB-related deaths among 
a cohort of 1,000 individuals at high risk of HIV infection (Burgos, Kahn, Strathdee, 
Valencia, Bautista, Laniado, Castañeda, Deiss & Garfein, 2009:962). 
Economic evaluations of TB-HIV integrated services are necessary as countries move 
to establish or scale up intensified TB case finding and IPT services to reduce the 
burden of TB among HIV patients. Adherence to IPT study at Battambang, Cambodia, 
IPT clinic was high (86%) relative to other reported studies of IPT among HIV patients in 
developing countries (Sutton, Arias, Chheng, Eang & Kimerling, 2009:713). 
Integration of TB screening among VCT clients benefits early diagnosis of active TB 
infection. The finding from Haiti, even before the concept of TB/HIV collaborative 
activity, showed clear evidence that of the 241 clients evaluated for cough, 76 (32%) 
were diagnosed with pulmonary TB. Of the 76 patients diagnosed with pulmonary TB, 
28 (37%) had a positive smear for acid-fast bacilli (AFB), 14 (18%) had a negative AFB 
smear but a positive sputum culture for Mycobacterium TB, and 34 (45%) had culture-
negative TB (Burgess, Fitzgerald, Severe, Joseph, Noel, Rastogi, Johnson & Pape, 
2001:1875). 
 
2.10 CONCLUSION 
 
The policy for collaborative TB/HIV care service was initiated by the WHO after the 
concern of gradual rise in both HIV and TB prevalence globally. That both TB and HIV 
occur more frequently in a single patient draws the attention of public health experts to 
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the urgent need for collaborative activity to decrease the burden of TB-HIV within the 
existing setups. There has been no cause of global health concern greater than TB and 
HIV, next to malaria in general and in SSA in particular, for the last two decades. There 
are 12 priority TB/HIV collaborative activities to decrease the burden of TB/HIV 
proposed by WHO, categorised under three main themes as described in this chapter. 
The first one is mechanisms for collaboration, under which four activities were 
described: set up a coordinating body for TB/HIV activities effective at all levels; conduct 
surveillance of HIV prevalence among TB patients; carry out joint TB/HIV planning; and 
conduct monitoring and evaluation. The second theme is activities to decrease the 
burden of TB in people living with HIV, which are classified under three I’s: establishing 
intensified TB case-finding; Isoniazid prevention therapy; and ensuring TB infection 
control in healthcare and congregate settings. The third theme is decreasing the burden 
of HIV in TB patients, under which five activities were classified: providing HIV testing 
and counselling; HIV prevention methods; Cotrimoxazole preventive therapy; HIV care 
and support; and antiretroviral therapy for all HIV-TB patients.  
Different research worldwide regarding the burden of TB/HIV has indicated that there is 
a strong link between TB and HIV, with high chance of dual appearance in one patient. 
Following the introduction of policies for these collaborative activities, countries have 
adapted their guidelines for implementation of the TB/HIV collaborative activities. Many 
African countries, especially sub-Saharan, are far behind fully implementing all the 
recommended activities at all corners of their health system. Even those who are 
considered as better in implementing lack consistency, effectiveness and well-
developed monitoring and evaluation systems. 
Ethiopia began implementing TB/HIV collaborative activities in 2004, in selected pilot 
sites nationally. After lessons learnt from those pilot sites, national implementation was 
held in most of the government health facilities with support from international and 
bilateral donor organisations. The implementation status is said to be in a better 
condition, despite being devoid of well-established monitoring and evaluation systems, 
and poor knowledge with regard to scientific background on the implementation status 
nationally and regionally. Therefore, this research will explore the status of TB/HIV 
collaborative activities implementation in Addis Ababa, Ethiopia, with the aim of helping 
as a baseline for further nationwide study. 
 CHAPTER THREE 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1 INTRODUCTION 
In this chapter, the research design and methodology employed to conduct the study 
providing collaborative TB/HIV care services in Addis Ababa Ethiopia is stated. The 
chapter re-affirms the foundation of the research, explains the study design, study 
population, sampling and sampling designs, research tools, data collection procedure 
and data analysis. Issues related to ethical considerations and assuring validity, 
reliability are discussed. In addition, triangulation, design and mixed methods 
appropriate to this study are described. Both quantitative and qualitative methods are 
discussed in detail. Throughout this study, mixed method triangulation research design 
was applied during data collection, analysis, and interpretation. 
 
3.2 RESEARCH DESIGN 
 
Amin (2005:210) describes research design as an outline of what the researcher will do, 
starting from the formulation of research questions to the final analysis of data. 
Research design is the blueprint for any study as it facilitates smooth running of the 
various procedures making the study more efficient (Wikipedia, 2012e). Before the final 
decision for the appropriate research design to be used in this research, the researcher 
has considered a number of factors, including the orientation of the research, the plan 
for analysis and the time dimension as authors state (Bless & Higson-Smith, 1995:28; 
Creswell & Plano-Clark, 2007:58; Saunders et al., 2009:137). 
Therefore, in order to understand the full picture about the implementation status, the 
strengths, challenges, and lessons learnt for the TB/HIV collaborative activities in public 
health facilities in Addis Ababa city administration, the researcher implemented the 
mixed methods triangulation designs. In this case both quantitative and qualitative 
research methods were used. 
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3.2.1 Mixed methods research design 
 
Creswell, Plano-Clark and Garrett (2008:66) describe a mixed methods research model 
as “Ga plan for collecting, analysing and mixing both quantitative and qualitative 
research methods or data in a single study or a series of studies to understand the 
research problem”. In this study, the research problem is the implementation status of 
TB/HIV collaborative activities in public health facilities in the era of synergy between TB 
and HIV. In high HIV prevalence population, TB is the leading cause of morbidity and 
mortality and HIV is driving the tuberculosis epidemic in many countries, especially in 
SSA (WHO 2012a). The mixed methods research design brings together both the 
quantitative and qualitative data simultaneously. The justification for mixing both 
quantitative and qualitative data within one study is that neither are sufficient by 
themselves to capture the trends and details of the situation. Its central premise is that 
their use in combination provides a better understanding of research problems than 
either approach alone (Creswell et al., 2007:5). 
According to Polit and Beck (2008:309), there are three main advantages of mixed 
methods design: 
• Complementarity: allowing a study to use both numbers (quantitative) and words 
(qualitative) in order to minimise the limitations of using a single approach. 
• Incrementality: the progress on research topic tends to be incremental, lying on a 
feedback loops. Therefore, by using qualitative findings one can generate 
hypotheses that can be tested quantitatively, with qualitative findings that need 
clarification through in-depth probing of specific subjects. 
• Enhanced validity: when a model is supported by multiple and complementary 
types of data, the researcher can be more confident about the validity of the 
results (Polit & Beck, 2008:309).  
Both research designs were utilised in order to gain detailed information on what 
participants felt and understood as realistic findings about implementation of TB/HIV 
collaborative activities among public health facilities in Addis Ababa city administration 
in Ethiopia. Methodologists writing about mixed methods research have devoted a great 
deal of attention to classifying the different types (Creswell et al., 2007:59). Among the 
contemporary methodologists, Creswell et al. (2008:68) classify mixed methods 
research design into two major categories, namely concurrent and sequential designs. 
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In the concurrent designs both qualitative and quantitative data are collected at the 
same time or within the same period. They include triangulation and embedded designs. 
In sequential designs one category of data (quantitative or qualitative) builds on the 
other with emphasis put on one. Sequential designs may be explanatory, exploratory, or 
sequentially embedded. Although it is thought to be more inclusive, mixed methods 
design has its challenges, for example, requiring extensive data collection, time-
intensive analysis, decisions on which research methods to combine, and how to 
integrate and interpret research findings (Creswell et al., 2008:72; Stewart, 
Makwarimba, Barnfather, Letourneau & Neufeld, 2008:1407). 
For this study, the researcher used the concurrent triangulation design to describe, 
explain and explore how TB/HIV collaborative activities have been implemented in 
Addis Ababa city administration of Ethiopia. 
 
3.2.2 The triangulation design 
 
Triangulation is a term borrowed from cartography and military naval science that 
signifies the use of multiple reference points to locate an object’s exact position. It was 
later used to suggest that quantitative and qualitative data could be complementary 
(William, John, Vicki & Kelly, David, 2005:224). For Saunders et al. (2009:146) it refers 
to “Gthe use of different data collection techniques within one study in order to ensure 
that the data tells one what one thinks they are telling him/her.” Triangulation design is a 
one-phase plan in which the researcher implements the quantitative and qualitative 
methods during the same timeframe and with equal weight or priority (Creswell, Plano-
Clark, Gutmann & Hanson, 2003:209). The single-phase timing is the reason it is 
referred to as the ‘concurrent triangulation design’. 
The purpose of triangulation design is “to obtain different but complementary data on 
the same topic, with the intention of bringing together the differing strengths and 
minimise on the weaknesses of quantitative and qualitative research methods” (Morse, 
1991, as cited in Julia, 2005). In triangulation, simultaneous but separate quantitative 
and qualitative data collection and analysis is carried out. The researcher then attempts 
to merge the two sets of data by bringing the separate results together during 
interpretation or by transforming data to facilitate the integration of the two types during 
analysis. This enables the investigator to understand the research problem better 
(Creswell & Plano-Clark, 2007:64). 
63 
The researcher collected data using different methods (methodological triangulation) on 
implementation of TB/HIV collaborative activities at public health facilities from interview 
of both TB and HIV patients (beneficiaries) and their service providers (health workers) 
from different levels of health facilities (space triangulation and person triangulation), 
during the same period and integrated the findings during interpretation phase (data 
triangulation): 
• Methodological triangulation: involves using multiple research methods or data 
collection techniques about the same phenomenon, which in this case is the 
implementation of activities to decrease the burden of TB/HIV. The researcher 
used structured questionnaires to collect quantitative data and semi-structured 
interviews guide to collect qualitative data (Amin, 2005:65; Polit & Beck 
2008:543). 
• Space triangulation: involves collecting data on the same topic from different 
sites to test for cross-site consistency (Amin, 2005:65; Polit & Beck, 2008:543). 
The researcher collected data from eight randomly selected public health centres 
and two hospitals and from all the ten sub-cities administered by Addis Ababa 
city administration health bureau. 
• Person triangulation: involves collecting data from different types or levels of 
people (Polit & Beck 2008:543). This is aimed at validating data through multiple 
perspectives on the topic. The researcher collected data from TB and HIV 
patients, from service providers and TB/HIV care coordinators. 
• Data triangulation: involves the use of multiple data sources with similar focus to 
obtain diverse views through a range of data on a given topic in order to increase 
the validity of the findings. The data collected can be analysed using different 
strategies for validation (Amin, 2005:65; Polit & Beck, 2008:543). The researcher 
collected data from both TB and HIV patients, health service providers and 
coordinators at different level of healthcare system (Health centre and Hospital). 
The researcher employed semi-structured questionnaires, in-depth interviews 
and focused group discussions among patients to gain diverse views on the 
same subject matter. Similar questions were used for in-depth understanding of 
the implementation status of TB/HIV collaborative activity for interview of 
healthcare providers and TB/HIV care coordinators at all levels. The different 
sources of information provide insights into the phenomenon, provide an 
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enriched explanation of the problem, and assist in validating conclusions (De 
Vos, Strydom, Fouche & Delport, 2005:362). 
• Investigator triangulation: this refers to a situation in which two or more 
investigators with diverse background examine the same phenomenon with each 
having a specific role to play in the study (Amin, 2005:65). This removes the 
potential bias likely to occur if there is only one investigator. The researcher used 
the services of 10 trained research assistants and one overall data collection 
coordinator, all with background in public health or social sciences to interview 
the patients and health service providers/coordinators during the qualitative 
phase. This reduced the potential bias since the research assistants were not 
involved in analysis or interpretation stages of the study. At the same time, the 
researcher employed a statistician to analyse the quantitative data and another 
scientist experienced in analysing qualitative data. All this was aimed at 
enhancing the validity and reliability of this study. 
 
3.2.3 Variants of triangulation design 
 
Creswell and Plano-Clark (2007:64) describe four main variants of triangulation design, 
namely convergence, data transformation, data validating quantitative, and multilevel. 
The researcher used the convergence model, by which collecting and analysing both 
quantitative and qualitative data separately on the same phenomenon and then the 
different results are converged (by comparing and contrasting the different results) 
during the interpretation. By doing so the researcher wanted to compare results or to 
validate, confirm or corroborate quantitative results with qualitative findings. The 
purpose of this model is to draw valid and well-substantiated conclusions about a single 
phenomenon. Figure 3.1 (below) illustrates the convergence model of the triangulation 
design in which quantitative data represents purely the reception of relevant TB/HIV 
collaborative activities for both TB and HIV patients (beneficiaries), and the qualitative 
part from patients, healthcare providers and coordinators for the TB/HIV collaborative 
activity implementation phenomenon. 
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Figure 3.1: Triangulation design: Convergence Model (Adapted from Creswell & Plano-Clark 2007:63) 
 
In this design, different but complementary data was collected on the same topic by 
means of both quantitative and qualitative techniques with equal priority.  
A survey approach using interviewer-administered questionnaires was used to collect 
quantitative data for receiving relevant services of TB/HIV collaborative activities for 
both TB and HIV patients while in their follow-up visits at TB and HIV chronic care 
clinics, respectively. Qualitative data was collected using structured interviews with 
patients, healthcare providers, and coordinators for the TB/HIV collaborative activities at 
the health facilities and city administration levels to explore the phenomenon of 
implementation of TB/HIV collaborative activities in general. The reason for collecting 
both quantitative and qualitative data was to bring together the strengths of both forms 
of research and hence produce more credible results. The data was analysed in parallel 
and then merged to develop a more complete understanding about the implementation 
of TB/HIV collaborative activities (Creswell et al., 2008:68). 
 
3.3 THE QUANTITATIVE RESEARCH DESIGN 
 
Quantitative research design was used to collect data from both TB and HIV patients 
(clients) at the health facility. Amin (2005:210) describes quantitative design as “‘Ga 
plan for carrying out research oriented towards data quantification and is applied in 
order to describe or investigate current conditions and relationships”. Polit and Beck 
(2008:16) explain that the quantitative approach involves the use of a general set of 
organised and controlled procedures to gather information. In quantitative research, 
evidence is generated according to the specified plan, using formal instruments such as 
questionnaires to collect the required information, which is generally numerical and is 
analysed using statistical procedures in order to enhance objectivity (Polit & Beck, 
2008:16; Somekh & Lewin, 2005:215). According to Polit and Beck (2008:63), the 
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quantitative design can be experimental, quasi-experimental, or non-experimental and 
used for descriptive and inferential statistics. They can be cross-sectional or longitudinal 
in nature. This study is cross-sectional and non-experimental because data was 
collected at a specific time in the natural environment of the health facilities and without 
experimental manipulation of the participants. 
The researcher therefore used quantitative non-experimental cross-sectional designs to 
identify and collect numerical data on receptive of appropriate TB/HIV collaborative 
activities from both TB and HIV patients accordingly. By doing so, it was possible to 
explain, describe, understand, and predict the service provision status of TB/HIV 
collaborative activities at public health facilities in the city administration.  
  
3.3.1 Descriptive research design 
 
Descriptive research is a broad class of non-experimental studies (Polit & Beck, 
2008:274). Saks and Allsop (2007:6) also describe a descriptive study as “Gproviding 
current information or intelligence on a research problem”. Polit and Beck (2008:274) 
add that in descriptive study the researcher observes, relates, and describes 
measurable attributes of the phenomenon in a natural environment as a starting point 
for theory development. The main purpose of descriptive study is to generate precise 
measurement of the phenomena being studied that can be explained by the 
accumulation of statistical data (Burns & Grove, 2007:34; Saunders et al., 2009:140). 
The researcher explored and described the implementation status of TB/HIV 
collaborative activities in public health facilities of the city administration, in relation to 
the healthcare delivery system in the current working environment. In addition, the 
researcher described the various approaches currently used to implement TB/HIV 
collaborative activities among the different healthcare delivery levels (health centres and 
hospitals). This made it possible to identify their strengths and weaknesses, which 
formed the basis for development of appropriate workable pocketbook for 
implementation of TB/HIV collaborative activities. 
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3.3.2 Survey research 
 
The researcher implemented a survey approach to collect both the qualitative and 
quantitative data. Amin (2005:212) defines a survey as “Ga research activity that is 
used to gather data from a sample of a population.” A survey approach may be used in 
descriptive, explanatory, and exploratory studies. According to Polit and Beck 
(2008:323), a survey is designed to obtain information about the prevalence, 
distribution, and interrelations of variables within a population. Babbie (2001:238) 
argues that a survey is probably the best method available for researchers who are 
interested in collecting original data for describing a given population. The purpose of a 
survey is to generalise data from a sample to the population so that inferences can be 
produced about their characteristics or attitudes. Surveys are mainly used in studies in 
which individuals are the units of analysis. 
The researcher used the survey approach because of its cost-effectiveness and 
usefulness in covering a large population using a sample. A survey is an excellent way 
to gain knowledge from the target population of a study, and it allowed both clients and 
healthcare providers to answer questions comfortably and therefore more truthfully, 
since answers were handled anonymously. Additionally, a survey helps the researcher 
to be creative in shaping the areas for further research (Saunders et al., 2009:144).  
Although a survey has certain advantages it also has some drawbacks. First, it does not 
provide in-depth picture of why certain features are there or not, and why stakeholders 
hold different perspectives. Second, in a survey participants may sometimes want to 
portray themselves in a better light. Third, a survey may lead to bias since people who 
respond to them are usually on extremes of the continuum, mostly the opinionated, 
generally better educated, and wealthier. Fourth, a survey may lead to less 
representation of the minority groups (Lange, 2002:78; Saunders et al., 2009:145). 
 
3.4 QUANTITATIVE RESEARCH METHODS 
 
The quantitative data collection methods were used to collect data from both TB and 
HIV patients on their follow-up care at their respective health facilities. The specific 
methods employed are described as follows. 
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3.4.1 Population and sampling 
 
The research methods used in sampling and collection of data from patients (TB and 
HIV) are described in the following sub-sections. 
 
3.4.1.1 Study population for patients (TB and HIV) 
 
According to Amin (2005:235), a study population is “Ga complete collection of all 
elements or individuals that are of interest in a particular investigation to the researcher 
and where inferences are to be made.” On the other hand, Trochim (2006:32) describes 
it as a group to which the results of the study are generalised, and Saunders et al. 
(2009:212) as “Gthe full set of cases from which a sample is taken.” The study 
population may include study objects such as individuals, groups, organisations, human 
products and events to which they are exposed. Taking this into consideration, the 
study population in this study were diagnosed TB patients and HIV patients residing in 
Addis Ababa City administration, Ethiopia. 
 
3.4.1.2 Target population for patients (TB and HIV) 
 
According to Polit and Beck (2008:338), the target population is “Gthe aggregate of 
cases about which the researcher would like to make generalisations.” Similarly, Burns 
and Grove (2007:324) describe it as the entire set of individuals or units that meet the 
sampling criteria, and Amin (2005:235) as the parent population that may not be 
accessible but from which the researcher would wish to generalise the results. For the 
purpose of this study the target population for this category comprised TB and HIV 
patients who were attending follow-up care at public health facilities in Addis Ababa City 
Administration of Ethiopia. as well as health workers involved in the care of TB/HIV 
patients and coordinators of TB/HIV care at health facility level working in Addis Ababa 
City Administration. 
 
3.4.1.3 Accessible population for patients (TB and HIV) 
 
According to Burns and Grove (2007:324), an accessible population is “Gthe portion of 
the target population to which the researcher has access.” Polit and Beck (2008:338) 
define it as “Gthe aggregate of that conform to the designated criteria and are 
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accessible as participants of the study”, and Amin (2005:235) describes as one from 
which the sample is actually drawn. This implies that results from the sample should 
only be generalised to the sampled population and generalisation to the target 
population will depend on similarities that exist across the population. 
The researcher interviewed all patients found on the days of interviews, until the 
allocated number of samples was reached for that specific health facility from both TB 
and HIV patients separately from the 10 public health facilities. The study health 
facilities were selected randomly, with at least one each from the ten sub-cities; namely: 
Zewditu Memorial Hospital, Menelik II Hospital, Health centres of Lideta, Yeka, 
Kazanchis, Nifas-Silk Lafto No-1, Woreda 7, Kality, Bole and Gulele.  
 
3.4.1.4 Sampling frame for patients (TB and HIV) 
 
Saunders et al. (2009:214) and Trochim (2006:32) describe the sampling frame as “Ga 
list of elements from which the probability sample is selected.” The proposed sampling 
frame for the quantitative design consisted of all TB and HIV patients found on the 
respective health facilities at the time of data collection period until the sample size 
quota was filled for the site. On average, 18 patients (ranged 11 - 29) from both clinics 
were interviewed per day. More patients were found in the hospitals than health centres. 
The minimum number of days taken by data collectors to complete the specified sample 
size for particular health facility was eight, and maximum 12 days. 
 
3.4.1.5 Sampling and sampling techniques of patients (TB and HIV) 
 
According to Polit and Beck (2008:339), a sample is a portion of population whose 
results can be generalised to the entire population for a particular study. Therefore, 
sampling is the process of extracting a portion of the population from which 
generalisation of the findings can be made (Amin, 2005:237; Polit & Beck, 2008:339). 
Sampling is useful because it is more practical and economical, and saves cost and 
time compared to larger populations. Furthermore, sampling ensures completeness and 
high degree of accuracy due to the limited area of operation. As Amin (2005:239) and 
Burns and Grove (2007:327) state, the main disadvantage is that the selected units may 
not be representative of the population, even when the best statistical methods have 
been applied, especially when the sample size is small. In addition, accessible 
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population is not usually 100% representative since elements that are not accessible 
might be different from the accessible ones. 
A sample may be selected using probability or non-probability sampling methods, the 
former being selected randomly such that all the elements in each sampling frame have 
an equal chance of being chosen. Probability sampling methods include simple random 
sampling, stratified sampling, systematic sampling, cluster sampling, and panel 
sampling (Amin 2005:244; Polit & Beck 2008:340; Saunders et al., 2009:222). The 
researcher used the probability proportional to size (PPS) technique to select 
participants in the quantitative design from each health facility. If one primary sampling 
unit has a larger population than another it should be given twice the chance of being 
selected. Equal probability sampling is inappropriate because if the units are selected 
with equal probability (i.e., the same sampling fraction) then a large unit may yield too 
many sample members, whereas a small unit would yield too few. Instead, one could 
stratify the units by size and select a sample of them within each size group, with 
variable sampling fractions. Alternatively, one could sample the units with PPS, then the 
probability of selection for each person would be the same and the larger units would 
not exert too great an influence on the total sample. The sizes of the primary sampling 
units must be known in order to carry out this method (Ann, 2005:198). The selection of 
the total sample from each health facility depended on its cumulative TB/HHIV patient 
load, which implies that large samples were selected from a large number of patients 
and small samples from the smaller patient load. This was to ensure representativeness 
of all the health facilities.  
In order to avoid disruption of service delivery, data collectors usually arrived early 
(morning and afternoons) before normal working hours, so that patients who were found 
in the waiting area would be interviewed privately. In addition, patients who had just 
completed their services for the day were also approached for interview. Therefore, 
maximum effort was employed to maintain the normal service delivery. Once an HIV 
patient registers in a facility for follow-up care he or she becomes a regular attendee, 
which ultimately increases the cumulative patient load through time. In principle, when 
the number of daily new HIV patients increases in a facility so does the cumulative 
number. Unfortunately, in this study the cumulative TB/HIV patient load in health 
centres was found less than that in the hospitals. In addition, the patients’ loads among 
the different health centres were comparable, as were  those for hospitals. Therefore, 
the researcher decided to take an equal number of samples from all the health centres 
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and an equal number from the hospitals. However, the latter were more than the 
samples from the health centres, as reasoned in the preceding paragraph above. 
 
3.4.1.6 Sample size determination for patients (TB and HIV) 
Sample size is dependent on the accuracy required and the variation among the target 
population. Saks and Allsop (2007:219) state that the larger the sample size the smaller 
the error in estimating the characteristics of the target population, but the more costly it 
will be to conduct the study. The researcher used EPI INFO version 2002 statistical 
software to calculate the sample size for quantitative data for both TB and HIV patients. 
In addition, an unmatched comparative cross-sectional study was employed; i.e., TB 
patients from TB clinics and HIV patients from HIV care clinics.  
According to a study by Wesen and Getnet (2009:109), the prevalence of TB among 
HIV patients for Addis Ababa was 43% (P1). However, due to lack of recent data for 
HIV prevalence among TB patients for the study area, 50% were taken (P2) for 
maximum sample size. Therefore, the sample size was calculated using a two 
population proportion sample size equation designed for a comparative cross-sectional 
study (Casagrande, Pike & Smith, 1978, as cited in Sample Size Calculator [s.a]).  
Formula: 
   Define  be the upper 100(1-p) percentile of the standard normal distribution, 
  m be the required sample size from the first population, 
  rm be the required sample size from the second population,  
,  and  
          
  where  
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Notations: 
α: The probability of type I error (significance level) is the probability of rejecting the true 
null hypothesis.  
 β: The probability of type II error (1 – power of the test) is the probability of not rejecting 
the false null hypothesis. 
Assumptions were also made using 95.0% confidence interval, 5% level of significance, 
with power of 80%, r=1;i.e, allocation ratio of HIV patients to TB patients (n1:n2) of 1:1 
and taking none response rate of 5%. The calculated sample was 865 participants for 
HIV patients and 865 for TB patients. 
 
3.4.2 Data collection for quantitative study of patients 
 
Burns and Grove (2007:536) define data collection as “Gidentification of respondent 
and the precise, systematic gathering of information relevant to the aim, and objectives 
of the study.” Saunders et al. (2009:256) add that data collection is the gathering of 
information required to address the research problem.  
The researcher used structured interviewer administered quantitative data collection 
methods, because of its advantages. As with face-to-face interview, they only require 
the participant to speak the same language in which the questions are asked, and to 
have basic verbal and listening skills. No reading skills are required, unless written 
materials for the participant are contained within the interview. A friendly, motivating 
interviewer can increase response and item response rates, maintain motivation with 
longer questionnaires, probe for responses, clarify ambiguous questions, help 
participants with enlarged show cards of response choice options, use memory jogging 
techniques for aiding recall of events and behaviour, and control the order of the 
questions. Interviewers can also be trained to follow complex question routing and 
skipping instructions (Ann and Shah 2005).  Although the use of face-to-face interview 
is advantageous, it has its own drawbacks, as questionnaires are costly compared to 
other methods and usually offer less assurance of anonymity than mailed ones. 
Additionally, they cannot cover a wider geographical area since the researcher and 
research assistants have to approach participants one by one. 
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3.4.3 Data collection approach and method for patients 
 
The researcher utilised a structured data collection approach, which involves the use of 
formal instruments comprising pre-defined items and response options (Polit & Beck 
2008:371; Saunders et al., 2009:601). In the quantitative part of this study the 
researcher used interviewer-administered questionnaires. The questionnaire items 
consisted mainly of closed-ended and a few open-ended questions. The development of 
the questionnaire was guided by the objectives of the study and the theoretical model 
(Saunders et al., 2009:362). The structured methods yield data that is relatively easy to 
quantify and analyse. 
Burns and Grove (2007:551) define a questionnaire as “Ga printed, structured self 
report form designed to collect information through written or verbal responses”, whilst 
for Amin (2005:269) it is a form consisting of interrelated questions prepared by 
researcher about the problem under investigation, based on objectives of the study. It is 
assumed that if a questionnaire is to be used the participants must understand the 
items, possess information to answer the questions and be willing to do so honestly. 
 
3.4.4 Construction of the questionnaires 
 
In triangulation design the researcher used different tools to collect data on the same 
topic. The researcher developed three separate tools, one for each level of the data 
collection process (quantitative and qualitative). An interviewer-administered 
questionnaire was developed for quantitative strand and a structured interview guides 
for the qualitative (interview and FGD) strand. A questionnaire must be clear, simple, 
and unambiguous, arranged in an orderly manner in such a way that data analysis is 
easy (Polit & Beck 2008:425; Saunders et al., 2009:387). The questionnaire was based 
on the reviewed literatures related to TB/HIV collaborative activities, the research 
objectives, and the conceptual framework. The researcher also looked at other tools 
that have been used by investigators in similar studies and used some of the questions 
appropriate for this study.  
Almost all questionnaire items were closed and worded in such a way that the 
participants were limited to specified mutually exclusive response options. Closed 
options facilitate coding and statistical analysis of data. It also ensures that the 
researcher obtains the desired information, which can increase the reliability of the 
study (Saunders et al., 2009:374). Therefore, the assistance of the study promoter and 
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a statistician were incorporated in this regard. The questionnaires were interpreted in 
Amharic (regional official language) by interviewers and some words and phrases were 
clarified to facilitate understanding (Annexures E - J).  
 
3.4.5 Structure of the questionnaire for patients 
 
There were two questionnaires for the quantitative part of patients, consisting of one for 
TB patients and the other for HIV patients. They were very similar except for the focus 
of disease of interest, that is of similar structure but the questions were relevant to the 
respective TB or HIV patients. The quantitative questionnaires were divided into three 
parts (I-III), with questions designed to elicit information about actual service provision 
of TB/HIV collaborative activities to the respective patients on their follow-up care. As 
stated, all the questions were closed-ended, with the parts arranged as follows.  
Part I: consisted of seven items of closed-ended questions about socio-demographic 
characteristics, namely age, sex, marital status, religion, ethnicity, educational status 
and occupation.  
Part II: consisted of 12 items of closed-ended questions about prevalence of HIV 
among TB patients and prevalence of TB among HIV patients for TB and HIV patient 
questionnaires respectively.  
Part III: consisted of six items of closed-ended questions about activities to decrease 
the burden of HIV among TB patients and vice versa, for TB and HIV patients 
respectively.  
 
3.4.6 Study population for healthcare providers and/or coordinators  
This study has a quantitative section in the questionnaire for healthcare providers 
and/or coordinators working specifically in TB/HIV collaborative activities from all study 
health facilities, in addition to patients. Therefore, the study population for healthcare 
providers were all health workers working on TB/HIV collaborative activities residing in 
Addis Ababa city administration, Ethiopia. The selected TB/HIV care service providers 
were also coordinators for their respective facilities for the programme TB/HIV 
collaborative care. The target population for this category were healthcare 
providers/TB/HIV care coordinators working at either TB or HIV in TB/HIV clinics at 
public health facilities of Addis Ababa city administration of Ethiopia. The researcher 
included one healthcare worker either from TB or HIV clinics from each of the ten study 
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health facilities; therefore, purposive sampling technique was used to select study 
participants for health workers/coordinators. 
For the patient’s questionnaires, the researcher used structured interviewer-
administered quantitative data collection methods for health workers as well. The 
questionnaire items (part I and II) were closed and worded in such a way that the 
participants were limited to specified mutually exclusive response options (Annexure H). 
The questionnaires were prepared in English and the research assistants (interviewers) 
translated them into the local language for ease of communication. However, the 
responses were stated in English on the questionnaires, therefore data presentation 
and analysis was conducted directly from the stated responses.  
The questionnaires were divided into five parts (I-V), with questions designed to elicit 
information about qualification, job related trainings attended, years of services, 
opinions of programme implementation of TB/HIV collaborative activities, and impact of 
programme implementation on staff performances and infrastructure.  
 
3.4.7 Structure of the questionnaire for healthcare workers and/or coordinators 
for TB/HIV care  
The questionnaire was divided into five parts (I-V), these questions being designed to 
elicit information about actual programme implementation of collaborative TB and HIV 
services at their respective health facilities, impact of programme implementation on 
staffs’ performances, on infrastructure and on human resource development.  
Part I: consisted of four closed-ended questions about socio-demographic 
characteristics information, such as age, sex, professional and number of years of 
services on the programme.  
Part II: consisted of 20 closed-ended questions about programme implementation of 
collaborative TB and HIV services in their health facilities.  
Most parts of the questionnaire were constructed with qualitative open-ended questions 
to be responded in short answers, parts III-V. 
Part III: consisted of eight open-ended questions about the impact of collaborative 
TB/HIV activities implementation on staff performance.  
Part IV: consisted of five open-ended questions about impacts implementation on 
infrastructure. 
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Part V: consisted of seven open-ended questions about the impact of TB/HIV 
collaborative activities implementation on human resource development. 
 
3.4.8 Pilot testing of the questionnaire 
 
Polit and Beck (2008:213) define a pilot study as “Ga small-scale version or trial 
designed to test the methods to be used in a larger and more rigorous study.” It is 
conducted in order to identify possible weaknesses in the research instruments. For 
Saunders et al. (2009:394) its purpose is to refine questionnaires so that the 
participants will have no problems in answering questions and there will be no problems 
in recording data. The researcher will obtain some assessment of the questions’ validity 
and reliability of the data that will be collected.  
Polit and Beck (2008:214) and Saunders et al. (2009:394) write that pre-testing a 
questionnaire assists the researcher to find out: 
• how long it will take to complete the questionnaire, 
• the clarity of the instructions, 
• questions that are unclear or ambiguous, 
• whether there are any major omissions in the questionnaires, 
• whether the layout is clear and attractive, and 
• identify potential confounding variables that need control. 
The researcher pre-tested the questionnaire on 12 participants from each of the TB and 
HIV patients from two health centres by all the research assistants, which were not 
among the selected study health facilities (health centres of Woreda-24 and 
Shiromeda), to identify any gaps in the questionnaire. This exercise assisted in 
estimating the time required to complete the questionnaire, and helped to identify the 
questions that were not clear or too difficult in terms of language and conceptualisation 
(Saunders et al., 2009:394). 
 
3.4.9 Training of the Research Assistants 
 
The researcher recruited and employed 10 research assistants to assist in data 
collection for both quantitative and qualitative phases of this study. The research 
assistants conducted interviewers, administered quantitative and short answered 
interview questionnaires in collecting data from patients. In addition, an overall data 
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collection coordinator, who was a highly educated and experienced public health expert, 
was employed to conduct interviews with healthcare providers and facility coordinators, 
facilitate the FGD discussion, and supervise the research assistants. The researcher 
recruited the research assistants for their training in public health and social sciences 
background, a first degree graduate level and prior experience in conducting research, 
good communication skills and fluency in both written and spoken English and Amharic 
(official language of the Addis Ababa city administration).  
Training was necessary in order to ensure standardisation of the data collection 
process. Depending on the prior experience, the training covered both the general 
procedures (such as how to conduct an interview), and those specific to this study (e.g., 
how to administer questions), as well as the ethical standards for conducting research. 
The theoretical training was followed by rehearsals and role plays, until the research 
assistants had mastered the skills (Polit & Beck 2008:382-383). The training took two 
days and the researcher involved the senior public health expert (overall coordinator) 
during the training and for the qualitative research methodology. Finally, data collectors 
were sent to two health centres for the pilot testing (section 3.4.2.6). Initially, 13 data 
collectors were trained but three were not qualified after the evaluation so that the 
remaining ten continued for the contract of data collection activity. During the data 
collection period the overall data collection process coordinator was meeting all of them 
daily for immediate corrective measures. There were no poor performers during the 
process, however, inconsistency and incomplete questionnaires were discarded before 
data entry, which did not impose any drawbacks to the planned sample size (Chapter 4: 
Table 4.1). 
 
3.5 ADMINISTRATION OF THE QUESTIONNAIRE 
 
After completion of design, the questionnaires were pilot tested, modified and the study 
participants identified. The questionnaires were used to collect the main data. The 
research assistants conducted interviewer-administered questionnaires by interviewing 
the selected sample until the calculated sample size for that specific health facility was 
reached. Each research assistant (data collector) was assigned randomly in one of the 
study health facilities (health centre or hospital). The data collection period was 6 June 
2011 – 8 July 2011 (including the training and pilot testing period). The sample for each 
of the health centres was set 160 patients of TB and HIV each, with each of the 225 TB 
patients and HIV patients for each of the hospitals. The sample size for each facility was 
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based on sampling proportional to the facilities’ cumulative TB/HIV patient load. As this 
was found similar across the health centres, the sample for all health centres was set 
160 each for both TB and HIV patients (80 TB patients and 80 HIV patients). Similarly, 
the cumulative TB/HIV patient load for hospitals was comparable; the sample for the 
two hospitals was set 225 each of both TB and HIV patients (112 TB patients and 113 
HIV patients). 
Data collectors were given transportation allowances to and from the facility. They were 
also supposed to be in their respective assigned health facility by 7:00am. Interviewing 
was carried out without interfering with the normal service delivery, mainly before the 
working hours while patients were at their waiting areas. The maximum number of 
interviews allowed per day by each data collector was set at 20, assuming 20 minutes 
duration for each. This was to maintain the quality of the data as the collectors would 
not rush. In addition, all data collectors were to meet every evening at the data 
collection coordinator to submit the filled questionnaires and discuss the daily activities. 
Each interview followed an appropriate ethical formality. As a principle, the purpose, 
risks, and benefits of the research were described to potential participants in a language 
they understood, so that they had the information needed to decide whether to 
participate in the research (Annexure D). Providing initial information allowed for 
informed consent of participants. They were told that they did not have to participate if 
they did not want to, that they had the right to refuse to answer any question(s), and that 
they could quit at any time if they wished (US Department, [s.a]).  
 
3.5.1 Validity and reliability of the questionnaire 
 
Two vital concepts that determine the suitability of a questionnaire to use for research 
purposes are validity and reliability, described briefly as follows. 
 
3.5.1.1 Validity of the questionnaire 
 
Validity is the suitability of an instrument while reliability is its consistency in measuring 
anything it is deliberated to measure (Polit & Beck, 2008:457). Amin (2005:285) 
describes validity as the ability to produce findings that are in conformity with theoretical 
or conceptual values. A research instrument is said to be valid if it actually measures 
what it is intended to. For Burns and Grove (2007:365) the validity of a research 
instrument lies in the determination of how well it reflects the theoretical concept being 
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examined. Different writers (De Vos et al., 2005:160; Polit & Beck, 2008:458; Saunders 
at al., 2009:372) have identified four main approaches for measuring the validity of 
research instruments, namely face, construct, content, and criterion related validity. 
In this study, the researcher made use of construct and content validity. Saunders et al. 
(2009:373) define construct validity as the extent to which the measurement questions 
actually measure the presence of those variables intended. The researcher ensured 
construct validity by rooting the measures in wide literature search that it defined 
meanings of the construct and its elements. The researcher ensured that categories of 
meanings were relevant to the participants in a natural setting. The content validity on 
the other hand refers to the extent to which a measurement tool provides adequate 
coverage of the research questions (Saunders et al., 2009:373).  
In this study, content validity was ensured through careful sampling and good 
formulation of the research questionnaires. This ensured that the questionnaire items 
were relevant to the study subjects. The experts in the field of this research topic, such 
as the promoter, lecturers at school of public health of Addis Ababa University, and 
national TB/HIV collaborative activity coordinator at the Ministry of Health in Ethiopia, 
consulted upon whether or not the instrument items adequately covered the known 
content of the subject matter (De Vos et al., 2005:161). Despite all these, the researcher 
observed that using these methods might introduce bias due to their subjectivity. 
Validity in terms of research instruments can be external or internal.  
 
External Validity  
External validity is the degree to which the research findings can be generalised to the 
wider population (Polit & Beck, 2008:287; Saunders et al., 2009:216). In this study, 
external validity was ensured through the use of probability sampling, specifically 
stratified sampling (TB-HIV patients separately, health centres and hospitals) in order to 
have adequate representation from the major categories of patients and healthcare 
delivery setups (health centres and hospitals). In addition, the researcher tried as much 
as possible to get the right composition of study participants with regard to socio-
demographic characteristics and maximum sample size (p=50%). The researcher 
selected constructs relevant to the study population in general and took samples from 
each health facility by applying probability proportional to size of their patient load. 
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Internal validity  
Internal validity seeks to demonstrate that the explanation for a particular event or set of 
data derived from that research can actually be sustained by data, in other words, the 
findings of the study must describe accurately the phenomena being investigated (Polit 
& Beck, 2008: 295). Internal validity was ensured through construction of questionnaires 
in agreement with study objectives, and by ensuring voluntary and consensual 
participation. 
 
3.5.1.2 Reliability of the questionnaire 
 
Polit and Beck (2008:452) define reliability as “the consistency with which the study 
instruments measure the targeted attribute”, whilst Saunders et al. (2009:156, 373) refer 
to it as “Gthe extent to which data collection techniques or analysis procedure yields 
consistent findings.” Hence, when a research instrument is administered by various 
researchers it will produce comparable results under similar conditions (De Vos et al., 
2005:163). The researcher believed that reliability was ensured through pre-testing of 
the questionnaires to ensure clarity of the test items and by ensuring anonymity of the 
participants. Reliability of test items was also tested by means of Chronbach’s 
coefficient Alpha (α), which is an index for testing internal consistence of the test items 
using SPSS. As a rule, Alpha (α) should be at least 0.70 or higher (Amin, 2005:298; 
Polit & Beck 2008:454-456), though in this study the value of α was set as 0.5%. 
 
3.5.2 Data analysis for quantitative data 
 
Amin (2005:306) defines data analysis as “Gclosely related operations which are 
performed for the purpose of summarising the collected information and organising it in 
such a way that they answer the research questions.” The researcher employed 
temporary skilled statistician to assist with data entry and analysis, and used computer 
software called Statistical Package for Social Sciences (SPSS, 2006) for both data entry 
and analysis of quantitative data. Analysis of closed-ended questions was made using 
descriptive statistics and inferential statistics such as frequencies and percentages, p 
value and odds ratio.  
The researcher analysed open-ended questions using thematic qualitative content 
analysis, with the aim of quantifying emerging descriptions and ideas. Polit and Hungler 
(1993, as cited in Research [s.a]) explain content analysis as “the process of analysing 
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verbal or written communication in a systematic way to measure variables 
quantitatively.”  
 
3.5.3 Data presentation 
 
The analysed data was presented in the form of frequency tables, charts, and texts 
where applicable. Therefore, tables, graphs, and figures were used in the data 
presentation. Graphs have the advantage of communicating a large amount of 
information in a summary at a glance (Polit & Beck, 2008:561). The presented 
percentages were rounded off to one decimal point. The research results of the 
statistical tests were discussed with reference to the sample characteristics of the 
participants. References are only made to the frequencies of responses that showed 
significant variations. 
 
3.6 THE QUALITATIVE RESEARCH DESIGN 
  
Amin (2005:43) defines a qualitative research design as “Gone whose data is basically 
descriptive in nature.” Amin (2005:45) outlines the characteristics that define qualitative 
research as including: 
• detailed description of the phenomenon,  
• explicit description of data collection and analysis, 
• inductive reasoning applied to evidence gained from sources, 
• synthesised interpretation, and  
• Extension of understanding by others.  
Qualitative research design was used to collect data from both clients (TB and HIV 
patients) and healthcare providers for the TB/HIV collaborative service provision at 
health facilities and TB/HIV collaborative activities coordinators at the same health 
facilities and regional level. The data obtained using qualitative methods was mostly 
expressed in non-numerical terms, although sometimes it was transformed into 
numerical variables. Even though description is emphasised this does not mean that 
numerical figures cannot be used. In qualitative methodology the researcher usually 
collected open-ended data with the primary intention of developing themes from it. Both 
in-depth interview and focus group discussions (FGD) were the qualitative data 
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collection techniques used, the advantages being that they provided depth to the data, 
allowing for probing and improving the confirmation of quantitative data.  
In this study, the researcher collected qualitative data from both clients and healthcare 
providers using structured interview and FGD guides. The qualitative patients’ interview 
procedures assessed how collaborative TB/HIV care service affected their health, its 
feasibility, healthcare provider’s behaviour and quality of services in general, whereas 
that for healthcare providers was to assess how collaborative TB/HIV care 
implementation impacts on  staff performance, infrastructure, human resource in the 
health sector, diagnosis and case-holding for both TB and HIV cases, and progression 
of HIV-related immuno-suppression.  
This research approach also enabled the researcher to gain in-depth information on 
why TB/HIV collaborative activity implementation is delivered in the way it is. Lastly, the 
research used this method to collect the views of both TB and HIV patients, healthcare 
providers and coordinators on how implementation can be improved. 
 
3.7 QUALITATIVE RESEARCH METHODS 
 
The qualitative data collection procedures were used in parallel or together with the 
quantitative data collection from the patients themselves and healthcare providers at the 
respective health facilities and regional (Addis Ababa City administration) level. As 
described above, the researcher collected data from both patients (TB and HIV) and 
healthcare workers using qualitative research methods as well. This enabled the 
researcher to explore and explain the implementation status of TB/HIV collaborative 
activities among the study health facilities, impacts of the programme on human 
resource, staff performances, and infrastructure. Furthermore, the researcher used this 
method to collect the views of health workers and patients on how TB/HIV care 
implementation can be improved. The qualitative questions to be responded, using 
interview, were placed together with the quantitative part in both patients and health 
workers questionnaires which is placed in the last parts of the questionnaires. The focus 
group discussion guide questions for patients of both TB and HIV were prepared 
separately. 
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3.7.1 Population and sampling 
  
The research methods used in sampling and collection of data from patients (TB and 
HIV) and healthcare providers in the qualitative study are as follows. 
 
3.7.2 Study population for patients (TB and HIV) 
 
The study population for the qualitative part of the study are also people diagnosed with 
TB who are under treatment, and HIV patients enrolled at the HIV chronic care clinics 
living in Addis Ababa City administration, Ethiopia. 
 
3.7.3 The target population for qualitative part of patients 
 
The target population for the qualitative strand of short-answered questions were the 
same patients (TB and HIV) and TB/HIV care providers/coordinators who were residing 
in Addis Ababa City Administration. In addition, the targets for FGD study were both TB 
and HIV patients who reside in Addis Ababa City administration.  
 
3.7.4 Accessible population for patients (TB and HIV) 
 
For the qualitative section, the researcher did not embark on selecting a new group of 
samples, but rather the same patients who participated for the quantitative section were 
enrolled. However, very few inclusion and exclusion criteria were used (Section 3.7.7). 
 
3.7.5 Sampling frame for qualitative research 
 
Study participants who were included in the quantitative part were those who continued 
for short-answered interview guided questions. Therefore, there is no separate sampling 
frame for qualitative part for the patients (TB and HIV) and healthcare providers. For 
FGD participants, selected TB and/or HIV patients were included with a mix of age 
categories from both sexes. In addition, those who were not willing were excluded. 
However, those who participated in the quantitative and qualitative interview 
questionnaires were also excluded from the FGD. The proposed sampling frame for the 
qualitative design was to select samples conveniently among TB and HIV patients who 
had participated in the first parts of the quantitative part.  
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3.7.6 Sampling techniques for patients 
 
The researcher employed convenient sampling techniques to interview patients among 
those enrolled for the quantitative section for the short answer qualitative section. 
Therefore, it was decided to interview maximum number of patients from those who 
could deliver relevant information for the open-ended questions presented. 
 
3.7.7 Inclusion and Exclusion criteria 
 
Inclusion criteria were used to accept  those who volunteered to continue for the open-
ended questions, were able to communicate and understood the questions very well. 
Exclusion criteria were used to reject non-volunteers and those who could not 
communicate maturely. 
 
3.7.8 Sampling of healthcare providers or coordinators 
 
The researcher conveniently sampled one TB/HIV care provider from each of the ten 
study health facilities, who at the same time were coordinators for TB/HIV collaborative 
activities for their respective facilities, and regional coordinator of TB/HIV collaborative 
activity for the city administration at the health bureau. Therefore, participants of this 
category for the qualitative study were selected using purposive sampling techniques. 
Purposive sampling is a non-probability sampling method in which the researcher uses 
his/her own judgement regarding the participant from whom information will be collected 
(Polit & Beck 2008:355).  
The researcher usually chooses the sample based on knowledge of the group to be 
sampled and has in mind that respondents have the information required. The main 
disadvantage of this method is its potential for inaccuracy in the researcher’s criteria 
and the resulting sampling selection (Amin, 2005:242; Saunders et al., 2009:237). 
However, all the ten eligible health workers who at the same time were coordinators 
were included, which was not prone to sampling bias and no sample size determination 
technique was applied. 
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3.7.9 Sample size for short-answer interview of patients 
 
The sample size for patient (TB and HIV) interviews was not set initially, as the 
researcher decided on convenient sampling, However, as the quantitative size was 
large,  most patients were approached to continue interviewing the short-answered 
questions that follows the quantitative sections. The number of participants for 
qualitative was less than the quantitative for reasons mentioned above. Similarly, the 
sample size for the health worker interview was 10, i.e., one health worker from each of 
the ten study health facilities. In addition, one regional collaborative TB/HIV care 
coordinator was interviewed for the overall understanding of TB/HIV care using the 
standard monitoring checklist (WHO 2006b).  
 
3.7.10 Sample size for focus group discussion of patients 
 
Polit and Beck (2008:357) suggest that the sample for qualitative study should be based 
on the information needs, hence, the guiding principle in sampling is data saturation 
(sampling to the point at which no new information is obtained and redundancy is 
achieved). In this study, five FGDs for each of TB and HIV patients were planned 
separately but it was conducted with four FGDs among each of TB and HIV patients, as 
information was saturated at the end of the fourth FGDs.  
 
3.7.11 Data collection approach and methods for interview 
 
For the qualitative strand of this study, the researcher used a structured interview guide 
in order to have uniformity in the questions. According to Saunders et al. (2009:320), 
structured interviews are based on identical sets of questions. The interview technique 
is unique in that it involves the collection of data through direct verbal interaction. The 
response rates are usually high during face-to-face interactions, given that many people 
cannot easily fill out questionnaires. The interview situation permits the researcher to 
follow up verbal leads and thus obtain more data and greater clarity of questions which 
seem to be ambiguous or confusing to the participants. The interview also permits 
greater depth than other methods of collecting data, such as questionnaires (Amin, 
2005:274; Polit & Beck, 2008:424). 
Cognizant of this, Polit and Beck (2008:424) highlight that the strengths of interviews 
outweigh those of questionnaires, although they are costly, prevent anonymity and carry 
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the risk of interviewer bias. In addition, the interviewees are less likely to give ‘I don’t 
know’ answers, hence missing information is minimised. In an interview, the order of 
questioning does not matter greatly since the interviewer is at liberty to change the 
order in which the questions are asked. Interviews also help to control the sample since 
the researcher knows whether the participants are the intended target. Lastly, with face-
to-face interviews, additional information such as understanding and the level of 
cooperation can be obtained through the non-verbal observations (Polit & Beck 
2008:425).  
Tthe structured interview guide consisted mainly of open-ended questions based on the 
objectives of the study (Annexures F, G and H).  
 
3.7.12 Data collection during the qualitative study 
 
As mentioned above (section 3.6), the researcher used structured data collection 
techniques to collect data from the healthcare providers, guiding questions for FGD and 
interview guides for interview questions.  
 
3.7.13 Structure of the qualitative questionnaires 
  
The structured interview guide for patients consisted of open-ended questions. The 
interview guide consisted of one part, embedded at the end of the quantitative 
questionnaire (Part IV) for both HIV and TB patients separately (Annexures F and G). 
Separate focus group discussion guides were used for the discussion of patients of both 
TB and HIV separately. In addition, the regional TB/HIV collaborative activity 
coordinator was interviewed for the overall city administration TB/HIV care activity 
implementation status using the standard monitoring checklist developed by the Stop 
TB department of the WHO headquarters (WHO, 2006b). These questions were 
designed to explore information about the status of service delivery and impacts of 
collaborative TB/HIV care services from the clients’ perspectives, and providers’ 
attitudes towards patients and the effect of the services on their lives. Therefore, all the 
questions in all the qualitative sections were open-ended.  
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Patients’ interview questionnaire 
Parts I, II and III of patients’ interview questionnaire consisted of quantitative closed-
ended questions of socio-demographic characteristics, prevalence of TB/HIV, and 
activities to decrease the burden of TB and HIV, as stated in section 3.4.2.3. 
Part IV: consisted of 7 and 10 items of qualitative open-ended questions for TB and HIV 
patients, respectively. The questions explored how collaborative TB/HIV activities 
impact on patients lives. 
 
Patients’ FGD Guide 
A total of 13 questions were used as a guide for the focus group discussion for both TB 
and HIV patients separately (Annexures I and J). The questions explored knowledge 
about TB and HIV diseases, the role of the TB/HIV care services on patients’ health 
conditions, their perceived quality of services and behaviour of healthcare providers 
towards patients. 
 
3.7.14 Construction of the interview schedule 
 
The interview guide for both patients and health service providers was based on the 
theoretical frameworks, literature reviewed, and the objectives of this study. This 
structured interview guide was meant to provide in-depth information about joint TB/HIV 
collaborative activities in the implementation of public health facilities in Addis Ababa. 
 
3.7.15 Structure of the discussion and interview guide for patients and healthcare 
providers 
  
The FGD interview guide consisted of 10 questions or items about the effect of 
provision of integrated TB and HIV services on their health, how patients thought health 
workers assisted them in improving their health, their opinion on the quality of service 
provision in general regarding TB and HIV in their health facilities, how they evaluated 
the behaviour and performances of healthcare providers towards their patients and 
comments of patients to improve the service provision of HIV and TB care in their 
respective health facilities. Finally, HIV patients were asked additional questions to 
understand the occurrences of common HIV-related opportunistic infections for the 
preceding year. Similarly, the structured interview guide for healthcare providers also 
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consisted of open-ended questions. The interview guide consisted of three parts, Parts 
III-V following the quantitative questionnaire. 
Part III consisted of 12 open-ended questions, designed to probe about impacts of 
programme implementation on staff performance. Aspects related to whether related 
trainings had been attended, effects on health workers performances following 
integrated service provision, issues regarding logistical supply, convenience of health 
facility’s physical structure for integrated TB/HIV service provision, facility administration 
conditions and challenges or problems encountered while implementing integrated 
TB/HIV services. Finally, study participates were given a chance to forward their 
recommendations to improve the care provision of collaborative TB and HIV care 
services in public health facilities in Addis Ababa. 
Part IV consisted of five questions on the impact on infrastructure of integrated TB/HIV 
programme implementation. Questions were on imposed renovation or rearrangement 
of health facility infrastructure following commencement of collaborative TB/HIV 
activities, restructured or other instigated cross-cutting services in effect with 
infrastructure change, and the effect on the provision of existing services of the health 
facility, among other topics.  
Part V consisted of seven questions regarding the impact of human resource following 
the commencement of TB/HIV collaborative activities on their respective health facilities. 
Among the questions, effects on human resource workload due to the commencement 
of TB/HIV collaborative activities, how the performance of health workers in the health 
facility affected the new programme, be it through training or experience, schemes of 
assignment of health workers in one of the TB/HIV collaborative activity clinics, 
opportunities created for human resources concerning incentives, and challenges faced 
following TB/HIV collaborative activity. Finally, participants were asked to recommended 
human resource development for TB/HIV collaborative activity improvement.  
 
3.7.16 Administration of the interviews and discussions 
 
The semi-structured interviewer-administered questionnaires used formal and written 
questions that were asked face to face with interactions between the interviewers and 
the study participants. Polit and Beck (2008:429) point out that administering interview 
schedules requires different skills. The quality of interview data relies heavily on 
interviewer proficiency. The researcher tried as far as possible to put the participants at 
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ease so that they felt comfortable in expressing their opinions. The interviews were 
conducted at the respective health facilities of patients and healthcare providers. The 
interviewers tried to keep to the participant’s convenient time and strived to be unbiased 
(Polit & Beck 2008:429). Questions were asked orally in Amharic (official language of 
the city administration), as they appear sequentially on the interview schedule. The 
responses to the qualitative interview questions were recorded with participants’ own 
words in a meaningful way. Audio recording and note taking were both used for all 
FGDs sections.  
The interviewers tried to keep the level of understanding of participants’ pace for 
responses and sometimes had to repeat the questions when required, in order to elicit 
more useful information. Before the interviews commenced, the interviewers explained 
the purpose and procedure, and requested written and oral consent to use an audio 
tape-recorder (Polit & Beck 2008:386). The study participants were assured that all the 
information they provided would be treated with utmost confidentiality. The interviews 
commenced after informed written consent had been given. The participants were 
assured that they were free to terminate the interview at any time, even if they had 
consented earlier. Immediately after the interviews for the qualitative part, the data was 
transcribed in full (Saunders et al., 2009:485),  immediately after each session.  
 
3.7.17 Criteria for enhancing quality and integrity of qualitative data 
 
Strauss and Corbin (1990:17) define qualitative research broadly as “Gany kind of 
research that produces findings not arrived at by means of statistical procedure or other 
means of quantification and instead as a kind of research that produces findings arrived 
from real-world setting where the ‘phenomenon of interest unfold naturally,” as Patton 
(2002:39) states. Both qualitative and quantitative researchers need to test and 
demonstrate that their studies are credible. While credibility in quantitative research 
depends on instrument construction, the researcher is the instrument in qualitative 
research (Patton, 2002:14). Although reliability and validity are treated separately in 
quantitative studies, these terms are not viewed separately in qualitative research, but 
rather the terminology that encompasses both, such as credibility, transferability, and 
trustworthiness, is used (Golafshani, 2003:600).  
Lincoln and Guba (1985, cited in Polit and Beck, 2008:539) propose four constructs for 
measuring the trustworthiness or soundness of the qualitative research design, namely 
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credibility, transferability, dependability, and confirmability. The researcher made use of 
these to ensure the trustworthiness of the findings. Different techniques were utilised to 
ensure that these four qualitative assumptions were tested and met.  
• Credibility: refers to the how well the subjects of the study are accurately 
identified and described by the inquiry (Troiano, 2003:404). Polit and Beck 
(2008:539) refer to credibility as the confidence in truth of data and its 
interpretation. Credibility was ensured through member checking and peer 
debriefing (Lincoln & Guba, 1985, cited in Polit & Beck, 2008:545). The 
researcher took comprehensive field notes, audio-taped the interviews and as far 
as possible used participants’ own words in transcription of the interviews.  
• Dependability: refers to the stability of data over time and over relatively similar 
conditions (Polit & Beck, 2008:539). For Troiano (2003:404) it measures the 
researcher’s ability to account for changes in the phenomenon under study. The 
researcher strengthened dependability through checking and re-checking of the 
presence or absence of the phenomenon by careful documentation of the 
interviews. In addition, dependability was ensured through space, person, 
investigator, and methodological integration (triangulation) of data. Lastly an 
‘inquiry audit’ by an external reviewer was used to enhance the dependability 
(Polit & Beck 2008:549). 
• Confirmability: Polit and Beck (2008:539) refers to this the congruence between 
two or more independent people about the accuracy, relevance, and meaning of 
data. In other words, it is a measure of the researcher’s objectivity. It was 
reinforced through an audit trail, inter-coder checks or inquiry auditor as well as 
peer review and debriefing (Polit & Beck 2008:544).  
• Transferability: refers to the extent to which the findings can be applied or have 
applicability in other settings or groups (Polit & Beck 2008:539). The applicability 
of one set of data was achieved through triangulation by use of multiple 
informants and data collection methods. The applicability was also ensured 
through taking of comprehensive field notes and ensuring that adequate sample 
until data saturation was reached (Polit & Beck, 2008:544; Troiano, 2003: 404).  
• Authenticity: refers to the extent to which the researcher fairly and faithfully 
showed a range of different realities. According to Polit and Beck (2008:540), 
authenticity emerges in a report when it conveys the feeling tone of participants. 
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It was ensured through audio-taping and verbatim transcription of the interviews, 
as well as through prolonged engagement with the participants.  
 
3.7.18 Data analysis 
 
Qualitative research is increasingly common in health service research (Bradley, Curry 
& Devers 2007:1758). The analysis of qualitative data is a labour-intensive activity and 
requires creativity, conceptual sensitivity, and hard work (Polit & Beck 2008:507). The 
analysis of qualitative data is an active and interactive process. Generally, qualitative 
data is challenging, even to experienced researchers, because of the lack of universal 
rules for data analysis, the large amount of work required and the necessity to reduce 
data for reporting purposes. Data analysis in qualitative research usually begins during 
the process of data collection, mainly because the results of early data collection guide 
subsequent data collection and allow timely theorising about results (Polit & Beck, 
2008:507-508). 
 
3.7.19 Processing of interview data 
 
According to Miles and Huberman (1994, cited in Cohen, Manion & Morison, 2000:283), 
the following tactics are suggested for generating meanings from transcribed and 
interviewed data: 
• counting frequencies of occurrences of themes; 
• noting patterns of the themes, which may originate from repeated themes; 
• seeing plausibility – trying to make good sense of data, using informed intuitions 
to reach conclusion; 
• clustering-setting items into categories;  
• identifying and noting relations between themes; 
• building a logical chain of evidence by noting causality and making conclusions;  
• Making conceptual coherence by moving from constructs to theories to explain 
the phenomena. 
The researcher employed the following steps when processing the data from the audio-
taped interviews and field notes: 
• listening to the data from each set without writing down anything; 
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• listening to the data the second time and noting the themes and patterns that 
emerged as characteristics about implementation status of TB/HIV collaborative 
activities;  
• writing down the themes as categories as they appeared in each set of data. 
These themes were laid out on a chart such that the information from each case 
was visible. Codes were developed from these themes that related to the 
research questions; 
• using the codes form each theme, to revisit the data sets and code the relevant 
segment in each theme;  
• from the data recorded against each theme, aggregating the answers to the 
relevant research questions. 
 
3.7.20 Analysis of interview data 
  
Bradley et al. (2007:1758) and Polit and Beck (2008:509) write that the analysis of 
interview data involves a systematic approach for discovering and categorising ideas 
that are conveyed by the study participants. The first step in data analysis is a data-
coding process, defining categories and giving a wealth of ideas order and structure. 
The codes are tags or labels assigned to the whole or segments of the document to 
help catalogue key concepts while preserving the context in which they occur (Bradley 
et al., 2007:1761). From the different approaches that may be followed in qualitative 
data analysis, the researcher selected Strauss and Corbin’s (2008) grounded theory 
approach (in Saunders et al., 2009:509). This was used to analyse both the patients 
and heath service providers’ interviews. 
 
3.7.21 Strauss and Corbin’s grounded theory approach 
 
Strauss and Corbin’s approach (in Saunders et al., 2009:509) involves a complex 
coding process designed to break down the data, create meaning, and then put data 
back together in new and different ways. The analysis consists of three major types of 
coding: open, axial, and selective (Saunders et al., 2009:509). Open coding involves the 
naming and categorising of phenomena through close examination of the data with 
similar events and incidents grouped together. (Saunders et al., 2009:509; Troiano, 
2003:406). The grouping of events and incidents led to the discovery of a number of 
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categories during open coding. The axial coding allowed the researcher to reassemble 
data that was ‘fractured’ during open coding in new ways, by linking categories with 
subcategories. Therefore, based on the results of the interviews, the researcher yielded 
a set of categories for further analysis (Saunders et al., 2009:510; Troiano, 2003:406). 
Selective coding is the process by which the categories are integrated to form core 
category as the central phenomenon around which all other categories are related 
(Saunders et al., 2009:510; Troiano, 2003:407). 
Open coding involved the process by which the content of the interview was carefully 
searched for discrete instances of both patients and health services providers’ ideas 
about implementation status of TB/HIV collaborative activities. Once the main idea was 
identified, the identified concepts were grouped according to their properties. After 
performing these coding procedures, combined axial coding was performed on a 
collection of results. Once the categories were identified and given a name, they were 
characterised by their relationships to the main phenomenon or idea. The coding results 
therefore provided a comprehensive summary of the contents of the collection of the 
interviews. 
 
3.8 ETHICAL CONSIDERATIONS 
 
De Vos et al. (2005:57) define ethics as “Gpreferences that influence behaviour in 
relations”. Ethics are mostly associated with morality and deal with issues of rights and 
wrong among societies. Therefore, ethics in the use of human subject for research 
should not go without careful examination. Amin (2005:28) writes that ethics refers to  
“well based standards of right and wrong that prescribe what humans ought to do 
usually in terms of rights, obligations benefits to society, fairness, or specific virtues.” 
Polit and Beck (2008:753) describe ethics as a system of moral values concerned with 
the degree to which research procedures adhere to professional, legal, and social 
obligations of the participants. Therefore, ethical consideration in research should 
consider fairness, honesty, openness, disclosure of methods and the purpose for which 
the research is being carried out. Based on this understanding, the researcher followed 
the following ethical standards. 
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3.8.1 Protecting the participants 
 
Every individual is entitled to the right of privacy and dignity, and the researcher treated 
the participants with respect and sought their cooperation through informed consent 
(Polit & Beck, 2008:171). Amin (2005:40) and Saunders et al. (2009:187) write that 
participants should be told of the research interest and should give permission to 
proceed. The researcher ensured that the study participants were identified are 
protected, and that the information collected does not harm them in any way. Therefore, 
no participants’ names were recorded in any form on the questionnaires, thus ensuring 
anonymity and confidentially (Polit & Beck, 2008:170). The researcher did not at any 
time relate any information collected to any other individual. The researcher only 
collected data necessary for this study and made the necessary effort to disclose and 
explain how the participants would benefit from the results of this study. It was important 
for the participants to understand the value of the study and how the information will be 
used before they give their consent. Participation was voluntary and participants were 
informed of their right to withdraw from the study even if they had initially given their 
written consent. No form of coercion was used for those individuals who refused to 
participate in the study (Polit & Beck, 2008:172). For participants younger than 18, 
consent was obtained from their guardians, but discussions were held mainly with the 
patients themselves under the support of their guardians. 
 
3.8.2 Protecting the right of the Institution 
 
The researcher had already been awarded ethical clearance from the Research and 
Ethics Committee at the Department of Health Studies of the University. The researcher 
had presented the certificate of ethical clearance of UNISA to Addis Ababa City 
Administration Heath Bureau to gain clearance to collect data in Addis Ababa City 
Administration public health facilities. At the health facility levels, permission was 
requested from regional health bureau and the respective heads of the hospitals and 
health centres. The researcher made a promise to abide with the agreements made 
during the negotiations for permission to conduct the study (Polit & Beck, 2008:188). 
Furthermore, the study health facilities from which the participants were drawn were 
identified by level of health facility and name.  
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3.8.3 Scientific integrity of the research 
 
The researcher respected the work of others through acknowledging the sources. The 
researcher was objective and used objective methods to collect, analyse and reporting 
the study results. Therefore, the researcher has chosen the methodology to use based 
on the research objectives and not any other reason. The data was interpreted 
according to methodological standards and not the researcher’s opinion or bias. The 
researcher described the truth of the findings when writing and reporting them up by 
properly explaining the methods used and reasons for doing so. No fabrication or 
distortion of data was done to fit what the researcher wanted to achieve (Polit & Beck, 
2008:188). The researcher reported what data revealed as outlined by Amin (2005:30) 
and Saunders et al. (2009:188.).  
The researcher protected the privacy and confidentiality of study participants. The 
conducted study was considered as having low risk as it did not introduce any invasive 
procedures or collection of any specimen from the participants. Therefore, there was no 
anticipated harm this study would cause to the participants. 
 
3.9 CONCLUSION 
 
In this chapter, the researcher has presented the research design and methodology 
employed for the study. The mixed methods and triangulation designs have been 
presented in detail and the sampling techniques have been outlined. The structure of 
the data collection instruments have been presented and strategies used to ensure 
validity and reliability of study were presented in detail. Lastly, the researcher has 
outlined the methods used to ensure that data was collected, analysed and reported in 
an ethical way.  
In the next chapters (chapters 4 and 5), the researcher presented analysis and 
interpretation of the research findings. 
 CHAPTER FOUR 
QUANTITATIVE DATA PRESENTATION, ANALYSIS AND DISCUSSION 
 
4.1 INTRODUCTION 
 
In this chapter, the findings of the quantitative data are presented, interpreted, analysed 
and discussed in comparison with previous researches on the area of the study. The 
chapter begins with an introduction, followed by details of  how questionnaires were 
administered, and then described the findings of the quantitative data under several 
sub-topics. The chapter will be summarised by key findings from the quantitative data. 
The purpose of this study was to provide guidance in promoting the implementation of 
collaborative TB/HIV activities in Addis Ababa and to increase better knowledge to 
healthcare workers in this area of practice.  
The research objectives for quantitative design were to:  
• determine HIV prevalence among TB patients in Addis Ababa 
• determine TB prevalence among HIV patients in Addis Ababa 
• determine the implementation status of collaborative TB and HIV Care services 
(quantitative finding) 
• recommend to policymakers and practitioners the technical basis to guide the 
implementation of collaborated TB/HIV activities based on findings of this study. 
In the following sections, the quantitative findings which answer some of the research 
questions are presented. In the next chapter (5), findings from the qualitative data are 
discussed. 
 
4.2 ADMINISTRATION OF QUESTIONNAIRE 
 
The questionnaires (Annexures F and G) for both TB and HIV patients were 
administered by ten research assistants by interview (interviewer administered). Sample  
size of study participants for each category (health centre and hospital) of the health 
facilities was set (Chapter 3, section 3.5). Each study facility was given a unique 
identification code number for data entry purpose, and questionnaires for each facility 
were numbered consecutively, starting from 001 up to the last questionnaire until the 
required sample size for the study site reached. Assigning consecutive numbers for the 
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questionnaires was carried out to re-check the data completeness and consistency 
during and after data entry or data clearing, but not for identifying participants. In 
addition, collecting unique identification from study participants was minimised to ensure 
the anonymity of the study participants.  
The research sample for quantitative data for both TB and HIV patients was 1,730 (865 
for each of the TB and HIV patients). The questionnaires for TB and HIV patients were 
of similar design, but constructed differently based on their disease conditions in a way 
designed to gather information for activities to decrease the burden of TB/HIV in respect 
to their current disease. As a result, data from 1,683 (834 TB patients and 849 HIV 
patients) data was collected from the interviewer-administered quantitative parts from 
both TB and HIV patients, which made a 97.3% (96.4% TB patients and 98.2% HIV 
patients) response rate (section 4.3).  
Data analysis and presentation was based on the number of complete responses to 
each of the respective question. The missing data did not pose any problem with 
analysis or interpretation because respondents still totalled more than 1,557, which was 
the minimum figure the researcher aimed at. Data was presented according to the three 
sections of the quantitative part in a sequence presented on the questionnaire. 
 
4.3 RESPONSE RATE 
 
Polit and Beck (2008:765) describe the response rate as calculated by dividing the 
number of persons participating in the study by the number sampled. Table 4.1 shows 
the response rate for quantitative data of this study. 
 
Table 4.1: Response rate for the quantitative study, Addis Ababa City Administration, August 2011 
Data type 
Number of 
questionnaire 
administered 
Number of 
questionnaire 
completed 
Percent 
(%) 
Reason for 
difference 
Quantitative questionnaire for TB 
patients 
865 834 96.4 
Incompleteness 
or inconsistency 
of data 
Quantitative questionnaire for HIV 
patients 
865 849 98.2 
Incompleteness 
or inconsistency 
of data 
Quantitative questionnaire for TB/HIV 
care providers and/or Facility TB/HIV 
care coordinators 
10 10 100  
Total number of usable 
questionnaires  
1730 1683 97.3  
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As shown in Table 4.1, the response rate for the quantitative study was 97.3%, which is 
considered to be very good. This high rate of study participation was the result of the 
interviewer administered questionnaire and may be an indication that the questions 
were interesting to the participants given that the questionnaire items were directly 
related to the patients’ health conditions.  
 
4.4 DATA ANALYSIS 
 
Data analysis is the systematic organisation, synthesis of research data and testing of 
the hypothesis using the raw data (Polit & Beck, 2008:751). Saunders et al. (2009:587) 
describe data analysis as the ability to break down data and clarify the nature of the 
factors and the relationships between them. Therefore, the objective of data analysis is 
to respond to the research questions or study objectives. According to Wood and Ross-
Kerr (2006:243), a plan for data analysis comes from the research objectives, the 
research design, methods of data collection used, and the level of measurement of 
data. The following sub-sections describe data analysis principles employed in this 
study. 
 
4.4.1 Statistical analysis programme 
 
A Statistical Package for Social Sciences Study (SPSS, 2006) version 15 was used to 
analyse the data. A statistician was contracted to assist the researcher to analyse the 
data. Both descriptive and inferential statistics were used for data analysis. A P-value of 
less than 0.05 (p<0.05) was set as the level of statistical significance for the tests 
performed. 
 
4.4.2 Data cleaning, checking for completeness and consistency 
 
According to Arthur (2005), data cleaning:  
‘’...is a process used to determine inaccurate, incomplete, or unreasonable data 
and then improving the quality through correction of detected errors and 
omissions. The process may include format checks, completeness checks, 
reasonableness checks, limit checks, review of the data to identify outliers 
(geographic, statistical, temporal or environmental) or other errors, and 
assessment of data by subject area experts.’’ 
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In this study, data was manually cleaned during data collection, entry and before 
analysis. During data cleaning, completeness and consistency of each of the 
questionnaires were checked before analysis. As a result, all data found to be 
incomplete or inconsistent was discarded from the final analysis.  
Consistency of the data was checked before data entry and after entry by SPSS data 
split and select analysis. For example, the sex of the participant is denoted by male and 
female on the questionnaire, therefore, SPSS Data ‘select cases’ identifies those who 
are male, but occupation denoted to be housewives, so that data would be either 
checked from the hard copy of the questionnaire for correction or discarded. Another 
example, if an HIV patient said s/he had never received IPT, one should not expect this 
study participant to report where s/he refilled the drug INH. This is actually skipping 
patters where data collectors sometimes miss to skip. 
 
Completeness of data is the extent to which its expected attributes are provided 
(Execution MiH, [s.a]). All the questionnaires were checked for completeness by data 
entry personnel before data entry. Incomplete questionnaires were not included for data 
entry or final analysis.  
 
4.4.3 Reliability of the data collection tool 
 
Reliability is defined as the degree of consistency with which a research instrument 
measures a given attribute (Polit & Beck, 2008:764), hence, a reliability test measures 
how consistent the participants were in answering a group of related questions. Before 
collecting the data for individual groups of patients (TB and HIV patients), the 
researcher had to make sure all the questionnaire items were reliable. The reliability of 
the data collection tool was insured by correlating the individual questionnaire items to 
complementary ideas, such that it measured the same thing. This was made possible 
by adopting the standard TB/HIV monitoring tool (WHO, 2006a) and cross-checking the 
policy documents of TB/HIV collaborative activities (WHO, 2012a) to insure all activities 
mentioned were included in a sequential manner during developing the questionnaire 
items. 
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4.5 QUANTITATIVE DATA PRESENTATION, ANALYSIS AND DISCUSSION 
 
Data that can be quantified and verified, and is amenable to statistical manipulation. 
Quantitative data defines whereas qualitative data describes (BusinessDictionary, [s.a]).  
Quantitative Research options have been predetermined and a large number of 
participants were involved. By definition, measurement must be objective, quantitative, 
and statistically valid. It involves numbers and objective hard data (Qualitative and 
Quantitative research, [s.a]).  
 
4.5.1 Data from Patients (TB and HIV patients) 
 
The findings from interviewer-administered patient interview quantitative data is 
presented in the following sub-sections. 
 
4.5.2 Descriptive Statistics 
 
Descriptive statistics are used to describe the basic features of the data in a study. They 
provide simple summaries about the sample and the measures. Together with simple 
graphics analysis they form the basis of virtually every quantitative analysis of data 
(Research Methods, [s.a]). Descriptive Statistics are used to present quantitative 
descriptions in a convenient type. In a large research study, a large number of people 
may be measured on any measure. Descriptive statistics help to simplify a large 
quantity of data in a meaningful way. All descriptive statistics reduce large quantities of 
data to a simpler summary (Measurement, [s.a]). In the following sections, the findings 
of the quantitative data are described. 
 
4.5.2.1 Section I: Socio-Demographic Data 
 
Section I of both TB and HIV questionnaires consisted of seven items, namely age, sex, 
marital status, religion, ethnicity, educational status, and occupation. The socio-
demographic characteristics of both TB and HIV patients are presented in the following 
sections. 
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4.5.2.1.1 Study participants by number 
A total of 1,683 of both TB and HIV patients participated in this study, of whom 834 
were TB patients and 849 HIV patients (Table 4.1). From each of the ten sub-city 
administrations in Addis Ababa, one health facility was selected randomly, of which two 
hospitals were included, based on their optimal cumulative TB/HIV patient load (detailed 
in Chapter 3). Data was collected from different parts of the city and facility set-ups 
(health centre and hospital) to minimise information bias. Accordingly, the number of 
sampled study participants for each level of health facility was calculated based on their 
overall TB/HIV follow-up patient load of both TB and HIV (Chapter 3).  
Based on this, the two hospitals’ patient load was found to be approximately equal; from 
each of them, 225 of both TB and HIV (each of 112 and 113 patients) were included. 
Similarly, the average patient loads for most of the health centres were again 
comparable; therefore, from each a total of 160 of both TB and HIV (each of 80 
patients) were enrolled in this study (detailed in Chapter 3, section 3.5), and 1730 
participants were planned to be included. Finally, however, 1683 patients of both TB 
and HIV (834 TB patients and 849 HIV patients) were found to be valid for final 
presentation and analysis in the study (Table 4.2). 
 
Table 4.2: Number of Study Participants by health facility and category of disease 
Name of Health Facility 
TB Patients HIV Patients 
Frequency Percent Frequency Percent 
Zewditu Memorial hosp 112 13.4 124 14.6 
Menelik II hospital 113 13.5 106 12.5 
Kazanchis health centre 79 9.5 79 9.3 
Bole health centre 80 9.6 80 9.4 
Nefasilik lafito No2 health 
centre 
79 9.5 77 9.1 
Lideta health centre 54 6.5 69 8.1 
Kality health centre 80 9.6 79 9.3 
Yeka health centre 80 9.6 78 9.2 
Woreda 7 health centre 78 9.4 80 9.4 
Gulele health centre 79 9.5 77 9.1 
Total 834 100.0 849 100.0 
 
102 
4.5.2.1.2 Age of study participants 
The mean ± SD age of TB patients was 31.3 ± 11.9 years with minimum age of 15 
years and maximum of 86; whereas, the mean ± SD age of HIV patients was 33.8 ± 9.9 
years with minimum and maximum age of 16 and 76, respectively. Children under the 
age of 18 (15-17) accounted for small proportions in both groups of study participants. 
But the proportion of study participants whose age <18 was slightly higher for TB 
patients than the proportion for HIV patients. On the other hand, the proportion of late 
age (50+ years) study participants in both groups was approximately equal (table 4.3).  
 
Table 4.3: Proportion of study participants by age group and category of disease 
Age 
Group 
TB Patients HIV Patients 
Frequency Percent Frequency Percent 
(15-17) 36 4.3 11 1.3 
(18-24) 223 26.7 110 13.0 
(25-29) 195 23.4 198 23.3 
(30-39) 231 27.7 334 39.3 
(40-49) 80 9.6 126 14.8 
(50+) 69 8.3 70 8.2 
Total 834 100.0 849 100.0 
 
As shown above in Table 4.3, the larger group of participants were in the age group of 
18-39 in both groups, accounting for 77.8% of TB patient study participants. The same 
age group of HIV patients accounted for 75.6%. In general, the TB patients were slightly 
younger than HIV patients (Figure 4.1).  
 
Figure 4.1: Age Group of Participants by Category of disease, Addis Ababa, August 2011 
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4.5.2.1.3 Sex of study participants 
 
 
Table 4.4: Proportion of study participants by Sex and category of disease 
Sex 
TB Patient HIV Patient 
Frequency Percent Frequency Percent 
Male 364 43.6 257 30.3 
Female 470 56.4 592 69.7 
Total 834 100.0 849 100.0 
 
As it is shown in the above table (table 4.4), females were in a higher proportion in both 
groups. This was not because of sample selection, as samples were taken randomly 
without any preference. Also, the proportion of females (about 2.3 times higher than 
males) in HIV patients was significantly higher than the proportion in TB patients (about 
1.3 times higher). This finding is consistent with the national HIV prevalence of Ethiopia 
(FMOH 2007a), which shows females to be more commonly affected than males. 
However, this proportion is unlike a research finding in India which showed males to be 
about 1.3 times more likely to be infected than females (Neeraj, Lakbir, Ajay, Jotna, 
Fraser, Suvanand, Rahul & Puneet 2008: e2970). 
 
    
Figure 4.2: Proportion of study participants by sex and category of disease (4.2a-TB Patients, 4.2b-HIV 
Patients), Addis Ababa August 2011  
 
These findings may be similar to those elsewhere in other countries. Exposure to 
infectious diseases is related to activities that dictate where people spend the day. Men 
and women have different activity patterns related to gender differences in occupation 
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and in family roles. For example, in many societies females spend more time at home 
than males during the day, and therefore experience greater daytime household 
exposure to infection. Caring for the sick carries an increased risk of exposure, 
especially for diseases that are spread directly from person to person. In most societies 
females are more likely to care for the sick than are males (WHO, 2007a).  
 
4.5.2.1.4 Marital status of study participants 
 
Table 4.5: Proportion of study participants by Marital Status and category of disease 
Marital 
Status 
TB Patients HIV Patients 
Frequency Percent Frequency Percent 
Single 357 42.8 198 23.3 
Married 386 46.3 415 48.9 
Divorced 48 5.8 80 9.4 
Widowed 28 3.4 124 14.6 
Separated 15 1.8 32 3.8 
Total 834 100.0 849 100.0 
 
In both TB and HIV participants, married patients accounted for the highest (46.3% and 
48.9%, respectively) compared with the other statuses. However, nearly half (48.9%) of 
HIV patient study participants were married, which was slightly more than double the 
singles (23.3%); whereas, 46.3% of TB patients were married, which was slightly higher 
than the singles (42.8%).  
 
Figure 4.3: Proportion of study participants by marital status and category of disease, Addis Ababa 
August 2011  
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As shown above (Figure 4.3), the majority of study participants were either single or 
married (89.1% =TB patients and 72.2% = HIV patients). The proportion of unmarried 
(single) for TB patients was significantly higher (42.8%) than those of HIV (23.3%) 
counterparts. On the other hand, the proportion of HIV patients in all marital statuses, 
except single, were higher than TB patients. Significantly, a higher proportion of HIV 
patients (14.6%) than TB patients (3.4%) were widowed, which may indicate that deaths 
attributed to HIV infection lead to loss of partner among PLHIV. Therefore, from this 
study one can conclude that those who had not married were more highly exposed to 
HIV than to TB disease.  
 
4.5.2.1.5 Religion of study participants 
Table 4.6: Proportion of study participants by Religion and category of disease 
Religion 
TB Patient HIV Patient 
Frequency Percent Frequency Percent 
Christian 674 80.8 701 82.6 
Muslim 160 19.2 148 17.4 
Total 834 100.0 849 100.0 
 
 
 
 
 
Figure 4.4: Proportion of study participants by religion and category of disease (4.4a-TB Patients, 4.4b-
HIV Patients), Addis Ababa August 2011 
 
Table 4.6 (above) shows Christians of all types accounted for the majority of the religion 
shared among both sets. This finding could be consistent with the overall demographic 
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situation of Addis Ababa, where the majority of the residents of the City Administration 
are Christians (Central Statistical Agency of Ethiopia [CSA-E], 2007).  
The reason for merging all types of Christians together in this study is the similarity of 
the doctrines and to reduce bias attributed to the differences in the findings during 
analysis. In the demographic and health survey of Ethiopia, all subtypes of Christians 
who follow the doctrine of the Bible are put in different categories. Based on the 
Ethiopian 2007 CSA (CSA, 2007) data for Addis Ababa, the religion with the most 
believers in the city is Ethiopian Orthodox, with 74.7% of the population, while 16.2% 
are Muslim, 7.77% Protestant, and 0.48% Catholic. The finding in this study reflects 
these figures.  
There may be those who were neither Christian nor Muslim, but the finding could not 
detect any, despite the option of ‘other’ on the questionnaire.  
 
4.5.2.1.6 Ethnicity of study participants 
Table 4.7: Proportion of study participants by Ethnicity and category of disease 
Ethnicity 
TB Patients HIV Patients 
Frequency Percent Frequency Percent 
Amhara 373 44.7 433 51.0 
Oromo 220 26.4 217 25.6 
Gurage 135 16.2 100 11.8 
Tigre 68 8.2 81 9.5 
Not mentioned 2 .2 0 0 
Other 36 4.3 18 2.1 
Total 834 100.0 849 100.0 
 
Amhara and Oromo dominated for the ethnic groups in both groups. Among the HIV 
patients, the proportion of Amhara (51.0%) was almost double that of Oromo (25.6%), 
whereas among the TB patients, Amhara and Oromo together accounted for 44.7% and 
26.4%, respectively (Table 4.7).  
According to the 2007 national census conducted by the Central Statistical Agency of 
Ethiopia (CSA 2007), the proportion of ethnic groups in Addis Ababa include the 
Amhara (47.04%), Oromo (19.51%), Gurage (16.34%), Tigray (6.18%), Silte (2.94%), 
and Gamo (1.68%). Therefore, the proportion found in this study is almost consistent 
with the CSA demographic data for Addis Ababa City Administration. 
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Figure 4.5: Proportion of study participants by Ethnicity and category of disease 
 
4.5.2.1.7 Educational Status of study participants 
 
Table 4.8: Proportion of study participants by Educational status and category of disease 
Educational 
Status 
TB Patient HIV Patient 
Frequency Percent Frequency Percent 
Illiterate 179 21.5 197 23.2 
Primary (1-6) 232 27.8 247 29.1 
Secondary (7-12) 344 41.2 325 38.3 
Tertiary (12+) 79 9.5 80 9.4 
Total 834 100.0 849 100.0 
 
In both groups of study participants, those who completed secondary education 
accounted the largest proportion, with 41.2% and 38.3% for TB and HIV patients, 
respectively. Similarly, those illiterate, primary educated and tertiary levels shared 
almost similar proportions across both groups. In general, those who learned above 
secondary (tertiary) levels shared the least in both TB and HIV patients.  
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Figure 4.6: Proportion of study participants by educational status and category of disease 
 
4.5.2.1.8 Occupation of study participants 
 
Table 4.9: Proportion of study participants by occupation and category of disease 
Occupation 
TB Patient HIV Patient 
Frequency Percent Frequency Percent 
House wife 147 17.6 168 19.8 
Government 
employee 
61 7.3 68 8.0 
Nongovernmental 
employee 
23 2.8 29 3.4 
Private employee 201 24.1 153 18.0 
Self 
employed/merchant 
118 14.1 159 18.7 
Unemployed 231 27.7 225 26.5 
Other 53 6.4 47 5.5 
Total 834 100.0 849 100.0 
 
 
Slightly more than a quarter of study participants in both TB and HIV patients were 
found to be unemployed, with rates of 27.7% and 26.5% respectively. Nearly a quarter 
(24.1%) of TB patients included in the study were employees of private organisations, 
whereas about a fifth (19.8%) of HIV patients were housewives. In both groups these 
accounted for the second larger proportions in the classification of occupation. The rest 
of the occupations shared almost similar proportions in both groups of patients. 
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The findings of greater unemployment rate (27.7% for TB patients and 26.5% for HIV 
patients) in this study were higher than those from other sources of urban 
unemployment rates in Ethiopia; for example, an article posted by Daniel Berhane on 
April 27, 2011 on a web page (Daniel, 2011) showed the urban unemployment rate in 
Ethiopia had dropped to 18.9%.  
 
 
Figure 4.7: Proportion of study participants by occupation and category of disease 
 
However, it can be clearly explained that those groups who are unemployed are highly 
vulnerable to communicable diseases, which is consistent with findings elsewhere in the 
world. For example, a study by Cohen (1999:246) examined the prospective association 
of several markers of social status (unemployment, perceived and observed social 
status) with host resistance to upper respiratory infections, which 
showed unemployment was associated with increased susceptibility to infection in adult 
humans. 
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4.5.2.2 Section II: Prevalence of HIV among tuberculosis patients and 
tuberculosis prevalence among HIV patients 
 
Section II of TB and HIV questionnaires consisted of 13 and 12 items, respectively. The 
main aim was to determine the prevalence of HIV among TB patients and vice versa.  
 
4.5.2.2.1 How long have you been diagnosed with current disease and length of 
treatment? 
In this section, the two categories of study participants were asked how long they had 
been in their disease conditions. In addition, the two categories were asked accordingly 
how long they had been on treatment for their disease conditions. Results are 
presented below. 
 
4.5.2.2.2 How long have you been diagnosed for TB and duration on treatment? 
 
Table 4.10: Duration of TB disease and duration since on anti-TB treatment in months 
Duration of TB disease 
and length of treatment 
TB disease Anti-TB treatment 
Frequency Percent Frequency Percent 
Less than 2 months 394 47.2 428 51.3 
2-5 months 322 38.6 306 36.7 
6-8 months 79 9.5 72 8.6 
More than 8 months 39 4.7 28 3.4 
Total 834 100.0 834 100.0 
 
As shown above (Table 4.10), the majority of the interviewed TB patients were in their 
intensive phase therapies (less than 2 months). On the other hand, less than 10% were 
in their 6-8 final months of continuation therapy phases. Nearly 5% were in more than 
the DOTS range of treatment (6-8 months), which could be either in their treatment 
failure or retreatment phase, or mean they were defaulters.  
Another explanation for the higher proportion of TB patients in their earlier phase could 
be the increasing incidence of the infection in the city administration, perhaps 
attributable to HIV infection, high rates of malnutrition and poor housing standards. A 
study in Adama Ethiopia by Ligidi, Gebre-Selassie and Tsegaye (2011:75) on ‘The 
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immunological status of newly diagnosed tuberculosis patients co-infected with human 
immunodeficiency virus-1 revealed that 85.3% of TB patients were not aware of their 
HIV sero-status prior to the screening in the study. 
Slightly higher than half (51.3%) of the TB patient were found at their intensive phase 
therapy, whereas the second larger proportion (36.7%) were on their 2-5 months of 
continuation therapy (Figure 4.8). 
 
 
Figure 4.8: Duration of TB disease and duration of treatment by percentage, TB patients 
 
4.5.2.2.3 How long have you been diagnosed HIV-positive? 
Table 4.11: How long have you been diagnosed HIV-positive? 
Duration since first diagnosed for 
HIV+ 
Frequency Percent 
Less than 6 months 124 14.6 
6-11 months 91 10.7 
1-3 years 300 35.3 
More than 3 years 334 39.3 
Total 849 100.0 
 
It can be clearly observed from Table 4.11 (above) that for quite larger proportions of 
HIV patients it had been more than three years (39.3%) since diagnosis for the 
infection. Similarly, those for whom it was 1-3 years since they learnt their positive HIV 
status accounted for 35.3% of all HIV-positive study participates. For only about a 
quarter (25.3%) was it less than a year since they had been diagnosed HIV-positive. 
This finding may lead to various conclusions, new infection (incidence rate) for HIV 
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could be decreasing, and/or death rates could be decreasing (prevalence rate 
increasing) attributed to HIV infection. On the other hand, the lower proportion of HIV-
infected people at their short duration could be due to increased awareness of the 
general population to get tested for HIV. As a result, a higher proportion of the low risk 
sub-group diluted the proportion of the overall HIV-positive status.  
 
4.5.2.2.4 How long have you been on HAART?  
 
Table 4.12: How long have you been on HAART? 
Duration since on HAART Frequency Percent 
Less than 6 months 149 17.6 
6 months – one year 105 12.4 
More than one year 451 53.1 
Not yet started 144 17.0 
Total 849 100.0 
 
More than half (53.1%) of the HIV-positive study participants had been on HAART for 
more than one year, whilst those on HAART for less than six months (17.6%) were 
proportional to those who had not yet started on treatment (17.0%) at the time of 
interview (Table 4.12, above).  
 
4.5.2.2.5 Have you ever been tested for HIV or diagnosed with TB before you knew 
your current disease?  
In this question, the two categories were asked accordingly whether they had been 
tested for HIV or diagnosed for TB before they knew their current disease of TB and 
HIV, respectively. The findings for both TB and HIV study participants are presented 
below (Table 4.13). 
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Table 4.13: Have you ever been tested for HIV before you knew your TB disease or ever been diagnosed 
with TB before your HIV-positive status? 
Ever been tested for HIV or 
TB before diagnosed with TB 
or HIV disease 
TB Patients HIV Patients 
Frequency Percent Frequency Percent 
Yes 445 53.4 167 19.7 
No 381 45.7 676 79.6 
I do not remember 8 1.0 6 0.7 
Total 834 100.0 849 100.0 
 
Just above half (53.4%) of TB participants had been tested for HIV before they were 
diagnosed with TB. This may be attributed to increased awareness amongst the general 
population of voluntary counselling and testing for HIV, and improved access to 
counselling and testing centres for HIV in the country. In Ethiopia, there are about 2,023 
(NARC-E, 2012b) HIV testing and counselling centres and in Addis Ababa alone, with 
around 299 (NARC-E, 2012c) HIV counselling and testing centres available free of 
charge.  
  
Figure 4.9: Proportion of patients diagnosed for TB for HIV patients and tested for HIV for TB before 
being diagnosed for the current disease 
 
The finding revealed that a fifth of people living with HIV had a history of being 
diagnosed for TB before they learnt their HIV-positive status, with 19.7% having had TB 
disease before they knew they were HIV-positive. This could be logical evidence that 
some HIV-positive people might have been infected with HIV before their TB diseases, 
and so supplements prior findings that HIV is one risk factor for development of TB 
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disease (National Prevention Information Network [NPIN] [s.a]). Conversely, the finding 
may show that people who are HIV-positive do not learn their status early. Those who 
failed to do so would continue to transmit the virus to non-infected people. A study by 
Anandaiah, Dheda, Keane, Koziel Moore and Patel (2011:987) on novel developments 
in the epidemic of human immunodeficiency virus and tuberculosis co-infection revealed 
that increased risk of TB disease begins early in the course of HIV infection. However, 
the mechanism by which HIV increases this risk is not well understood.  
 
4.5.2.2.6 When were you tested for HIV or diagnosed with TB before you knew your TB 
disease or before your HIV-positive status, respectively? 
In this question, the two categories of study participants who had been tested for HIV or 
diagnosed for TB before their current diseases were asked when they had been tested 
for HIV or diagnosed for TB in reference to the time of current disease of TB and HIV, 
respectively. The findings for both TB and HIV study participants are presented below. 
 
4.5.2.2.7 When have you been tested for HIV before diagnosed for your current TB 
disease? 
Table 4.14: When were you tested for HIV? TB patients 
When have you been tested for HIV before, 
in reference to the current TB disease 
Frequency Percent 
Before <6 months 192 43.1 
Before 6-11 months 79 17.8 
Before 1-2 years 109 24.5 
Before >2 years 65 14.6 
Total 445 100.0 
 
Most of those TB patients who tested for HIV (43.1%) had been tested just within the 
previous six months before being diagnosed with TB. In addition, nearly a quarter 
(24.5%) of those tested had conducted an HIV test between 6 and 11 months prior to 
their diagnosis for TB. This implies that the majority of the TB patients had better 
perceived behaviour on the relationship between TB and HIV. 
 
 
115 
4.5.2.2.8  When were you diagnosed with TB before diagnosed for your HIV disease? 
 
Table 4.15: When were you diagnosed with TB before you knew your Positive HIV status? 
When were you diagnosed with TB before, in 
reference to the date tested for HIV-positive  
Frequency Percent 
Within less than 6 months before knowing HIV-
positive status 
52 31.1 
Within 6 months -1 year before knowing HIV-positive 
status 
49 29.3 
Within 1.1-2 year before knowing HIV-positive status 28 16.8 
Within 2.1-3 years before knowing HIV-positive 
status 
9 5.4 
More than 3 years before knowing HIV-positive 
status 
29 17.4 
Total 167 100.0 
 
Around 60.4% of HIV patients were diagnosed with TB less than one year prior to 
knowing their positive HIV status. In addition, 16.8% and 17.4% of those diagnosed 
HIV-positive TB cases had been diagnosed for TB before 2-3 years and more than 3 
years prior to knowing their positive HIV status, respectively. 
  
4.5.2.2.9  How were your results for HIV test or site of TB diagnosed? 
In this question, the two categories of participants who had been tested for HIV or 
diagnosed for TB before their current diseases were asked how their HIV test result 
was, or the site of TB for which they diagnosed with TB and HIV, respectively. The 
findings for both TB and HIV study participants are presented below separately.  
 
4.5.2.2.10 How were your results for the HIV test? 
Table 4.16: If tested for HIV, how were your results? 
HIV test result Frequency Percent 
Negative 357 80.2 
Positive 87 19.6 
Don’t want to 
disclose 
1 0.2 
Total 445 100.0 
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Of those tested 445 TB patients prior to their knowledge of TB disease, 19.6% had been 
found to be HIV-positive. This finding is exactly the same as the prevalence of TB 
among the HIV-positive study participants prior to their knowledge of HIV status. From 
these two findings, the prevalence of HIV among the previously tested TB patients and 
the prevalence of TB among the previously diagnosed HIV-positive individuals is around 
a fifth of patients.  
 
4.5.2.2.11 Which site of TB was that? 
Table 4.17: Which site of TB was that? 
Site of TB diagnosed Frequency Percent 
Pulmonary 137 82.0 
Extra-Pulmonary 30 18.0 
Total 167 100.0 
 
Table 4.17 (above) shows that the majority (82.0%) of previously TB-diagnosed HIV 
patients had had pulmonary tuberculosis. However, this proportion is less than from 
findings in Poland for 2009 (Korzeniewska-Koseła, 2011:301), which showed that 93% 
were pulmonary and only 7% were extra-pulmonary. On the other hand, the proportion 
in this study is more than a study in Spain on Extra pulmonary tuberculosis 
epidemiology and risk factors by García-Rodríguez, Álvarez-Díaz, Lorenzo-García, 
Mariño-Callejo, Fernández-Rial and Sesma-Sánchez (2011:502), which showed the 
proportion of pulmonary tuberculosis to be 55%. 
  
4.5.2.2.12 Have you started on care and treatment or completed treatment? 
In this question, the two categories of study participants who had been tested positive 
for HIV or diagnosed for TB before were asked whether they had started care and 
treatment for HIV or completed treatment for TB, respectively. The findings for both are 
presented below separately. 
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4.5.2.2.13 Have you started on HIV care and treatment? 
 
 
Table 4.18: Have you started of HIV care and 
treatment? 
Started on HIV 
care and 
treatment 
Frequency Percent 
Yes 77 88.5 
No 10 11.5 
Total 87 100.0 
 
 
Figure 4.10: Started care and treatment by 
percent, TB patients 
In recent years, great advances in HIV treatment, care, and support have allowed many 
people living with HIV to regain their health, live longer and to plan for their futures. 
Cognizant of this, the findings in this study revealed that the majority (88.5%) of the 
HIV-positive individuals had already enrolled in the care and treatment centres of public 
health facilities.  
 
4.5.2.2.14 Have you completed your treatment for TB? 
Treatment of tuberculosis with the recommended chemotherapy is the single effective 
way to treat a patient with confirmed tuberculosis disease. 
Table 4.19: Have you completed your anti-TB treatment? 
Completed of anti-TB 
treatment 
Frequency 
Valid 
Percent 
Yes 163 97.6 
Still on treatment 4 2.4 
Total 167 100.0 
 
The internationally recommended DOTS strategy is the standard for treatment of 
tuberculosis in all countries. This study also confirmed that people living with HIV who 
had been diagnosed for TB had all undergone treatment based on the DOTS strategy, 
with the majority (97.6%) having completed and 2.4% on their follow-up treatment 
(Table 4.19, above).  
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4.5.2.2.15 Have you ever been offered for HIV test or diagnosed for TB after/while you 
know your current disease? 
In this question, the two categories of participants were asked whether they had been 
tested for HIV or diagnosed for TB while they were on their follow-up treatment of TB or 
care and treatment for HIV, respectively. The findings for both are presented below. 
 
4.5.2.2.16 Have you been offered for HIV test now during your TB treatment and tested 
for HIV (offered vs tested)? 
Table 4.20: Have you been offered (self experience) for HIV test now and tested  
for it during your TB treatment? 
 
HIV testing being 
encouraged at TB clinics 
Offered for HIV test Tested for HIV 
Frequency Percent Frequency Percent 
Yes 726 87.1 579 79.8 
No 108 12.9 147 20.2 
Total 834 100.0 726 100.0 
 
 
 
In 2007, the WHO recommended that countries with high co-infection rates should 
implement TB/HIV collaborative activities, including routine provider-initiated HIV testing 
and counselling (PITC) of TB patients in TB clinical settings, using an "opt-out" 
approach (WHO, 2007c).  
One of the activities in the interim policy for collaborative TB/HIV activity is offering 
voluntary HIV counselling and testing services for all TB patients under their follow-up 
treatment care (WHO, 2012a). All TB patients who have not previously been diagnosed 
with HIV infection should be encouraged to have an HIV test. Failing to do so is to deny 
people access to the care and treatment they might need, especially in the context of 
the wider availability of treatments that prevent infections associated with HIV (Williams, 
Alarcon, Jittimanee, Walusimbi, Sebek, Berga & Villa, 2008:889).  
In this study, 87.1% of TB patients had been offered voluntary HIV testing, and only 
12.9% not. This finding is slightly less than that in Malawi (Zachariah, Spielmann, 
Harries and, 2003:65), where 96% were pre-test counselled, 91% underwent HIV 
testing, and 87% were post-test counselled. 43 (4%) patients refused HIV testing. 
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However, the findings in this study are higher than a study in Uganda (Nansera, 
Bajunirwe, Kabakyenga, Asiimwe and Mayanja-Kizza, 2010), where 55.6% were offered 
an HIV test, and in Ruwanda (Pevzner, Vandebriel, Lowrance, Gasana & Finlay, 
2011:550), where 76% of TB patients were offered HIV testing (Figure 4.11, below). 
 
  
Figure 4.11: Have you been offered for HIV test and tested for it now during your TB treatment by 
Percent, TB patients (offered vs tested)? 
 
The majority (79.8%) had accepted the HIV test offered, a finding less than that for 
Malawi, 91% (Zachariah et al., 2003:65), Rwanda, 99% (Pevzner et al., 2011:550) and 
Ukraine, 84% (van der Werf, Yegorova, Chechulin, Hasker, Veen & Turchenko, 
2005:733). However, it is higher than the finding in Uganda, 65% (Nabbuye-Sekandi, 
Okot-Chono, Rusen, Dlodlo, Katamba, Tumwesigye & Fujiwara, 2010:896). 
 
 
 
 
 
 
 
 
 
120 
4.5.2.2.17 In which department did you take the HIV test? 
Table 4.21: If tested for HIV, who conducted the test? 
Clinic where HIV test 
conducted 
Frequency Percent 
TB clinic health worker 465 80.3 
At HIV VCT room 80 13.8 
At outpatient department 16 2.8 
Inpatient room 1 0.2 
Other 17 2.9 
Total 579 100.0 
 
Voluntary HIV testing and counselling should be offered at a TB clinic without further 
referral. It is recommended that provider-initiated HIV testing and counselling be 
conducted by TB clinic staff, or patients can be referred to HIV VCT clinic for a client-
initiated counselling and testing service. However, the former is more cost-effective for 
the service provider, and ‘one stop shopping’ for the client. This study revealed that 
80.3% had been tested by TB clinic staff and 13.8% by VCT clinic staff (Table 4.2.1, 
above). 
 
4.5.2.2.18 When have you been tested for HIV? 
 
Table 4.22: If tested for HIV, when were you tested in reference to 
day first diagnosed for TB? 
 
Time when HIV test was conducted Frequency Percent 
During the same time of TB diagnosis 443 76.5 
Within 2 months while on TB treatment 121 20.9 
Within 3-5 months during TB treatment 8 1.4 
After 5 months during TB treatment 6 1.0 
I don’t remember 1 .2 
Total 579 100.0 
 
More than three quarters (76.5%) of TB patients had been tested for HIV at the time of 
diagnosis for TB, the remaining (20.9%) during the intensive phase period. This could 
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be because some clients might have needed to decide on an HIV test for some other 
reason. However, it is highly recommended that patients be encouraged at every visit if 
they resist or decline HIV testing. 
 
4.5.2.2.19 How were your HIV test results? 
Table 4.23: If tested for HIV, how were your results? 
HIV test result Frequency Percent 
Negative 456 78.8 
Positive 117 20.2 
Don’t want to 
disclose 
6 1.0 
Total 579 100.0 
 
The HIV prevalence of TB patients in this study was 20.2%, which is similar to a 
previous study by Jerene, Endale and Lindtjørn (2007:4) in Southern Ethiopia, for which 
20.6% were HIV-positive. On the other hand, this finding was much less than previous 
findings in other countries. For instance, in Cameroon, the prevalence of HIV infection 
among TB patients was 51.6%, (Sume, Etogo, Kabore, Gnigninanjouena, Epome & 
Metchendje 2008:529). In a cohort of TB patients between 1993 and 2003 in North 
Carolina, HIV was newly diagnosed in 34.2% of those TB presentations (Gadkowski, 
Hamilton, Allen, Fortenberry, Luffman, Zeringue & Stout, 2009:845). In South Africa, 
about 210,000 people with TB were tested for HIV in 2010 and 60% were identified as 
HIV-positive (SANAC 2011). HIV prevalence among TB patients in general has been 
estimated to be as high as 80%-90% in some areas of SSA (WHO, 2004g).  
 
Despite the increasing trend of HIV testing for TB patients, researches revealed that the 
prevalence of HIV is decreasing among TB patients; for example, in a report from 
summarised HIV data collected from Kenya's extended TB surveillance system during 
2006-2009, HIV testing among TB patients increased from 60% in 2006 to 88% in 2009, 
and the prevalence of HIV infection among TB patients tested decreased from 52% to 
44% (CDC 2010:1514). 
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4.5.2.2.20 Have you started on HIV care and treatment? 
Table 4.24: If test results were positive, have 
you started HIV care and treatment? 
Started of Care 
and Treatment 
Frequency Percent 
Yes 110 94.0 
No 7 6.0 
Total 117 100.0 
 
 
Figure 4.12: Started of HIV care and treatment 
by Percent, TB/HIV patients 
 
To combat morbidity and mortality from the worldwide epidemic of HIV, the United 
States Congress implemented a President's Emergency Plan for AIDS Relief (PEPFAR) 
in 30 resource-limited countries to integrate combination antiretroviral therapy for both 
prevention and cure. 
 
Technical assistance staff of one implementing partner representing seven African 
countries met to clarify domains of palliative care compared with the substituted term 
"care and support" to understand potential gaps in ongoing HIV care. They 
prioritised care needs as: 1) mental health (depression and other mood disorders); 2) 
communication skills (age-appropriate disclosure of HIV status); 3) support of care-
providers (stress management for sustainability of a skilled HIV workforce); 4) tied 
Priorities: symptom management in opportunistic infections; end-of-life care; spiritual 
history-taking; and 5) tied priorities: attention to grief-related needs of patients, their 
families and staff; and management of HIV co-morbidities (Alexander, Memiah, Henley, 
Kaiza-Kangalawe, Shumbusho, Obiefune, Enejoh, Stanis-Ezeobi, Eze, Odion, Akpenna, 
Effiong, Miriti, Aduda, Oko, Melaku, Baribwira, Umutesi, Shimabale, Mugisa & Amoroso, 
2012:279). 
According to the finding in this research, 94% of the HIV-infected TB patients were 
already attached to the comprehensive HIV care and treatment centres in the health 
facility (Table 4.24). 
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4.5.2.2.21 Have you already started HAART? 
Table 4.25: If patient is tested HIV-positive 
(before or after TB disease), have you already 
started HAART? 
Started 
HAART 
Frequency Percent 
Yes 138 75.0 
No 46 25.0 
Total 184 100.0 
 
 
Figure 4.13: Started HAART by Percent, TB 
patients 
 
Flows of bilateral and multilateral aid over the past decade, combined with the domestic 
financial contributions of many countries, have fuelled a remarkable scale up in AIDS 
treatment and prevention programmes in low and middle income countries. Starting with 
just a few thousand patients in 2002, UNAIDS and WHO report that by the end of 2009 
more than five million people were enrolled in ART programmes in these countries 
(UNAIDS, 2010a). Despite these impressive gains, only a third of the estimated 15 
million HIV-infected persons with the most acute needs (WHO & UNAIDS, 2000) have 
access to treatment (UNAIDS, 2010b). Each year two million people still die from AIDS, 
most without having ever received ART, and approximately 2.7 million are newly 
infected by HIV (UNAIDS, 2011b).  
Despite all these challenges, several countries are progressing in terms of providing 
ART to PLHIV. The finding in this study is encouraging, in that around 75% of those 
found HIV-positive from TB clinics are receiving HAART. The finding is far higher than 
those in seven other African countries, for which over 35% of PLHIV have been treated 
with HAART (Alexander et al., 2012:279). 
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4.5.2.2.22 Have you been diagnosed with TB after you knew your HIV status? 
 
Table 4.26: Have you been diagnosed for TB 
after you knew your HIV-positive status? 
Ever been 
diagnosed for TB 
after knowing HIV 
status 
Frequency Percent 
Yes 88 10.4 
No 761 89.6 
Total 849 100.0 
 
 
 
Figure 4.14: Have you ever been diagnosed 
with TB after knowing HIV status by Percent, 
HIV patients 
 
There is considerable scientific evidence supporting the use of ART in prevention of 
human immunodeficiency virus and tuberculosis infections. The findings in this study 
may support this. The proportion of PLHIV diagnosed with TB disease while on their 
follow-up care and treatment is 10.4%, which is approximately less than half those 
diagnosed (19.7%) before they knew their HIV-positive status.  
These findings are a clear justification that PLHIV through care and treatment improves 
quality of life and decreases opportunistic infections associated with HIV infection. 
Several studies have suggested that the intrinsic value of the health gains generated 
from ART is worth the cost of treatment (Bishai, Colchero & Durack 2007:1333; Daniel, 
Rob, Chika, Jeremy & Joshua 2005:1431). The prevalence of TB among PLHIV in this 
research is less than previous findings in Saudi Arabia, where 34.4% of 
HIV patients had tuberculosis (Rajasekaran, Mahilmaran, Annadurai, Kumar & Raja 
2007:58), and in Bangladish, 23% (Matin, Shahrin, Pervez, Banu, Ahmed, Khatun & 
Pietroni 2011:14). 
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4.5.2.2.23 When were you diagnosed? 
Table 4.27: When were you diagnosed? 
Time when being diagnosed for 
TB after knowing HIV status 
Frequency Percent 
During the same time up to 1 
month of HIV test 
38 43.2 
Within 2-6 months after HIV test 23 26.1 
Within 7-11months after HIV test 5 5.7 
Within 1-2 years after HIV test 15 17.0 
Within 2.1-3 years after HIV test 4 4.5 
More than 3 years after HIV test 3 3.4 
Total 88 100.0 
 
Table 4.27 above shows that the majority (43.2%) of HIV-positive individuals diagnosed 
for TB during the first one month of learning their HIV status. The second group, with 
the largest proportion, developed within 2-6 months following their HIV test result. This 
is an indication that delay in HIV testing resulted in increased susceptibility to 
opportunistic infections, including tuberculosis. These findings are consistent with 
previous researches on ART in prevention of HIV and TB by Granich, Gupta, Suthar, 
Smyth, Hoos, Vitoria, Bavicchi, Simao, Hankins, Schwartlander, Ridzon, Bazin, 
Williams, Lo, McClure, Montaner and Hirnschall (2011:446), which states:  
‘’Despite expanding access to ART to treat HIV infection in resource-limited 
settings, many individuals in need of therapy initiate ART too late and have 
already developed clinically significant TB by the time they present for care. 
Many co-infected individuals are in need of concurrent ART and anti-TB therapy, 
which dramatically improves survival, but also raises several management 
challenges, including drug interactions, shared drug toxicities and TB immune 
reconstitution inflammatory syndrome.’’  
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4.5.2.2.24 Which site of TB was that? 
Table 4.28: Which site of TB was that? 
Site of TB 
diagnosed 
Frequency Percent 
Pulmonary 74 84.1 
Extra-Pulmonary 14 15.9 
Total 88 100.0 
 
 
Figure 4.15: Site of TB disease by Percent, HIV 
patients 
 
The proportion of pulmonary TB, compared with extra-pulmonary, before and after 
knowing HIV status for PLHIV is almost the same (82% before and 84.1% after). The 
proportion of being diagnosed for pulmonary TB in this study is slightly higher than 
previous research findings. For example, a study in 8 sub-Saharan African countries on 
incidence of TB in HIV-infected patients before and after starting HIV chronic care 
services indicated that, throughout patients’ follow-up, the rates of pulmonary TB 
remained 2-3 fold higher than extra-pulmonary TB rates (Nicholas, Sabapathy, 
Ferreyra, Varaine & Pujades-Rodríguez, 2011:311). Another study in Saudi Arabia 
revealed that, out of the surveyed HIV patients, only 37% had pulmonary tuberculosis, 
44% had either disseminated or extra-pulmonary tuberculosis and the remaining 19% 
had both (Omair, Al-Ghamdi and Alrajhi, 2010).  
 
4.5.2.2.25 Did/do you take your treatment? 
 
Table 4.29: Treatment completion among those diagnosed for TB 
Completed of anti-TB 
treatment 
Frequency Percent 
Yes 88 100.0 
No 0 0 
Total 88 100.0 
 
According to the research finding, all of the TB patients completed their treatment based 
on the internationally recommended DOTS strategy (Table 4.29). 
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4.5.2.2.26 Have you already started HAART during your diagnosis for TB? 
 
Table 4.30: Have you already started HAART during your diagnosis for TB? 
Started on HAART Frequency Valid Percent 
Yes 46 52.3 
No 42 47.7 
Total 88 100.0 
 
 
Figure 4.16: Started HAART by Percent, TB patients 
 
More than half (52.3%) of those diagnosed with TB had already been on HAART while 
they developed TB. However, the finding contradicts those from previous research. 
Beginning combination antiretroviral therapy for patients infected with HIV has reduced 
morbidity of AIDS-related opportunistic infections and subsequently reduced HIV-related 
mortality. Effective ART leads to significantly reduced viral loads and increased CD4+ T 
cell counts, especially in the first few months after initiation. ART stimulates immune 
system reconstitution, thereby reducing the risk of exacerbation or acquisition of an 
opportunistic infection (Roberson & Bowers 2011:345). 
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4.5.2.3 Section III: Activities to decrease the burden of TB/HIV 
 
Section III of both TB and HIV questionnaires consisted of six items, the main aim being 
to determine the implementation status of activities to decrease TB/HIV among TB and 
HIV patients who were on their follow-up care.  
The section also describes additional information about patients’ awareness on key 
interventions to decrease the burden of TB/HIV. The questions asked whether: 
• HIV testing was offered or encouraged at TB clinic for TB patients or whether TB 
screening was offered or encouraged at HIV chronic care clinics for HIV patients  
• TB patients knew about Cotrimoxazole preventive therapy or HIV patients knew 
INH preventive therapy 
• TB patients knew access of CPT and IPT as part of the package of HIV care in 
their health facility  
• they had been provided with CPT or IPT ever and, finally, from which clinic 
patients refill Cotrimoxazole or Isoniazid drugs in the health facility. 
  
4.5.2.3.1 Is HIV testing offered or encouraged at TB clinic, or is TB screening offered or 
encouraged at HIV care centres? 
 
Table 4.31: Is HIV testing offered or encouraged (knowledge) at TB clinic, and Is TB screening 
offered or encouraged at HIV care centres by percent, Addis Ababa City Administration 
 
HIV testing offered for TB 
Patients, or TB screening offered 
for HIV Patients 
TB Patients HIV Patients 
Frequency Percent Frequency Percent 
Yes 771 92.4 788 92.8 
No 7 .8 31 3.7 
I do not know 56 6.7 30 3.5 
Total 834 100.0 849 100.0 
 
Exactly 92.4% of TB patients witnessed that HIV counselling and testing had been 
offered at TB clinics for newly diagnosed TB patients and for those under follow-up 
treatments. However, 87.1% (section 4.4.7.1) of all TB patients were offered testing or 
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encouraged by TB clinic staffs to be tested for HIV. The difference among those 
witnessed to those offered is 5.3%, meaning this portion of TB patients were well aware 
of the service being given in the clinic but were not offered or encouraged to use it.  
 
Figure 4.17: Is HIV testing offered or encouraged at TB clinics and Is TB screening 
offered at HIV care clinics? by percent 
 
 
The annual risk of developing tuberculosis in a PLHIV who is co-infected with M 
tuberculosis ranges from 5-15% (Raviglione, Harries, Msiska, Wilkinson & Nunn 
1997:115). In addition, HIV increases the rate of recurrent tuberculosis, which may be 
due to either endogenous reactivation (true relapse) or exogenous re-infection. Various 
research findings revealed that increasing tuberculosis cases in PLHIV pose an 
increased risk of tuberculosis transmission to the general community, whether or not 
HIV-infected (Daley, 1993:756; Fitzgerald, Desvarieux, Severe, Joseph, Johnson & 
Pape, 2000:1470). 
Therefore, the WHO policy on collaborative TB/HIV activities, recommends offering and 
encouraging TB screening for all HIV-positive individuals on every contact with a 
healthcare provider (WHO, 2012a). The findings for this study are that 92.8% of HIV 
patients are screened routinely for TB at their care and treatment clinics. These findings 
are greater than in a previous study conducted in Addis Ababa, Ethiopia, which showed 
89.7% (Wesen & Mitike 2009). From a study in South Africa, the results revealed almost 
60% of the 3.9 million people in HIV care were screened for tuberculosis (SANAC, 
2011). However, other research has provided evidence that people attending HIV care 
centres benefit from TB screening, i.e., those found to be both HIV-positive and with 
active TB needed referral for TB treatment, whilst those without active TB offered TB 
preventive treatment with Isoniazid (Godfrey-Faussett, Maher, Mukadi, Nunn, Perriëns 
& Raviglione, 2002). 
130 
4.5.2.3.2 Do you know about Cotrimoxazole preventive therapy for TB patients or INH 
preventive therapy for HIV patients? 
 
Table 4.32: Knowledge about Cotrimoxazole preventive therapy for TB patients 
and INH Preventive therapy for HIV patients? 
 
Knowledge of CPT 
TB Patients HIV Patients 
Frequency Percent Frequency Percent 
Yes 193 23.1 359 42.3 
No 641 76.9 490 57.7 
Total 834 100.0 849 100.0 
 
 
Quite a small proportion of TB/HIV patients knew about CPT, 23.1%, but it is the 
responsibility of the healthcare system to make people aware of its benefits based on 
the national TB/HIV policy guideline (FMoH 2007b). The provision of Cotrimoxazole as 
a prophylaxis is an inexpensive and highly efficacious preventative intervention in HIV-
infected individuals. In Africa it works by reducing bacterial infection, malaria, and 
isosporiasis, reducing morbidity by 43% and hospital admission by 23% among children 
with HIV/AIDS and reducing mortality by 31% and morbidity by 27% among adults with 
HIV/AIDS (Chintu, Bhat, Walker, Mulenga, Sinyinza, Lishimpi, Farrelly, Kaganson, 
Zumla, Gillespie, Nunn & Gibb, 2004:1865, Grimwade & Swingler, 2003:CD003108). 
Two clinical trials on the efficacy of CPT undertaken in Cote d’Ivoire showed that CPT 
was effective at an early stage of HIV disease: reducing morbidity and mortality in HIV-
infected TB patients, and reducing severe clinical events in HIV-infected adults 
(Anglaret, Chene, Attia, Toure, Lafont, Combe, Manlan, N'Dri-Yoman, Salamon & group 
C-CS, 1999:1463; Wiktor, Sassan-Morokro, Grant, Abouya, Karon, Maurice, Djomand, 
Ackah, Domoua, Yapi, Combe, Tossou, Roels, Lackritz, Coulibaly, De Cock, Coulibaly 
and Greenberg. 1999:1469). 
A research on extended TB surveillance system of Kenya from 2006 to 2009 showed 
that 92% of HIV-infected TB patients received Cotrimoxazole prophylaxis for the 
prevention of opportunistic infections. Although the data showed the increase in HIV 
services provided to TB patients, only 34% of HIV-infected TB patients started ART 
while being treated for TB (CDC, 2010). 
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Figure 4.18: Knowledge of Cotrimoxazole Preventive Therapy for TB patients and INH 
Preventive Therapy for HIV patients by Percent, Addis Ababa City Administration, August 2011. 
 
Therefore, besides the knowledge of HIV care providers on providing IPT, patients 
themselves should be aware of it for improved adherence. The finding in this study 
about the knowledge of HIV patients about IPT is less than half (42.3%).  
 
4.5.2.3.3 Do PLHIV who have TB have access to CPT as part of the package of care? 
 
Table 4.33: Do PLHIV who have TB have access to CPT as  
part of the package of care in the health facilities? 
 
Knowledge of access to CPT Frequency Percent 
Yes 176 91.2 
No 1 0.5 
I do not know 16 8.3 
Total 193 100.0 
 
In the 1990s, two clinical trials on the efficacy of Cotrimoxazole Preventive Therapy 
(CPT) were undertaken in Cote d’Ivoire. The results showed that it was effective at an 
early stage of HIV disease, reducing morbidity and mortality in HIV-infected TB patients 
and reducing severe clinical events in HIV-infected adults (Anglaret et al., 1999:1463; 
Wiktor et al., 1999:1469). 
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The WHO and UNAIDS released provisional recommendations about CPT in 2000, 
stating that it can be given to all HIV-infected adults with a CD4 count of 500 cells/mm3 
or less, or with WHO clinical stage 2-4, to all infants HIV-infected or HIV-exposed; and 
to all children over the age of 15 months with symptomatic HIV disease (WHO & 
UNAIDS, 2000).  
The value of Cotrimoxazole in reducing the morbidity and mortality associated with HIV 
infection has been well established through clinical trials conducted in industrialized 
(Institute for Global Health 2004; Jones, Hanson, Dworkin, Alderton, Fleming, Kaplan, 
and Ward, 1999:1) and developing countries (Nunn, Mwaba, Chintu, Mwinga, 
Darbyshire and Zumla, 2008:a257; Mulenga, Ford, Walker, Mwenya, Mwansa, Sinyinza, 
Lishimpi, Nunn, Gillespie, Zumla, Chintu and Gibb, 2007:77; Lowrance, Makombe, 
Harries, Yu, Aberle-Grasse, Eiger, Shiraishi, Marston, Ellerbrock & Libamba 2007:56).  
Based on that, most countries have adopted CPT a policy on their HIV care package. 
For example, a study on 41 countries in all WHO regions showed, 38 (93%) had 
developed a national policy to provide CPT to people living with PLHIV, but only 66% 
(25/38) of the countries with a national policy had implemented it on a nationwide scale 
(Anand, Marco, Reuben, Mazuwa, Mayada & Charlie, 2010:253). Countries in all WHO 
regions have made progress in the development and nationwide implementation of a 
CPT policy, and of 25 countries with nationwide implementation a median of 90% of the 
facilities that provided ART (range: 80-100) and of 75% of the facilities that provided 
HIV care (range: 60-100) were providing CPT (Anand et al, 2010:253).  
According to the WHO guideline (WHO, 2006a:5), CPT is a simple, well-tolerated and 
cost-effective intervention for people living with HIV. It should be implemented as an 
integral component of the HIV chronic care package and as a key element of pre–ART 
care. CPT needs to continue after ART is initiated until there is evidence of immune 
recovery (WHO, 2006a:5). 
Ethiopia is one country which incorporated CPT on its guideline on implementation of 
TB/HIV collaborative activities (FMoH, 2005; FMOH, 2007b). People living with HIV 
through frequent contacts should know the packages of care for PLHIV.  
According to the finding in this study, out of the 193 TB patients who know about CPT, 
91.2% witnessed that CPT is provided as a package of care for PLHIV who have also 
active TB disease (Table 4.33). 
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4.5.2.3.4 Do PLHIV who do not have active TB have access to IPT as part of the 
package of care? 
 
Table 4.34: Do PLHIV who do not have active TB have access to IPT 
as part of the package of care in the health facilities 
 
 
 
 
 
 
 
 
 
 
In 1998, the WHO and the United Nations Joint Programme on HIV/AIDS (UNAIDS) 
issued a new IPT policy with six key steps as part of the package of care for PLHIV 
(UNAIDS, 2010c).  
First, people living with HIV should be counselled to encourage early diagnosis and 
treatment of TB. Second, to avoid mono-therapy, all persons infected with HIV should 
be screened for active TB before administration of IPT. Third, programmes should 
target persons most likely to benefit from IPT, specifically individuals with a positive 
tuberculin skin test (TST) result. However, TST is not feasible in most settings, and 
therefore IPT without prior TST should be considered in populations with >30% 
prevalence of M. tuberculosis infection, healthcare workers, household contacts of 
patients with TB, prisoners, and miners. Fourth, IPT should be given as six months of 
daily, self-administered Isoniazid. The fifth and sixth key steps involve monitoring of 
adherence, toxicity, and outcomes (WHO, 1999a:385). The policy recommends a chest 
radiograph before initiation of IPT (UNAIDS 2010c). Studies suggest that IPT is cost-
effective and beneficial, further supporting these policy recommendations (Fern, Lilani, 
Rokaya, Helen, Ignatius, Mary & Peter, 2008:2; Foster, Godfrey-Faussett & Porter, 
1997:919). 
The WHO recommends 12 collaborative TB/HIV activities, including the “Three I's for 
TB/HIV” (Isoniazid preventive therapy (IPT), intensified TB case finding (ICF), and 
infection control (IC) for TB), which should be seen as core prevention, care, and 
treatment services for HIV infection (WHO, 2004d). 
Knowledge of access to 
IPT 
Frequency Percent 
Yes 334 93.0 
No 2 .6 
I do not know 23 6.4 
Total 359 100.0 
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ART in some studies provides up to 80% reduction in the risk of TB; however, the 
incidence of TB remains higher among people living with HIV receiving ART than 
among HIV uninfected persons (Badri, Wilson & Wood, 2002:2059; Girardi, Sabin, 
d'Arminio, Hogg, Phillips, Gill, Dabis, Reiss, Kirk, Bernasconi, Grabar, Justice, 
Staszewski, Fätkenheuer & Sterne, 2005:1772; Lawn, Myer, Edwards, Bekker & Wood 
2009:1717). 
Even among persons with a good response to ART, other interventions (such as IPT) 
may be needed to prevent TB in people living with HIV. Observational cohort studies in 
Brazil and South Africa showed a 76%–89% reduction in TB risk among patients 
receiving both ART and IPT (Golub, Saraceni, Cavalcante, Pacheco, Moulton, King, 
Efron, Moore, Chaisson, & Durovni, 2007:1441; Golub, Saraceni et al., 2009:631). 
TB prevention in the context of HIV infection demands a comprehensive approach that 
effectively marshals evidence-based interventions for prevention of HIV infection and 
TB, including earlier diagnosis of HIV infection and ART (WHO, 2008a). 
 
4.5.2.3.5 Have you ever been treated with CPT? 
 
Table 4.35: Have you ever been treated with 
Cotrimoxazole preventive therapy among 
PLHIV? 
Ever been 
treated with 
CPT 
Frequency Percent 
Yes 111 57.5 
No 82 42.5 
Total 198 100.0 
 
 
Figure 4.19: Ever been treated with CPT by 
Percent, HIV patients? 
 
The provision of Cotrimoxazole as a prophylaxis is an inexpensive and highly 
efficacious preventative intervention in HIV-infected individuals. In Africa it works by 
reducing bacterial infection, malaria, and isosporiasis; reducing morbidity (by 43%) and 
hospital admission (by 23%) among children with HIV and reducing mortality (by 31%) 
and morbidity (by 27%) among adults with HIV (Chintu, Bhat, Walker, Mulenga, 
Sinyinza, Lishimpi, Farrelly, Kaganson, Zumla, Gillespie et al., 2004:1865; Grimwade et 
al., 2003:CD003108). 
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Despite widespread recommendations and availability of convincing evidence of the 
effectiveness of TMP-SMX, the implementation of its use has been poor (Zachariah, 
Harries, Luo, Bachman & Graham,  2007:686). In Africa, barriers to implementation 
include shortages of trained staff, stock-outs of Cotrimoxazole, and failure of healthcare 
systems to identify individuals eligible for Cotrimoxazole prophylaxis (Zachariah et al., 
2007:686). In addition, there is anxiety that it may not be cost-effective. However new 
evidence of the intervention's cost-effectiveness may alleviate these concerns (Ryan, 
Griffin, Chitah, Walker, Mulenga, Kalolo, Hawkins, Merry, Barry, Chintu, Sculpher & 
Gibb, 2008:749; Yazdanpanah, Losina, Anglaret , Goldie, Walensky, Weinstein, Toure, 
Smith, Kaplan & Freedberg, 2005:1299).  
According to a global TB report 2009 (WHO, 2009b), almost 80% of global TB patients 
who were known to be HIV-positive were started on CPT. The 2011 global TB report 
showed that, the number of global TB patients living with HIV who were enrolled on 
CPT levelled off between 2009 and 2010 was at just over 0.3 million, equivalent to 77% 
of TB patients known to be HIV-positive (WHO, 2011a).  
The African and South-East Asia regions achieved particularly high levels of enrolment 
on CPT, with 76% and 87% of TB patients known to be living with HIV provided with 
CPT, respectively (WHO, 2011a). Countries that achieved the highest rates of 
enrolment on CPT in 2010 included Burkina Faso (96%), Burundi (95%), India (90%), 
Kenya (100%), Lesotho (96%), Mozambique (97%), Malawi (94%), Mali (100%), 
Myanmar (100%), Namibia (92%), Rwanda (97%), Swaziland (93%), the United 
Republic of Tanzania (92%) and Uganda (90%), [WHO, 2011a]. The global Plan to Stop 
TB, 2011–2015 targets to reach 100% for provision of CPT (WHO, 2010a). 
This study revealed that, 57.5% of TB patients co-infected with HIV have been provided 
with CPT, this result is less than the global achievement for 2010 (77%) and African 
region (76%). But it is close to the finding in Uganda in 2009 [52%] (Okot-Chono et al., 
2009:955). 
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4.5.2.3.6 Have you ever been provided with IPT? 
Table 4.36: Have you ever been provided with 
IPT? 
Ever been 
treated with IPT 
Frequency Percent 
Yes 244 28.7 
No 605 71.3 
Total 849 100.0 
 
 
Figure 4.20: Ever been treated with IPT by 
Percent, TB/HIV patients 
 
Tuberculosis is the most frequent life-threatening opportunistic disease among people 
living with HIV and remains a leading cause of mortality, even among persons receiving 
ART. Clinical trials have shown that IPT dramatically reduces the incidence of TB 
among people living with HIV (Golub, Saraceni, et al., 2007:1441; Woldehanna & 
Volmink, 2004:CD000171). 
According to the global TB report 2011 (WHO, 2011a), monitoring of access to IPT 
interventions at country level is considered weaker than for interventions such as ART. 
For example, in 2010, 2.3 million PLHIV were screened globally for TB (up from 1.7 
million in 2009) and 178 000 of those without active TB were enrolled on IPT (double 
the level achieved in 2009), which is about 12% of the reported number of PLHIV newly 
enrolled in HIV care in 2010 (WHO, 2011a:66).  
A 2004 Cochrane Review found that IPT reduced the risk of TB by 33% overall and by 
64% when targeted at people living with HIV who had a positive tuberculin skin test 
(Golub et al., 2007:1441). A recent retrospective study also showed that IPT 
significantly reduced the incidence of TB, even among people living with HIV and 
receiving ART (Golub et al., 2007:1441). In 1998, the WHO and UNAIDS issued a 
statement that recognized the effectiveness of IPT among people living with HIV and 
recommended its use as part of an essential care package for these patients (WHO, 
1998). This statement recommends IPT for all people living with HIV in areas with a 
prevalence of latent TB infection > 30% and for all people with documented latent TB 
infection or exposure to an infectious TB case, regardless of where they live. These 
recommendations were reinforced in a statement released by the TB/HIV working group 
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of the Stop TB Partnership in October 2007 (Consensus statement of the core group of 
TB/HIV Working Group of STOP TB partnership. Geneva: Stop TB partnership).  
WHO (2008c) guidelines on essential prevention and care interventions for people living 
with HIV also recommend IPT for PLHIV without active TB disease. However, countries 
have been slow to adopt these recommendations and many limitations seem to be 
delaying effective nationwide implementation. In 2007, only 30 000 (0.1%) people living 
with HIV worldwide had started IPT (WHO, 2009d). 
A study at 41 WHO region countries for the implementation of IPT for PLHIV revealed 
that 21 of the 41 respondent countries (51%) had developed a national policy, but only 
28% (6/21) of these countries had implemented it on a nationwide scale (Anand et al., 
2010:253).  
Respondent countries in all WHO regions have experienced delays in the development 
and nationwide implementation of IPT policy. In the six countries with nationwide 
implementation, a median of 3% of the facilities that provided ART and HIV care were 
also providing IPT. A median of 50% of the facilities that provided TB services were 
providing IPT to people with HIV infection (Anand et al., 2010:253).  
Of the 20 countries that reported having no IPT implementation policy, 14 provided 
reasons for not developing the policy. The main reasons were: (1) inadequate 
intensified TB case-finding because of the inability to exclude active TB, (2) logistic 
difficulties in performing tuberculin skin tests to diagnose latent TB infection, and 
(3) concerns regarding inadequate patient adherence potentially leading to Isoniazid 
mono-resistance. Other reasons included lack of consensus among policymakers and 
experts and uncertainty about the long-term benefits of IPT. Countries that had 
developed an IPT policy also faced the challenges mentioned above in achieving 
nationwide implementation. Interventions suggested by the respondent countries to 
encourage the development of an IPT policy or to improve nationwide implementation 
included: (1) advocacy of IPT at the national and international level; (2) dissemination of 
evidence-based information regarding the benefits and feasibility of IPT; and 
(3) developing operational guidelines for the implementation of IPT in HIV care and 
treatment settings (Anand et al., 2010:253). 
The 2008 WHO Three I's Meeting for TB/HIV re-emphasised the importance of IPT for 
PLHIV as part of a comprehensive approach to prevention, care, and treatment of HIV 
infection (WHO, 2008a). Forty-two countries, including Botswana, South Africa, 
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Mozambique, Ethiopia, and the USA use IPT for people living with HIV as part of their 
TB-control strategy (Mosimaneotsile, Talbot, Moeti, Hone, Moalosi, Moffat, Lee & 
Kenyon, 2003:1551; WHO, 2009d;). Globally, although access to IPT is still limited, from 
2005 through 2007, IPT provision increased from 26,000 persons in 10 countries to 
29,000 persons in 42 countries (WHO, 2008a). 
This study showed that 28.7% of all PLHIV had ever been provided with IPT. This 
finding is higher than previous findings in Ethiopia and other countries, for example, the 
2011 global TB report (WHO, 2011a) found that the IPT coverage for PLHIV, 
Bangladish (3.6%), Cambodia (1.5%), Ethiopia (9.9%), Mozambique (21.9%), Myanmar 
(11.8%), Nigeria (2.4%); on the other hand, this finding was lower than the report from 
South Africa (58.2%) (WHO, 2011a:89)  
 
4.5.2.3.7 From where did/do you re-fill/collect Cotrimoxazole drug? 
 
Table 4.37: If you were taking or currently under 
CPT, from where did/do you collect the drug? 
Clinic where 
CPT is re-filled 
Frequency Percent 
HIV clinic 90 81.1 
TB clinic 21 18.9 
Total 111 100.0 
 
 
Figure 4.21: Clinic where CPT was re-filled in 
Percent, TB/HIV patients 
 
As shown in Table 4.37 above, the majority (81.1%) of TB-HIV co-infected patients 
treated with CPT re-filled their drug from HIV clinics; whereas 18.9% collected them  
from TB clinics. According to the national TB/HIV implementation guideline (FMOH, 
2005; 2007), the placement for Cotrimoxazole should be at an HIV clinic. This is 
because provision of CPT is more HIV chronic care than TB treatment care.  
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4.5.2.3.8 From where did/do you re-fill INH drug? 
 
Table 4.38: If you were taking or currently under 
IPT, from where did/do you collect the drug? 
Clinic where 
IPT is re-filled 
Frequency Percent 
HIV clinic 240 98.4 
TB clinic 4 1.6 
Total 244 100.0 
 
 
Figure 4.22: Clinic where IPT was re-filled by 
Percent, HIV patients 
 
As shown in Table 4.38 above, almost all (98.4%) TB-HIV co-infected patients treated 
with IPT re-filled their drug from HIV clinics, whereas, only 1.6% collected their drugs 
from TB clinics. According to the national TB/HIV implementation guideline (FMOH, 
2005; 2007b), the placement for INH should be at an HIV clinic, because provision of 
IPT is, in a broader sense, more HIV care package than TB care. 
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4.5.3 Inferential Statistics 
 
Inferential statistics, also known as statistical induction, is defined by Dodge (2003, cited 
in Wikipedia, [s.a]c) as the process of applying statistical methods in order to draw 
conclusions from sets of data that arise from systems affected by random variation. 
Upton and Cook (2008, as cited in Wikipedia [s.a]c) write that some of the sources of 
such variation are observational errors, random sampling, or random experimentation. 
In this study, inferences have been made for the different dependent variables. 
 
Table 4.39: Association of selected variables with Ever had been tested for HIV before diagnosed for TB 
among TB patients in Addis Ababa City Administration, July 2011. n=826 
 
 
Variable 
Ever been tested for HIV 
before diagnosed for TB Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) 
Yes (445) No (381) 
 
Age Group 
    
15-17 19 17 1.00 1.00 
18-24 108 112 0.86(0.43-1.75) 0.83(0.39-1.73) 
25-29 122 71 1.54(0.75-3.15) 1.54(0.71-3.34) 
30-39 129 101 1.14(0.57-2.31) 1.12(0.51-2.47) 
40-49 42 38 0.99(0.45-2.17) 1.10(0.45-2.59) 
50+ 25 42 0.53(0.23-1.21) 0.68(0.28-1.68) 
 
Marital Status 
 
Single  192 161 1.00 1.00 
Married 204 179 0.96(0.72-1.28) 1.10(0.76-1.58) 
Divorced 29 19 1.28(0.69-2.37) 1.39(0.72-2.71) 
Widowed 11 16 0.58(0.26-1.28) 0.84(0.35-2.01) 
Separated 9 6 1.26(0.44-3.61) 1.49(0.49-4.50) 
 
Educational Status 
 
Illiterate 79 99 1.00 1.00 
Primary (1-6) 116 111 1.31(0.88-1.94) 1.27(0.82-1.96) 
Secondary (7-12) 207 135 1.92(1.33-2.77) 1.89(1.22-2.91) 
Tertiary (12+) 43 36 1.49(0.88-2.55) 1.47(0.79-2.72) 
 
Occupation 
    
Housewife 73 74 1.00 1.00 
Government employed 33 27 1.24(0.68-2.26) 0.93(0.48-1.81) 
Non government 12 11 1.11(0.46-2.67) 0.77(0.30-1.95) 
Private employee 120 79 1.54(1.00-2.37) 1.36(0.85-2.18) 
Self employed/merchant 66 50 1.34(0.82-2.18) 1.13(0.66-1.91) 
Unemployed 115 114 1.02(0.68-1.55) 0.99(0.62-1.57) 
Other 26 26 1.01(0.54-1.91) 1.13(0.56-2.27) 
 
As shown in Table 4.39 above, age group, occupation and marital status did not have 
significant association with being tested for HIV before they had been diagnosed with 
TB. In addition, occupation seems to have no statistical significant difference for being 
tested for HIV before TB disease, except for those who learnt up to secondary 
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education, who were nearly twice as likely to have been tested for HIV [AOR (95%CI): 
1.89(1.22-2.91) than the illiterate patients. Otherwise, no other variables showed any 
significant association with the dependent variable under analysis.  
 
Table 4.40: Association of selected variables with Ever been offered for HIV test during TB treatment 
among TB patients in Addis Ababa City Administration, July 2011. n=834 
 
Variable 
Ever been offered for HIV 
test during TB treatment Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) 
Yes (726) No (108) 
 
Age Group 
    
15-17 23 13 1.00 1.00 
18-24 194 29 3.78(1.73-8.28) 4.56(1.93-10.77) 
25-29 170 25 3.84(1.73-8.55) 4.19(1.67-10.56) 
30-39 208 23 5.11(2.29-11.43) 4.72(1.78-12.51) 
40-49 75 5 8.48(2.73-26.31) 7.84(2.18-28.21) 
50+ 56 13 2.45(0.98-6.04) 2.32(0.78-6.89) 
 
Marital Status 
 
Single  298 59 1.00 1.00 
Married 348 38 1.81(1.17-2.80) 1.65(0.96-2.84) 
Divorced 42 6 1.39(0.56-3.41) 1.29(0.49-3.43) 
Widowed 24 4 1.19(0.39-3.55) 1.38(0.40-4.72) 
Separated 14 1 2.77(0.36-21.49) 2.43(0.29-20.00) 
Religion  
Christian 590 84 1.00 1.00 
Muslim 136 24 0.81(0.49-1.32) 0.89(0.52-1.49) 
 
Educational Status 
 
Illiterate 154 25 1.00 1.00 
Primary (1-6) 196 36 0.88(0.51-1.54) 1.19(0.63-2.25) 
Secondary (7-12) 304 40 1.23(0.72-2.11) 1.67(0.87-3.20) 
Tertiary (12+) 72 7 1.67(0.69-4.04) 1.82(0.68-4.89) 
 
Occupation 
    
Housewife 135 12 1.00 1.00 
Government employed 57 4 1.27(0.39-4.09) 0.99(0.28-3.46) 
Non government 21 2 0.93(0.19-4.47) 0.76(0.15-3.85) 
Private employee 171 30 0.51(0.25-1.03) 0.51(0.23-1.09) 
Self employed/merchant 105 13 0.72(0.32-1.64) 0.66(0.27-1.58) 
Unemployed 190 41 0.41(0.21-0.81) 0.53(0.25-1.13) 
Other 47 6 0.69(0.25-1.96) 1.36(0.43-4.30) 
 
Comparing the above figures among the various age categories, those who were 18-24, 
25-29, 30-39 and 40-49 years were 4.56, 4.19, 4.72 and 7.84 times more likely to have 
been offered for HIV test than those of 15-17 years of age [AOR (95%CI): 4.56(1.93-
10.77), 4.19(1.67-10.56), 4.72(1.78-12.51) and 7.84(2.18-28.21)], respectively. None of 
the remaining independent variables showed significant differences on the adjusted 
odds ratio. HIV counselling and testing (HCT) is being offered by informed consent for 
all TB patients in Addis Ababa City Administration public health facilities. Those under 
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the age of 18 years were also offered HCT services through the consent of their 
guardians (AACAHB, 2009). Care givers for age group 15-17 years responded for most 
of the previous treatment services offered on their behalf. 
 
Table 4.41: Association of selected variables with is HIV testing offered at TB clinics among TB patients 
in Addis Ababa City Administration, July 2011. n=834 
 
 
Variable 
Is HIV testing offered at 
TB clinic Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(726) 
No 
(108) 
 
Age Group 
    
15-17 23 13 1.00 1.00 
18-24 194 29 4.11(1.41-11.99) 4.43(1.87-10.49) 
25-29 170 25 2.61(0.93-7.29) 4.05(1.60-10.23) 
30-39 208 23 2.99(1.08-8.28) 4.46(1.67-11.95) 
40-49 75 5 6.52(1.51-28.15) 7.23(1.97-26.52) 
50+ 56 13 3.59(0.93-13.91) 2.06(0.66-6.44) 
 
Sex 
 
Male 319 45 1.00 1.00 
Female 407 63 0.98(0.58-1.67) 0.85(0.52-1.37) 
 
Marital Status 
 
Single  298 59 1.00 1.00 
Married 348 38 2.04(1.14-3.67) 1.66(0.97-2.86) 
Divorced 42 6 0.94(0.35-2.55) 1.37(0.51-3.68) 
Widowed 24 4 1.29(0.29-5.72) 1.47(0.42-5.09) 
Separated 14 1 1.46(0.19-11.51) 2.61(0.31-21.71) 
 
Religion 
 
Christian 590 84 1.00 1.00 
Muslim 136 24 0.83(0.44-1.58) 0.88(0.52-1.49) 
 
Educational Status 
 
Illiterate 154 25 1.00 1.00 
Primary (1-6) 196 36 0.69(0.32-1.50) 1.17(0.62-2.21) 
Secondary (7-12) 304 40 0.89(0.43-1.88) 1.63(0.85-3.13) 
Tertiary (12+) 72 7 1.02(0.34-3.05) 1.76(0.65-4.75) 
 
Occupation 
    
Housewife 135 12 1.00 1.00 
Government employed 57 4 1.28(0.33-4.89) 0.90(0.25-3.25) 
Non government 21 2 0.71(0.14-3.49) 0.71(0.14-3.67) 
Private employee 171 30 0.82(0.35-1.95) 0.47(0.21-1.04) 
Self employed/merchant 105 13 0.69(0.27-1.77) 0.59(0.24-1.49) 
Unemployed 190 41 0.59(0.27-1.35) 0.49(0.23-1.08) 
Other 47 6 3.02(0.37-24.52) 1.27(0.39-4.09) 
 
Comparing being offered for HIV test at TB clinic among the various age categories; 
those who were 18-24, 25-29, 30-39 and 40-49 years were 4.43, 4.05, 4.46 and 7.23 
times more likely to had been offered for HIV test than those of 15-17 years of age 
[AOR (95%CI):4.43(1.87-10.49), 4.05(1.60-10.23), 4.46(1.67-11.95) and 7.23(1.97-
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26.52)], respectively. None of the remaining independent variables showed significant 
differences on the adjusted odds ratio.  
 
Table 4.42: Association of selected variables with ‘Is screening for TB offered at HIV clinics among HIV 
patients?’ in Addis Ababa City Administration, July 2011. n=819 
 
Variable 
Is screening for TB 
offered at HIV clinic Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(788) 
No 
(31) 
 
Sex 
 
Male 240 9 1.00 1.00 
Female 548 22 0.93(0.42-2.06) 1.00(0.44-2.29) 
 
Marital Status 
 
Single  180 10 1.00 1.00 
Married 387 12 1.79(0.76-4.22) 1.89(0.79-4.50) 
Divorced 77 1 4.28(0.54-33.99) 4.55(0.57-36.34) 
Widowed 117 5 1.28(0.43-3.83) 1.42(0.45-4.47) 
Separated 29 3 0.54(0.14-2.07) 0.56(0.14-2.21) 
 
Educational Status 
 
Illiterate 179 7 1.00 1.00 
Primary (1-6) 227 12 0.74(0.29-1.92) 0.69(0.26-1.86) 
Secondary (7-12) 305 10 1.19(0.45-3.19) 1.19(0.42-3.39) 
Tertiary (12+) 77 2 1.51(0.31-7.41) 1.52(0.29-7.98) 
 
There was no significant association of being offered TB screening among the various 
socio-demographic characteristics. Being divorced, married and widowed were more 
likely to be screened than those who were single in their marital status. In addition, the 
higher the educational status of study participants the more likely to be screened, 
despite the association being non-significant.  
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Table 4.43: Association of selected variables with Ever been provided with CPT at TB clinics among TB 
patients in Addis Ababa City Administration, July 2011. n=834 
 
 
Variable 
Ever been provided with 
CPT Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(111) 
No 
(723) 
 
Age Group 
    
15-17 2 34 1.00 1.00 
18-24 9 214 0.72(0.15-3.45) 0.73(0.15-3.67) 
25-29 23 172 2.27(0.51-10.09) 2.51(0.53-11.95) 
30-39 48 183 4.46(1.03-19.22) 4.86(1.01-23.33) 
40-49 23 57 6.86(1.52-30.93) 7.19(1.40-36.96) 
50+ 6 63 1.62(0.31-8.46) 1.59(0.26-9.63) 
 
Sex 
 
Male 44 320 1.00 1.00 
Female 67 403 1.21(0.80-1.82) 1.07(0.63-1.81) 
 
Marital Status 
 
Single  32 325 1.00 1.00 
Married 52 334 1.58(0.99-2.52) 1.04(0.59-1.81) 
Divorced 13 35 3.77(1.81-7.85) 1.65(0.73-3.73) 
Widowed 10 18 5.64(2.40-13.26) 2.79(1.01-7.79) 
Separated 4 11 3.69(1.11-12.27) 1.81(0.49-6.76) 
 
Religion 
 
Christian 98 576 1.00 1.00 
Muslim 13 147 0.52(0.28-0.95) 0.64(0.33-1.22) 
 
Educational Status 
 
Illiterate 31 148 1.00 1.00 
Primary (1-6) 26 206 0.60(0.34-1.06) 0.85(0.45-1.59) 
Secondary (7-12) 47 297 0.76(0.46-1.24) 1.25(0.68-2.32) 
Tertiary (12+) 7 72 0.46(0.19-1.11) 0.70(0.26-1.91) 
 
Occupation 
    
Housewife 22 125 1.00 1.00 
Government employed 7 54 0.74(0.29-1.83) 0.59(0.21-1.69) 
Non government 4 19 1.19(0.37-3.85) 1.11(0.31-3.92) 
Private employee 19 182 0.59(0.31-1.14) 0.65(0.30-1.41) 
Self employed/merchant 17 101 0.96(0.48-1.89) 0.83(0.37-1.85) 
Unemployed 40 191 1.19(0.68-2.09) 1.71(0.86-3.38) 
Other 2 51 0.22(0.05-0.98) 0.49(0.10-2.36) 
 
Comparing the figures among the various age categories, those who were 30-39 and 
40-49 years were 4.05 and 7.19 times more likely to had been offered for HIV test than 
those of 15-17 years of age [AOR (95%CI): 4.86(1.01-23.33) and 7.19(1.40-36.96)], 
respectively. In addition, being widowed, from the marital status, was about 2.79 times 
more likely to have been provided with CPT than those who were single [AOR (95%CI): 
2.79(1.01-7.79)]. None of the remaining independent variables showed significant 
association on the adjusted odds ratio. 
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Table 4.44: Association of selected variables with Ever been provided with IPT at HIV clinics among HIV 
patients in Addis Ababa City Administration, July 2011. n=849 
 
Variable 
Ever been provided with 
IPT Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(244) 
No 
(605) 
 
Age Group 
    
15-17 2 9 1.00 1.00 
18-24 28 82 1.54(0.31-7.54) 1.03(0.19-5.42) 
25-29 57 141 1.82(0.38-8.68) 1.15(0.22-6.06) 
30-39 108 226 2.15(0.46-10.12) 1.30(0.25-6.86) 
40-49 34 92 1.66(0.34-8.09) 1.01(0.18-5.63) 
50+ 15 55 1.23(0.24-6.29) 0.79(0.13-4.69) 
 
Sex 
 
Male 64 193 1.00 1.00 
Female 180 412 1.32(0.95-1.84) 1.29(0.84-1.98) 
 
Marital Status 
 
Single  48 150 1.00 1.00 
Married 129 286 1.41(0.96-2.07) 1.19(0.77-1.85) 
Divorced 16 64 0.78(0.41-1.48) 0.65(0.33-1.27) 
Widowed 40 84 1.49(0.91-2.45) 1.35(0.75-2.43) 
Separated 11 21 1.64(0.74-3.64) 1.53(0.65-3.61) 
 
Religion 
 
Christian 202 499 1.00 1.00 
Muslim 42 106 0.98(0.66-1.45) 1.04(0.66-1.63) 
 
Ethnicity 
 
Amhara 132 301 1.00 1.00 
Oromo 55 162 0.77(0.54-1.12) 0.78(0.53-1.13) 
Gurage 26 74 0.80(0.49-1.31) 0.77(0.44-1.32) 
Tigre 25 56 1.02(0.61-1.70) 1.06(0.62-1.81) 
Other 6 12 1.14(0.42-3.10) 1.31(0.46-3.76) 
 
Educational Status 
 
Illiterate 58 139 1.00 1.00 
Primary (1-6) 74 173 1.03(0.68-1.54) 1.05(0.68-1.61) 
Secondary (7-12) 89 236 0.90(0.61-1.34) 0.96(0.62-1.48) 
Tertiary (12+) 23 57 0.97(0.55-1.72) 1.02(0.50-2.05) 
 
Occupation 
    
Housewife 57 111 1.00 1.00 
Government employed 21 47 0.87(0.48-1.59) 1.05(0.49-2.25) 
Non government 8 21 0.74(0.31-1.78) 0.93(0.37-2.35) 
Private employee 42 111 0.74(0.46-1.19) 0.91(0.53-1.56) 
Self employed/merchant 47 112 0.82(0.51-1.30) 1.05(0.61-1.81) 
Unemployed 63 162 0.76(0.49-1.17) 0.84(0.53-1.35) 
Other 6 41 0.29(0.11-0.71) 0.35(0.13-0.93) 
 
Provision of IPT among the various socio-demographic variables did not show any 
association (Table 4.44).  
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Table 4.45: Association of selected variables with Ever had been diagnosed for TB before HVI positive 
among HIV patients in Addis Ababa City Administration, July 2011. n=843 
 
Variable 
Ever been diagnosed for 
TB before HIV-positive Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(167) 
No 
(676) 
 
Sex 
 
Male 67 188 1.00 1.00 
Female 100 488 0.58(0.40-0.82) 0.52(0.34-0.79) 
 
Marital Status 
 
Single  35 161 1.00 1.00 
Married 73 338 0.99(0.64-1.55) 1.09(0.67-1.75) 
Divorced 24 56 1.97(1.08-3.59) 2.23(1.19-4.19) 
Widowed 30 94 1.47(0.85-2.55) 1.75(0.97-3.17) 
Separated 5 27 0.85(0.31-2.37) 0.91(0.32-2.62) 
 
Religion 
 
Christian 144 555 1.00 1.00 
Muslim 23 121 0.73(0.45-1.19) 0.74(0.43-1.28) 
 
Ethnicity 
 
Amhara 82 348 1.00 1.00 
Oromo 48 166 1.23(0.82-1.83) 1.30(0.86-1.97) 
Gurage 21 79 1.13(0.66-1.93) 1.35(0.73-2.47) 
Tigre 14 67 0.89(0.48-1.66) 0.86(0.45-1.65) 
Other 2 16 0.53(0.12-2.35) 0.63(0.14-2.89) 
 
Educational Status 
 
Illiterate 35 160 1.00 1.00 
Primary (1-6) 46 199 1.06(0.65-1.72) 0.99(0.60-1.66) 
Secondary (7-12) 74 251 1.35(0.86-2.11) 1.29(0.79-2.13) 
Tertiary (12+) 12 66 0.83(0.41-1.70) 0.58(0.24-1.38) 
 
Occupation 
    
Housewife 24 140 1.00 1.00 
Government employed 18 49 2.14(1.07-4.28) 1.79(0.76-4.25) 
Non government 6 22 1.59(0.59-4.33) 1.05(0.36-3.06) 
Private employee 24 129 1.09(0.59-2.01) 0.74(0.37-1.48) 
Self employed/merchant 38 121 1.83(1.04-3.23) 1.20(0.63-2.29) 
Unemployed 48 177 1.58(0.92-2.71) 1.29(0.73-2.31) 
Other 9 38 1.38(0.59-3.22) 1.26(0.50-3.13) 
 
Females were less likely than males to have been diagnosed for TB before HIV-positive 
by 48% [AOR (95%CI): 0.52(0.34-0.79)]. In addition, those who were divorced were 
about twice as likely to have been diagnosed for TB than those who were single [AOR 
(95%CI):2.23(1.19-4.19)]. However, the other variables did not show any significant 
association with the dependent variable under analysis.  
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Table 4.46: Association of selected variables with Ever had been diagnosed for TB after HIV-positive 
among HIV patients in Addis Ababa City Administration, July 2011. n=849 
 
Variable 
Ever been diagnosed for 
TB after HIV-positive Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(88) 
No 
(761) 
 
Sex 
 
Male 32 225 1.00 1.00 
Female 56 536 0.74(0.46-1.17) 0.64(0.36-1.14) 
 
Marital Status 
 
Single  13 185 1.00 1.00 
Married 46 369 1.77(0.94-3.37) 1.54(0.78-3.04) 
Divorced 10 70 2.03(0.85-4.85) 2.03(0.82-4.99) 
Widowed 16 108 2.11(0.98-4.55) 2.03(0.89-4.64) 
Separated 3 29 1.47(0.39-5.48) 1.51(0.39-5.91) 
 
Religion 
 
Christian 71 630 1.00 1.00 
Muslim 17 131 1.15(0.66-2.02) 1.14(0.60-2.14) 
 
Ethnicity 
 
Amhara 43 390 1.00 1.00 
Oromo 21 196 0.97(0.56-1.68) 0.98(0.56-1.71) 
Gurage 8 92 0.79(0.36-1.73) 0.84(0.36-1.98) 
Tigre 12 69 1.58(0.79-3.14) 1.47(0.71-3.04) 
Other 4 14 2.59(0.82-8.23) 2.74(0.80-9.33) 
 
Educational Status 
 
Illiterate 26 171 1.00 1.00 
Primary (1-6) 21 226 0.61(0.33-1.12) 0.62(0.33-1.17) 
Secondary (7-12) 28 297 0.62(0.35-1.09) 0.65(0.35-1.21) 
Tertiary (12+) 13 67 1.28(0.62-2.63) 1.20(0.46-3.11) 
 
Occupation 
    
Housewife 21 147 1.00 1.00 
Government employed 11 57 1.35(0.61-2.98) 0.82(0.28-2.38) 
Non government 1 28 0.25(0.03-1.94) 0.21(0.03-1.78) 
Private employee 17 136 0.88(0.44-1.73) 0.78(0.35-1.73) 
Self employed/merchant 15 144 0.73(0.36-1.47) 0.67(0.29-1.52) 
Unemployed 21 204 0.72(0.38-1.37) 0.71(0.36-1.42) 
Other 2 45 0.31(0.07-1.38) 0.31(0.07-1.48) 
 
Being diagnosed for TB after HIV-positive did not show any significant association 
among all socio-demographic variables in both adjusted and crude odds ratio (Table 
4.46).  
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Table 4.47: Association of selected variables with Knowledge about CPT among TB/HIV patients in Addis 
Ababa City Administration, July 2011. n=834 
 
 
Variable 
Do you know about CPT 
Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(193) 
No 
(641) 
 
Age Group 
    
15-17 2 34 1.00 1.00 
18-24 9 214 1.08(0.31-3.85) 1.18(0.32-4.29) 
25-29 23 172 3.69(1.08-12.57) 4.43(1.23-16.01) 
30-39 48 183 5.72(1.70-19.23) 7.02(1.90-25.89) 
40-49 23 57 6.26(1.76-22.20) 7.68(1.95-30.34) 
50+ 6 63 2.55(0.68-9.63) 3.45(0.82-14.59) 
 
Sex 
 
Male 44 320 1.00 1.00 
Female 67 403 0.98(0.71-1.35) 1.06(0.69-1.59) 
 
Marital Status 
 
Single  32 325 1.00 1.00 
Married 52 334 1.07(0.75-1.52) 0.72(0.46-1.12) 
Divorced 13 35 3.35(1.79-6.25) 1.79(0.89-3.62) 
Widowed 10 18 2.97(1.35-6.55) 1.87(0.75-4.69) 
Separated 4 11 1.98(0.66-5.97) 0.85(0.26-2.80) 
 
Religion 
 
Christian 98 576 1.00 1.00 
Muslim 13 147 0.49(0.31-0.80) 0.65(0.39-1.09) 
Educational Status  
Illiterate 31 148 1.00 1.00 
Primary (1-6) 26 206 0.78(0.49-1.25) 1.09(0.64-1.86) 
Secondary (7-12) 47 297 0.89(0.59-1.38) 1.27(0.75-2.16) 
Tertiary (12+) 7 72 1.74(0.98-3.08) 2.08(1.02-4.25) 
 
Occupation 
    
Housewife 22 125 1.00 1.00 
Government employed 7 54 1.69(0.87-3.31) 1.03(0.47-2.26) 
Non government 4 19 3.43(1.38-8.51) 2.14(0.79-5.79) 
Private employee 19 182 0.74(0.43-1.27) 0.64(0.34-1.21) 
Self employed/merchant 17 101 1.33(0.75-2.36) 0.96(0.49-1.89) 
Unemployed 40 191 1.34(0.82-2.19) 1.55(0.86-2.79) 
Other 2 51 0.57(0.23-1.38) 0.92(0.34-2.47) 
 
Comparing knowledge about CPT among TB patients across the various age 
categories, those who were 20-29, 30-39 and 40-49 years were 4.43, 7.02 and 7.68 
times more likely to had been informed about CPT than those of 15-17 years of age 
[AOR (95%CI): 4.43(1.23-16.01), 7.02(1.90-25.89) and 7.68(1.95-30.34], respectively. 
In addition, being divorced and widowed, from the marital status, were about 1.79 and 
1.87 times more likely to had been informed about CPT than those who were single, 
[AOR (95%CI): 1.79(0.89-3.62) and 1.87(0.75-4.69)]. In addition, those who had 
educational status of tertiary were about twice as likely to knew about CPT than those 
who were illiterate [AOR (95%CI): 2.08(1.02-4.25)] .  
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Table 4.48: Association of selected variables with Knowledge about IPT among TB/HIV patients in Addis 
Ababa City Administration, July 2011. n=849 
 
 
Variable 
Do you know about IPT 
Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(359) 
No 
(490) 
 
Age Group 
    
15-17 3 8 1.00 1.00 
18-24 38 72 1.41(0.35-5.62) 1.02(0.24-4.35) 
25-29 77 121 1.69(0.44-6.59) 1.19(0.28-5.08) 
30-39 161 173 2.48(0.65-9.52) 1.64(0.39-6.98) 
40-49 54 72 2.00(0.51-7.89) 1.36(0.30-6.09) 
50+ 26 44 1.58(0.38-6.47) 1.18(0.25-5.54) 
 
Sex 
 
Male 103 154 1.00 1.00 
Female 256 336 1.14(0.85-1.53) 1.33(0.90-1.95) 
 
Marital Status 
 
Single  74 124 1.00 1.00 
Married 182 233 1.31(0.93-1.85) 1.08(0.73-1.61) 
Divorced 32 48 1.12(0.66-1.90) 0.87(0.49-1.55) 
Widowed 58 66 1.47(0.93-2.32) 1.26(0.73-2.18) 
Separated 13 19 1.15(0.54-2.46) 0.99(0.44-2.25) 
 
Religion 
 
Christian 299 402 1.00 1.00 
Muslim 60 88 0.92(0.64-1.32) 1.06(0.70-1.60) 
 
Ethnicity 
 
Amhara 192 241 1.00 1.00 
Oromo 83 134 0.78(0.56-1.09) 0.78(0.55-1.09) 
Gurage 39 61 0.80(0.52-1.25) 0.81(0.49-1.32) 
Tigre 38 43 1.11(0.69-1.79) 1.09(0.67-1.79) 
Other 7 11 0.79(0.30-2.10) 0.86(0.31-2.39) 
 
Educational Status 
 
Illiterate 78 119 1.00 1.00 
Primary (1-6) 105 142 1.13(0.77-1.65) 1.15(0.77-1.72) 
Secondary (7-12) 133 192 1.06(0.74-1.52) 1.10(0.74-1.65) 
Tertiary (12+) 43 37 1.77(1.05-2.99) 1.79(0.95-3.40) 
 
Occupation 
    
Housewife 75 93 1.00 1.00 
Government employed 35 33 1.32(0.75-2.31) 1.12(0.55-2.26) 
Non government 16 13 1.53(0.69-3.37) 1.61(0.69-3.74) 
Private employee 61 92 0.82(0.53-1.28) 0.95(0.57-1.57) 
Self employed/merchant 69 90 0.95(0.61-1.47) 1.08(0.65-1.78) 
Unemployed 92 133 0.86(0.57-1.29) 0.92(0.59-1.43) 
Other 11 36 0.38(0.18-0.79) 0.46(0.21-1.02) 
 
Knowledge of IPT by TB/HIV patients did not have any association with any of the 
socio-demographic characteristics in the adjusted odds ratio. However, study 
participants who learnt up to tertiary level, educationally, were about 1.77 times more 
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likely to know about IPT than those of illiterates on crude odds ratio [AOR (95%CI): 
1.77(1.05-2.99)].  
 
Table 4.49: Association of selected variables with Ever had been tested for HIV before diagnosed for TB 
among TB patients in Addis Ababa City Administration, July 2011. n=826 
 
Variable 
Ever been tested for HIV 
before diagnosed for TB Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(445) 
No 
(381) 
 
How long have you been 
diagnosed for TB? 
 
Less than 2 months 199 193 1.00 1.00 
2-5 months 177 140 1.23(0.91-1.65) 1.24(0.92-1.67) 
6-8 months 44 34 1.26(0.77-2.05) 1.24(0.76-2.02) 
More than 8 months 25 14 1.73(0.87-3.43) 1.72(0.87-3.42) 
 
Ever been offered for HIV 
test during TB treatment 
 
Yes 377 341 1.00 1.00 
No 68 40 1.54(1.01-2.33) 1.54(1.01-2.34) 
 
Those who were not offered for HIV test during TB treatment were about 1.5 times more 
likely to had been tested for HIV before being diagnosed for TB than those who were 
offered during their TB treatment [AOR (95%CI): 1.54 (1.01-2.34)].  
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Table 4.50: Association of selected variables with Ever had been diagnosed for TB after HIV-positive for 
HIV patients in Addis Ababa City Administration, July 2011. n=849 
 
Variable 
Ever been diagnosed for 
TB after HIV-positive Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(88) 
No 
(761) 
 
How long have you been 
diagnosed for HIV? 
 
Less than 6 months 7 117 1.00 1.00 
6 -11 months 5 86 0.97(0.29-3.17) 0.83(0.24-2.89) 
1-3 years 30 270 1.86(0.79-4.35) 0.82(0.26-2.53) 
More than 3 years 46 288 2.67(1.17-6.08) 1.11(0.35-3.49) 
 
How long have you been 
on HAART? 
 
Less than 6 months 7 142 1.00 1.00 
6 months-1 year 9 96 1.90(0.69-5.28) 2.18(0.66-7.14) 
More than 1 year 63 388 3.29(1.47-7.36) 3.53(1.17-10.65) 
Not yet started 9 135 1.35(0.49-3.73) 1.29(0.45-3.72) 
 
Ever been diagnosed for 
TB before HIV-positive 
 
Yes 7 160 1.00 1.00 
No 79 597 3.03(1.37-6.68) 3.78(1.69-8.43) 
Do not remember 2 4 11.43(1.78-73.30) 14.71(2.17-99.54) 
 
HIV-positive study participants who had been on HAART for more than one year were 
about 3.5 times more likely to have been diagnosed with TB after their HIV-positive test 
result than those of less than six months on HAART [AOR (95%CI): 3.53(1.17-10.65)], 
which is statistically significant. In addition, those HIV patients who had never been 
diagnosed for TB before being HIV-positive were about 3.8 times more likely to have 
been diagnosed for TB after their HIV-positive test result than those who had been 
diagnosed for TB before their HIV-positive status [AOR (95%CI): 3.78(1.69-8.43)]. 
In addition these figures, those who knew their HIV-positive status for more than three 
years were about 2.7 times more likely to have been diagnosed for TB after their HIV-
positive status than those who knew for less than six months on crude odds ratio.  
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Table 4.51: Association of selected variables with Ever had been diagnosed for TB before HIV-positive 
for HIV patients in Addis Ababa City Administration, July 2011. n=843 
 
Variable 
Ever been diagnosed for 
TB before HIV-positive Unadjusted Odds 
Ratio(95%CI) 
Adjusted Odds 
Ratio(95%CI) Yes 
(167) 
No 
(676) 
 
How long have you been 
diagnosed for HIV? 
 
Less than 6 months 13 111 1.00 1.00 
6 -11 months 12 79 1.29(0.56-2.99) 1.11(0.47-2.64) 
1-3 years 55 242 1.94(1.02-3.69) 1.13(0.49-2.58) 
More than 3 years 87 244 3.04(1.63-5.69) 1.64(0.71-3.79) 
 
How long have you been 
on HAART? 
 
Less than 6 months 18 130 1.00 1.00 
6 months-1 year 19 85 1.61(0.80-3.25) 1.51(0.67-3.39) 
More than 1 year 114 334 2.47(1.44-4.22) 1.88(0.89-3.97) 
Not yet started 16 127 0.91(0.44-1.86) 0.84(0.40-1.77) 
 
On crude odds ratio logistic regression analysis, the longer the time to know HIV-
positive status the greater the chance of being diagnosed for TB before their HIV-
positive status. In addition, the longer on HAART the higher the chance of being 
diagnosed with TB before their knowledge of positive status. However, on the adjusted 
odds ratio there is hardly any association observed for being diagnosed for TB before 
HIV-positive status.  
 
4.5.4 Data from healthcare providers and/or facility TB/HIV coordinators 
 
The findings from interviewer administered TB/HIV care providers and/or facility TB/HIV 
care coordinators’ quantitative data is presented in the following sub-sections. 
 
4.5.4.1 Socio-demographic characteristics of study participants 
 
Table 4.52: Socio-demographic characteristics of TB/HIV collaborative activity health facility 
coordinators and TB/HIV care providers, Addis Ababa City Administration. n=10 
 
Age Sex Profession 
Number of yrs of service 
in TB/HIV clinic 
Average – 42.2 yrs 
Minimum – 26 yrs 
Maximum – 54 yrs 
Male – 4 
Female – 6 
Medical 
Doctor - 1 
Nurse - 9 
Average – 2yrs+10mons 
Minimum – 1yr 
Maximum – 6 yrs 
153 
As shown in Table 4.52, most of the TB/HIV service providers were nurses and female. 
The average age was 42.2 years, which showed they had been highly experienced in 
other programmes before engaging in TB/HIV collaborative activities. However, their 
average length of experience in TB/HIV care service was slightly less than 3 years (2 
years and10 months), with minimum and maximum of 1 and 6 years, respectively.  
 
4.5.4.2 Implementation Status of collaborative TB and HIV Care services  
 
The TB/HIV policy (WHO, 2012a) recommends the establishment of a coordinating 
body; surveillance of HIV prevalence among TB patients; joint TB/HIV planning; and 
monitoring and evaluation. According to the participants in this study, eight of the ten 
study health facilities have functional coordinating body for TB/HIV activities effective at 
their health facility level. In all the eight health facilities, representatives from the TB 
clinic and HIV care clinics were in attendance. However, only in two of these facilities 
were representatives from partner organisations (NGOs) and sub-city health 
departments in attendance on the coordinating body. Surveillance of HIV prevalence 
among TB patients has not been conducted in any of the study health facilities at any 
time. In addition, in all of the eight health facilities that had a TB/HIV coordinating body, 
joint TB/HIV planning, monitoring and evaluation for activities have been conducted 
regularly.  
All of the study TB/HIV collaborative activities health facility coordinators mentioned that 
they were providing services of routine screening for coughing of more than two weeks 
for HIV patients, routine diagnosis of tuberculosis being, based on cardinal signs for 
each of the HIV patients at their follow-up visits and prompt treatment being given for all 
confirmed TB cases among PLHIV within the health facility.  
All but one of the ten participants from the study health facilities reported that they were 
providing IPT for all PLHIV having latent TB. Regarding TB infection control in the 
health facilities, six out of the ten health facilities’ TB/HIV clinics had ventilation of rooms 
and enough waiting area for HIV-positive patients to prevent transmission of TB in 
health facilities; whereas, in only four of the health facilities, healthcare providers used 
personal protective masks to prevent transmission of TB for themselves and to patients. 
According to the report from the study participants, all except one health facilities 
provided regular health education to HIV-positive and/or TB patients about TB 
transmission and prevention at a session.  
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All interviewed health workers from the ten study health facilities reported that all TB 
patients were being offered HIV counselling and testing services, whilst all health 
workers at TB clinics in the health facilities conveyed messages of safer and more 
responsible sexual behaviour to reduce transmission of HIV. In addition, all health 
workers at the health facilities practiced measures to ensure the safety of the blood 
supply and medical equipments to reduce transmission of HIV. In addition, all 
participants reported that health facilities were providing ART treatment or prophylaxis 
for pregnant women infected with HIV for TB suspects and patients.  
Concerning CPT, all health workers responded that their respective study health 
facilities had established a system to provide CPT to eligible PLHIV for those with active 
TB.  
In addition, all the study health facilities ensured a continuum of care and support for 
people living with HIV during and after TB treatment, created mechanisms to provide 
ART to eligible TB patients and ensured continuity of ART after completion of TB 
treatment.  
 
4.6 CONCLUSION 
 
This chapter has presented the analysis, interpretation, and discussion of the 
quantitative data from both patients and healthcare providers. The presentation began 
with an introduction to the chapter and review of research questions of the study. The 
findings of the study were presented in the order stated on the questionnaires.  
Both descriptive and inferential statistics were applied for data presentation, analysis 
and discussion. For descriptive analysis, data was analysed by person, place and time. 
Tables and graphs were widely used for presentation of data for these statistics.  
On the other hand, inferential statistics were applied to draw inferences (cause and 
effect relationships) from associations of dependent variables against the various 
independent variables. Those variables with significant associations have been 
analysed and interpreted in comparison with similar research conducted elsewhere. 
Tables were extensively used to present data from inferential analysis. 
Quantitative data from interviews of healthcare providers for TB/HIV care was 
presented, but only with descriptive statistics as the sample size was very small. 
In the next chapter, the qualitative data is presented, analysed, interpreted and 
discussed in detail.  
 CHAPTER FIVE 
QUALITATIVE DATA PRESENTATION, ANALYSIS AND 
DISCUSSION 
 
5.1 INTRODUCTION 
 
In this chapter, the findings on the qualitative study are presented, interpreted, 
analysed, discussed in detail. The chapter begins with an  introduction then describes 
how the various qualitative questionnaires were administered. In addition, the qualitative 
findings were presented in themes and sub-themes. Finally, the findings of the 
qualitative data are described under sub-sections. The chapter will be summarised by 
key findings from the qualitative research.  
Qualitative research is much more subjective than quantitative research and uses very 
different methods of collecting information, mainly individual, in-depth interviews and 
focus groups discussions. The nature of this type of research is exploratory and open-
ended. Small numbers of people are interviewed in depth and/or a relatively small 
number of focus groups discussions are conducted (GuideStar, [s.a]). 
The research objectives for the qualitative research were:  
• Describe implementation status of collaborative TB and HIV care services 
(qualitative findings). 
• Identify how programme implementation impacts on both TB and HIV patients. 
• Identify how programme implementation impacts on staff development. 
• Describe the programme implementation in relation to infrastructure. 
• Recommend to policymakers and practitioners the technical basis to guide the 
implementation of collaborated TB/HIV activities based on findings of this study. 
In this chapter, the qualitative findings which answer the exploratory research questions 
are presented.  
The findings from interview of patients, healthcare providers, and coordinators of 
collaborative TB/HIV activities from regional health bureau (Addis Ababa City 
Administration) and health facility levels are discussed. Focus group discussions among 
patients are presented and discussed in the following sections. 
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5.2 ADMINISTRATION OF INTERVIEW GUIDES 
 
The qualitative part for interview of patients, coordinators of health facility TB/HIV 
collaborative activities/health workers and focus group discussions were conducted by 
the researcher and supervisor of overall data collection process with the assistance of a 
note-taker. However, the regional TB/HIV coordinator was interviewed by the 
researcher alone using TB/HIV monitoring tool (WHO, 2006b). 
The researcher took samples for short answer qualitative data for both TB and HIV 
patients conveniently, meaning, selected patients (keen on open-ended questions and 
able to respond evocatively) from those who had participated on the quantitative 
sections (part I-III) and were enrolled directly for part IV of the qualitative section 
(ANNEXURES F and G). The questionnaires for TB and HIV patients were similar, but 
designed in a different way based on their disease conditions, and purposefully to 
gather information for activities to decrease the burden of TB/HIV with respect to their 
current disease. The response rate for patient interviews among the total approached 
TB and HIV patients is presented in Table 5.1. 
In addition, all 10 health facilities’ collaborative TB/HIV care coordinators and/or 
(coordinators are also service providers of collaborative TB/HIV care) health workers 
were interviewed. In addition, eight out of the 10 planned FGDs were conducted among 
TB and HIV patients separately, which gives a response rate of 90%. 
Data is presented according to the sequence of questions as it appeared on part IV of 
the short answered qualitative part for each of the groups of TB and HIV patients 
individually. On the other hand, ten interviews among TB/HIV collaborative activity 
coordinators/health workers of the health facilities and eight FGDs among the TB and 
HIV patients (each of four FGDs) were presented, based on the interview questions in 
themes and sub-themes. In addition, for the overall city administration, using the WHO 
TB/HIV monitoring tool (WHO, 2006b), data was collected to gather the overall regional 
TB/HIV collaborative activity implementation status by interviewing the regional TB/HIV 
collaborative activity coordinator. 
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5.3 RESPONSE RATE 
 
Table 5.1: Response rate for the qualitative study, Addis Ababa City Administration, August 2011 
Data type 
Number of 
questionnaires 
or sessions 
administered 
Number of 
questionnaire or 
sessions completed 
or conducted 
Percent 
(%) 
Reason for 
difference 
Qualitative short answer 
interview questionnaire of 
HIV patients 
865 843 97.5 
No response 
or interrupted 
Qualitative short answer 
interview questionnaire of 
TB patients 
865 807 93.3 
No response 
or interrupted 
Qualitative FGD discussions 10 8 80.0 Saturation 
Qualitative interview for 
health workers 
10 10 100  
Qualitative interview of City 
Administration TB/HIV 
collaborative activity 
coordinator 
1 1 100  
Total number of usable 
questionnaires and 
sessions 
1751 1669 95.3  
 
5.4  DATA ANALYSIS 
 
Analysis of the qualitative data collected from participants from interviews of patients, 
service providers, and TB/HIV collaborative activity coordinators are presented in the 
following sub-sections. 
 
5.5 QUALITATIVE DATA PRESENTATION, ANALYSIS AND DISCUSSION 
 
Qualitative research is conducted by collecting, analysing and interpreting data by 
observing what study participants do or say. Hence, qualitative research yields very 
rich, detailed and valid data that gives in-depth understanding of a phenomenon.  
Analysis of qualitative data relies on the continual interplay between the theoretical 
concepts  and analysis of facts. Therefore, in analyzing qualitative data, researchers 
seek to discover trends in patterns of changes with time or possible causal links 
between study variables (Qualitative and Quantitative research, [s.a]). 
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5.5.1 Short Answered Interview Questions for Patients 
 
In this section, 10 short answer questions for HIV patients and 7 questions for TB 
patients were presented to be noted the responses in short in two to three lines. The 
questions were, among others, as follows:  
1) how collaborative TB/HIV service provision of health facilities affected 
patients’ health  
2) how patients thought health workers at TB and HIV clinics in their health 
facilities assisted them in improving their health regarding their HIV or TB 
risks and status  
3) their opinion on whether provision of both HIV and TB care services at the 
same health facility was feasible or practical 
4) their personal feelings of the service provision quality in general regarding TB 
and HIV in their respective health facilities  
5) how they perceived the behaviour and performance of healthcare providers 
towards patients  
6) the patients’ general comments on improving the service provision of 
collaborative HIV and TB care in their health facilities.  
 
In addition to these questions, participants of HIV-positive subjects were asked the 
approximate number of episodes of diarrhoea, upper respiratory tract infections (URTIs) 
and lower respiratory tract infections (LRTIs) for the preceding one year. However, the 
findings of numbers of episodes of morbidities of these diseases from HIV patients were 
not presented here. This was because data was frequently found to be too subjective 
and prone to recall bias.  
The findings from interview of patients are presented in the thematic areas as follows.  
  
5.5.1.1 How does health facility TB/HIV service provision impact on your 
health? 
Various research in different countries has confirmed that a number of factors are 
associated with better health-related quality of life in TB/HIV patients besides healthcare 
delivery and including younger age, higher household income, low stigma, low 
depression and family support (Babikako, Neuhauser, Katamba & Mupere, 2010:93; 
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Deribew, Tesfaye, Hailmichael, Negussu, Daba, Wogi, Belachew, Apers & 
Colebunders, 2009:105; Kittikraisak, Kingkaew, Teerawattananon, Yothasamut, 
Natesuwan, Manosuthi, Chongsuvivatwong & Whitehead, 2012:1 e29775; Hansel, 
Albert, Wu, Chang & Diette 2004:639; Wig, Lekshmi, Pal, Ahuja, Mittal & Agarwa, 
2006:3). 
In this study, participants expressed various opinions on the impact of health facilities’ 
services of collaborative TB/HIV care on their health. However, almost all (93.2%) of the 
interviewed TB and/or HIV patients reported that provision of collaborative TB and HIV 
services improved their health conditions. Of the responses obtained from 1579 
patients, 963 (61.0%) had obtained significant improvement in their health conditions 
following collaborative TB/HIV care services, whereas 509 (32.2%) just appreciated 
services of collaborative TB/HIV, which was attributed to their better health conditions. 
On the other hand, 107 (6.8%) of the participants were not happy with provision of 
integrated TB and HIV care services.  
Some patients expressed their feelings for or against the effect of collaborative TB/HIV 
care services on their health conditions, as follows. 
 A 17 year old female student HIV patient from Bole health centre said that: 
 “I am absolutely healthy and it helped me to be strong and clever student on my 
education.”  
A 21 year old female HIV patient from Lideta health centre said: 
“They (TB/HIV care service providers) have made me survive almost from my 
last breath; I was almost to die at my young age, thanks to God!”  
A 37 year old male HIV patient from Zewditu Memorial hospital said: 
“It helped me a lot; after I have known my HIV status, I am now protecting myself 
and my family.”  
A 35 year female HIV patient from Menelik II hospital said:  
“There is great change on my health, initially I was depressed and anxious, but 
now I am taking care of myself and am very healthy.”  
A 25 year old female co-infected with both TB and HIV from Yeka health centre said: 
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“I was not healthy when I take anti HIV drugs alone, but after I have been 
diagnosed for TB and taking anti TB, I have much improvements on my health 
and I am now okay.”  
A 26 year old female TB patient from Lideta health centre said:  
“When I had being wasted, me and my family suspected HIV infection, but I have 
been diagnosed for TB only and after starting the drugs I have great 
improvement and found HIV negative.”  
A 40 year old female both TB and HIV patient from Zewditu Memorial hospital said:  
“I have survived because of the care of both TB and HIV which I get, but my 
husband has died of refusing for HIV test and the care then after.”  
A 19 year old male MDR-TB patient from Menelik II hospital said:  
“Initially I did not know that I have MDR-TB but while I was attending a family 
member I was diagnosed and now I am under treatment though I am not 
improving much.”  
A 27 year old female both TB and HIV patient from Nifas-Silk lafto health centre said:  
”Integrated TB/HIV care improves our health very fast; otherwise, if we get 
treatment for only one disease, while missing for the other one, will not protect 
from deterioration of health.”  
A 31 year male both TB and HIV patient from Kazanchis health centre said:  
“Initially life was so bitter for me and once I preferred to die but when I get 
treatment and care for both of my diseases I become very eager to live long.”  
A 42 year old male TB patient from Gulele health centre said:  
“I was tested for HIV when I came for tuberculosis treatment and now I knew that 
I am HIV negative and I will maintain my status.”  
 
5.5.1.2 How did health workers at TB clinic assist you in improving your health 
regarding your HIV risks and status? 
 
Previous studies identified provider-level barriers to implementing HIV Counselling and 
Testing for TB patients in SSA and South Africa include lack of nursing staff, lack of 
space, increased workload, and work-related stress, including stress experienced by 
breaking bad news and handling ethical dilemmas (Coetzee, Hilderbrand, Goemaere & 
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Boelaert, 2004:A11; Okot-Chono, Mugisha, Adatu, Madraa, Dlodlo, Fujiwara, 
2009:955).  
In this study, the majority (91.8%) of the interviewed TB and/or HIV patients said that 
healthcare providers in the clinics of TB/HIV collaborative services assisted them to 
have improved health conditions, particularly regarding HIV risks and statuses. Of the 
responses obtained from 1,599 patients, 1,014 (63.4%) obtained significant 
improvement in their health conditions following keen support from health workers in the 
TB/HIV collaborative service clinics, whereas, 454 (28.4%) just appreciated for the 
support of health workers of collaborative TB/HIV services, which was attributed for their 
better health conditions. On the other hand, 128 (8%) of the participants were not happy 
with the support of health workers in the TB/HIV collaborative care service clinics to 
bring better health conditions. Study participants of three HIV patients were not happy 
with the professional ethics of their healthcare providers in the TB/HIV clinics.  
Some interviewed patients expressed their feeling for or against the support of 
healthcare providers working in clinics of collaborative TB/HIV services, as follows. 
A 40 year old female HIV patient from Woreda 7 health centre said:  
“I have being attending the follow-up care regularly, they regularly counsel and 
advice me like a family member; so I am very happy with their support and 
brought significant change on my health.”  
A 40 year male HIV patient from Kazanchis health centre said:  
“I regularly attend my follow-up care but I have no improvement on my health; 
health workers are not very keen and supportive for me.”  
This participants’ perceptions are in contrast to those of healthcare providers in another 
study in South Africa, which revealed the opinion that, for increasing the acceptance of 
HIV Counselling and Testing, they needed to encourage and motivate TB patients 
(Christo, Edwin, Wynne, Michelle, Gladys, Anjali & Camille 2011:27). 
 A 35 year old male HIV patient from Kaliti health centre said:  
“I was desperate initially, but when I started attending regular counselling, advice 
and care from healthcare providers, I have much improvement on my health and 
now I am living for my child.”  
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A 17 year old female HIV patient from Menelik II hospital said:  
“Health workers in TB/HIV clinics are very kind for me, they advice and treat me 
very well and I have significant change on my health, I am very well physically 
and mentally; once I was thinking to commit suicide.”  
A 28 year old female TB patient said:  
“I did not know that I had HIV until I was tested here while I was on anti-TB 
treatment through their counselling services; after I started integrated TB/HIV 
care services, I have improved and regained my health back.”  
A 42 year old female both TB and HIV patient said:  
“Once, I had stopped taking anti-HIV drugs as it was very boring for me, but due 
to their advice, counselling and close follow-up care, I have re-started and now 
on my regular follow-up care with improved health condition.”  
A 28 year female TB patient from Yeka health centre said:  
“Health workers at TB clinic helped me to take my daily pills through their directly 
observed treatment scheme, which helped me to stick to my treatment and 
benefited from better health condition.”  
A 20 year old female TB patient form Woreda 7 health centre said:  
“When I was told that I had TB, I felt loneliness and hopelessness but due to their 
kind advice, counselling and support I have started my treatment to bring 
significant change on my health condition.”  
Finally, a 52 year old male TB patient from Zewditu Memorial hospital said:  
“Health workers at the TB clinic advised and supported me to live hopefully and 
the treatment helped me to improve very well” 
 
5.5.1.3 Do you think provision of both HIV and TB care services at the same 
health facility be feasible or practical? How is that? 
 
The Majority (92.2%) of the interviewed TB and/or HIV patients agreed that integrated 
TB/HIV care services in the same health facility were feasible and practical. Of the 
responses obtained from 1,593 patients, 1049 (65.9%) strongly supported the feasibility 
and practicability of integrated TB/HIV care services, whereas, 419 (26.3%) just 
appreciated for the feasibility of collaborative TB/HIV care services being provided in 
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one health facility. The reasons mentioned in favour of integrated TB/HIV care services 
were: less transportation cost and time spent to get services than had been in more 
than one centre; reduction of stigma and discrimination while visiting one service 
provider; avoidance of overlapping of treatments if it were given in different centres; and 
belief it would be ‘one stop shopping’. On the other hand, 96 (6.0%) of the participants 
thought, integrated TB/HIV care services in single health facility would not be practically 
feasible. The reasons mentioned not to favour integrated TB/HIV care services were: 
belief that one healthcare worker cannot address both diseases; patients may be 
exhausted getting more than one treatment at a time; and an assumption that TB and 
HIV care services need separate specialised centres. In addition, 28 (1.8%) participants 
from both TB and HIV patients strongly disagreed on thepracticality of collaborative 
TB/HIV care services which exposed them to long waiting time for services.  
Some interviewed patients expressed their feelings in favour of or against the support of 
integrated TB/HIV care services, in one centre as follows:  
A 26 year old HIV patient from Kazanchis health centre said:  
“The services are very fast, we are getting all the necessary medical services in 
one centre without any problem.”  
A 40 year old female HIV patient from Zewditu hospital said:  
“Getting all the services in one place is very comfortable for patients; it increases 
the confidentiality of TB/HIV patients as we are not mixing with other patients 
coming for other services.”  
A 42 year old male HIV patient from Yeka health centre said:  
“Both TB and HIV care services are given at once in one place, which saves time 
and expenses for transportation.”  
A 24 year old female HIV patient from Kaliti health centre said:  
“Integrated TB/HIV care services help to stick to the recommended treatment 
schedules besides saving money and patients’ effort to get the services if it were 
provided in different centres.”  
An 18 year old male HIV patient from Nefasilik Lafto health centre said:  
“Getting both services in one health facility avoids the exhaustion of patients to 
go here and there.”  
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On the other hand, a 41 year old male HIV patient from Menelik II hospital said:  
“The coordination of the services is not always the same, sometimes it becomes 
fast and other times they become disorganized; they do not have sustained and 
systematized services.”  
A 29 year old female TB patient from Zewditu Memorial hospital said:  
“Integrated TB and HIV care service helps to adjust appropriate treatment for TB 
patients, and it maintains the confidentiality of patients’ history.”  
A 24 year old TB patient from Gulele health centre said:  
“Integrated TB/HIV service is successful, because TB and HIV diseases are 
inter-related so that the patient benefit from getting the services in one centre.”  
A 28 year old female TB patient from Yeka health centre said:  
“Getting both services in one place is ‘killing two birds with one stone’, because a 
patient who comes for TB can get also services for HIV and vice-versa.”  
A 15 year old female TB patient from Woreda 7 health centre said:  
“Integrated health centres also help patients to share ideas and experiences 
among themselves, besides shortens the time to get both services in one place.” 
A 24 year old male TB patient from Kazanchis health centre said:  
“It is good to get both services in one centre because it reduces ignorance and 
tiresome.”  
On the contrary, a 24 year old male TB patient from Lideta health centre said: 
“Providing both services in one centre is not feasible because healthcare 
providers may not focus on one disease which becomes cumbersome.” 
 
5.5.1.4 What do you think of the service provision quality in general regarding 
TB and HIV in this health facility? 
 
Almost all (94.5%) of the interviewed TB and/or HIV patients believed that the quality of 
TB and HIV care services were good. Of the responses obtained from 1,620 patients, 
757 (46.7%) strongly trusted the quality of the services which they believed contributed 
to the improvement of their health conditions, whereas, 774 (47.8%) just appreciated for 
the quality of the services of collaborative TB/HIV, which was attributed to their better 
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health conditions. On the other hand, 82 (5.1%) of the participants were not happy with 
the quality of integrated TB and HIV care services.  
Some participants expressed various feeling towards or against the quality of 
collaborative TB/HIV care services as follows: 
A 45 year old male HIV patient from Zewditu Memorial hospital said:  
“The quality of integrated TB/HIV service is very high, I see a lot of change from 
time to time; for example, fixed dose therapy is more convenient and acceptable 
by patients.”  
A 34 year old female HIV patient from Menelik II hospital said:  
“They (health workers) need slight improvement; otherwise the services are at 
high quality to the best satisfaction of patients.”  
A 53 year old female HIV patient from Kazanchis health centre said:  
“As I am getting a lot of change on my health condition, I can say the quality of 
the service is excellent.”  
A 38 year old female HIV patient from Yeka health centre said:  
“The service quality is at high standard, because we are benefiting from the 
treatment to live healthily and productively.”  
On the other hand, some participants commented on the need to improve the quality of 
the services. A 61 year male HIV patient from Gulele health centre said:  
“I think the quality is low, because I don’t see any change on my health 
condition.”  
A 28 year old female HIV patient from Nefas-Silik lafto health centre said:  
“Despite the service is at good quality, it needs to improve more in the future.”  
A 28 year old female TB patient from Lideta health centre said:  
“The quality is at high standard; rather it is more than that for me.”  
Another 28 year old male TB patient from Yeka health centre said:  
“It is an excellent service, because we are getting all the services at one centre.” 
A 33 year old male TB patient from Menelik II hospital said:  
“I can say it is of good quality as I have benefited from improved health 
condition.”  
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A 22 year old female TB patient from Gulele health centre said:  
“I suggest if they can improve the quality of care, as they did not identify my TB 
disease in the health centre.”  
A 72 year old male TB patient from Lideta health centre said:  
“I believe it is in good quality, previously we have been given many drugs but 
now it is changed to one tablet only.”  
A 28 year old male TB patient from Bole health centre said:  
“I have to say the quality is good as I have benefitted from the existing services.” 
A 27 year old female TB patient from Kazanchis health centre said:  
“The quality is good, as I have been given care and treatment for the two 
diseases while I came for one problem.”  
A 29 year old female from Kality health centre said:  
“It is because of the good quality that I have improved health conditions now.”  
 
5.5.1.5 How do you evaluate the behaviour of healthcare providers towards 
their patients? 
 
Of the responses obtained from 1,650 participants, 1,504 (91.2%) of the interviewed TB 
and/or HIV patients believed that the behaviour of TB and HIV care service providers 
was good. On the other hand, 146 (8.8%) of the participants were not happy with the 
behaviour of TB/HIV care service providers. Some complained of poor maintenance of 
confidentiality of their clients history and favouritism for some clients. In addition, some 
healthcare providers were not opening services on time and/or there was a long waiting 
time.  
Some patients expressed different feelings towards or against the behaviour of TB/HIV 
care service providers, as follows.  
A 24 year’s old female HIV patient from Yeka health centre said:  
“Most of them are very kin to their patients but some are not behaving well.”  
A 20 year old female HIV patient from Zewditu hospital said:  
“They are not bad, but those working at the registration room are nagging.”  
A 34 year old female HIV patient from Lideta health centre said:  
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“Some health workers are consulting while facing patients at the back on the 
circulating chair.”  
A 29 year old female HIV patient from Kazanchis health centre said:  
“In general, their behaviour is good, but sometimes they feel dull.”  
A 32 year old female HIV patient from Woreda 7 health centre said:  
“Some service providers have downhearted me and need to be improved.”  
A 45 year old female HIV patient from Menelik II hospital said:  
“Their behaviour varies; some are good and some are rude.”  
A 21 year old male TB patient from Nefasilk Lafto health centre said:  
“Their behaviour is good; they advice, encourage and support us to continue our 
follow-up care.”  
A 38 year old male TB patient from Bole health centre said:  
“The behaviour of health workers helped me to be patient until I see my progress, 
so they have good behaviours towards their patients.”  
A 47 year old male TB patient from Zewditu hospital said:  
“Most of the time they have good behaviour, but sometime they become rude 
and rough.”  
A 34 year old male TB patient from Kaliti health centre said:  
“I am very comfortable with TB/HIV healthcare workers’ behaviour; for example, 
for questions I raise, they respond me politely to my satisfaction” 
 
5.5.1.6 How do you evaluate the performance of healthcare providers in your 
opinion towards their patients? 
 
Of the responses obtained from 1,547 patients, 1,410 (91.1%) of the interviewed 
TB/HIV patients believed that the performances of TB and HIV care providers were 
good. On the other hand, 129 (8.3%) of the participants were not happy with the 
performances of TB/HIV care providers; participants were not happy with service 
providers regarding maintaining their confidentiality.  
Some patients expressed their feelings towards or against the performances of TB/HIV 
care providers, as follows.  
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A 35 year old female HIV patient from Kazanchis health centre said:  
“They do not have enough knowledge; they just give the drugs without enough 
advice.”  
A 29 year old female HIV patient from Zewditu Memorial hospital said:  
“They are the safeguard of patients, they have enough knowledge.”  
A 35 year old female HIV patient from Menelik II hospital said:  
“Sometimes they don’t listen to our complaints, maybe they lack enough 
knowledge.”  
A 40 year old female HIV patient from Zewditu hospital said:  
“They have very good knowledge; if health workers were not there, I would have 
died; they supported me a lot.”  
A 35 year old male HIV patient from Yeka health centre said:  
“Their knowledge is medium; I have very small change on my health, I am 
decreasing weight; when I tell them, they are not serious.”  
A 39 year old female HIV patient from Gulele health centre said:  
“They are knowledgeable; they are the ones responsible for the well fare of our 
health next to God; therefore, they are competent.”  
A 28 year old male TB patient from Zewditu Memorial hospital said:  
“They have very good knowledge, because they advice us on the medications 
very well; in my opinion, they have enough knowledge.”  
A 50 year old female TB patient from Zewditu Memorial hospital said:  
“I have observed weakness in their advice and education; for example, I have 
been informed about my disease after 5 months, until then, I did not know that 
my MDR-TB is communicable.”  
A 27 year old female TB patient from Kaliti health centre said:  
“Their knowledge is low; because, whenever TB patients have some complaints, 
they only associate to the anti-TB drug adverse effect and do not investigate for 
other diseases.”  
A 36 year old female TB patient form Woreda 7 health centre said:  
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“I believe that they have enough knowledge.”  
A 48 year old male TB patient from Gulele health centre said:  
“It is because of their good knowledge that I become healthy.”  
A 27 year old female TB patient from Lideta health centre said:  
“Their knowledge is not as such competent; they had treated me for pneumonia 
with wrong diagnosis.”  
A 28 year old female TB patient from Kazanchis health centre said:  
“I believe their knowledge to be comprehensive; the ways they handle patients 
differ from provider to provider.”  
A 29 year old female TB patient from Yeka health centre said:  
“I believe their knowledge is enough; they listen and understand to my problems 
to give me solutions to my satisfaction.”  
 
5.5.1.7 What comments do you have on improving the service provision of HIV 
and TB care? 
 
Out of the responses obtained from 1,523 TB and/or HIV patients on their comments to 
improve the service provision of collaborative TB/HIV care services, half (773, 50.8%) 
said the services in general was fairly good, whereas the remaining half commented on 
different issues to be improved, including those who frankly just said ‘not good’ (1.1%).  
The most important comment was on improving the long waiting time to receive 
services, and commencing service strictly at the official working hours in the morning 
and afternoons, which was commented on by 207 (13.6%) of participants. 106 (10.9%) 
suggested availing sustainable drug supply; whereas, 145 (9.5%) said healthcare 
providers should abide by their professional ethics in maintaining patients’ confidentiality 
and be free of favouritism. In addition, 98 (6.4%) of study participants commented on 
providing continuous health education on prevention of HIV and TB for patients 
attending collaborative TB/HIV care clinics. 62 (4.1%), 45 (3.0%) and 10 (0.7%) of the 
participants recommended provision of food and shelter for patients attending TB and/or 
HIV clinics, availing all TB and HIV laboratory investigations at all health facilities, and 
preparation of anti-HIV drugs with injectable formulations, respectively.  
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5.5.2 Interview of TB/HIV Collaborative activity Health Facility Coordinators 
 
Ten TB/HIV collaborative activity health facility coordinators from all the study health 
facilities were interviewed using a semi-structured questionnaire. Fortunately, all the 
coordinators at health facility level were also service providers for either TB or HIV care 
clinics in their respective health facility. Therefore, for the sake of this study, interview of 
TB/HIV collaborative activity facility coordinator means interview of healthcare provider; 
i.e., the interviews were conducted for TB/HIV health workers who at the same time 
were TB/HIV care coordinators for the respective health facilities.  
The qualitative part of this group had two sections, comprising: 
1) impacts of TB/HIV collaborative care implementation on staff development, 
performance and other allied resources, and  
2) impacts on infrastructure.  
 
The findings are presented according to the thematic areas described above, as follows. 
 
5.5.2.1 Impacts of TB/HIV collaborative care implementation on health human 
resource development, performance and other allied resources 
  
TB/HIV collaborative activity facility coordinators/TB/HIV care providers were 
interviewed on issues of on-the-job training, flow of systematic logistics supply for 
TB/HIV care, support from the administrative environment for the clinics, major 
problems encountered, and recommendations for TB/HIV care improvement. 
 
Staff training and career development 
According to the responses, all study participants had trained on some kind of TB and 
HIV services. Most of them trained on TB/HIV care, TB and leprosy control programme, 
MDR-TB, ART, PIHCT, STIs prevention and control and VCT for HIV. So, in general, all 
of them had trained for the specific clinical care and treatment protocols of TB or HIV 
control programmes.  
Regarding the effect of integrated TB and HIV care services in the same facility on their 
technical performances, all except one said it did not have any effect on their 
performance, but one said it was good for professional competency and in reducing 
burden on healthcare workers when both diseases were dealt with vertically. Therefore, 
171 
a patient having two diseases does not necessarily visit two or more healthcare 
providers to get the services for the two diseases. One health worker in the same room 
would address both diseases, as ‘one stop shopping’, which reduces the time or cost of 
both patients and healthcare workers if dealing with two or more healthcare providers. 
This finding was consistent with a similar study in Cameroon, which reported that “... 
collaboration between TB and HIV units has been beneficial both to the patients and the 
staff” (Barnabas, Kerstin, Miguel & Anna-Karin, 2011)  
In addition the professional developments which care providers believed attained, it was 
expressed by most that being a TB/HIV care provider needs sympathy and willingness. 
Participants felt a caring attitude for TB and HIV patients involved patience and 
acceptance. The finding in this study is similar to a research finding from Cameroon, in 
which a participant from ‘Voices from the frontline: counsellors' perspectives on TB/HIV 
collaborative activities’ in the Northwest Region, said: "It is because of my sympathy for 
humans. It is my joy when I assist people in need and I see some of them picking up 
health wise, I am very happy, that inspires me to go on" (Female counsellor, 32 years 
old) [Barnabas et al., 2011]. 
 
Logistics and supplies 
Supply for TB/HIV care is the backbone of sustained service provision. Interviewed 
healthcare providers reported that logistics supply for the TB and HIV care services had 
not been a major problem, but three of the interviewed ten healthcare providers 
reported that they had experienced some supplies being out of stock, especially, INH 
and TB diagnostic reagents.  
 
Administrative support 
Concerning health facilities’ administrative support for the TB/HIV care clinics, eight of 
the ten study health facilities said that they used to receive good support and have good 
relationships, whereas two of the coordinators from two study health facilities (a health 
centre and a hospital) frankly expressed their frustration of being either neglected or 
having poor communication with them for no reason.  
The interviewed coordinators expressed some of their challenges and problems 
encountered while delivering TB/HIV care services in their respective health facilities. 
Six mentioned key challenges they encountered. The most serious challenge for health 
workers was absence of personal infection prevention protective materials. As a result, 
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healthcare providers were working in an un-conducive environment, not only for them 
but also for patients. The second challenge collaborative TB/HIV care service delivery 
was facing was poor adherence of some patients to their treatments. Patients 
disappeared during their course of treatment and care, for which, most of the time, 
defaulter tracing mechanisms were either ill equipped or non-existent.  
In addition these, inadequacy of the service provision rooms, which were either very 
narrow or unventilated rooms, exposed healthcare providers to stress and frustration on 
their service provision performance. Frequent stock-outs of the drug INH for IPT was 
mentioned as a challenge for health workers in maintaining the quality of 
comprehensive TB/HIV care service provision. In addition, fear of patients having the 
dual disease stigma was mentioned as a major challenge by most of the study health 
facilities. Healthcare providers also expressed their concerns of ever increasing TB/HIV 
patient load with the existing infrastructure, which gained very little attention from 
administrators of the healthcare care delivery system.  
However, reports from other studies outline additional factors affecting the 
implementation of collaborative TB/HIV services. For example, a study in Uganda 
identified a range of health systems factors, including poor TB-HIV planning; weak 
coordination and leadership; inadequate dissemination of policy; inadequate provider 
knowledge; limited TB-HIV inter-clinic referral; poor service integration and recording; 
logistical shortages; and high costs of services (Mukherjee & Eustache, 2007:S73).  
An earlier study in South Africa identifying constraints to integrating TB and HIV care 
services in primary healthcare facilities pointed out high service loads at both the TB 
and HIV entry points, duplication of services and underutilization of staff, and 
independent functionality of TB and HIV services (Chopra, Doherty, Jackson & 
Ashworth, 2005: 357). 
A recent qualitative study on patient and delivery level factors related to constraints for 
HIV testing services for TB patients in South Africa revealed that both interviewed 
health workers and programme managers referred to infrastructural problems, concern 
about lack of information, education, and communication materials, as well as concern 
about limited access to antiretroviral treatment (Christo et al., 2011:27). 
Finally, the TB/HIV collaborative activity facility coordinators recommended improved 
TB/HIV care in their respective health facilities. Based on this, seven out of the ten 
participants recommended different issues relevant to their respective health facilities as 
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follows: regarding staff training and deployment, health workers recommended: 
continuous training of healthcare workers on all TB/HIV collaborative care services, both 
saying basic and refresher schemes, staff rotation among the different clinics in the 
health facility should be regular, incentives for healthcare workers and increasing 
additional staffs in relation to the continual patient loads.  
 
Regarding service expansion of collaborated TB/HIV care: rooms for TB/HIV care clinics 
should be either renovated or changed, or standardised rooms with minimum clinic 
facilities (e.g., hand washing, window); availing laboratory and pharmacy services close 
to the TB/HIV clinics in the same corner; decentralisation of the services to other health 
facilities (private or new facilities) and improvement in linkage of the TB/HIV services 
with care and support programmes. These were among other recommendations. 
 
5.5.2.2 Impacts of TB/HIV collaborative care implementation on infrastructure 
 
TB/HIV collaborative activity health facility coordinators were also interviewed on 
changes to the infrastructure of the health facilities following the commencement of 
TB/HIV integrated services. Questions related to renovation, re-arrangement of existing 
facilities, other cross-cutting services commenced, restructuring of existing services, 
effect on provision of other services and needed infrastructural changes.  
Of the ten health facilities (two hospitals and eight health centres), only in one of the 
hospitals had a new building for TB and HIV care clinics been constructed. This was 
initiated and financed by an NGO, which supported the TB/HIV care services. The 
intention of the construction of a new separate new building specifically for TB/HV care 
clinic was with the intention of having a centre of excellence for integrated TB/HIV care 
for the Addis Ababa City administration. There were no renovations made for the 
remaining nine study health facilities, but rearrangement of rooms, office furniture and 
waiting areas in most of the health facilities.  
Additional supportive services for the TB and HIV collaborative activities were 
established in all of the health facilities:  
• ART pharmacy/drug store  
• data management specifically for TB and HIV care services, 
• mother support group, 
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• VCT/PITC rooms 
• nutritional rehabilitation service  
• youth-friendly services  
However, the mentioned services were not established in all of the health facilities.  
 
Services restructured due to the change in infrastructure of the health facilities as a 
result of the TB/HIV collaborative activities commencement included:  
• administrative service restructured in one health facility  
• VCT service restructured in one health facility 
• PMTCT service restructured in one health facility 
• ART pharmacy in one health facility.  
Otherwise, in the remaining health facilities, there was no restructuring of existing facility 
services.  
Responses of participants on the effect of the TB/HIV collaborative activity on the 
provision of other services showed that in six of the health facilities there were no 
reported changes, whereas, in four of the health facilities it affected either of the 
following: sharing of rooms with other services and waiting area, negative effect on 
performances of IMCI, EPI, FP, adolescent reproductive health services, shortage of 
health workers and workload of existing healthcare providers. 
The facilities’ physical structures were assessed briefly from the TB/HIV collaborative 
coordinators’ perspectives. Specifically, the TB and HIV care clinics rooms were 
focused on, to get opinions of the healthcare providers. Based on their responses, six of 
the facilities had good conducive rooms for both TB and HIV care services. That means, 
both clinics were wide enough, had windows for ventilation and close to patient waiting 
areas, and had good natural illumination. On the other hand, four facility coordinators 
were not comfortable with either the TB or HIV clinic rooms, concerning ventilation, 
water supply, lighting or adequacy of the rooms to accommodate a convenient working 
environment. 
This finding is similar to a study result in South Africa which identified several factors 
that contributed for the success of integrating TB and HIV services, including buy-in 
from management, clinicians and other service providers, providing training that 
improves competencies to treat both diseases, mentoring TB staff on ARV care in the 
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initial stages of integration, and changing management processes to clarify defined 
areas of accountability for health staff (Bernhard, Katherine, Andrew, David, Eric, 
Virginia & Gilles, 2012). 
Participants commented on the requirement of some additional infrastructural set-ups 
for improved implementation of TB/HIV collaborative activities. Convenient and wider 
rooms for HIV and TB clinics, waiting areas for TB and HIV patients and additional staff 
rooms were mentioned by two of the participants. The remaining eight study participants 
responded that there was no need for additional infrastructure, except mentioning 
additional staff. These recommendations are similar to findings in other study which 
include improving staff constraints, space, patient flow, provision of drugs, and clinical 
challenges (Bernhard et al., 2012). 
 
5.5.3  Focus group discussion among patients of TB and HIV 
 
A focus group is a form of qualitative research in which a group of people are asked 
about their perceptions, opinions, beliefs and attitudes towards a product, service, 
concept, advertisement, idea, or packaging (Henderson & Naomi 2009:28). Questions 
were asked in an interactive group setting where participants were free to talk with other 
group members.  
Group discussion produces data and insights that would be less accessible without 
interaction found in a group setting-listening to others’ verbalised experiences. It 
stimulates memories, ideas, and experiences in participants, which is also known as the 
‘group effect’, where group members engage in “a kind of ‘chaining’ or ‘cascading’ 
effect; talk links to, or tumbles out of, the topics and expressions preceding it” (Lindlof & 
Taylor, 2002:182).  
A total of 10 FGDs (each of 5 FGDs among TB and HIV patients; i.e., 50% of study 
health facilities) were planned for this research, but due to saturation of information on 
the eighth FGD, the last two FGDs were cancelled. The participants were selected 
randomly from four health facilities among the 10 study facilities. However, none of the 
participants who participated for the FGD participated in the individual quantitative and 
short answer questions. In addition, for an FGD, participants from the same facility were 
selected from each of TB and HIV separately. Four FGDs were conducted for TB 
patients alone and four among HIV patients. This allowed the researcher to compare 
the findings among the two groups. For both clusters of participants, similar discussion 
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guide points were used and efforts made to mix participants for the two groups from 
different age groups, sex proportion and venues for discussion.  
After brief introductions among participants (age and sex only) and moderators, the 
discussions were conducted. Before the start of each discussion, participants gave 
consent to participate in the group and for confidential use of a tape-recorder to retain 
discussion points.  
The discussion points for both groups of participants contained:  
1) their knowledge about TB and HIV in general, 
2) how the healthcare delivery system assisted people of these two diseases  
3) what services were being rendered by health facilities to decrease the burden of 
TB/HIV in their health facilities 
4) how provision of service by health facilities for both TB and HIV patients affected 
their health  
5) how they thought health workers at TB/HIV clinics in their health facilities 
assisted them in improving their health regarding their TB/HIV risks and statuses  
6) whether they thought provision of both HIV and TB care services in the same 
health facility was feasible or practical 
7) how they felt about the service provision quality 
8) behaviour and performances of healthcare providers and their opinions regarding 
TB and HIV care in their health facilities.  
Finally, participants were probed to give comments to improve the service provision of 
HIV and TB care in their health facilities. The findings from the two groups were 
transcribed separately, based on the discussion point thematic areas. These are 
analysed as follows.  
 
5.5.3.1 Focus group discussion among TB patients 
  
A total of four focus group discussions were conducted among TB patients each in four 
study health facilities (Lideta HC, Nefasilk Lafito No 2 HC, Yeka HC and Kazanchis HC). 
As socio-demographic characteristics, age and sex were taken from each of the 
participants. The average number of participants per session was 8, with minimum of 7 
and maximum 8 participants. Sixteen were female and 15 males. The average age of 
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the participants in all the four FGD participant was 28.3 years, with minimum and 
maximum age of 15 and 47, respectively. The findings are presented in the following 
thematic areas.  
 
Knowledge about TB and HIV, and their relationship 
Participants among TB patients expressed their understanding of the meaning of the 
diseases TB and HIV quite differently. Some of them defined TB as, for example one 
participant said:  
‘... a disease which affects different body parts, but I don’t know its cause’; 
whereas, an others participant said: 
‘... a disease which is caused by cold and malnutrition, which can transmit from 
infected person to healthy person’. 
In addition, a third study participant said: 
‘... a disease which can transmit from person to person and unless treated well, 
can be converted to HIV. 
This finding is similar to the result from a study on Lay beliefs of TB and TB/HIV co-
infection in the same area by Mekdes, Gunnar and Jan (2011:277) that pointed out the 
most common factor patients thought caused TB was ‘bird’ (wind), which literally means 
cold. Many patients recalled being "hit" by bird some time before they started coughing. 
A participant with from the same study (Mekdes et al 2011:277), explained: 
"I have been in Italy, and there is a lot of snow there, and that is what 
predisposed me to TB. It is very cold there, and we wear a lot of clothes, but 
sometimes, mainly when you are working, you forget to wear good clothes, and 
the bird hits you. That is why I had TB. Bird had gone into my body." 
Another group of participants agreed that TB could be treated but not HIV, but both 
diseases affect similarly in terms of socially, psychologically and physiologically. On the 
other hand, they defined HIV as a disease caused by a virus and transmitted by 
unprotected sexual intercourse, by living together, eating together, sharing cups and 
plates with infected persons and being transmitted by sharing sharp materials. In 
contrary to these, a 21 year female TB patient defined TB as:  
“TB is a disease caused by mycobacterium tuberculosis; which affects the 
human body which is transmitted by coughing, talking, sharing cups. The disease 
178 
can be identified by prolonged cough, chest pain and decreasing in body weight 
or swelling of glands. It can be treated by effective drugs if taken properly.” 
Knowledge of participants among TB patients varied significantly among themselves.  
A 38 year male patient from Yeka health centre honestly expressed his knowledge 
about TB:  
.”.. I don’t have much knowledge on the differences between the two diseases TB 
and HIV; for me both are the same, if a person has one of the diseases I 
perceive he must has also the other disease...”  
This participant’s view was similar to those in a similar study in Addis Ababa (Mekdes et 
al., 2011:277), where a patient explained how TB changed into HIV in her case:  
"It is from TB that I got this disease (HIV). They go side to side. The samba (TB) 
went into HIV. Initially, I was saying, can it be from sharp objects, but it is not. It is 
the samba that changed’’. 
Another young TB patient, aged 19 years, from Lideta health centre said:  
.”.. if a person has TB, he may have also HIV, this is because HIV decreases the 
body’s disease protection capacity so it can expose to TB disease. And if both 
diseases occur together, they affect the person seriously.”  
Previous researches reported misperceptions about etiology and transmission of TB 
(Edginton, Sekatane & Goldstein, 2002:1075; Getahun, Aragaw, 2001: 283; Sagbakken 
& Bjune, 2008:1356;) 
It has been found from the focus group participants that knowledge on the diseases TB 
and HIV was poor and they had a wide knowledge gap among themselves. Even their 
knowledge of their own current TB disease was so low that most could not define how 
TB disease came about, how it was transmitted, how it could be prevented, or the 
availability of effective treatments. Some blamed healthcare workers for not giving them 
regular health education on the diseases during their follow-up cares.  
 
The support of the healthcare system to assist patients of TB and HIV 
The focus group participants expressed their view that the healthcare systems were well 
equipped and capable of assisting people with the diseases. Some of them said that 
health workers were keen to encourage them to know their HIV status through 
counselling and testing services. All services were available in the same health facility, 
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so, if a TB patient was found to have HIV s/he would be referred to an HIV clinic within 
the facility to get the necessary medical care. Services mentioned by participants being 
rendered to assist patients were:  
1) follow-up counselling  
2) laboratory check-ups 
3) nutritional counselling 
4) encouraging patients to complete anti-TB treatment, among others.  
Most of these services were being offered by health workers at TB clinics, but during 
service provision it was common to see certain defects from both the healthcare 
system’s and patients’ sides. For example, patients sometimes missed their 
appointment (follow-up) dates to attend their follow-up care, so it affected the scheduled 
health facilities’ service provision and treatment outcome.  
On the other hand, participants expressed their feelings on what they perceived to be 
challenges from the healthcare system. For example, frequent changes of healthcare 
providers of TB clinics results in perceived effects on quality of services, psychological 
feelings of patients to get relationships with new staff due to patients’ sense of being 
attended to by a health worker who had little knowledge of their diseases, and possible 
change in norm of service provision. A 42 year male patient from Kazanchis health 
centre expressed the frustration he encountered during his initial HIV testing process.: 
.”.. on the first day of my visit to the health centre, the health worker in the TB 
clinic opted me to have HIV test without any counselling and my consent; I was 
feeling anxious about that sudden HIV testing process. Later, the health worker 
became so nervous to inform my HIV-positive status, which she realized she did 
not counselled me before the test. Finally, I convinced myself to accept the result 
remembering the information which I had ‘people can live positively’ from media 
and other sources; but had it been other person, s/he would have committed 
suicide.”  
 
Services provided by health facilities to decrease the burden of TB and HIV 
Participants of TB patients among the different health facilities mentioned a wide range 
of services rendered by health facilities to decrease the burden of TB and HIV. Most of 
them agreeably mentioned intensive care treatments for TB, health education on how 
TB disease transmission to others, prevention of TB transmission (mouth covering 
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during coughing and sneezing, using personal cups to spit sputum, ventilating rooms to 
protect family members and use of personal cups for drinking), routine HIV testing for all 
TB patients, follow-up laboratory examinations, counselling services and referral 
services.  
On the other hand, some expressed their negative feelings on lack of certain services. 
Some basic laboratory investigations (x-ray, FNA, CD4 count, liver function tests) were 
ordered to be done at private health facilities, which became expensive for most of the 
patients. Health education about TB and HIV was not being rendered regularly and did 
not use attractive teaching aids (video, drama) in a manner that increased the level of 
understanding of patients.  
 
Effect of integrated TB/HIV services on patients’ health 
Focus group participants from the different health facilities expressed their feelings 
about the benefits of integrated TB and HIV services provided by health facilities on 
their health. Most of the study participants appreciated the encouragement by service 
providers and offering of HIV test for TB patients, which gives an opportunity to know 
their HIV status before the debilitated effect of the virus. Participants agreed on the 
benefit of knowing early HIV status for informed decisions of HIV prevention, care, 
treatment and support interventions. In addition, implementation of integrated TB/HIV 
care services help people know better about TB and HV for early notification of signs 
and symptoms and for early medical care. TB patients who are tested positive for HIV 
benefit from the care and treatment services within the facility, without delaying for 
further investigation and at no cost of time and transportation. It helped them also to be 
more conversant with both diseases during family and community interactions, at which 
time the basic facts of TB and HIV were easily disseminated.  
 
Support of health workers at TB clinics regarding HIV risks and status 
A 39 year female TB patient from Yeka health centre reported that: 
.”..had the nurse in the TB clinic not encouraged me the HIV test through her 
good counselling session, I would have not known my HIV-positive status early 
and I would have not been healthy by now.”  
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Participants who become HIV negative said that they gained a better understanding and 
knowledge about HIV transmission risks and become more protective. A 26 year old 
male TB patient from Kazanchis health centre expressed his feeling:  
.”.. I now know my negative HIV status after being tested in TB clinic, since then I 
have never committed risky sexual practices and am very curious for my health.”  
Most of the participants were happy with the services of HIV testing and counselling 
offered in the TB clinic. But some of them expressed their concerns with the quality of 
the pre-test counselling for HIV test.  
 
Perceived feasibility and practicality of integrated TB/HIV services provision at the same 
health facility 
Most of the participants in this group (TB patients) supported the feasibility of integrated 
TB/HIV care services in one health facility. They reasoned in terms of saving resources 
needed to implement the integrated services compared to vertical services; time and 
costs incurred for transportation for patients if services were in two different centres; 
and the stigma and discrimination imposed if HIV care service were offered in separate 
health facility. On the other hand, some felt integrated TB/HIV care to be unfeasible and 
non-practical. The reasons given were: the quality of services would be compromised if 
services were integrated; and sharing of resources undermines the attention given to 
individual diseases separately. A 22 year female participant from Nefas-Silk lafto #2 
health centre disagreed about integrated TB/HIV services in one health facility, and did 
not think that would be feasible or practical:  
.”..I don’t think it is feasible, there is crowding of both TB and HIV patients; the 
health centre does not have all diagnostic equipments, and; for example, if I have 
both diseases, I need to take some rest after I dealt with one disease to get 
dealing for the second disease; therefore, I prefer TB and HIV care services to be 
provided in separate health facilities each alone.” 
 
Perceived quality of integrated TB/HIV services in health facilities 
Participants of TB patients from most of the health facilities expressed their perceived 
opinion on quality of collaborated TB/HIV care services to be fair and good. Though 
some were unsure of the technical quality, they expressed their concern over lack of 
important laboratory examinations and some investigations for tuberculosis (x-ray and 
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FNA). Lack of these investigations incurred extra expenses for patients at private 
diagnostic centres.  
Some participants were not happy with the quality of the services. There was crowding 
of the clinics with patients; very long waiting times; disorganised service provision; 
waiting areas not convenient and/or sufficient; no confidentiality or privacy of services; 
care givers spent very brief consultation time with each patient; health workers too few 
in number; service usually started late in the morning and closed early; and delays in 
laboratory results. These are among other factors that were mentioned as 
compromising quality.  
A 32 year male patient from Yeka health centre complained:  
.”.. I am a daily labourer, I do not get daily permission from my boss, I have to 
come to collect my daily anti-TB pills, I had told the nurse to give me for at least 
for one week period or to my relatives so that I do my work, she refused; and 
now I have stopped work... on the other hand, they teach us to get nutritious 
food, how can I buy to get those foods?” 
 
Perceived behaviour of healthcare providers towards their patients 
Most focus group participants among the different health facilities witnessed that 
healthcare providers working at TB and HIV clinics were sympathetic, caring, concerned 
and supportive of their patients. Most of the healthcare providers were young, easily 
understood the feeling of patients and acted accordingly. A 29 years female patient 
commented that “...even the experienced providers are cooperative, they advice us to 
adhere on our treatments and willing to listen our problems patiently.”  
On the other hand, some participants were not happy with the behaviour of some 
service providers. A 29 year female patient from Kazanchis health centre expressed her 
feeling that:  
.”.. I am not happy with their behaviour, they are rough and insults us if we fail to 
act accordingly, I feel depressed when I come to this health centre because of 
their bad facial expression, they undermine us, so they have to improve their 
approach.”  
Other participants in general expressed their concern about the behaviour of some 
health workers:  
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“They do not start work on time, they rush during patient examination and 
discussion; they are not communicative to patients about our disease conditions; 
they do not accommodate patients’ excuses; they are rough and not counselling 
patients very well”, A 39 year old housewife TB patient expressed. 
 
Perceived performances of healthcare providers for integrated TB/HIV services 
Most focus group participants from all the groups felt that their health workers were 
performing well. They thought that health workers were trained and qualified for the 
services they provided for their patients, but some had concern about the performances 
of young health workers. Participants perceived they had little experience or maturity to 
deal with all patients problems during the consultation. Behaviourally, they were good 
compared to the mature health workers, but during patient care and counselling they 
usually rushed and simplified things.  
Most participants debated on government health workers’ performances, especially 
during the initial diagnosis of TB diseases. Most complained about the delay in 
diagnosing their diseases, which was aggravated by the scarcity of important diagnostic 
equipments (eg X-ray), and health workers at public health facilities delaying diagnosis 
of TB. If a patient is referred from private health facilities with adequate documents, they 
receive and automatically enrol on their treatments schedule immediately.  
A 39 male patient from Nefas-Silk lafto #2 health centre said:  
.”.. initially I came to this health centre with cough of 3 weeks and they gave me a 
one week injection drug; but I did not get better and they prescribed me again a 
two weeks oral tablets but I refused and went for a private clinic for examination. 
I came back with an x-ray result and referral paper from the private clinic and 
they enrolled me immediately for the treatment. I would have died, if I had not 
been referred from the private clinic, so I doubt their professional competency.” 
Comments to improve the service provision of HIV and TB care 
Finally, all focus group discussion participants among TB patients commented on some 
actions to be taken to improve provision of HIV and TB care in public health facilities.  
Recommendations included: 
The first recommendation was to improve laboratory services and x-ray services. 
Though very difficult for the government to equip all public health facilities with 
those diagnostic machines, it may be enough to establish one public diagnostic 
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centre per sub-city to serve for patients from public health facilities in that 
respective sub-city.  
Improvement of counselling quality and health education for patients of TB and 
HIV at each of the follow-up care was emphasised.  
Motivating of healthcare providers through additional on-the-job training and 
improving payments would help staff behave politely in their patient interaction.  
Participants also recommended retaining mature and aged health workers, who 
they perceived to be more knowledgeable and expert than the younger 
practitioners.  
It was recommended that the physical structure of some health facilities be 
improved; specifically, here should be consultation rooms, waiting area, seats for 
patients at waiting areas, clean toilets, and separation of TB and HIV clinics from 
the other patients buildings.  
Some participants recommended hiding the HIV counselling room sign, as it 
exposed clients to stigma and discrimination once identified in that area by the 
public. In addition, participants recommended deployments of additional health 
workers in public health facilities, so that each health worker would manage a 
reasonable number of patients per day with quality care.  
Finally, participants recommended to avail suggestion boxes at each of the clinics, 
should patients want to write their comments. In addition, patients suggested to 
implement performance appraisal of health workers to upgrade those who need 
training and to reward those who are doing well.  
 
5.5.3.2 Focus Group Discussion among HIV Patients 
 
 A total of four focus group discussions were conducted among TB patients each in four 
study health facilities (Zewditu Hospital, Kality HC, Gulele HC and Bole HC). The socio-
demographic characteristics, age and sex were noted for each of the participants. The 
average number of participants per session was 8, half of whom were female. The 
average age of the participants who participated in all the four FGDs was 30.6, with 
minimum and maximum age of 17 and 47 years, respectively. The findings are 
presented in the following thematic areas.  
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Knowledge about TB and HIV, and their relationship 
Participants among HIV patients defined TB and HIV differently, based on their prior 
knowledge about the diseases. Some groups defined TB as a disease caused by micro-
organisms transmitted from an infected person to healthy person by coughing, which is 
an HIV-related opportunistic disease that the damages human body. Some said HIV 
damages the disease prevention capacity of the body and exposes it to TB disease. On 
the other hand, they defined HIV as a disease which has to be treated to keep the 
patient alive; “HIV means possible to live”; HIV means .”.. a disease which comes from 
sexual intercourse”, said a 21 year old female HIV patient from Menelik II hospital.  
Regarding the relationship between TB and HIV, participants had inconsistent and/or 
poor understanding:  
“Gif a person is infected with both TB and HIV, it is very difficult to treat the HIV, 
but if treated early, it is possible to live longer. HIV is not comfortable for human 
beings and to treat it; whereas, TB can be cured, but HIV is very difficult to cure, 
unless people get tested for HIV and know their status early, it is very difficult to 
survive.”  
 “PLHIV should not be involved in heavy labour work and should not eat raw 
foods as their body becomes very week.”  
Some participants frankly expressed that they did not know the exact relationship 
between the two diseases. In general, PLHIV had very low and inconsistent knowledge 
about HIV and TB and most were unaware of the relationship between the two 
diseases. It was very clear to surmise from the discussion sessions that most of the 
participants were low in educational and socio-economic status. In addition, most of the 
participants’ level of understanding seemed very low, and the moderator had to simplify 
the questions to a level they could understand. However, participants in this study were 
more knowledgeable about the major routes of transmission of HIV than those of TB. 
This finding is similar to previous studies (Mekdes et al 2011:277; Ngamvithayapong, 
Winkvist & Diwan, 2000:1413). 
It was clearly understood from most focus group discussions that the health education 
system of health facilities about TB and HIV for patients either not using appropriate 
teaching aids or not being delivered on a level which most of them could understand, 
were important issues.  
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The support of the healthcare system to assist patients of TB and HIV 
Participants of the focus group discussion from the different public health facilities 
expressed their belief in favour of the support of the healthcare delivery system for the 
lives of patients with both diseases, particularly HIV.  
Participants praised the benefits of the public health facilities in supporting them while 
dealing with their disease conditions. The following was typical:  
“Pfor patients of either of TB and/or HIV, treatment is free, laboratory 
investigation is also free, provided that, the test is available in the facility. There 
is no discrimination of patients based on social, economic or educational status. 
There are gradual improvements of quality of services by increasing health 
workers, upgrading physical infrastructure, increasing medical supplies [drugs, 
laboratory investigation] and in strengthening referral linkages to care, support 
and treatment facilities.”  
The follow-up adherence counselling has paramount benefit in increasing the motivation 
and attitude of HIV and TB patients on sticking to their intensive treatment schedules 
and exercising with healthy living practices. Participants added that nutritional 
counselling, preventive therapy for TB and other bacterial infections, and health 
education on personal and environmental hygiene helped to improve the life style of 
patients with TB and HIV. In addition, the counselling given to patients helps to 
decrease risks of transmitting the diseases to the community, particularly to family 
members.  
A 30 years male patient from Zewditu memorial hospital witnessed the following:  
.”..I have benefited a lot from this hospital, initially I was very emaciated, weak 
and hopeless but now as you can see me, I am strong physically and 
psychologically, so I really thank the government and health workers for 
establishing free treatments centres and for their continued support for us” 
Participants also raised their concerns of shortages of some drugs, which sometimes 
exposed them to extra expense, and, if not able to take them, worsened their disease 
conditions. Drugs mentioned were vitamins, anti-helmentics and antifungal treatments.  
Services provided by health facilities to decrease the burden of TB and HIV 
Participants of all groups mentioned a wide list of services which they received from 
their respective health facilities and in their areas. Among these were:  
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1) counselling services, 
2) health education on personal care to be taken during treating their disease and 
prevention of disease transmission to others  
3) risk reduction and knowledge and skills 
4) HIV testing 
5) TB screening and TB prevention therapy  
6) laboratory services 
7) treatment services  
8) referral to care and support giving organisations.  
Some participants were also frank in expressing their concerns about the rough 
behaviour of some health workers, limited laboratory services, frequent change of 
health workers, long waiting time and sustained drug supply.  
A 23 years female patient from Bole health centre said:  
.”.. the services were good, but sometimes they prescribe some drugs to buy 
outside the health centre, sending out for some laboratory investigation and 
frequent change of health workers.” 
Effect of integrated TB/HIV services on patients’ health 
The focus group participants in all groups raised similar ideas in support of the health 
facilities on benefits of integrated TB/HIV care services. Participants agreed on ‘one 
stop shopping’, meaning a patient having concerns that patients with both diseases 
benefit from services provided in the same clinic at no expense. They mentioned, a 
health worker who considers both disease and harmonises the investigations and 
treatment to be of most benefit to the patient.  
A 46 years male participant from Gulele health centre pointed out his experiences 
during his follow-up care in the health centre:  
“I have learnt my HIV-positive status while I had been on my anti-TB treatment 
follow-up in this health centre two years back. Since then, I have been enrolled in 
the HIV clinic and getting my monthly treatment drugs and check-ups every three 
months at no cost. I am healthy now, I am doing my daily business without 
limiting myself as an HIV-positive person; so, I can say because of the 
collaborative TB/HIV services, I benefited a lot.” 
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Support of health workers at HIV clinics regarding TB risks and status 
The focus group discussion participants from all groups appreciated the integrated 
TB/HIV care services and benefited from TB screening and preventive therapy for TB 
from the HIV clinics. Participants reported that health workers continually asked and 
screened for signs and symptoms for TB at each of the follow-up visits. In addition, 
provision of INH preventive therapy is one of the basic package of care provided for all 
HIV patients. Health workers are conducting health education about TB disease; how it 
comes, its route of transmission, disease prevention and availability of free diagnostic 
and treatment services at all of the public health facilities.  
A 25 years old female participant from Kaliti health centre reported that:  
“I know very well about TB disease; health workers teach me at every visit; 
whenever I have some cough, I report to my doctor and he orders sputum 
examination; in addition, I have taken INH for prevention of TB for six months; 
therefore, I have never had TB disease.” 
 
Perceived feasibility and practicality of integrated TB/HIV services provision at the same 
health facility 
Most HIV positive focus group participants mentioned some advantages of integrated 
TB/HIV care service provision in the same health facility, among others: 
• Getting all the services at one place reduces the time spent and costs incurred 
for transportation to less than the time it would have been separately.  
• It also increases the acceptance of getting both services from one health facility; 
as the diseases usually occur in one patient.  
A female participant of 19 years of age HIV patient from Kality health centre expressed 
her view that:  
“...in my opinion providing services for TB and HIV should be continued in one 
health facility. This was set by educated people with clear evidences due to the 
fact that TB and HIV are highly related and occur commonly on one patient. In 
addition, the drugs and counselling services are similar, so there should not be 
any negotiation for TB/HIV integrated services.” 
Some participants felt that integrated TB/HIV care services were not practical or 
feasible. The reasons included:  
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• the stigma and discrimination attached to HIV may discourage TB patients from 
attending the clinics publicly, as the public may consider all patients attending 
those clinics to be HIV-positives.  
• participants worried about disease transmission from TB patients to others in the 
waiting area.  
• HIV patients prefer to be treated in a separate health facility where other people, 
including TB patients, have limited access, due to the widespread stigma 
attached to HIV disease.  
 
Perceived quality of integrated TB/HIV services in health facilities 
The quality of integrated TB/HIV services in general was discussed by focus group 
discussion participants of all groups. Even though most were unsure of the quality, 
some were confident in expressing their views in this regard. For example, they 
mentioned that patients of HIV and TB were benefiting from the services. Currently, HIV 
patients have a better status than before because of the comprehensive care, support 
and treatment services available in the country. Once an HIV-positive status had been 
considered a death sentence.  
Participants argued that TB and HIV diseases were highly inter-related diseases and 
health workers were professionals assigned by government to serve the public with 
certain qualities and standards. For patients to benefit from the services, there must be 
an organised physical structure. Health workers counsel patients professionally, 
examine and treat them, conduct essential investigations and advise them on their 
disease conditions. Therefore, the quality of TB and HIV care services in public health 
facilities, in general, is good and to the optimal satisfaction of TB and HIV patients.  
Participants also appreciated the government’s commitment to gradual improvement 
and upgrading of the services given to TB and HIV patients in public health facilities. In 
general, focus group participants felt that the service provision quality regarding TB and 
HIV care was good.  
 
Perceived behaviour of healthcare providers towards their patients 
Participants of all groups of HIV patients shared their views and opinions on the 
behaviour of healthcare providers of TB and HIV in general. Most seemed to be happy 
with the behaviour of healthcare providers. According to most participants, health 
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workers are keen to serve their patients, behave professionally, encourage patients to 
adhere to their care and treatment schedules, supportive, patient, are sympathetic, 
respond to questions and respect their patients. In addition, participants thought that 
most health workers were in the younger age group, therefore, they tend to simplify 
things so they are understood, solve patients issues promptly and be cooperative in 
general.  
On the other hand, some participants were very worried about the unprofessional 
behaviour of some healthcare providers towards their patients. They mentioned some of 
the behaviour which they did not like to see from healthcare workers:  
• lack of respect for time, i.e., they started late and closed early 
• shouting at patients, demoralising them, being impolite and unfeeling  
• complicated services which are not educative for patients  
• rushing uncaringly to finish work early and close the clinic  
• not receiving late comers and approaching them rudely.  
A 20 years male participant from Gulele health centre angrily witnessed:  
“If it were for the behaviour of healthcare workers, I would have interrupted my 
follow-up care and died by now; they do not consider us as a human being, some 
of them consider because of our promiscuous behaviour that we infected with 
HIV, but the reality is not that!; therefore, they need training and advice how to 
behave and handle especially HIV patients.” 
 
Perceived performances of healthcare providers for integrated TB/HIV services 
Though most participants found this discussion point somewhat difficult to evaluate, 
some shared their opinions. Most believed that health workers at TB and HIV clinics 
were competent and knowledgeable, and capable of solving most of the problems of 
patients, as they were deployed by the government after being licensed.  
Some mentioned lack of important investigations in most of the health centres, such that 
they found it very difficult to evaluate performances. Other participants thought that 
health workers at public health facilities were less experienced and less qualified. This 
made initial diagnosis of disease very difficult and delayed conclusions.  
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In addition, they performed very well during the initial contact with the patient, but there 
was a perception that during follow-up care they left everything to the patients and failed 
to continue counselling and educating the patient. For example, a 39 years male HIV-
positive participant from Kality health centre said:  
“When I first come to this health centre, the advice and encouragement I 
received was very good, but during my follow-up visits, I have never been given 
any advice and encouragement; the health workers become very fast and even 
they do not greet us; in addition, there is long waiting time in the health centre to 
get the consultation” 
 
Comments to improve the service provision of HIV and TB care 
HIV-positive focus group participants were given the chance to comment for 
improvement of the service provision of integrated HIV and TB care in their respective 
health facilities in general. Recommendations included:  
• improve the laboratory services  
• increase the number of health workers  
• improve the service quality (waiting time, behaviour of health workers),  
• separate the HIV clinic building from the other health centre health service 
building  
• remove the sign of ‘HIV clinic’ as it exposes people to stigma and discrimination 
once a patient is seen by outsiders or other patients in the health centre  
• improve the counselling and health education services during the follow-up visits  
• make system flexible so as to provide continuation treatment drugs for relatives; 
at times patients are unable to go to the health centre 
• Avoid rotation of health workers and assign experienced and mature health 
workers.  
 
5.5.4 TB/HIV Policy Implementation in Addis Ababa City Administration 
 
The WHO’s Interim Policy on Collaborative TB/HIV Activities outlines a set of concrete 
recommendations for joint TB/HIV activities and calls upon countries to establish and 
implement mechanisms to decrease the burden of TB among people with HIV/AIDS and 
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the burden of HIV among TB patients (WHO, 2004d). According to the policy document, 
there are 12 activities to be implemented at various levels of the healthcare system. The 
findings from interviews with the regional (Addis Ababa City Administration) TB/HIV 
collaborative activity coordinator have been presented in the following sub-sections 
under three main TB/HIV collaborative activities themes, as follows.  
 
5.5.4.1 Mechanisms for Collaboration 
  
The TB/HIV Policy recommends the establishment of a coordinating body; surveillance 
of HIV prevalence among TB patients; joint TB/HIV planning; and monitoring and 
evaluation.  
 
5.5.4.1.1 Set up a coordinating body for TB/HIV activities at all levels 
According to the Addis Ababa City Administration Health Bureau TB/HIV collaborative 
activity regional coordinator, there are joint coordinating bodies for TB/HIV activities at 
national, regional and sub-city levels, but not at community level. The reason given was 
the existing regional health service structure does not have a well established system at 
community level. However, public health research suggests that in the absence of 
public awareness and engagement around TB and HIV, political and financial 
accountability for TB/HIV control efforts falters (Open Society Institute, 2006). 
The structure of the joint TB/HIV coordinating body at regional level was integrated by 
the newly developed regional business processing re-engineering (BPR), which is under 
one sub-process (section). Based on the regional adaptation, TB and HIV programmes 
are being run together with one regional coordinator. However, the planning, 
implementation, monitoring and evaluation of the activities is being carried out by 
experts from both TB and HIV control programmes. Therefore, members from both are 
included in the joint coordinating body at regional and sub-city levels. However, 
representatives from TB/HIV co-infected communities, PLHIV organisations or TB 
patient support groups are not included on the coordinating body. 
  
5.5.4.1.2 Conduct surveillance of HIV prevalence among TB patients 
Information about HIV prevalence among TB patients is being collected at regional 
level, where there are two hospitals and two health centres as sentinel sites from which 
blood specimens (serum) from TB patients are collected every month, and sent to the 
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Ethiopian Health and Nutrition Research Institute (EHNRI) for anonymous HIV testing. 
The information for collecting blood specimens is not available for the community, as it 
is being done in unlinked anonymous mechanisms. However, all TB patients are being 
offered voluntary HIV testing and counselling at each of the health facilities. The data 
from sentinel sites and populations is only utilised at national and regional level as a 
summary. According to the findings from EHNRI, the HIV prevalence among TB 
patients reflects the trend of the routine data from the health facilities’ recording and 
reporting (EHNRI, 2010).  
 
5.5.4.1.3 Carry out joint TB/HIV planning  
The regional TB/HIV coordinating body has a strategic plan for TB/HIV care, a copy of 
which is available (Genet, 2011). Neither community activists nor people infected with 
TB/HIV participate in the formulation of the plan, therefore it is very difficult to conclude 
on this research whether the strategic plan reflects community’s priorities or not. The 
role of community advocates was not outlined on the implementation of the plan. There 
is a plan to incorporate community’s participation in the planning, monitoring and 
evaluation of TB/HIV collaborative activities through the currently deployed urban health 
extension workers (AACAHB, 2009). These are frontline health cadres deployed at 
community level, whereby the community will actively participate in the planning, 
implementation, monitoring and evaluation of health programmes outlined for them, 
among which TB and HIV programmes are inclusive.  
Funding for TB/HIV collaborative activity implementation is exclusively available from 
non-governmental sources. The government’s role is to solicit and plan for activities 
based on the allocated fund, but the information is publicly available on how 
international funds are being used to support TB/HIV collaborative activities. The 
government at regional, sub-city and health facility level is implementing the TB/HIV 
activities outlined on the policy with the current available funding. When the fund for 
TB/HIV activities is insufficient, activities which are not supported are surveillance of 
HIV among TB patients or vice-versa, INH preventive therapy and Cotrimoxazole 
preventive therapy. In addition, activities which are not supported, though not main 
umbrellas, are community sensitisations, production, distribution of health education 
materials and health education activities. In general, there is no funding gap or, if there 
is, it is minimal. The cause is mostly lack of capacity for absorbability of the available 
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funds. This is because there is international funding for TB/HIV activities through the 
global fund to fight TB, HIV, and Malaria.  
Regarding training of healthcare providers on TB/HIV cares, the health bureau is using 
guidelines developed at national level. There is a national training manual for TB/HIV 
collaborative activities which clearly outlines how to manage co-infected patients 
(FMOH, 2007b). In addition to healthcare workers, PLHIV networks are involved in the 
training and capacity-building preparations.  
Associations of PLHIV, NGOs, community representatives, urban health extension 
workers and private for-profit health facilities working on TB and HIV care services are 
also key stakeholders in the TB/HIV collaborative activity implementation. However, the 
TB/HIV plan does not include training for community organisations or advocates.  
The training manual is modular and involvement of PLHIV in the training adds extra 
value for more firsthand experience and practical knowledge, especially for healthcare 
providers, who are responsible for care and support of patients of TB and HIV. TB and 
HIV testing services are available in all health facilities, including private-for-profit and 
non-profit. The government is supporting private-for-profit and non-profit health 
institutions with supplies and training to provide these testing services at subsidised 
prices. Special emphasis is given by the government to supporting private-for-profit and 
non-profit health facilities for HIV testing by providing test kits, working protocol and 
training on HIV testing and counselling for healthcare providers. The services are mostly 
given free of charge or at subsidised prices.  
There is functional system of referral linkage at health facilities, both intra- (among the 
various clinics in the same facility) and inter-facility (among the different health facilities) 
for patients with TB and HIV.  
There is a referral feedback system, whereby both the sender and receiver facilities 
(health workers) communicate on the outcome of their patients. In addition, the referral 
systems’ implementation obstacles are being discussed on the bi-annual review 
meeting, in which all stakeholders from both governmental and non-governmental (for 
profit and non-profit) organisations meet, which is organised by the regional health 
bureau.  
Concerning advocacy, programme communication and social mobilisation on TB/HIV 
care services, the government is providing continuous information to the public about 
the elevated risk of TB among PLHIV, dangers of TB/HIV co-infection, prevention 
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methods, signs/symptoms, availability of free services, care, treatment and support 
options.  
The joint coordinating body has a plan to make sure this information reaches the 
communities through leaflets, radio broadcasts, television advertisements, printed 
advertisements, posters and billboards. The effectiveness of this use of the media to 
transmit relevant information to the affected communities may vary. For example, 
people of low educational status may not have access to printed materials, those with 
low economic status may not have access to television, and those in wealthier 
communities may not give attention to television and radio transmissions.  
Therefore, effectiveness of the media depends on the timing of transmission, selection 
of appropriate media and target audience, message type (e.g., dramatic, poetic) and 
mixture of methods. Sometimes live radio transmission is effective, whereby the 
community participates directly. People affected and infected by the diseases can 
participate in the live transmission and experts will be invited to deliver appropriate 
messages for the community. In addition, public holidays and major events can be an 
opportunity to convey messages on TB and HIV.  
There are no community activists on TB and HIV control programmes in the city 
participating in the advocacy activities with decision makers to ask for improved TB/HIV 
care services. Sensitisation workshops for community leaders (religious leaders, EDIR 
leaders, prominent individuals) will help to motivate community groups to become more 
involved in TB/HIV social mobilisation and advocacy activities. In addition, the principles 
of community voluntary services need to be developed to sensitisation the community to 
TB/HIV. 
Community-based and non-governmental organisations have integrated TB prevention, 
diagnostic and care services into the HIV prevention, care and support services under 
the coordination of the government. These are implemented in some private for profit 
and private for non-profit health facilities who are providing TB and HIV collaborative 
services for the community in their catchment areas.  
People living with HIV are not involved in the planning, implementation or evaluation of 
TB/HIV care services in the city administration. In addition, there is no plan to involve 
them currently. There were no reasons given by the regional TB/HIV collaborative 
activity coordinator. 
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5.5.4.1.4 Conduct monitoring and evaluation of TB/HIV collaborative activities 
There are official efforts to monitor and evaluate TB/HIV collaborative activities through 
TB programmes, however, the monitoring data is not readily available to community 
organisations. During the evaluation activities, people who use TB and HIV care 
services were being consulted for information on the implementation status of TB/HIV 
care services. These evaluation findings are being used to improve the quality of TB 
and HIV services.  
The government is producing a report on the core TB/HIV indicators as recommended 
by the WHO (2012a). The regional health bureau has a comprehensive Health 
Management Information System (HMIS) through which all health activities at all levels 
are registered and reported to the next level. TB/HIV collaborative activities are also 
included on the HMIS tools, compiled regularly on the stated indicators at all levels. On 
the other hand, the Interim Policy for collaborative TB/HIV activities recognises 
community-led monitoring and advocacy as an important way to promote and increase 
public demand for accelerated and improved TB/HIV programmes and services. 
Nevertheless, community groups are not involved in the monitoring and evaluating of 
TB/HIV activities and services in Addis Ababa City Administration. 
 
5.5.4.2 Activities to Decrease the Burden of TB among PLHIV 
 
There are three main recommended activities (WHO, 2004d) to be done regularly at 
HIV clinics to decrease the burden of TB among PLHIV. Sometimes it is called the 3Is, 
which is an output of the Joint World Health Organization HIV/AIDS and TB Department 
Meeting report in 2008 (WHO, 2008a). The finding from the Addis Ababa City 
Administration Health Bureau TB/HIV coordinator on these activities implementation is 
presented as follows. 
 
5.5.4.2.1 Establish intensified TB case-finding 
Screening for TB is being offered or encouraged at HIV testing and counselling centres. 
In addition, PLHIV who are on their follow-up cares at HIV care clinics are eligible for 
these services at each of their follow-up visits. The screening is done clinically and by 
history. If a patient is found to have some clinical justifications for TB, sputum smear 
and radiographic examinations would be made to rule out tuberculosis. However, there 
is no system of tuberculin skin test examinations in Addis Ababa. If a patient is found to 
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have active TB disease, referral to TB clinics will be done immediately and a TB clinic 
health worker automatically registers him or her for DOTS management.  
 
5.5.4.2.2 Introduce Isoniazid preventive therapy 
Isoniazid preventive therapy (IPT) is offered to PLHIV in all public health facilities for 
those who do not have active TB. People living with HIV have access to information for 
IPT through group and individual health education, leaflets or pamphlets and electronic 
teaching aids in the health facilities. The information provided is also part of the 
adherence counselling for all PLHIV in their follow-up cares. It is believed that once 
patients have had accurate and full information about their disease conditions and 
treatment modalities, adherence to treatment will be high (Jin, Sklar, Oh &, 2008; 
Lindval, Colstrup, Wollter, Klemenz, Loogna, Grönhaug & Thykjaer, 2006). Therefore, 
all PLHIV who do not have active TB have access to IPT as part of the package of care 
in all HIV care clinics of public health facilities in the city. The drug (INH) is available in 
HIV clinics at ART pharmacy free of charge.  
 
5.5.4.2.3 Ensure control of TB infection in healthcare and congregate settings 
There is a guideline for TB infection control in healthcare and congregate settings, 
developed by the WHO  (2009e). The guideline outlines how people presenting with TB 
symptoms would be managed and isolated from the rest of people living with HIV and 
others at high risk of TB (WHO 2009e). The guideline describes TB infection control at 
TB clinics, waiting areas, HIV chronic care clinics and outpatient departments, which are 
available for all healthcare providers working on TB/HIV care services. The guideline 
addresses four sets of interventions: managerial, administrative measures, 
environmental and personal protective measures.  
According to the response by the regional TB/HIV collaborative activity coordinator, 
infection control of TB in the health facilities is being carried out.  
 
5.5.4.3 Activities to decrease the burden of HIV among TB patients 
 
There are five main recommended activities (WHO 2004d) to be implemented regularly 
at TB clinics to decrease the burden of HIV among TB patients: 
Primary HIV preventive interventions:  
• HIV testing and counselling and  
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• HIV prevention methods,  
Secondary HIV prevention interventions (treatment and care):  
• Cotrimoxazole preventive therapy and  
• ART, 
Tertiary HIV prevention interventions (support and rehabilitative care):  
• Ensure HIV/AIDS care and support. 
The findings from interviews with the regional TB/HIV collaborative activities are 
presented under each of these five activities, as follows.  
 
5.5.4.3.1 Provide HIV testing and counselling 
HIV testing and counselling is being offered to all TB patients as a provider-initiated 
testing and counselling strategy. HIV testing and counselling services are offered free of 
charge at all public health facilities. The service is being offered by TB clinic health staff 
and is part of the TB control programme activity. However, if patients want the services 
to be offered at Voluntary Counselling and Testing (VCT) centres, intra-facility referral 
linkage will be made to the VCT clinic. Currently, all public as well as private health 
facilities in Addis Ababa city administration are providing HIV counselling and testing 
services.  
To explore how VCT for HIV can contribute to a more coherent response to TB, the 
WHO is coordinating the ProTEST Initiative. The name "ProTEST" is derived from the 
‘Promotion of voluntary testing’ as an entry point for access to the core interventions of 
intensified TB case-finding and Isoniazid preventive treatment. Other interventions may 
be added to finally provide a comprehensive range of HIV and TB prevention and care 
interventions. Under the ProTEST Initiative, pilot districts are establishing links between 
centres for VCT for HIV and TB prevention and care. This will pave the way for large-
scale operationalisation of the comprehensive range of interventions needed to control 
TB in settings with high HIV prevalence (Godfrey-Faussett et al., 2002).  
In addition, voluntary counselling and testing for HIV can link TB and HIV programme 
activities. The benefits of VCT for HIV to TB patients include referral for appropriate 
clinical care and support for those testing HIV-positive (Godfrey-Faussett et al., 2002). 
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5.5.4.3.2 Introduce HIV prevention methods 
The TB programme has an HIV prevention strategy. There is regular health education 
for TB patients at their follow-up treatment care, at which times HIV prevention 
messages are being conveyed through leaflets, brochures and electronic media, as well 
as through face-to-face education. In addition, there is a strong referral linkage with HIV 
treatment, care and support programmes at intra- and inter-facility level. These HIV 
prevention services are available through the TB control programme.  
All TB clinic staffs offer HIV prevention services and information on mother-to-child 
transmission, harm reduction, reduction of work place and hospital acquired exposure to 
HIV infection. In addition these, all TB centres have HIV prevention services. When a 
TB patient is found to be HIV-negative, there is counselling, supporting partner testing, 
counselling on faithfulness, and encouragement of consistent condom use and 
abstaining from sex until marriage. However, there is no trend of screening for other 
STIs for TB clients, as was reported by the regional coordinator.  
 
5.5.4.3.3 Introduce Cotrimoxazole preventive therapy 
Cotrimoxazole preventive therapy is available to eligible PLHIV who have active 
tuberculosis in the TB clinics. The preventive therapy is given after thorough adherence 
counselling and ongoing patient monitoring of drug side effects is being done regularly. 
It has been reported that there is no shortage of Cotrimoxazole and the drug is available 
at HIV clinics in all health facilities to be given free of charge. 
 
5.5.4.3.4 Ensure HIV/AIDS care and support 
People living with HIV who are diagnosed with tuberculosis are provided with nutritional 
support, palliative care, HIV prevention, PMTCT and ART services in the same health 
facility. Therefore, the TB programme has established a referral linkage with the HIV 
control programme to provide the continuum of care and support for PLHIV who are 
receiving or have completed TB treatments. When a TB patient is found to be HIV-
positive, the patient is immediately linked with HIV clinic through intra-facility referral 
linkage for chronic HIV care.  
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5.5.4.3.5 Introduce antiretroviral therapy (ART) 
All HIV-positive TB patients are assessed for eligibility of ART, which is available for all 
HIV-positive TB patients within the public health facilities. Efavirenz-based ART drugs 
are available for someone who is co-infected with TB and HIV to prevent drug-drug 
interactions. In addition, side effects are monitored during the follow-up care by the 
treating health worker. In general, HIV-positive TB patients have access to many kinds 
of treatment, care and support through intra- and inter-facility referral linkage to all 
TB/HIV care centres in the Addis Ababa City Administration. The administrative TB/HIV 
collaborative activities coordinator commented that the IPT uptake in Addis Ababa is 
very low, because of the debate between clinicians and public health experts, and for 
fear of INH drug resistance and lack of objective screening to rule out active 
tuberculosis.  
The TB/HIV collaborative activities implementations are stronger on the TB clinic side 
than on the HIV care clinic side. Activities to decrease the burden of HIV among TB 
patients are thus more operational than those to decrease the burden of TB among HIV 
patients, according to the report from the coordinator. However, the findings from the 
quantitative data revealed that there were high rates of intensified TB case finding 
among PLHIV though provision of IPT is low (Chapter 4, section 4.1.1.3). Also, 92.8% of 
HIV patients were screened for TB (Chapter 4, section 4.1.1.3.1) at HIV clinics. 
The suggestion can be reinforced by the findings from the quantitative data, i.e., the 
proportion of TB patients offered for HIV is nearly 90%, i.e., out of 834 TB patients, 726 
patients were offered for HIV test (Chapter 4, section 4.1.1.2.16).  
 
5.6 CONCLUSION 
 
This chapter presented the analysis, interpretation, and discussion of qualitative data. 
The presentation began with an introduction to the chapter and review of research 
questions of the study. The findings of the qualitative study were presented on the order 
stated on the questionnaires:  
Qualitative data presentation, analysis, and discussion 
• Short answered qualitative questions for both TB and HIV patients: 
o Effect of integrated TB and HIV care service on patients’ health. 
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o Support of health workers at TB and HIV clinics in improving the health of 
patients regarding TB and HIV risks and status. 
o Feasibility and practicality of integrated HIV and TB care services at the 
same health facility, from patients’ perspectives. 
o Quality of the service provision in general regarding TB and HIV care, 
from patients’ perspectives. 
o The behaviour of healthcare providers towards their patients. 
o Performances of healthcare providers from patients’ perspectives. 
o Comments of patients to improve the service provision of TB/HIV care.  
• Interview of TB/HIV collaborative activity facility coordinators: 
o Programme implementation of collaborative TB and HIV services. 
o Programme implementation impacts on staff performances. 
o Impacts of programme implementation on infrastructure. 
o Impact of TB/HIV collaborative activities on human resources. 
• Focus group discussion among patients of TB and HIV: 
o Patients’ knowledge about TB/HIV and their relationship. 
o Healthcare delivery system support for people of those diseases. 
o Knowledge of patient for types of services provided by health facilities to 
decrease the burden of TB and HIV. 
o Effect of integrated TB and HIV care service on patients’ health. 
o Support of health workers at TB and HIV clinics in improving the health of 
patients regarding TB and HIV risks and status. 
o Feasibility and practicality of integrated HIV and TB care services at the 
same health facility, from patients’ perspectives. 
o Quality of the service provision in general regarding TB and HIV care, 
from patients’ perspectives. 
o The behaviour of healthcare providers towards their patients. 
o Performances of healthcare providers from patients’ perspectives. 
o Comments of patients to improve the service provision of TB/HIV care.  
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• TB/HIV policy implementation in Addis Ababa city administration, interview with 
regional TB/HIV collaborative activity coordinator: 
o Mechanisms for collaboration. 
o Activities to decrease the burden of TB in PLHIV.  
o Activities to decrease the burden of HIV in TB patients.  
Each theme was discussed under several sub-themes which were also sub-divided into 
numerous categories.  
The research findings indicated that collaborative TB/HIV care services are being 
implemented in a satisfactory way to the extent patients’ benefit to become healthier 
and more productive in their life. In addition, the uptake of public health facilities for TB 
and HIV care service clients was very high.  
Despite all these achievements and benefits to patients, many activities need to be 
improved to promote implementation of collaborative TB/HIV care services in the city 
administration. Among the factors which were hindering the activities were: shortage of 
well trained health human power; poor educational schemes for patients about their 
disease conditions; inadequate infrastructural set-ups; shortages of medical supplies 
and drugs; and absence of vital investigation equipment and laboratory examinations in 
the public health facilities.  
The healthcare providers were generally of the view that improvement of both the 
intrinsic and extrinsic motivational factors would boost the performance of TB/HIV 
collaborative service providers. Specifically noted were: improvement of infrastructural 
set-ups, sustained supply of medical supplies, continuous upgrading of healthcare 
providers performances by training, improvement in the laboratory investigation services 
and continuous health education of patients on their disease conditions for better 
prevention, care and treatment of TB and HIV diseases.  
Although the current practices of collaborative TB/HIV care services in Addis Ababa city 
administration are encouraging, boosting mechanisms have to be put in place to 
accelerate better care and treatment services. These include availing up to date 
guidelines on collaborative TB/HIV care, training new cadres of health workers, 
cascading the activities down to the community levels and ongoing monitoring of 
activities are paramount. Also, health workers and patients who participated in this 
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research mentioned a range of recommendations in promoting better implementation of 
collaborative TB/HIV care services; among others: 
• Improved coordination and evaluation of collaborated TB/HIV care services by 
regional and central experts,  
• Involvement of TB/HIV patients in the planning, implementation, monitoring and 
evaluation of the activities,  
• Sustained supply of medical supplies and upgrading some of the facilities to 
more specialised centres which serve as tertiary level referral and research 
centres.  
The next chapter presents the conclusions, limitations, and recommendations of the 
study. 
 CHAPTER SIX 
CONCLUSIONS, LIMITATIONS AND RECOMMENDATIONS 
 
6.1 INTRODUCTION 
 
This chapter presents the summary of the main findings, implications of the findings, 
limitations and concluding remarks of the study. In addition to these, the researcher 
outlines practical recommendations for promoting the implementation of collaborative 
TB/HIV care services in public health facilities in Addis Ababa city administration, as 
well as areas for further research. The proposed modalities for promoting the 
implementation of collaborative TB/HIV care services arising from the research findings 
are outlined. 
 
6.2 THE AIM AND OBJECTIVES OF THE STUDY 
  
This concluding chapter is presented in line with the aim the objectives of the study. The 
overall aim was to assess the implementation of collaborative TB and HIV care services 
in support of local health services in Addis Ababa City Administration, Ethiopia.  
The objectives of this research were to: 
• Determine HIV prevalence among TB patients in Addis Ababa. 
• Determine TB prevalence among HIV patients in Addis Ababa. 
• Describe implementation status of collaborative TB and HIV care services. 
• Identify how programme implementation impacts on both TB and HIV patients. 
• Identify how programme implementation impacts on staff development. 
• Describe the programme implementation in relation to infrastructure. 
• Recommend to policymakers and practitioners the technical basis to guide the 
implementation of collaborated TB/HIV activities based on findings of this study. 
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6.3 RESEARCH DESIGN AND METHOD 
 
The study used both quantitative and qualitative research methodologies. Patients of TB 
and HIV at TB and HIV clinics, respectively, were interviewed at exit using an 
interviewer-administered structured questionnaire to determine the implementation 
status of recommended (see Chapter 3) TB/HIV collaborative care services as the 
package of follow-up cares. On the other hand, selected patients from the same 
participating units were interviewed for short-answered qualitative questions for 
exploration of how the service provision affected their health condition, how health 
workers assisted in improving their health, how feasible and practical was collaborative 
TB/HIV care services, how they evaluated the quality of the services, the behaviour and 
performances of healthcare providers, and finally their recommendations to improve 
collaborative TB/HIV care services. 
 
Qualitative data included focus group discussions conducted among separate groups of 
TB and HIV patients to further explore and validate the individual short-answered 
questions and quantitative questions. Healthcare providers at all levels (service 
providers, TB/HIV collaborative activity health facility and regional coordinators) were 
interviewed to understand the status of implementation of collaborative TB/HIV care 
services in respect to both technical and administrative aspects. Data collection and 
analysis for both qualitative and quantitative was done concurrently (see Chapter 3). 
 
6.3.1 Quantitative data 
  
The population for this level of data collection comprised TB and HIV patients from TB 
and HIV care clinics. Data was collected using an interview-administered structured 
questionnaire, encircling the relevant answer (Annexures F and G). Hence, a total of 
834 TB patients and 849 HIV patients participated in this level of data collection, all 
selected from 10 study health facilities proportional to the size of the cumulative TB/HIV 
patient load. Sample size was calculated using EPI info for comparative cross sectional 
study. The data analysis was done using SPSS version 15.0. 
 
6.3.2 Qualitative data collection 
 
The population for this level of data collection also comprised TB and HIV patients from 
TB and HIV care clinics. The same participants from the quantitative data collection 
206 
were individually interviewed for open short-answered questions, whereby, 834 TB 
patients and 849 HIV patients were interviewed. In addition, a total of 8 FGDs among 
TB or HIV patients separately were conducted until saturation. In addition, 10 TB/HIV 
care providers and health facility TB/HIV care coordinators from all study health facilities 
were purposively interviewed for open-ended questions. Finally, the regional TB/HIV 
collaborative activity coordinator was interviewed using a checklist for assessing the 
overall regional TB/HIV collaborative activity implementation status. The data analysis 
was done manually with themes and sub-themes.  
 
6.4 CONCLUSIONS  
 
The findings of the study are summarised according to the study objectives as follows. 
 
6.4.1 Determine HIV prevalence among TB patients in Addis Ababa 
 
The study enrolled 834 TB patients of both types (extra and pulmonary tuberculosis) 
from the ten study public health facilities. Nearly half (51.3%) of these study participants 
were interviewed while in their intensive phase therapy (0-2 months). According to the 
findings of this study, a little more than half 445 (53.4%) of TB patient participants had 
been tested for HIV before they knew their current TB disease. Of these patients who 
tested for HIV before, slightly less than half (43.1%) had been tested within the 
preceding six months before the current diagnosis of TB disease; whereas, 42.3% had 
been tested before 6-24 months prior to the current TB disease; the remaining 14.6% 
had been tested before they were diagnosed more than two years preceding their 
current disease.  
The prevalence of HIV among study participants who tested for HIV before they knew 
their current TB disease was 19.6% (87 of 445). Of these HIV-positive patients, 77 had 
already enrolled at HIV care and treatment clinics in public health facilities. On the other 
hand, (87.1%) of all TB patients who participated in this study were offered for HIV 
testing during their current treatment. Of these who had been offered for HIV test, 
79.8% had been tested for HIV. The majority, 80.3%, tested at TB clinics and the 
remaining in other departments. The majority of these tested TB patients (76.5%) had 
been tested during the same time as being diagnosed for the TB disease. According to 
the findings, 20.2% were found to be HIV-infected, which is nearly the same proportion 
(19.6%) as those who had been tested before they diagnosed for their current TB 
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disease. Similarly, 94.0% of these HIV-positive patients had been enrolled at HIV care 
and treatment centres.  
From these findings, HIV prevalence among TB patients was found to be high, but the 
proportion of TB patients who had been tested before (53.4%) they knew their current 
disease was less than those who had been tested during (79.8%) their TB treatment. 
This implies that offering HIV test for TB patients as a package of care increases the 
uptake of available services. In addition, collaborative TB/HIV care services promoted 
HIV testing for all TB patients irrespective of their previous test history. 
 
6.4.2 Determine TB prevalence among HIV patients in Addis Ababa 
 
The study enrolled 849 HIV patients from the ten study health facilities. The majority 
(74.6%) of the patients were interviewed within at least one year of having learned their 
HIV status, whereas a quarter (25.4%) of all study participants were less than a year 
into knowing their status at the time of the interview. According to the finding in this 
study, for a little more than half (53.1%) it was more than one year since they started 
HAART.  
A total of 167 (19.7%) of the interviewed HIV patients had been diagnosed and treated 
for TB before they knew their HIV-positive status. The Majority (60.4%) of these TB-
diagnosed HIV study participants had had TB disease within the preceding one year of 
being tested HIV-positive. A significantly higher proportion (82.0%) of the diagnosed 
TB/HIV patients had pulmonary tuberculosis. Of those diagnosed TB patients, all except 
2.4% had already completed their anti-TB treatment.  
On the other hand, 88 out of 849 (10.4%) of all HIV patients have been diagnosed for 
TB after they knew their HIV-positive status. Quite large proportions (69.3%) of these 
diagnosed TB patients were detected during the first six months following their positive 
HIV status. Similarly, 84.1% of those cases were pulmonary tuberculosis. In addition, 
more than half, 46 out of 88 diagnosed TB patients had already started HAART after 
they learnt their HIV status.  
From these findings, TB prevalence among study participants was high (19.7%) before 
they knew their HIV-positive status and low (10.4%) after knowing HIV-positive status. 
However, the proportion of HIV patients who had been diagnosed for TB (19.7%) before 
they knew their current HIV disease was the same as the proportion of TB patients who 
had become HIV-positive (19.6%) before they knew their current TB disease. From this 
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finding it can be concluded that HIV care and treatment decreases the prevalence of 
opportunistic diseases such as TB. 
On the other hand, the prevalence of TB among HIV patients after they enrolled at HIV 
clinics was very low (10.4%) compared to the proportion of HIV-positives (20.2%) 
among TB patients during anti-TB treatment follow-up. This can be explained as HIV 
patients having a better quality of life after enrolling at HIV chronic care clinics due to 
the package of care following TB/HIV collaborative activities implementation. In addition, 
some people may not be ready for HIV test unless there is a reason to go to a health 
facility for diseases associated to HIV, in this case tuberculosis. Therefore, according to 
this study, prevalence of TB among HIV patients is lower than prevalence of HIV among 
TB patients (see Chapter 4, section 4.1.1.3). 
 
6.4.3 Describe implementation status of collaborative TB and HIV care services 
 
In this section, the implementation status of TB/HIV collaborative activities at public 
health facilities in Addis Ababa city administration are summarised. The section is 
subdivided into three parts, from both quantitative and qualitative data obtained from 
patients, TB/HIV care service providers and coordinators at health facility and regional 
health bureau levels. 
 
6.4.3.1 Activities to decrease the burden of TB/HIV, quantitative findings 
 
Section 4.5 (chapter 4) described the findings of implementation status of activities to 
decrease the burden of TB/HIV from interviews with both TB and HIV patients who, at 
the time of interview, were on their follow-up care.  
Key activities to decrease the burden of TB/HIV which are included in the package of 
care for TB and HIV patients are, among others:  
• encouraging and offering of HIV testing for all TB patients at TB clinics and TB 
screening for all HIV patients at HIV clinics,  
• provision and awareness creation of TB/HIV patients for Cotrimoxazole 
preventive therapy and INH preventive therapy for HIV patients,  
According to the findings, a larger proportion (92.4%) of TB patients reported that HIV 
counselling and testing was being offered for all TB patients at TB clinics, whereas, 
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almost the same proportion (92.8%) of HIV patients observed that TB screening was 
being offered regularly for all HIV patients at their respective HIV clinics.  
Knowledge about CPT among TB patients was found to be low, only 23.1% of all 
interviewed TB patients knew the importance of CPT as a package of care for TB/HIV 
patients. This may be because not all TB patients had HIV and awareness creation 
about CPT might be restricted to HIV clinics only. On the other hand, 42.3% of HIV 
patients were aware that IPT was one of the packages of care for all HIV patients at 
their health facilities. Still, the proportion of HIV patients who had the knowhow of IPT 
was very low; in principle, all HIV patients should have some knowledge of all the 
packages of care available as collaborative TB/HIV care services.  
Among those TB patients who knew CPT as one of the package of care for TB/HIV 
patients, the implementation of provision of CPT was asked. Based on the findings, 
91.2% of these were aware that all people living with HIV who also have TB have 
access to CPT as part of the package of care in their health facilities.  
On the other hand, among HIV patients who have awareness about IPT as a package 
of care for all HIV patients who do not have active TB, were some who inquired whether 
the service was available in their health facilities. Based on that, 93.0% reported that 
people living with HIV who did not have active TB did have access to IPT as part of the 
package of care in their follow-up health facilities.  
Of those TB patients who had the know how (193), about CPT, 57.5% had not been 
provided with CPT. The reason for not including all interviewed TB patients in this 
analysis was that not all TB patients were eligible for CPT, as most of them did not have 
HIV infection. On the other hand, 28.7% of all interviewed HIV patients (849) had not 
been provided with INH during their follow-up care at HIV clinics.  
The findings in this study also revealed that, the placement of drugs Cotrimoxazole and 
INH were mainly at HIV clinics, 81.1% and 98.4%, respectively. Nearly a fifth (18.9%) of 
TB/HIV patients re-filled their Cotrimoxazole tablet from the TB clinics. 
 
6.4.3.2 Findings from interview of service providers and coordinators 
 
The TB/HIV collaborative activity has 12 activities under three major classifications, as 
described in chapter 2, sections 2.7.1 – 2.7.3: 
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• Mechanism for collaboration:  
o Set up a coordinating body for TB/HIV activities at all levels, Conduct 
surveillance of HIV prevalence among tuberculosis patients, Carry out joint 
TB/HIV planning, Conduct monitoring and evaluation for TB/HIV care. 
• Activities to decrease the burden of TB in PLHIV: 
o Establish intensified TB case-finding, Introduce Isoniazid preventive therapy 
and Ensure control of TB infection in healthcare and congregate settings 
• Activities to decrease the burden of HIV in TB patients: 
o Provide HIV testing and counselling, Introduce HIV prevention methods, 
Introduce Cotrimoxazole preventive therapy, Ensure continuum of HIV care 
and support and Introduce antiretroviral therapy 
Implementation statuses of these 12 collaborative TB/HIV activities were explored 
during the interview and presented in Chapter 6. The summary of the findings are 
presented below.  
According to the findings in this study, eight out of the 10 study health facilities have 
coordinating bodies for TB/HIV collaborative activities effective at the health facility 
level. The coordinating bodies for collaborative TB/HIV care services in those health 
facilities were represented by professionals from both TB and HIV control programmes. 
In addition, there was operational joint TB/HIV planning, monitoring and evaluation for 
TB/HIV collaborative activities, but surveillance of HIV prevalence among TB patients 
has never been conducted in all of the study health facilities..  
Provision of routine screening for tuberculosis among HIV patients, diagnosis and 
treatment for active TB cases were being done routinely in all of the study health 
facilities. Nine out of the 10 study health facilities provide IPT for all PLHIV without 
active TB disease. In addition, six out of 10 had some kind of TB infection control 
mechanisms in the health facilities, such as ventilated rooms and wide waiting areas for 
patients to prevent transmission of TB in health facilities. On the other hand, healthcare 
providers from only four of the health facilities used personal protective masks to 
prevent transmission of TB to themselves and to patients.  
Concerning activities to decrease the burden of HIV among TB patients, interviewed 
healthcare providers and/or TB/HIV facility coordinators reported that all TB patients 
were being offered HIV counselling and testing services, and health workers promoted 
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safer and responsible sexual behaviour to reduce HIV transmission. In addition, health 
facilities were practicing measures to ensure the safety of blood supply and medical 
equipments to reduce transmission of HIV. All health facilities were providing ART 
services for treatment of HIV or prophylaxis for eligible PLHIV as a package of care. 
Participants also reported that Cotrimoxazole preventive therapy was being provided for 
eligible PLHIV in all of the study health facilities.  
Finally, the interview findings revealed that all the study health facilities ensured a 
continuum of care and support for PLHIV, created mechanisms to provide ART to 
eligible TB patients and ensured continuity of ART after completion of TB treatment. 
 
6.4.3.3 Findings from interview of regional coordinator 
 
In section 4.6.4 (Chapter 4), collaborative TB/HIV policy implementation in Addis Ababa 
city administration was discussed from the findings of interviews with the city 
administration coordinator for TB/HIV collaborative activity using a WHO monitoring tool 
(WHO, 2006b) for the programme. The findings were discussed based on the 12 key 
thematic areas of activities of collaborative TB/HIV activities, as follows. 
 
6.4.3.4 Set up a coordinating body for TB/HIV activities at all levels 
 
According to the response of the Regional Coordinator of collaborative TB/HIV care 
activities for Addis Ababa City Administration, there is a joint coordinating body for 
TB/HIV activities at national, regional and sub-city level. The joint TB/HIV coordinating 
body at regional level was integrated into the newly restructured administrative health 
Bureau Business Processing and Re-engineering (BPR), which is under one 
department. Therefore, TB and HIV programmes are facilitated by a regional 
coordinator, but the planning, implementation, monitoring and evaluation of the activities 
is being carried out by representatives from both TB and HIV prevention and control 
programmes. In addition, the coordinating body is represented by the two programmes 
at sub-city and health facility levels. Nevertheless, the joint coordinating body at all 
levels is not represented by TB/HIV co-infected communities, associations of PLHIV or 
TB patient support groups. 
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6.4.3.5 Conduct surveillance of HIV prevalence among TB patients 
 
Surveillance of HIV prevalence among TB patients was being collected at regional level 
but it is under the national HIV surveillance activity. Two health facilities (a hospital and 
a health centre) are serving as sentinel sites from which random blood samples are 
collected from TB patients every month and being sent to Ethiopian Health and Nutrition 
Research Institute (EHNRI) for anonymous and unlinked HIV testing.  
However, the information for collecting blood specimens was not communicated to the 
community, as it is using leftover blood collected for other purposes and was using 
unlinked anonymous techniques to be analysed collectively. However, all TB patients 
were being offered voluntary HIV testing and counselling services at each of the health 
facilities. The data from sentinel sites and populations is only utilised at national and 
regional levels as an input for developing policy in designing better implementation 
strategies. 
 
6.4.3.6 Carry out joint TB/HIV planning 
  
The Addis Ababa City Administration Regional Health Bureau has a strategic plan for 
TB/HIV care activities which was developed by representatives from both TB and HIV 
care programmes. In order for a strategic plan to be more representative, it should be 
developed by all stakeholders for the programme (Office of Quality Improvement, 2003). 
The joint TB/HIV planning did not include representatives from either the community 
activists or from people infected with TB/HIV; therefore, it is very difficult to conclude 
whether the regional strategic plan reflects community’s priorities. In addition, the roles 
of community advocates and people infected with TB and HIV were not outlined on the 
implementation of the strategic plan.  
According to the finding, funding for TB/HIV collaborative activity for the city 
administration is available only from NGOs. The role of the government is to solicit and 
plan for activities based on the allocated funds. However, the information on funding of 
TB/HIV collaborative activities is publicly available, notably how they are being used to 
support the programme. The government at regional (City Administration health 
Bureau), sub-city health department and health facility level are implementing the 
TB/HIV activities outlined on the policy with the available funding. 
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6.4.3.7 Conduct monitoring and evaluation 
 
There is some effort to monitor and evaluate TB/HIV collaborative activities in the city 
administration, but the information for monitoring and evaluation activities is not 
available to community organisations. During the evaluation activities, people who are 
utilizing TB and HIV care services were consulted for information of beneficiaries.  
Findings from the evaluation activities are being used for planning of TB and HIV 
services. The government is producing a report on the core TB/HIV indicators as 
outlined on the policy on implementation of TB/HIV care services (WHO 2012a). The 
Addis Ababa City Administration Health Bureau has a comprehensive Health 
Management Information System (HMIS) through which all health activities at all levels 
are registered and communicated to the next level. Information about TB/HIV 
collaborative activities are also included on the HMIS tools which is regularly compiled 
to the relevant indicators at all levels. However, the research findings also showed that, 
community groups and people infected with HIV and/or TB are not involved in the 
monitoring and evaluation activities of collaborative TB/HIV activities. 
 
6.4.3.8 Intensified TB case-finding 
 
In section 4.9.2 (Chapter 4), the three main activities to decrease the burden of TB 
among HIV patients were discussed in detail. As a summary, the interview findings from 
the regional coordinator confirmed that screening for TB is being encouraged and 
offered at HIV prevention, care and treatment centres in the study health facilities. 
According to the report, the screening for TB was being done clinically and by history, 
but if care takers suspected apparently, the patient would be referred to a clinician for 
further physical examinations and investigations. In addition, if patients were found to 
have active TB disease, referral and linkage to TB clinics would be undertaken for 
disease classification and DOTS management. 
 
6.4.3.9 Isoniazid preventive therapy 
Based on the interview finding in this study, IPT was being offered to PLHIV found to be 
negative for active TB. In addition, PLHIV have access to information for IPT in the 
health facility through routine health education. In general, all PLHIV who do not have 
active TB have access to IPT as part of the package of care in all HIV care clinics of the 
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study health facilities. The drug (INH) is also available free of charge in HIV clinics 
dispensed at ART pharmacy. 
 
6.4.3.10 Tuberculosis infection control in healthcare settings 
 
The findings in this study revealed that TB infection control in healthcare facilities was 
being implemented partially. TB patients in the waiting area were separated from the 
rest of the patients to prevent transmission of the disease to non-diseased patients. 
Some health facilities have separate waiting areas for TB and HIV so that other patients 
of the health facility have very low contact with these patients. In addition, TB clinics 
were being ventilated by opening the windows during service delivery. On the other 
hand, it has been found that most healthcare providers were not using mechanical 
protective devices (gloves, goggles) while providing the service, which might expose 
them to infection. Some health facilities have poor infrastructure to organise the clinics 
and waiting area so as to comply with implementation of the standards of infection 
prevention (WHO, 2009e). Some of the TB and/or HIV clinic rooms were narrow, lacked 
proper windows, had no separate waiting area, only a narrow waiting area, and/or 
shortages of infection prevention materials (goggles, gloves). 
 
6.4.3.11 Provide HIV testing and counselling for TB patients 
 
In section 4.9.3 (Chapter 4), the five main activities to decrease the burden of HIV 
among TB patients were discussed in detail. As a conclusion, the findings in this study 
revealed that HIV testing and counselling was being offered to all TB patients on their 
follow-up care, using a technique of provider-initiated testing and counselling strategy 
by service providers at TB clinics of all study health facilities (WHO 2007d). In addition, 
if TB patients wanted the services of HIV testing at Voluntary Counselling and Testing 
centres (VCT), intra-health facility referral linkage would be linked to the VCT clinics. In 
general, the uptake of HIV testing for TB patients in all the study health facilities was 
very high (section 4.5.1). 
 
6.4.3.12 Introduce HIV prevention methods for TB patients 
 
According to the interview findings in this study, the TB control programme of the city 
administration has HIV prevention and control activities. Among the services, regular 
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health education on HIV prevention skills for TB patients at TB clinics was being 
rendered in group and individual health education schemes, which use face-to-face 
education, leaflets, brochures and electronic media. In addition, there is a referral 
linkage with HIV treatment, care and support programmes at intra- and inter-facility 
level. In addition these, the TB control programme of the city administration offers HIV 
prevention services, information on mother-to-child transmission of HIV, harm reduction, 
reduction of workplace- and hospital-acquired exposure to HIV infection. 
 
6.4.3.13  Introduce Cotrimoxazole preventive therapy 
 
The interview with the regional coordinator found out that Cotrimoxazole preventive 
therapy was being offered to all PLHIV who had active tuberculosis in the TB clinics to 
prevent bacterial infections. The therapy was being given with appropriate adherence 
counselling and ongoing patient support for drug side effects. 
 
6.4.3.14  Ensure HIV/AIDS care and support 
 
The regional TB/HIV care coordinator reported that, TB-HIV co-infected patients were 
being provided with palliative care, HIV prevention, PMTCT and ART services in the 
same health facility and referral linkages for nutritional support to care- and support-
giving organisations. Therefore, the TB control programme has an established referral 
linkage with the HIV control programme to provide the continuum of care and support 
for all PLHIV who were receiving or had completed anti-TB treatments.  
 
6.4.3.15 Introduce antiretroviral therapy 
 
This study confirmed that all HIV-positive patients had access to free HAART at all of 
the public health facilities in the city administration. The ART drug of Efavirenz based 
were being available for patients co-infected with TB and HIV to prevent drug-drug 
interactions. In addition, side effects were being monitored during the follow-up care by 
the treating healthcare provider. In general, an HIV-positive TB patient has access to 
many kinds of treatment, care and support through intra- and inter-facility referral 
linkages at all public TB/HIV care centres in the Addis Ababa City Administration. 
The City Administrative TB/HIV collaborative activities coordinator reported that, the 
uptake for IPT was very low in almost all of the study facilities; reasoning that the 
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debate between clinicians and public health experts regarding drug resistance and 
objective screening to rule out active tuberculosis remained inconclusive. In addition, 
the coordinator mentioned that, the TB/HIV collaborative activities were stronger at TB 
clinics than at HIV care clinics. In other words, activities to decrease the burden of HIV 
among TB patients were being effective more than activities to decrease the burden of 
TB among HIV patients. 
 
6.4.4 Identify how programme implementation impacts on both TB and HIV 
patients 
 
Chapter 5 sections 5.2.1 - 5.2.3, qualitative short-answered patient interviews, and 
interview of TB/HIV collaborative activity facility and regional coordinators/service 
providers outlined the findings in detail.  
In this concluding chapter, findings directly related to the impacts of TB/HIV 
collaborative activity on patient health and knowledge is summarised in the relevant 
sub-sections as follows. 
 
6.4.4.1 Findings from the Focus Group discussion among patients 
 
Focus group discussion among TB and HIV patients revealed findings on: 
• the knowledge status of TB and/or HIV patients on their disease conditions,  
• the support of TB/HIV healthcare delivery system, in general, in improving their 
health conditions,  
• effect of integrated TB/HIV care on patients’ health,  
• support of the healthcare providers at TB and HIV clinics, and  
• patients’ comments to improve the services in promoting collaborative TB/HIV 
care services, as summarised below. 
 
6.4.4.1.1 Knowledge about TB and/or HIV, and their relationship 
In general, the findings in this study (Chapter 5 of section 5.2.3) revealed that, 
knowledge and understanding about diseases of TB and HIV among TB and HIV 
patients was low.  
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Some participants defined HIV as a disease caused by a virus and transmitted from 
person to person by unprotected sexual intercourse, living together, eating together, 
sharing cups and plates with infected persons and sharing sharp materials. However, 
TB participants agreed that there was a cure for TB but not HIV, albeit both diseases 
affect similarly in terms of socially, psychologically and physiologically.  
However, few of the participants from either TB or HIV groups understood well the 
diseases TB and HIV or gave correct definitions. In general, this study showed that 
knowledge about the diseases TB and HIV among HIV patient participants was better 
than their TB counterparts, but HIV participants also had poor understanding of the 
relationship between the two.  
Therefore, it was clearly understood from most focus group participants in this study 
that, patient health educational system of health facilities about TB and HIV for patients 
was neither using appropriate teaching aids nor being delivered on a level which most 
of them could understand. 
 
6.4.4.1.2 The support of the healthcare system to assist patients of TB and HIV 
Both TB and HIV patients, in general, expressed sincerely the indispensable support of 
the healthcare delivery system of collaborative TB/HIV care services in improving their 
quality of lives, particularly for HIV patients. In other words, participants expressed their 
view that the healthcare system was well equipped and capable of assisting people with 
both diseases. Some TB patients reported that health workers were keen to encourage 
them to know their HIV status through counselling and testing services.  
Participants raised the benefits of the integrated TB/HIV care in supporting them while 
dealing with their disease conditions. They said treatment was free; the laboratory 
investigation was free; and there was no discrimination of patients based on social, 
economic or educational status. There is a gradual improvement of quality of services 
by increasing the number of health workers, upgrading physical infrastructure, 
increasing medical supplies (drugs, laboratory investigation) and in strengthening 
referral linkages to care, support and treatment centres.  
In addition, adherence counselling during their follow-up cares has significant impact on 
increasing the knowledge of and improving attitudes to HIV and TB, as patients adhere 
to their intensive treatment schedules, particularly TB patients, and they practice healthy 
living styles. Nutritional counselling, preventive therapy (IPT and CPT) for TB and other 
218 
bacterial infections, health education on personal and environmental hygiene, helped to 
improve the lifestyle of patients with TB and HIV. In addition, the counselling given to 
patients helped them to decrease risks of transmitting the diseases to the community, 
particularly to family members.  
On the contrary, participants from both groups indicated their concerns with absence of 
some laboratory investigations and some drugs in public health facilities, which 
sometimes expose them to extra expense. For example, drugs which they mentioned 
were, vitamins, anti-helmentics and antifungal treatments, whilst laboratory 
investigations mentioned were, x-ray, FNA, and CD4 count. In addition, frequent 
changes of healthcare providers in some clinics resulted in perceived effects on quality 
of services, psychological feeling of patients to get relationships with the new staff due 
to sense of being attended by a health worker who has little knowledge of their disease, 
and fear of possible change in norm of service provision. 
 
6.4.4.1.3 Effect of integrated TB/HIV services on patients’ health 
The findings from both TB and HIV patients’ focus group discussions revealed that the 
support of integrated TB/HIV care services was paramount in improving their health 
conditions. Participants agreed on ‘one stop shopping’, meaning a patient having 
concerns of both diseases benefitting from services provided in the same health facility 
at no extra expense. Participants mentioned healthcare providers who consider both 
diseases and integrate the investigations and treatments to be of most benefit. 
Participants of TB patients, for example, expressed their feelings about the benefits to 
their health of integrated TB and HIV services provided by public health facilities. Most 
of the study participants appreciated the encouragement and offering of HIV tests for TB 
patients, as it gave them an opportunity to know their HIV status early. In addition, early 
HIV test helped them for informed decisions of HIV prevention, care, treatment and 
support interventions. Implementation of integrated TB/HIV care services helped people 
to know about TB and HV better for early notification of signs and symptoms of the 
diseases for early medical care. 
 
6.4.4.1.4 Support of healthcare providers at TB and HIV clinics regarding HIV or TB 
risks and status 
The focus group participants from both TB and HIV groups appreciated the support of 
service providers at integrated TB/HIV care clinics and benefited from their keen and 
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kind service provision. Healthcare providers continually asked and screened for signs 
and symptoms for TB at each of the follow-up visits for all HIV patients, and encouraged 
and offered HIV testing for all TB patients. In addition, health workers were giving health 
education about TB and HIV diseases, how it transmits, disease preventions and 
availability of free diagnostic and treatment services at all of the public health facilities. 
In general, most participants reported that health service providers of collaborative 
TB/HIV care were encouraging and enduring to solve many kinds of patients’ concerns 
regarding TB/HIV diseases along the continuum of care in the prevention, care and 
support services of these two diseases. 
 
6.4.4.1.5 Comments to improve the service provision of HIV and TB care 
Finally, most participants who participated in this study felt some action should be taken 
to further improve the implementation of integrated TB/HIV care services. Issues related 
to improvement of TB/HIV laboratory services, improving the counselling and patient 
awareness creation services, motivating service providers (trainings and top-up 
payments) and improving the physical structure of some of the TB/HIV clinics.  
 
6.4.4.2 Individual patient interview findings 
 
Individual TB and HIV patients’ interviews revealed findings on the effect of 
collaborative TB/HIV care services on their health conditions, how health workers 
assisted them in improving their health regarding TB and HIV risks and status, and how 
to improve the services in promoting collaborative TB/HIV care services. The findings 
are summarised below. 
 
6.4.4.2.1 How does the service provision of health facilities for both TB and HIV 
patients affect on your health? 
The finding in this study revealed that study participants believed provision of 
collaborative TB and HIV services improved their health conditions. Most obtained 
significant improvement on their health conditions from collaborative TB/HIV care 
services. However, a few participants were not happy with the overall service provision 
of collaborative TB and HIV care services. 
 
 
220 
6.4.4.2.2 How do you think health workers at TB/HIV clinics assisted you in improving 
your health regarding your TB or HIV risks and status? 
The study found that TB/HIV service providers at TB and HIV care clinics assisted 
patients to get improved health conditions. The majority of the study participants 
witnessed significant improvement in their general health conditions. However, there 
were some participants who were dissatisfied with the services of health workers in 
dealing with their TB or HIV diseases. Amongst the practices which made patients 
unhappy were poor professional ethics, as reflected by some healthcare providers 
working at TB or HIV care clinics. 
 
6.4.4.2.3 What comments do you have to improve the service provision of HIV and TB 
care in this health facility? 
About half (50.8%) of all interviewed TB/HIV patients said that the services in general 
were fairly good, whereas, the remaining half commented on different issues to be 
improved, including those who frankly just said ‘not good’ (1.1%).  
The most common comments are listed below, in the order of higher number of study 
participants favour: 
• Improving the long waiting time to get the services and commencing service 
on the scheduled official working hours on time.  
• To avail sustainable TB-HIV drugs supply to the public health facilities.  
• Healthcare providers ought to abide by their professional ethics in keeping 
patients’ confidentiality and they should be free of favouritism.  
• Providing continuous health education on prevention of HIV and TB for 
patients attending collaborative TB/HIV care clinics.  
• Providing food and shelter for some poor patients attending TB and/or HIV 
clinics during the follow-up days,  
• Availing all TB (FNA and X-ray) and HIV (CD4 count) laboratory 
investigations at all public health facilities, and 
• Preparation of anti-HIV drugs with injectable formulations. 
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6.4.5 Identify how programme implementation impacts on staff development 
 
In section 5.2.2 (Chapter 5), the impact of collaborative TB/HIV care activities on 
healthcare providers working at public health facilities was discussed in detail. The 
findings were discussed based on impacts on the-job trainings, flow of logistics supply 
of TB/HIV care, support from the administrative environment for the clinics, major 
problems encountered and recommendations for collaborative TB/HIV care 
improvement. In this summary chapter, the key findings are outlined below. 
 
6.4.5.1 On the-job trainings 
 
This study revealed that all the interviewed TB/HIV care facility coordinators and/or 
service providers had been trained in at least one course type on TB and/or HIV care 
services. The majority were trained in collaborative TB/HIV care service protocol, TB 
and leprosy control programme, MDR-TB, ART adherence counselling and treatment 
protocols, HIV counselling and testing skills and knowledge (PITCT or VCT), STIs 
prevention and control and on palliative care. Generally, all were trained for the type of 
clinical care that they were providing on TB or HIV care services.  
 
6.4.5.2 Flow of logistics supply for TB/HIV care 
 
Study participants of TB/HIV care providers reported that sustained supplies of medical 
and pharmaceutical items for TB and HIV care services did not pose a major problem, 
but some reported that they had occasional stock-outs of some supplies, mainly, INH 
tablet and TB diagnostic reagents.  
 
6.4.5.3 Support from the administrative environment for the clinics 
 
According to the interview findings from healthcare providers, the facility’s general 
administrative support for the TB/HIV care clinics in most of the study health facilities (8 
out of 10) were good and had good workable relationships. However, some (2 out of 10 
study facilities) frankly expressed their frustration of being either neglected or had poor 
communication with them. This study could not explore the reasons behind this. 
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6.4.5.4 Major challenges/problems encountered 
 
Interviewed TB/HIV care providers mentioned some challenges and problems they had 
in the process of delivering TB/HIV care services. They mentioned: shortages of 
personal infection protective materials, poor adherence of some patients to their 
treatments, inadequacy of consultancy rooms, frequent stock-outs of INH tablet, fear of 
patients of having the dual disease stigma, high patient load and less attention from 
administrators. 
  
6.4.5.5 Recommendations of health workers for improvement of collaborative 
TB/HIV care services 
 
TB/HIV collaborative activity facility coordinators/healthcare providers recommended for 
the improvement of TB/HIV care in their health facilities. Some of the recommendations 
mentioned by most of the interviewed study participants were:  
• Continuous on-the-job trainings of healthcare workers on all TB/HIV collaborative 
care services both with basic and refresher schemes,  
• Improvement in linkage of the TB/HIV services with care and support 
programmes,  
• Staff rotation among the different clinics in the health facility should be regular,  
• Deploying additional staffs to the clinics in relation to the continual patient loads,  
• Decentralisation of the services to other health facilities (private-for-profit and 
non-profit facilities),  
• Incentives for healthcare workers (training, pocket money, appreciation),  
• Consultation rooms of some TB/HIV care clinics should be either renovated, 
changed or constructed, 
• Laboratory and dispensary services should be integrated with TB/HIV clinics in 
the same compound. 
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6.4.6 Describe the programme implementation in relation to infrastructure 
 
Changes in infrastructure of health facilities since the commencement of collaborative 
TB/HIV care services were assessed by physical observation and interview of service 
providers, as discussed in sections 5.2.2.4 (Chapter 5). 
According to the interview findings from healthcare providers and/or coordinators, only 
one out of the 10 study health facilities (a hospital) had constructed a new building for 
TB/HIV care clinic. In addition, there were no major renovations made for the remaining 
nine study health centres. However, re-arrangement of rooms, shifting of office furniture 
and/or arrangement of waiting areas had been done in most of the study health 
facilities. Based on these re-arrangements, allied services for the TB/HIV collaborative 
care were established in all of the health facilities. These were: ART dispensary, TB/HIV 
data management, HIV/AIDS mother support group, VCT rooms, nutritional 
rehabilitation service and youth friendly services. All the mentioned services were not 
established in all of the study health facilities. 
On the other hand, re-structuring of one or more related services was done as a result 
of the commencement of TB/HIV collaborative care in all study health facilities, among 
which an administrative office was relocated in one health facility, VCT service relocated 
near to TB/HIV care clinic in one health facility, PMTCT service in one other health 
facility and ART dispensary in one health facility. 
Regarding the effect of collaborative TB/HIV care on the pre-existing facility services, 
the majority (six out of 10) study health facilities did not have any effect; whereas, in 
four of the study health facilities it affected one or more of the following resources: 
sharing of rooms with other services and waiting area, sharing of rooms/health workers 
on performances of IMCI, EPI, FP, adolescent reproductive health services, shortage of 
health workers and workload on existing healthcare providers. However, this study 
could not explore how collaborative TB/HIV care affected the abovementioned services. 
Some interviewed health workers/coordinators requested additional infrastructures for 
improved TB/HIV collaborative activities. Among others were suitable and wider rooms 
for HIV and TB clinics, separate waiting areas for TB and HIV patients and additional 
staff rooms. The majority of study participants responded that there was no need of 
additional infrastructure. 
The researcher visited all the study health facilities to assess the level of the 
infrastructural set-ups of collaborative TB/HIV care clinics. Based on the observation, 
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six of the facilities had convenient rooms for both TB and HIV care services. In other 
words, both clinics were wide enough, had enough windows for ventilation, were close 
to the waiting area and had good natural illumination. On the other hand, four study 
health facilities did not have convenient rooms for both the TB and HIV care (poor 
ventilation, lack of water supply, lighting problem and narrow rooms). 
 
6.5 LIMITATIONS OF THE STUDY 
 
The following limitations may affect the generalisation of the study results. 
• This study was conducted only in Addis Ababa City administration, capital city of 
Ethiopia, which may not reflect the situation in other regional administrations; hence, 
the results may not be generalised to the whole country. 
• The study did not include private health facilities; therefore, the findings may not be 
generalised to the entire health facilities (private-for-profit, private for non-profit and 
public) in the City Administration.  
• Study participants were inquired to remember disease occurrence in the relatively 
distant past, which may introduce recall bias. 
Despite these limitations, the study findings are reliable, valid, and trustworthy. The use 
of quantitative and qualitative data collection and analysis methods (triangulation), and 
the large sample size of study participants increased the validity, reliability and 
trustworthiness of the research findings. 
 
6.6  RECOMMENDATIONS 
  
Based on the results of the study, the researcher makes the following recommendations 
for promoting the implementation of collaborative TB/HIV care services in Addis Ababa 
City Administration. The researcher also recommends specific areas for further 
research in this section. 
 
6.6.1 Recommendations to decrease the burden of TB/HIV 
  
The research clearly showed that the burden of TB/HIV among patients of TB and HIV 
was high, which needs strengthening and acceleration of activities of collaborative 
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TB/HIV care services. For better implementation strategies, all stakeholders should 
contribute for synergistic outcomes, as per the following recommendations. 
 
 
6.6.1.1 Recommendations to the Addis Ababa City Administration Health 
Bureau and Sub-city Health departments 
 
It is recommended that: 
• The City Administration health Bureau strengthen training of the general 
health service providers on TB control programme in ensuring proper TB case 
detection and management, to complete a course of effective anti-
tuberculosis treatment and avoid the risk of drug resistance.  
• The City Administrative Health Bureau avail and supply medical supplies and 
infection prevention materials for health facilities for effective implementation 
of Intensified TB case finding and TB infection control in healthcare facilities. 
• The City Administrative health Bureau be organised and routinely conduct 
periodic review meetings among all stakeholders implementing collaborative 
TB/HIV care, including healthcare providers to create experience sharing 
forum. 
• Therefore, the City Administrative health Bureau gives special emphasis to 
strategies of HIV prevention activities to these sub-groups of the population. 
• The City Administrative Health Bureau continually update the effectiveness of 
IPT for clinicians to convince for effective implementation. 
• Decentralisation of the services to other health facilities (private-for-profit and 
non-profit facilities) should be well implemented. 
• The City Administration Health Bureau develop and coordinate 
implementation of researches to improve the prevention, early diagnosis and 
rapid treatment of TB in people living with HIV and incorporate results into the 
City Administration TB/HIV care plan.  
 
6.6.1.2 Recommendation to health facilities/healthcare providers 
• Tuberculosis control programmes have to be more effective in diagnosing 
more infectious cases earlier and maximising achievable treatment success 
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rates in order to interrupt transmission. The most efficient approach to 
detecting more cases and with shortened duration of infectivity involves 
intensified case-finding in settings where HIV-infected people are 
concentrated. Hence, health workers should place special emphasis on 
people with respiratory symptoms attending general health service providers 
in the public, private and NGO sectors (out-patients, in-patients and 
healthcare workers), people attending centres for voluntary counselling and 
testing for HIV, prisoners, and household contacts with infectious tuberculosis 
cases. 
• The high burden of TB among PLHIV underlies the importance of TB 
diagnosis, treatment and prevention for clinicians involved in HIV care. 
• Health facilities should exert maximum effort to use the scarce facility 
resources efficiently for implementation of collaborative TB/HIV care services. 
• Healthcare providers should be abided by their professional ethics and code 
of conducts at any time of their patient care. 
• Health workers should be punctual in commencing services on time and 
should serve patients during the full official working hours. 
• Health workers should conduct regular group and individual health education 
for TB and HIV patients on their disease conditions: TB/HIV prevention, care, 
support and treatment modalities as part of the package of care for TB/HIV 
patients. 
• Health facilities should avail suggestion boxes in their facilities to collect 
suggestions and comments on the overall service provision process for timely 
corrective actions. 
• Health facilities should monitor and evaluate TB/HIV care providers for 
performance appraisal which helps for planning trainings, reshuffling of care 
providers, so as to maintain the quality of the service. 
• Healthcare providers should maintain the privacy and confidentiality of their 
patients for maximum compliance of patients on their follow-up cares. 
• All health facilities should establish and/or strengthen TB/HIV coordinating 
body at facility level, represented by TB and HIV control clinics, and with 
representatives from TB and HIV patients. 
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• Health facilities administrative unit should support effective implementation of 
collaborative TB/HIV care services. 
• Adherence counselling to all TB/HIV patients should be a continuous service 
to ensure regular follow-up of patients for their treatment and care services. 
 
6.6.1.3 Recommendations to academic and research institutes 
 
The researcher recommends that: 
• Research institutes should conduct ongoing research, specifically on the 
implementation status of activities to decrease the burden of TB/HIV. Focus 
should be on outcome and impact assessment on patients’ quality of life 
following enrolled at TB/HIV care clinics so that policymakers, implementers 
and evaluators of the activities can use them for better implementation 
strategies. 
 
6.6.1.4 Recommendation to the community and TB/HIV patient support groups 
 
 It is further recommended that: 
• The community establish TB/HIV prevention, care and treatment support 
groups to support patients for effective utilisation of TB/HIV care services. 
• Members of the community need to develop a culture to refer patients 
suspected of having TB and HIV to public health facilities rather than focusing 
on traditional medical services and association of diseases occurrence with 
supernatural factors or ‘curse’. 
 
6.6.2 Recommendations to promote the implementation of collaborative TB/HIV 
care services 
  
According to the research findings, the implementation status of collaborative TB/HIV 
care services in Addis Ababa City Administration needs further promotion and boosting 
modalities. As the outcome of this research was to promote well functioning 
collaborative TB/HIV care services in the City Administration, stakeholders at all levels 
need to contribute for synergistic effect, as recommended as follows. 
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6.6.2.1 Recommendation to City Administration Health Bureau and sub-city 
health departments 
 
• The City Administrative Health Bureau should coordinate improving the 
linkage of the TB/HIV services with care and support programmes through 
facilitation, guidance, advocacy and promotion. 
• Staff rotation among the different clinics in the health facility should be regular 
and training-oriented.  
• Consultation rooms and waiting areas for some collaborative TB/HIV care 
clinics should be either renovated or constructed.  
• Laboratory and dispensary services should be integrated with all TB/HIV 
services in the same compound vicinity to TB and HIV clinics. 
• The City Administration Health Bureau should establish well functioning 
separate TB/HIV coordinating body for the region for planning, implementing, 
monitoring and evaluation of the collaborative TB/HIV care services at each of 
the health facilities. The coordinating body should include members from TB 
control programme, HIV control programme, representatives from TB and HIV 
patients, community representatives and NGOs supporting collaborative 
TB/HIV activities. 
• The Administrative Health Bureau should continually refine the prioritised 
research areas for collaborative TB/HIV activities and support operational 
research in TB/HIV at city administrative and sub-city level 
• The City Administrative Health Bureau should initiate the establishment of 
community activists for TB/HIV care services through facilitation of community 
sensitisation workshops and coordination of sub-city health department and 
urban health extension workers. 
• Monitoring and evaluation of collaborative TB/HIV care services in the City 
Administration should be conducted periodically for better implementation 
strategies which ultimately decrease the burden of TB and HIV. 
• Information from surveillance of HIV prevalence among tuberculosis patients 
should be readily available to the community and policymakers at the City 
Administration levels, and punctually. The information should be used for the 
planning, advocacy and community sensitisation purposes. 
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• There should be governments’ contribution in funding for collaborative TB/HIV 
care services, which creates sense of ownership, a landmark for sustainable 
services to the community. 
• The City Administration Health Bureau should strengthen continual training of 
the general health workers based on the national TB/HIV training manual for 
uniform service provision across all the health facilities. During the training, 
associations of PLHIV, NGOs, community representatives, urban health 
extension workers and private-for-profit health facilities working on TB and 
HIV care services should be involved. 
• The regional Health Bureau should strengthen mobilising technical, financial, 
and human resources.  
• Advocacy, programme communication and social mobilisation on 
collaborative TB/HIV care services should be planned, advocated and 
implemented by TB/HIV coordinating body for information to reach the public 
about the elevated risks of TB among PLHIV, dangers of TB/HIV co-infection, 
prevention methods, availability of local services of care, treatment and 
support options. 
• Develop a multi-sectoral approach to collaborative TB/HIV activities with 
strong programme planning, management and sustainable financing. 
• Increasing the health service coverage of the city administration indirectly 
increases access to health services for people infected with TB and/or HIV. 
• The City Administration should prepare and produce appropriate TB/HIV 
educational materials to be utilised for advocacy and social mobilisation 
activities. 
• Strengthen laboratory capacity for collaborative TB/HIV care activities. 
• Engage people with TB and HIV and affected communities in planning, 
delivering, monitoring and evaluation of collaborative TB/HIV activities. 
• The City Administrative Health Bureau should prepare an updated directory 
for TB/HIV prevention, care, support and treatment centres in the City for 
coordinated implementation of collaborative TB/HIV care services. 
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• Special emphasis should be given for capacity building of health human 
resource on collaborative TB/HIV care; capacity-building (including training 
and supervision) should be in line with the national policies and standards.  
• Though most health facilities have minimum infrastructures for 
implementation of TB/HIV care services, some facilities need additional 
rooms which should be constructed by the City Administration Health Bureau. 
• Strong and continued advocacy to involve all providers and to ensure buy-in 
of all relevant TB and HIV stakeholders for PPM TB/HIV activities. 
• Ensure the provision of continuous technical support for TB/HIV care staffs. 
• Identify regional (City Administration) and sub-city level focal persons from TB 
and HIV programmes and set up regional multi-stakeholder (e.g., public 
sector, private for profit and non-for-profit, professional associations) advisory 
group or link with existing TB/HIV coordinating bodies at regional, sub-city 
and facility levels. 
• Define drug regimens in accordance to the national TB/HIV control policy and 
ensure an effective drug supply management system in the regional context. 
• Determine process and outcome indicators to be monitored in accordance to 
the monitoring and evaluation guidance. 
 
6.6.2.2 Recommendation to Health facilities/healthcare providers 
 
• Diagnostic tests should be widely accessible, available and affordable to all 
TB-HIV patients. 
• Ensure continuity of services to end-users in cases when healthcare 
providers drop out. 
• Healthcare providers should maintain the medical ethics of privacy and 
confidentiality, and be free of favouritism. 
 
6.6.2.3 Recommendations to academic and research institutes 
 
• It is recommended that regular operational and academic researches on the 
implementation status of collaborative TB/HIV care activities be done as an 
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input for promoting better implementation strategies of collaborative TB/HIV 
activities. 
• Research areas should focus on the key components to decrease the burden 
of TB/HIV among the community following the implementation of collaborative 
TB/HIV care services. 
• Impact and outcome assessment research should be conducted on the lives 
of people infected with TB and/or HIV after enrolled for collaborative TB/HIV 
care services. 
• Qualitative research should be promoted to explore detailed understanding of 
quality of life of people infected with either TB or HIV. 
• Nationwide large-scale research on collaborative TB/HIV care services 
implementation should be conducted to understand the level of programme 
achievement in relation to other countries experiences. 
• Analyse the City Administration epidemiological situation of TB and HIV and 
the HIV-related TB problem.  
• Review any existing health seeking and knowledge, attitudes and practices 
surveys on TB, HIV and HIV-related TB among the community and people 
infected with TB and HIV. 
 
6.6.2.4 Recommendation to the community and TB/HIV patient support groups 
 
• The community has to participate in the planning, implementation, monitoring 
and evaluation of collaborative TB/HIV care activities at all levels (City 
administration, health facility and community levels). 
• Stigma and discrimination against people with TB and/or HIV is common 
among the society. Therefore, the community should develop sense of 
normality to diseases of TB and HIV like the other chronic diseases. 
 
6.6.3 Recommendations for further research 
 
Based on the study findings, the researcher recommends the following areas for further 
research: 
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• Qualitative research should be conducted among TB/HIV care service providers for 
detail information about the factors that enhance implementation of collaborative 
TB/HIV care services. This should be carried out in all the regions of the country and 
among both TB and HIV care services providers. 
• Research on quality of life of patients of TB and/or HIV should be conducted for in-
depth understanding of the impact of collaborative TB/HIV care services in the Addis 
Ababa City Administration. 
• Nationwide similar research is highly recommended to understand the national 
TB/HIV collaborative activity implementation, as this research may not be 
generalised to the national level. 
• Retrospective case-control study is recommended to understand cause of death of 
people infected with TB and/or HIV, who could not be included in this kind of study. 
• The impact of collaborative TB/HIV care activities on healthcare workers career 
objectives can be conducted focusing on those who left government health facilities 
following the additional trainings attended on any of the TB/HIV collaborative 
activities. 
• Specific research has to be done on TB and HIV infection control in health facilities 
and congregate areas in the City Administration. 
• Research has to be carried out to find out the optimal TB screening algorithm to be 
used in the existing settings, with different TB and HIV disease burden, to safely 
initiate preventive TB therapy. 
• Research which involves detailed document review supplemented with interview of 
healthcare providers and patients has to be conducted to find out the outcome of 
collaborative TB/HIV care services in the City Administration. 
• Research on TB/HIV collaborative care services among children and disabilities are 
recommended to understand the implementation status among these sub-groups of 
the population. 
• Exploratory research can be conducted on the barriers to care for PLHIV, adults, 
children and families, to access TB/HIV care, and ART for those co-infected with TB, 
from patient and health-care workers’ perspective and how to address them.  
• Community based research is highly recommended to find out the best models of 
community participation (i.e., effective, feasible, acceptable and sustainable) for 
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enhanced TB case-finding and early HIV detection, to reduce delay in initiation of TB 
and HIV care, and their impact on reducing TB and HIV transmission. 
 
6.7 CONTRIBUTION OF THE STUDY 
 
Hypothetically, this study falls into the present focus of the TB/HIV working group of the 
World Health Organisation on priority research questions for TB/HIV in HIV prevalent 
and resource limited settings (WHO, 2010e). The document points out that tuberculosis 
is a leading killer among people living with human immunodeficiency virus. At least one 
in four deaths among people living with HIV can be attributed to TB, and many of these 
deaths occur in resource-limited settings.  
Collaborative TB/HIV activities are essential to prevent, diagnose and treat TB among 
people with HIV and HIV among TB patients, and to ensure that HIV-positive TB 
patients are identified and treated appropriately. In recent years, the implementation of 
collaborative TB/HIV activities has been rising globally. This has created a need for 
additional research into how to deliver quality and integrated services for TB and HIV 
prevention, treatment and care, and thus prevent unnecessary deaths (WHO 2010e:3).  
The findings of this study have provided more understanding and awareness about the 
implementation status of collaborative TB/HIV care service in the Addis Ababa City 
Administration. The study has also produced some evidence on how activities to 
decrease the burden of TB/HIV were being implemented in public health facilities in the 
City Administration, and the challenges that need to be addressed in order to have an 
efficient TB/HIV care. It is therefore acceptable that this study has contributed to the 
existing body of knowledge on collaborative TB/HIV care services by generating greater 
understanding on implementation status for promoting the implementation of 
collaborative TB/HIV care services in Addis Ababa City Administration; a road in 
achieving the health related millennium development goals by 2015. 
Lastly, as a result of the findings of this study, the researcher has developed and 
proposed a pocket guide of collaborative TB/HIV care services for heath workers that 
can be used in delivering collaborative TB/HIV care services in the health facilities. If 
this pocketbook for collaborative TB/HIV care services in Addis Ababa is utilised, it is 
hoped that it will greatly assist in the improvement of collaborative TB/HIV care services 
not only in Addis Ababa but also in all the other regions of the country.  
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6.8 IMPLICATIONS OF THE STUDY 
  
The results of this research have implications for all internal and external stakeholders 
involved in the planning, implementation, monitoring, and evaluation of collaborative 
TB/HIV care services at Addis Ababa City Administration Health Bureau, sub-city health 
departments and health facility levels.  
The City Administrative health Bureau, health facilities, health workers, partner NGOs 
working on collaborative TB/HIV care services, people infected and affected with TB 
and/or HIV and the community at large need to consider the issues and 
recommendations outlined by the researcher. If these can be done by all responsible 
stakeholders, it is hoped that the main issues that are brought up to the attention of this 
study will be realised. Consequently, the recommendations outlined are a basis for 
promoting the implementation of collaborative TB/HIV care services for the needy which 
will in turn improve the outcomes and impacts of TB and HIV control activities related, 
which is in line with the fourth health sector development plan (HSDP IV) of Ethiopia 
(FDRE-MOH, 2010). 
 
6.9 CONCLUDING REMARKS 
 
The aim of this study was to assess the implementation of collaborative TB and HIV 
care services in support of local health services with a view of developing a pocket 
guide on implementation of collaborative TB/HIV care services for healthcare providers. 
In general, the study achieved its objectives. It has been discovered that the 
implementation status of collaborative TB/HIV care services was generally of in good 
status, despite many weaknesses, for improvements.  
Healthcare providers were knowledgeable, skilled and most of them have a positive 
attitude and behaviour towards their patients. However, it has been indicated that there 
were individual variations in the performances, which might be associated with absence 
of an easily portable pocket guide (quick reference) as a protocol for effective 
implementation of collaborative TB/HIV care services at health facility level. 
Although there is a national guideline for implementation of collaborative TB/HIV care 
services developed by the Ministry of Health of Ethiopia, the study was not sufficiently 
exhaustive to cover all specific issues outlined in the process of implementation. In 
many instances no target setting was done at all levels.  
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There was no planning for operational research, monitoring or evaluation of 
collaborative TB/HIV care services at all levels with targeted indicators. On the other 
hand, a study which covered all activities stated on the guideline has not been carried 
out in either the City Administration or nationally, to understand the status of 
collaborative TB/HV care services. In addition, healthcare workers had never been 
assessed for performances, facility infrastructures were not upgraded in most instances, 
systems for sustained supply of some medical supplies were not well developed, and 
healthcare providers did not possess a pocket guide as a protocol to assess patients at 
every visit for services to reduce the burden of TB/HIV.  
Despite the constraints of: 1) absence of a well established TB/HIV care physical 
infrastructure in most of the public health facilities; 2) workload against the limited 
healthcare providers; 3) shortages of laboratory and medical supplies (infection 
prevention materials, laboratory reagents, diagnostic machines, some prophylactic 
drugs); 4) limited involvement of the community; 5) limited monitoring and evaluation 
outputs; and 6) very low supportive supervision, the implementation status of 
collaborative TB/HIV care services was found to be in a better condition. 
The researcher is of the opinion that the development of a pocket guide for collaborative 
TB/HIV care services that has resulted from the findings of this study be published for 
use by all healthcare providers especially those engaged on collaborative TB/HIV care 
services. It will have the advantages of motivating and improving the performance of 
healthcare providers and will have some contribution in the overall improvement of 
collaborative TB/HIV care services.  
 
 
Prominent figure message to Promote Collaborative TB/HIV Care Services: 
"We cannot win the battle against AIDS if we do not also fight TB. TB is too often 
a death sentence for people with AIDS."  
Remarks by Nelson Mandela: "Confronting the Joint HIV/TB Epidemics", XV 
International AIDS Conference, Bangkok, 2004, Thailand.’’ 
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In achievement of the overall purpose of this study, COLLABORATIVE TB/HIV CARE 
SERVICES: a POCKET GUIDE FOR HEALTH WORKERS IN ETHIOPIA was 
developed. The pocket guide is developed based on the updated WHO policy on 
collaborative TB/HIV activities and guidelines for national programmes and other 
stakeholders. This simplified guide will be used by healthcare workers in Ethiopia to 
improve the provision of quality TB/HIV care services. 
 
The next chapter (Chapter 7) will present COLLABORATIVE TB/HIV CARE SERVICES: 
a POCKET GUIDE FOR HEALTH WORKERS IN ETHIOPIA. 
 
 CHAPTER SEVEN 
 
COLLABORATIVE TB/HIV CARE SERVICES: A POCKET GUIDE FOR HEALTH 
WORKERS IN ETHIOPIA 
 
 
7.1 INTRODUCTION 
 
The purpose of this study was to promote the implementation of collaborative TB/HIV 
care services in Ethiopia. In this chapter the Pocket Guide developed for collaborative 
TB/HIV care services for heath workers in Ethiopia is outlined. The pocket guide is 
compiled based on the updated WHO policy on collaborative TB/HIV activities, and is in 
line with the national guidelines. In addition, findings from reviewed literature and the 
research, and insights of the researcher were considered. 
In order to attain the purpose of this study the following objective should also be 
addressed: 
• To recommend to policymakers and practitioners the technical basis to guide the 
development of national implementation strategies for joint tuberculosis and HIV 
programme activities in delivering the available interventions. 
 
7.2 PROCESS OF COMPILING THE POCKET GUIDE 
 
The proposed pocket guide was formulated in relation to the available guidelines for 
national TB/HIV control programmes and WHO policy on Collaborative TB/HIV activities 
(WHO, 2012). The first step in the development of the pocket guide was consideration 
of the theoretical framework as described in Chapter One of this study. It was applied to 
provide the structure for each of the first sections. The second step was consideration of 
the existing body of knowledge, in particular the literature review from Chapter Two of 
this study. The three key components of collaborative TB/HIV care services were 
applied to each of the 12 themes to guide the description of procedures and activities 
based on their relevance to each of the TB and/or HIV patient. 
These three categories were:  
1. Establish and strengthen the mechanisms for delivering integrated TB and HIV 
services,  
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2. Reduce the burden of TB in people living with HIV and initiate early antiretroviral 
therapy, and  
3. Reduce the burden of HIV in patients with presumptive and diagnosed TB.  
 
Each of these three broad components was further divided in to sub-themes, which 
make up a total of 12 collaborative TB/HIV care activities. 
 
 
7.3 APPLICATION OF THE THEORETICAL FRAMEWORK TO THE 
DEVELOPMENT OF THE GUIDELINES 
 
Moleki (2008:162) outlines the building blocks of a guideline as: purpose (terminus), the 
agent, a recipient, framework (context), dynamics and the procedures. Each of these 
building blocks for the pocket guide has been described below. 
 
7.3.1 Purpose or terminus 
 
The purpose of the proposed pocket guide is to improve the performances of TB/HIV 
care service providers in delivering effective collaborative TB/HIV care services with all 
the available packages of patient care. In addition the pocket guide is designed to help 
health workers to make decisions consistent with professional ethics and patient 
preferences.  
 
7.3.2 Agent 
 
According to Moleki (2008:163), the agent is someone who has the knowledge or skill to 
perform an activity or provide a solution to a problem. Moleki (2008:163) and Stanhope 
and Lancaster (2006:215) view an agent as a person with varying kinds of influence or 
who acts as a precipitating cause of events. In this study an agent is a healthcare 
provider or professional who is qualified to deliver quality collaborative TB/HIV care in 
Ethiopia. The healthcare providers include doctors, health officers, nurses, pharmacists, 
laboratory professionals, and other paramedical staff. 
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7.3.3 Recipient 
 
The ‘recipient’ is the beneficiary of the activities designed by the agent. In this study the 
beneficiaries of collaborative TB/HIV care service are TB and/or HIV patients who are 
attending TB and/or HIV care clinics at public health facilities in Ethiopia. 
 
7.3.4 Framework (context) 
 
Moleki (2008:164) describes ‘framework’ as the context or environment in which 
activities take place. In this study the end-users are explored at public health facilities in 
which collaborative TB/HIV care services are provided.  
 
7.3.5 Dynamics 
 
The ‘dynamics’ provide the energy source or the motivating factors for quality of 
collaborative TB/HIV care (Moleki 2008:165). The dynamics in this study include the 
strategies, policies, guidelines, human resource, training, commodities, pharmacy 
practices, laboratory infrastructure and practices and documentation. Better 
performance of the dynamics results in better patient satisfaction and better health 
service outcomes.  
 
 
7.3.6 Procedures 
 
Moleki (2008:165) describes the ‘procedures’ as the techniques or protocols that guide 
the activities. In this study, the procedures are the 12 collaborative TB/HIV care 
activities presented in each of the categories of the three main categories of 
collaborative TB/HIV care services that are patient-focused.  
 
7.4 APPLICATION OF THE EXISTING GLOBAL TB/HIV CARE POLICY AND 
GUIDELINES TO THE COMPILATION OF THE POCKET GUIDE 
 
The HIV pandemic presents a significant challenge to the global TB control. It has been 
well documented that TB is a leading preventable cause of death among people living 
with HIV. To curb the dual burden of TB and HIV in populations at risk of or affected by 
both diseases, the WHO developed and published an Interim policy on collaborative 
TB/HIV activities in 2004. The policy, which provided guidance for member states and 
240 
other partners on how to address the HIV-related TB burden, has been one of the most 
widely accepted policies issued by either department. Many countries have 
implemented the policy in a relatively short time. In addition, a number of guidelines 
were produced by the WHO and other stakeholders following the interim policy. 
The following table shows the type of policy documents and implementation guidelines 
developed by global agencies for initiating, strengthening, and promoting collaborative 
TB/HIV care services. All of the documents were prepared with evidences from 
operational researches of TB/HIV care from all regions of the world. This pocket guide 
was extracted from these existing policies and guidelines (Table 7.1). 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
Guidelines on 
Cotrimoxazole 
prophylaxis for 
HIV-related 
infections among 
children, 
adolescents and 
adults: 
Recommendations 
for a public health 
approach. 
The guidelines 
are designed to 
make global 
technical and 
operational 
recommendations 
for the use of 
Cotrimoxazole 
prophylaxis in HIV 
exposed children, 
children living with 
HIV and 
adolescents and 
adults living with 
HIV in the context 
of scaling up HIV 
care in resource 
limited settings 
For use by national 
HIV programme 
managers, managers 
of nongovernmental 
organisations 
delivering HIV care 
services and other 
policymakers who are 
involved in planning 
HIV care strategies in 
resource-limited 
countries. It should 
also be useful to 
clinicians in resource-
limited settings. 
Integrating the recommendation for Cotrimoxazole prophylaxis into existing HIV-related 
treatment guidelines; 
Implementing Cotrimoxazole prophylaxis as an integral part of the chronic care package 
for all individuals living with HIV and as a key element of pre-antiretroviral therapy care 
and being part of the monitoring and evaluation process in preparation for initiating 
antiretroviral therapy; 
Developing and implementing explicit policies in countries on the use of Cotrimoxazole 
prophylaxis for children, adolescents and adults; 
Giving priority to guidelines for Cotrimoxazole prophylaxis for all HIV-exposed infants and 
people with TB who are living with HIV; 
Assessing legal and policy options to secure Cotrimoxazole for prophylaxis at reduced 
cost or free of charge; 
Ensuring the availability of appropriate and affordable doses and formulations for children; 
Ensuring effective and integrated management of procurement and supplies at all levels 
(national, district, community and household); 
Ensuring that programmes to scale up Cotrimoxazole prophylaxis are decentralised, 
available at the community level and are used to improve the quality of HIV chronic care 
and are linked to preparedness for and initiation of antiretroviral therapy; and 
Establishing surveillance systems to monitor the efficacy of Cotrimoxazole prophylaxis, 
bacterial resistance to Cotrimoxazole and malaria resistance to 
sulfadoxine/pyrimethamine 
Promoting the 
implementation of 
collaborative 
TB/HIV activities 
through public–
private mix and 
Best evidence-
based strategies 
to enhance non-
public sector 
involvement in 
scaling up 
Non-public health 
sector 
Existence of national TB and HIV control programmes and implementation of basic DOTS 
strategy and basic services for HIV prevention and treatment;  
An environment conducive to national policy, and capacity to support PPM TB/HIV 
activities;  
Coordination between the national HIV and TB control programmes at all levels (state, 
242 
Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
partnerships collaborative 
TB/HIV activities. 
regional, provincial, district) and among all private and public stakeholders involved in the 
initiatives; 
Strategic and regular advocacy to involve all providers and ensure buy-in of all relevant 
TB and HIV stakeholders in PPM TB/HIV activities; 
Medicines and consumables supplied free of charge to providers extended free of charge 
to patients; 
Diagnostic tests widely accessible and affordable;  
Capacity-building (including training and supervision) in accordance with national policies 
and standards; 
Strengthen existing collaborative mechanisms and/or emerging opportunities between 
private and public sector and national TB and AIDS control programmes optimised to 
ensure sustainability and avoid duplication of structures; 
Provision of technical assistance (internal and/or external) ensured; 
Ensured continuity of services to end users in cases of provider decisions to opt out of 
PPM scheme; 
Guidelines for HIV 
surveillance among 
tuberculosis 
patients 
The main 
objective of these 
guidelines is to 
provide a 
framework for the 
methods to be 
used for 
measuring HIV 
prevalence 
among 
tuberculosis 
patients and to 
National or provincial 
TB/HIV control 
programmes. In 
addition, health 
facilities can utilise the 
guideline based on the 
local situation. 
All countries with a generalised HIV epidemic (HIV prevalence consistently >1% in 
pregnant women) should aim to ensure that HIV counselling and testing are actively 
promoted and offered to all TB patients. Whenever possible, this should be done in 
conjunction with the provision of ART;  
The data obtained in this way can form the basis of a reliable surveillance system where 
high coverage (>80%) of testing among TB patients is achieved. One of the best systems 
for capturing this information is through a computerised TB notification system, which also 
captures information on HIV status; 
Periodic (special) surveys or sentinel surveys are also recommended, to calibrate the 
results of routine testing; 
In countries with a concentrated epidemic (HIV prevalence consistently >5% in at least 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
encourage 
implementation 
of. HIV 
surveillance. 
one defined sub-population, e.g. intravenous drug users (IDUs); sex workers (SWs), men 
who have sex with men (MSM), and <1% in pregnant women in urban areas), data from 
routine HIV counselling and testing of all TB patients should still form the basis for the 
surveillance. If this system is not yet in place, periodic (special) surveys or sentinel 
surveys are suitable alternatives; 
In countries with a low-level HIV epidemic (HIV prevalence has not consistently exceeded 
5% in any defined sub-population) and where HIV testing is not routinely offered to TB 
patients, periodic (special) surveys (at intervals of 2–3 years) or sentinel surveys should 
be conducted among TB patients. 
Policy guidelines 
for collaborative TB 
and HIV services 
for injecting and 
other drug users: 
an integrated 
approach 
The aim of these 
guidelines is to 
provide a 
strategic 
approach to 
reduce morbidity 
and mortality 
related to TB and 
HIV among at-risk 
drug users and 
their communities 
in a way that 
promotes holistic 
and person-
centred services. 
These guidelines are 
intended for 
professionals dealing 
with the drug users 
who have the most 
problematic patterns of 
use and who are at the 
greatest risk of 
contracting HIV and 
TB, especially those 
who inject drugs. 
All congregate settings in the health, drug service and criminal justice sectors should have 
a TB infection control plan supported by all stakeholders that includes administrative, 
environmental and personal protection measures to reduce the transmission of TB; 
All services dealing with drug users should have a case-finding protocol for TB and HIV 
so that personnel are aware of the symptoms of TB and HIV and can ensure that drug 
users have access to appropriate TB and HIV testing and counselling, preferably at the 
service where they initially present; 
TB and HIV services and services for drug users should ensure access to appropriate 
treatment for drug users by using global, regional and national clinical guidelines and 
should work in collaboration to ensure treatment supervision and to simplify the delivery of 
treatment; 
All health services should ensure access to Isoniazid preventive therapy for drug users 
living with HIV once active TB is reasonably excluded; 
All personnel working with TB suspects and patients, people living with HIV and drug 
users should be able to assess risk factors for HIV infection and transmission and should 
provide comprehensive HIV prevention information and services to their clients to 
minimise these risks. Personnel should also be aware of how to protect themselves from 
occupational exposure to HIV and TB. 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
Guidelines for 
implementing 
collaborative TB 
and HIV 
programme 
activities 
The main aim of 
the guidelines is 
to enable the 
central units of 
national TB and 
HIV programmes 
to support districts 
to plan, 
coordinate and 
implement 
collaborative 
TB/HIV activities.  
The guidelines are 
intended for countries 
either  with an 
overlapping TB-HIV 
epidemic or where 
there is an increasing 
HIV rate which may 
fuel the TB epidemic. 
Models of collaboration between TB and HIV control programmes; 
Defining executive responsibility and boundaries of TB and HIV programme collaboration; 
Developing a national collaborative TB/HIV strategic plan that uses the synergies and 
strengths of the two programmes; 
Developing tools to support district implementation; 
Planning the process of phased implementation of collaborative TB/HIV activities; 
Monitoring and evaluation of TB/HIV collaborative activities; 
Assessing the cost of collaborative TB/HIV activities; 
Research on collaborative TB/HIV care service implementation; 
International support is required for national collaborative TB and HIV responses. 
Treatment of 
tuberculosis 
Guidelines 
The principal 
purpose of these 
guidelines is to 
help national TB 
control 
programmes in 
setting TB 
treatment policy 
to optimise patient 
cure: Curing 
patients will 
prevent death, 
relapse, acquired 
drug resistance, 
and the spread of 
TB in the commu-
The primary target 
audience for the 
guidelines is the 
managers and staff of 
NTPs, together with 
other TB service 
providers working in 
public and private 
healthcare facilities at 
the central and 
peripheral levels. 
New patients with pulmonary TB should receive a regimen containing 6 months of 
rifampicine: 2HRZE/4HR (The 2HRZE/6HE treatment regimen should be phased out); 
Wherever feasible, the optimal dosing frequency for new patients with pulmonary TB is 
daily throughout the course of therapy; 
New patients with TB should not receive twice weekly dosing for the full course of 
treatment unless this is done in the context of formal research; 
In populations with known or suspected high levels of Isoniazid resistance, new TB 
patients may receive HRE as therapy in the continuation phase as an acceptable 
alternative to HR; 
TB patients with known positive HIV status and all TB patients living in HIV prevalent 
settings should receive daily TB treatment at least during the intensive phase; 
For the continuation phase, the optimal dosing frequency is also daily for these patients; 
If a daily continuation phase is not possible for these patients, three times weekly dosing 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
nity.  
 
The other 
purpose is to 
guide clinicians 
working in both 
public and private 
sectors. 
during the continuation phase is an acceptable alternative; 
It is recommended that TB patients who are living with HIV should receive at least the 
same duration of TB treatment as HIV-negative TB patients; 
For smear-positive pulmonary TB patients treated with first-line drugs, sputum smear 
microscopy may be performed at completion of the intensive phase of treatment; 
In new patients, if the specimen obtained at the end of the intensive phase (month 2) is 
smear-positive, sputum smear microscopy should be obtained at the end of the third 
month; 
In new patients, if the specimen obtained at the end of month 3 is smear-positive, sputum 
culture and drug susceptibility testing (DST) should be performed; 
In previously treated patients, if the specimen obtained at the end of the intensive phase 
(month 3) is smear-positive, sputum culture and drug susceptibility testing (DST) should 
be performed; 
In patients treated with the regimen containing rifampicine throughout treatment, if a 
positive sputum smear is found at completion of the intensive phase, the extension of the 
intensive phase is not recommended; 
Specimens for culture and drug susceptibility testing (DST) should be obtained from all 
previously treated TB patients at or before the start of treatment. DST should be 
performed for at least Isoniazid and rifampicine; 
In settings where rapid molecular-based DST is available, the results should guide the 
choice of regimen; 
TB patients whose treatment has failed or other patient groups with high likelihood of 
multidrug-resistant TB (MDR-TB) should be started on an empirical MDR regimen; 
TB patients returning after defaulting or relapsing from their first treatment course may 
receive the retreatment regimen containing first-line drugs 2HRZES/1HRZE/5HRE if 
country specific data show low or medium levels of MDR in these patients or if such data 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
are unavailable; 
In settings where DST results are not yet routinely available to guide the management of 
individual patients, the empirical regimens will continue throughout the course of 
treatment; 
National TB control programmes should obtain and use their country-specific drug 
resistance data on failure, relapse and default patient groups to determine the levels of 
MDR. 
Improving the 
diagnosis and 
treatment of 
smear-negative 
pulmonary and 
extra-pulmonary 
tuberculosis among 
adults and 
adolescents 
Recommendations 
for HIV prevalent 
and resource-
constrained 
settings 
It is intended to 
assist for the 
development of 
national policies 
to improve the 
diagnosis and 
management of 
smear-negative 
and extra-
pulmonary 
tuberculosis. 
This document is 
intended for those 
dealing with TB and 
HIV at all levels in 
HIV prevalent and 
resource-constrained 
settings.  
 
The recommendations 
and algorithms are 
designed for use by 
national tuberculosis 
and HIV control 
programmes and 
service providers. 
Smear-positive pulmonary tuberculosis 
One sputum smear examination positive for acid-fast bacilli (AFB) and Laboratory 
confirmation of HIV infection or Strong clinical evidence of HIV infection. 
Smear-negative pulmonary tuberculosis 
At least two sputum specimens negative for AFB and radiographical abnormalities 
consistent with active tuberculosis and laboratory confirmation of HIV infection or Strong 
clinical evidence of HIV infection and decision by a clinician to treat with a full course of 
anti-tuberculosis chemotherapy, OR 
A patient with AFB smear-negative sputum which is culture-positive for Mycobacterium 
Tuberculosis, Extra-pulmonary tuberculosis; 
One specimen from an extra-pulmonary site culture-positive for Mycobacterium 
tuberculosis or smear-positive for AFB, OR 
Histological or strong clinical evidence consistent with active extra-pulmonary tuberculosis 
and laboratory confirmation of HIV infection or strong clinical evidence of HIV infection 
and a decision by a clinician to treat with a full course of anti-tuberculosis chemotherapy. 
A guide to 
monitoring and 
evaluation for 
collaborative 
This guide to 
monitoring and 
evaluation has 
been developed 
This guide is intended 
for policy makers 
within ministries of 
health and other 
The existence of a TB/HIV coordinating body or mechanism effective at all administrative 
levels of the health service, with representation from the major stakeholders in 
collaborative TB/HIV activities, which meets at least quarterly; 
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Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
TB/HIV activities to assist in the 
management of 
TB and HIV 
programmes that 
are implementing 
or planning to 
implement 
collaborative 
TB/HIV activities. 
It is intended to 
facilitate the 
collection of 
standardised data 
and help in the 
interpretation and 
dissemination of 
these data for 
programme 
improvement.  
It also aims to 
ensure 
consistency 
across all 
agencies and 
stakeholders 
involved in HIV, 
TB and 
collaborative 
TB/HIV activities, 
avoiding wasteful 
institutions that have 
an impact on health; 
HIV and TB 
programme managers 
at all levels; national, 
regional and district 
TB/HIV coordinators or 
members of 
coordinating bodies; 
staff of development 
and technical 
agencies, 
nongovernmental 
organisations, civil 
society and community 
based organisations 
involved in supporting 
collaborative TB/HIV 
activities. 
Number of all newly registered TB patients who are HIV-positive, expressed as a 
proportion of all newly registered TB patients; 
Existence of joint planning at national level for collaborative TB/HIV activities between the 
National TB Programme (NTP) and National HIV Control Programme (NACP); 
Number of TB and HIV service delivery points where IEC materials giving information on 
both HIV and TB, their interaction and prevention are available, expressed as a proportion 
of all TB and HIV service delivery points; 
Presence of an integrated national Monitoring and Evaluation system for collaborative 
TB/HIV activities that informs annual NTP and NACP planning cycles and their mid-term 
(3–5-year) plans; 
Number of PLHIV, attending HIV testing and counselling or HIV treatment and care 
services, who were screened for TB symptoms, expressed as a proportion of all PLHIV 
attending for HIV testing and counselling or HIV treatment and care services; 
Number of cases of newly diagnosed TB identified in PLHIV attending for HIV testing and 
counselling or HIV treatment and care services (who were screened for TB symptoms), 
expressed as a proportion of all PLHIV attending HIV testing and counselling services 
and HIV treatment and care services (who were screened for TB symptoms); 
Number of newly diagnosed HIV-positive clients who are given treatment for latent TB 
infection (TB preventive therapy), expressed as a proportion of the total number of newly 
diagnosed HIV-positive people; 
Number of healthcare facilities and/or congregate settings with a written infection control 
policy, expressed as a proportion of the total number of healthcare facilities and/or 
congregate settings evaluated; 
Number of registered TB patients who are tested for HIV (after giving consent) expressed 
as a proportion of the total number of registered TB cases; 
Number of registered TB patients who are tested for HIV (after giving consent) and who 
test HIV-positive, expressed as a proportion of the total number of all registered TB 
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Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
duplication of 
effort in data 
collection by 
developing a core 
set of 
internationally 
accepted and 
standardised 
indicators for 
monitoring and 
evaluating 
programme 
performance. 
In addition, it is 
hoped that the 
data collected will 
provide further 
evidence of the 
benefits of 
collaborative 
TB/HIV activities.  
Data collection 
and reporting 
should be 
integrated into 
existing 
monitoring and 
evaluation 
systems wherever 
possible. 
patients who are tested for HIV; 
Number of registered TB patients who are tested for HIV (after giving consent) and who 
receive their results through post test counselling, expressed as a proportion of all 
registered TB patients who are tested for HIV;  
Number of TB facilities where free condom distribution is practised and condoms are 
available, expressed as a proportion of all TB facilities; 
Number of HIV-positive TB patients who receive (at least one dose of) CPT during their 
TB treatment, expressed as a proportion of the total number of HIV-positive TB patients; 
Number of HIV-positive TB patients referred to HIV care and support services (as defined 
in local or national HIV policy) during TB treatment, expressed as a proportion of the total 
number of HIV-positive TB patients; 
Number of HIV-positive registered TB patients who are started on ART or continue 
previously initiated ART, during or at the end of TB treatment, expressed as a proportion 
of all HIV-positive registered TB patients; 
National TB control policy, endorsed by government, addresses the link between TB and 
HIV, and the potential impact that HIV may have on TB control throughout the country; 
National HIV control policy, endorsed by government, addresses the link between TB and 
HIV and the importance of TB as a major treatable and preventable cause of morbidity 
and mortality among PLHIV; 
Number of potential partners in collaborative TB/HIV activities who are actively involved in 
the planning, implementation and monitoring of collaborative TB/HIV activities, expressed 
as a proportion of all potential partners; 
Total funds that were available for collaborative TB/HIV activities in the most recently 
completed fiscal year, expressed as a percentage of the total funds budgeted for 
collaborative TB/HIV activities in the annual plan(s) of the same year. 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
Guidelines for 
intensified 
tuberculosis case-
finding and 
Isoniazid 
preventive therapy 
for people living 
with HIV in 
resource-
constrained  
settings 
The objective of 
this guideline is to 
provide guidance 
for national TB 
and HIV 
programmes by 
updating existing 
WHO 
recommendations 
with new 
evidence, taking 
into consideration 
the changing 
context of HIV 
and TB 
prevention, 
treatment and 
care. The new 
guidelines focus 
on facilitating the 
implementation of 
IPT and ICF.  
 
The guidelines 
are also intended 
to highlight and 
strengthen the 
leadership role of 
national HIV 
programmes and 
The guideline is 
intended for healthcare 
workers providing care 
for PLHIV, policy-
makers and health 
programme managers 
working in the field of 
HIV and TB.  
 
The guidelines are 
also intended for 
governments, 
nongovernmental 
organisations, donors 
and patient support 
groups that address 
HIV and TB. 
Adults and adolescents living with HIV should be screened for TB with a clinical algorithm 
and those who do not report any one of the symptoms of current cough, fever, weight loss 
or night sweats are unlikely to have active TB and should be offered IPT; 
Adults and adolescents living with HIV and screened for TB with a clinical algorithm and 
who report any one of the symptoms of current cough, fever, weight loss or night sweats 
may have active TB and should be evaluated for TB and other diseases; 
Adults and adolescents living with HIV who have an unknown or positive tuberculin skin 
test (TST) status and who are unlikely to have active TB should receive at least six 
months of IPT as part of a comprehensive package of HIV care. IPT should be given to 
such individuals irrespective of the degree of immuno-suppression, and also to those on 
ART, those who have previously been treated for TB and pregnant women; 
Adults and adolescents living with HIV who have an unknown or positive TST status and 
are unlikely to have active TB should receive at least 36 months of IPT. IPT should be 
given to such individuals irrespective of the degree of immuno-suppression, and also to 
those on ART, those who have previously been treated for TB and pregnant women; 
Adults and adolescents living with HIV who have an unknown or positive TST status and 
are unlikely to have active TB should receive at least 36 months of IPT. IPT should be 
given to such individuals irrespective of the degree of immuno suppression, and also to 
those on ART, those who have previously been treated for TB and pregnant women; 
TST is not a requirement for initiating IPT in people living with HIV; 
People living with HIV who have a positive TST benefit more from IPT; TST can be used 
where feasible to identify such individuals; 
Providing IPT to people living with HIV does not increase the risk of developing INH 
resistant TB. Therefore, concerns regarding the development of INH resistance should 
not be a barrier to providing IPT; 
Children living with HIV who do not have poor weight gain, fever or current cough are 
unlikely to have active TB;  
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
HIV stakeholders 
to scale up the 
implementation of 
TB screening and 
provision of IPT 
among people 
living with HIV. 
Children living with HIV who have any one of the following symptoms – poor weight gain, 
fever, current cough or contact history with a TB case – may have TB and should be 
evaluated for TB and other conditions. If the evaluation shows no TB, they should be 
offered IPT regardless of their age; 
Children living with HIV who are more than 12 months of age and who are unlikely to 
have active TB on symptom-based screening, and have no contact with a TB case should 
receive six months of IPT (10 mg/kg/ day) as part of a comprehensive package of HIV 
prevention and care services;  
In children living with HIV who are less than 12 months of age, only those who have 
contact with a TB case and who are evaluated for TB (using investigations) should 
receive six months of IPT if the evaluation shows no TB disease; 
All children living with HIV who have successfully completed treatment for TB disease 
should receive INH for an additional six months. 
WHO policy on TB 
infection control in 
healthcare 
facilities, 
congregate 
settings and 
households. 
The aim of the 
policy is to 
provide member 
states with 
guidance on how 
to reduce the risk 
of TB 
transmission in 
healthcare 
facilities, 
congregate 
settings and 
households, and 
how to prioritise 
TB infection 
control measures. 
The document is 
targeted for national 
and sub-national policy 
makers, including 
health-system 
managers of 
programmes covering 
TB, HIV, infection 
prevention and control, 
hospital services, 
control and quality 
assurance 
programmes, and 
occupational health. 
Identify and strengthen a coordinating body for infection control, and develop a 
comprehensive budgeted plan that includes human resource requirements for 
implementation of TB infection control at all levels; 
Ensure that health facility design, construction, renovation and use are appropriate; 
Conduct surveillance of TB disease among health workers, and conduct assessment at all 
levels of the health system and in congregate settings; 
Address TB infection control advocacy, communication and social mobilisation (ACSM), 
including engagement of civil society; 
Monitor and evaluate the set of TB infection control measures; 
Enable and conduct research; 
Promptly identify people with TB symptoms (triage), separate infectious patients, control 
the spread of pathogens (cough etiquette and respiratory hygiene) and minimise time 
spent in healthcare facilities; 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
Provide a package of prevention and care interventions for health workers including HIV 
prevention, antiretroviral therapy and Isoniazid preventive therapy for HIV-positive health 
workers; 
Use ventilation systems; 
Use of upper room or shielded ultraviolet germicidal irradiation fixtures; 
Use of particulate respirators. 
WHO policy on 
collaborative 
TB/HIV activities: 
Guidelines for 
national 
programmes and 
other stakeholders. 
The purpose of 
the policy is to 
provide national 
programmes and 
stakeholders with 
guidelines on how 
to implement and 
scale up 
collaborative 
TB/HIV activities.  
It is 
complementary to 
and in synergy 
with the 
established core 
activities of TB 
and HIV 
prevention, 
diagnosis, 
treatment and 
care programmes. 
These policy guideline 
is intended for decision 
makers in the field of 
health and for 
managers of TB 
control programmes 
and HIV programmes 
working at all levels in 
the health sector, 
including the private-
for-profit sector, as 
well as donors, 
development 
agencies, 
nongovernmental 
organisations and 
other civil society 
organisations 
supporting such 
programmes, and 
people living with, at 
risk of or affected by 
HIV and TB. 
Set up and strengthen a coordinating body for collaborative TB/HIV activities functional at 
all levels; 
Determine HIV prevalence among TB patients and TB prevalence among people living 
with HIV; 
Carry out joint TB/HIV planning to integrate the delivery of TB and HIV services; 
Monitor and evaluate collaborative TB/HIV activities; 
Intensify TB case finding and ensure high quality anti-tuberculosis treatment; 
Initiate TB prevention with Isoniazid preventive therapy and early antiretroviral therapy; 
Ensure control of TB Infection in healthcare facilities and congregate settings; 
Provide HIV testing and counselling to patients with presumptive and diagnosed TB; 
Provide Cotrimoxazole preventive therapy for TB patients living with HIV; 
Ensure HIV prevention interventions, treatment and care for TB patients living with HIV; 
Provide antiretroviral therapy for TB patients living with HIV. 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
 
Priority 
Interventions: 
HIV prevention, 
treatment and care 
in the health sector 
The objective is to 
describe the 
priority health 
sector 
interventions that 
are needed to 
achieve universal 
access to HIV 
prevention, 
treatment and 
care. 
 
This document is 
intended for a broad 
readership of public 
health decision 
makers, national HIV 
programme managers, 
health providers and 
workers 
(governmental, 
nongovernmental and 
private), international, 
national and local 
donors, and civil 
society, including 
people living with and 
affected by HIV. 
Enabling people to know their HIV status 
Client-initiated HIV testing and counselling; 
Provider-initiated HIV testing and counselling; 
Blood donor HIV testing and counselling;  
Laboratory services for HIV diagnosis.   
 
Maximising the health sector’s response to HIV prevention 
Preventing sexual transmission of HIV; 
Interventions for injecting drug users; 
Treatment and prevention of HIV in pregnant women, infants and young children; 
Prevention of HIV transmission in health settings. 
 
Scaling up HIV treatment and care 
Interventions to prevent illness; 
Treatment and care interventions; 
Laboratory services for HIV monitoring. 
Antiretroviral 
therapy for HIV 
infection in adults 
and adolescents. 
To provide 
evidence-based 
recommendations 
outlining a public 
health approach 
to the delivery of 
ART for adults 
The target audiences 
are national treatment 
advisory boards, 
partners implementing 
HIV care and 
treatment, and 
organisations 
All adolescents and adults including pregnant women with HIV infection and CD4 counts 
of ≤350 cells/mm3 should start ART, regardless of the presence or absence of clinical 
symptoms. Those with severe or advanced clinical disease (WHO clinical stage 3 or 4) 
should start ART irrespective of their CD4 cell count; 
First-line therapy should consist of an NNRTI + two NRTIs, one of which should be 
zidovudine (AZT) or tenofovir (TDF). Countries should take steps to progressively reduce 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
and adolescents, 
with a focus on 
settings with 
limited health 
systems capacity 
and resources. 
To identify the 
most potent, 
effective and 
feasible first-line, 
second-line and 
subsequent 
treatment 
regimens as 
components of 
expanded 
national 
responses for HIV 
care. 
To develop 
recommendations 
applicable to the 
majority of 
populations 
regarding the 
optimal timing of 
ART initiation 
preferred first-line 
and second-line 
ARV regimens 
providing technical and 
financial support to 
HIV care and 
treatment programmes 
in resource limited 
settings 
the use of stavudine (d4T) in first-line regimens because of its well-recognised toxicities; 
Second-line ART should consist of a ritonavir-boosted protease inhibitor (PI) plus two 
NRTIs, one of which should be AZT or TDF, based on what was used in first-line therapy. 
Ritonavir-boosted atazanavir (ATV/r) or lopinavir/ritonavir (LPV/r) are the preferred PIs; 
All patients should have access to CD4 cell–count testing to optimise pre-ART care and 
ART management. HIVRNA (viral-load) testing is recommended to confirm suspected 
treatment failure. Drug toxicity monitoring should be symptom-directed; 
Irrespective of CD4 cell counts, patients co-infected with HIV and TB should be started on 
ART as soon as possible after starting TB treatment; 
Irrespective of CD4 cell counts or WHO clinical stage, patients who require treatment for 
HBV infection should start ART. First-line and second-line regimens for these individuals 
should contain TDF and either emtricitabine (FTC) or lamivudine (3TC). 
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Table 7.1 Table showing wide variety of documents prepared by different agencies as a guide for implementation of collaborative TB/HIV care services 
 
Document 
Presumed 
objectives of the 
document 
Intended target of the 
document 
Recommended procedures/activities for implementation of the guideline 
and improved 
criteria for ART 
switching, and to 
introduce the 
concept of third-
line ART 
regimens. 
Strategic 
framework to 
decrease the 
burden of TB/HIV. 
This framework 
paper provides 
the technical 
basis to inform 
and guide the 
development of 
national 
implementation 
strategies for joint 
tuberculosis and 
HIV programme 
activities in 
delivering the 
available 
interventions. 
This framework is 
intended to be used by 
those dealing with 
tuberculosis and HIV 
at all levels in HIV 
prevalent and 
resource-constrained 
settings. 
The new strategy for tuberculosis control in high HIV prevalence populations comprises 
interventions against tuberculosis (ICF and IPT) and interventions against HIV (and 
therefore indirectly against tuberculosis), e.g., condoms, STI treatment, safe injecting drug 
use (IDU) and highly active antiretroviral treatment (HAART); 
Several requirements are necessary for countries to strengthen general health service 
providers in implementing the interventions to control tuberculosis as part of the overall 
health service response to HIV; these include: increased funding (by national 
governments and the donor community); changes in international and national policy 
away from specific HIV activities towards responding to the care needs of high HIV 
prevalence populations through strengthened general health services; improved general 
health service capacity to deliver interventions (human resources, infrastructure and 
commodities); operational research to find out how best HIV and tuberculosis 
programmes can work together to help general health services deliver an effective 
response; effective coordination of activities on the part of the many role players often 
involved; 
Identify priority research needs in developing new and improved interventions, monitoring 
their impact, and implementing national strategies to decrease the burden of TB/HIV. 
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7.5 FORMULATION OF A POCKET GUIDE ON COLLABORATIVE TB/HIV CARE 
SERVICES FOR HEALTH WORKERS IN ETHIOPIA 
 
This section describes the contents of the pocket guide for healthcare workers engaged 
in TB/HIV care, based on synthesis of available global collaborative TB/HIV care 
policies and guidelines. In addition, the local situation was considered from findings of 
this research. Compilation of the pocket guide is also guided by the theoretical 
frameworks and literature review used in this study. Formulated thematic areas were 
followed to prepare the pocket guide in a simplified form so that any level of the 
healthcare providers will be able to use it. 
 
The pocket guide is presented in three main themes that emerged from global policy for 
collaborative TB/HIV care services. 
 
7.5.1 THEME 1: Establish mechanisms for integrated TB and HIV services (Joint 
HIV and TB Programmes activities) 
 
Four sub-themes have been compiled under this main theme, each of which has sets of 
specific activities outlined below.  
 
7.5.1.1 Set up or strengthen a TB/HIV coordinating body functional at all levels 
  
The HIV control programme and TB control programme should create and strengthen a 
joint national TB/HIV coordinating body, functional at regional, district, local and facility 
levels, with equal or reasonable representation of the two programmes, including of 
people at risk of or affected by both diseases, and other line ministries (e.g., those 
working on harm reduction and prison or mining health services). 
 
The TB/HIV coordination bodies should be responsible for the governance, planning, 
coordination, and implementation of collaborative TB/HIV activities as well as 
mobilisation of financial resources. 
 
HIV programmes and TB control programmes, including their partners in other line 
ministries (for example, in ministries responsible for prison or uniformed health 
services), the private-for-profit sector and civil society organisations should work 
together to provide access to integrated services, preferably at the same time and 
location, for the prevention, diagnosis, treatment and care of TB/HIV. 
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National coordinating bodies are needed at all levels of the health system to ensure 
strong and effective collaboration between HIV programmes and TB control 
programmes and to offer a platform for coordination and synergy among stakeholders. 
Representation of people at risk of or affected by both diseases is essential to ensure 
effective implementation of integrated services and programme success. National 
HIV/AIDS directorate, which coordinate the multi-sectoral response to HIV, should also 
be included in national TB/HIV control coordination efforts. 
 
A national coordinating body for collaborative TB/HIV activities should have clear and 
consensus-based terms of reference. The important areas of responsibility are: 
• Governance and coordination at national and sub-national levels, 
• Resource mobilisation, 
• Provision of general policy and programme direction for the management of 
collaborative TB/HIV activities, 
• Capacity building, including training of service providers, 
• Ensuring coherence of communications about TB and HIV, 
• Ensuring the involvement of civil society, nongovernmental and community 
organisations, and individuals. 
In Ethiopia, where coordinating bodies already exist (such as country coordinating 
mechanisms for the Global Fund to Fight AIDS, Tuberculosis and Malaria), 
strengthening their role through revised terms of reference and expansion based on 
performance and achievements may be needed to deliver integrated TB and HIV 
services, preferably at the same time and location. 
 
Evidence from operational research and descriptive studies has shown that effective 
coordinating bodies that operate at all levels and that include the participation of all 
stakeholders from HIV programmes and TB control programmes, civil society 
organisations, patients and communities are feasible and ensure broad commitment 
and ownership. A national coordinating body should also address governance issues, 
including the division of labour and resources for implementing joint plans. 
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7.5.1.2 Conduct HIV and TB surveillance among TB and HIV patients, 
respectively 
 
Surveillance of HIV should be conducted among TB patients and surveillance of active 
TB disease among people living with HIV in all countries, irrespective of national adult 
HIV and TB prevalence rates, in order to inform programme planning and 
implementation. 
 
• Countries with unknown HIV prevalence rates among TB patients should conduct 
a sero-prevalence (periodic or sentinel) survey to assess the situation.  
• In countries with a generalised epidemic state (>1% in pregnant women), HIV 
testing and counselling of all patients with presumptive or diagnosed TB should 
form the basis of surveillance. Where this is not yet in place, periodic surveys or 
sentinel surveys are suitable alternatives.  
• In countries with a concentrated epidemic state where groups at high risk of HIV 
infection are localised in certain administrative areas (>5% in at least one defined 
sub-population and <1% in pregnant women in urban areas), HIV testing and 
counselling of all patients with presumptive or diagnosed TB in those 
administrative areas should form the basis of surveillance. Where this is not yet 
in place, periodic (special) or sentinel surveys every two to three years are 
suitable alternatives. 
• In countries with a low-level epidemic state (<5% in any defined sub-population), 
periodic (special) or sentinel surveys are recommended every two to three years. 
• HIV testing should be an integral part of TB prevalence surveys and anti-
tuberculosis drug resistance surveillance. 
 
Surveillance is essential to inform programme planning and implementation. There are 
three key methods for surveillance of HIV among TB patients:  
• periodic surveys (cross-sectional HIV sero-prevalence surveys among a small 
representative group of TB patients within a country);  
• sentinel surveys (using TB patients as a sentinel group within the general HIV 
sentinel surveillance system); and  
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• data from the routine HIV testing and counselling of patients with presumptive or 
diagnosed TB.  
The surveillance method chosen will depend on the underlying HIV epidemic state, the 
overall TB situation, and the availability of resources and experience. Incorporating HIV 
testing with TB prevalence surveys and anti-tuberculosis drug resistance surveillance 
offers an opportunity to expand HIV testing and improve knowledge among national TB 
control programmes on the relationship between HIV and drug-resistant TB at the 
population level. It also provides critically important individual benefits to people living 
with HIV, including better access to testing, early case detection and rapid initiation of 
treatment. 
 
With the increasing availability of HIV treatment, unlinked anonymous testing for HIV is 
not recommended because results cannot be traced back to individuals who need HIV 
care and treatment. 
 
Surveys should follow nationally recommended guidelines. TB patients or people newly 
diagnosed with HIV identified during the surveillance should immediately be provided 
with TB and HIV treatment and services based on national guidelines. The surveillance 
of active TB disease among people living with HIV, whenever feasible, will be useful to 
inform programmes. Rates of TB among people newly enrolled in HIV care and/or 
among those initiating ART could be monitored based on analysis of routine programme 
data. 
 
Evidence from descriptive studies has shown HIV surveillance among TB patients to be 
a critical activity in understanding the trends of the epidemic and in the development of 
sound strategies to address the dual TB/HIV epidemic. 
 
7.5.1.3 Carry out joint TB/HIV planning to integrate the delivery of TB and HIV 
services  
Joint planning should clearly define the roles and responsibilities of HIV and TB control 
programmes in implementing, scaling-up and monitoring and evaluating collaborative 
TB/HIV activities at all levels of the health system. HIV programmes and TB control 
programmes should describe models to deliver client and family centred integrated TB 
and HIV services at facility and community levels compatible with national and local 
contexts. 
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HIV programmes and TB control programmes should ensure resource mobilisation and 
adequate deployment of qualified human resources to implement and scale up 
collaborative TB/HIV activities in accordance with country-specific situations. 
 
HIV programmes and TB control programmes should formulate a joint training plan to 
provide pre-service and in-service training, and continuing competency-based education 
on collaborative TB/HIV activities for all categories of healthcare workers. Job 
descriptions of health workers should be developed and/or adapted to include 
collaborative TB/HIV activities. 
 
HIV programmes and TB control programmes should ensure that there is sufficient 
capacity to deliver healthcare (e.g., adequate laboratories, supplies of medicines, 
referral capacity, private sector involvement, focus on key populations such as women, 
children, people who use drugs and prisoners), and effectively implement and scale up 
collaborative TB/HIV activities. 
 
HIV programmes and TB control programmes should develop specific strategies to 
enhance the involvement of nongovernmental and other civil society organisations and 
individuals affected by or at risk of both diseases in developing and implementing policy 
and programmes, and the monitoring and evaluation of collaborative TB/HIV activities at 
all levels. 
 
Well-designed TB/HIV advocacy activities that are jointly planned to ensure coherence 
between their messages and targeted at key stakeholders and decision-makers, should 
be carried out at global, national, regional and local levels. 
 
The joint communication strategies should ensure the mainstreaming of HIV 
components in TB communication and of TB components in HIV communication. 
All stakeholders of collaborative TB/HIV activities, including HIV programmes and TB 
control programmes, should support and encourage operational research on country -
specific issues to develop the evidence base for efficient and effective implementation 
of collaborative TB/HIV activities. 
 
Medium- and long-term joint strategic planning to successfully and systematically scale 
up collaborative TB/HIV activities nationwide and deliver integrated TB and HIV 
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services, preferably at the same time and location with due consideration to prevention 
of TB transmission should be developed.  
HIV programmes and TB control programmes should either devise a joint TB/HIV plan, 
or introduce TB/HIV components in their national plans for prevention, diagnosis, 
treatment and care. The roles and responsibilities of each programme in implementing 
specific TB/HIV activities at all levels must be clearly defined.  
 
Joint planning should be harmonised with the country’s national health strategic plans 
and health system strengthening agenda. Key areas to be covered include quality 
assured health services; a well-performing health workforce; well-functioning 
information systems; equitable access to essential medicinal products, vaccines and 
technologies; good health financing; and leadership and governance.  
Crucial elements for joint TB/HIV planning include the activities detailed in sections 
7.5.1 – 7.5.3 of this chapter, as well as resource mobilisation, capacity-building and 
training, TB/HIV advocacy, programme communication, the involvement of civil society 
organisations including nongovernmental organisations, people living with HIV, people 
who have been diagnosed with TB (including people who have completed anti-
tuberculosis treatment) and communities, engagement of private for profit and 
operational research. HIV programmes and TB control programmes should also plan 
and coordinate reviews of joint programmes as well as routine monitoring and 
evaluation of integrated services. 
 
 
7.5.1.3.1 Models of integrated TB and HIV service delivery system 
The selection of models for delivering quality-assured integrated TB and HIV services 
should consider local and national health system issues. The models described below 
are therefore not exhaustive or prescriptive. National HIV programmes and TB control 
programmes need to define the best model for delivering integrated services that 
enables the provision of quality-assured comprehensive services as soon as and as 
close as possible to where people living with HIV and TB and their families reside.  
 
Such efforts should include integrating services for the prevention, diagnosis, treatment 
and care of TB and HIV into maternal and child health services, including the prevention 
of vertical (mother to child) transmission of HIV, and treatment centres for drug 
dependency where applicable. 
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• Entry via TB service and referral for HIV testing and care 
 In this model TB service providers refer patients to services providing HIV testing, with 
or without subsequent HIV care. It requires minimal additional logistic and financial input 
and can be achieved through joint training of healthcare workers from both 
programmes, modification of existing record keeping systems and referral forms, and 
regular meetings of staff from both services to strengthen referral linkages. Strengths of 
this model include the simplicity of introducing the required measures and the low cost. 
The key weakness is loss of patients if referral fails (e.g., due to lack or cost of 
transportation). This model may not be the best option in high HIV prevalent settings 
where both services should be provided as close and as integrated as possible. 
 
• Entry via TB service and referral for HIV care after HIV testing 
 In this model, TB clinic staffs offer HIV testing on site and refer people found to be HIV-
positive for HIV care. It may require additional HIV testing counselling space and also 
additional staff members, depending on the burden in the clinic. Whatever the HIV test 
results, people should be provided with HIV prevention information. If referral for HIV 
care fails, consequences may include additional HIV transmission to partners and 
children and delays in initiating life-saving HIV care and treatment. 
 
• Entry via HIV service and referral for screening, diagnosis and treatment of TB 
 In this model, HIV care service providers refer people living with HIV for TB screening, 
diagnosis and treatment. Few reports described how patients were selected for referral. 
Appropriate referral criteria and system are essential for effective functioning of this 
model. Failure of the referral process can lead to ongoing TB transmission and 
progression of TB disease. 
 
• Entry via HIV service and referral for TB diagnosis and treatment after TB 
screening  
In this model, people living with HIV are screened for TB and referred for TB diagnosis 
and treatment based on the outcome of the screening. The infrastructure needed for 
this model varied considerably, depending on whether additional interventions such as 
Isoniazid preventive therapy (IPT) are offered by the HIV clinic or sputum sample 
collection on site that requires heightened infection control measures. The WHO 
recommended symptom based screening algorithm should be used and people living 
with HIV who are unlikely to have active TB should be provided with IPT. 
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• TB and HIV services provided at a single facility (at the same time and location):  
This model includes a spectrum of activities to provide patient-centred care by the same 
trained healthcare provider at the same visit, a “one-stop service.” It includes: a TB 
clinic providing HIV treatment; an HIV clinic providing TB treatment; a primary health 
centre providing integrated diagnosis and treatment for TB and HIV either in one or 
separate rooms; and a hospital providing integrated diagnosis and treatment for TB and 
HIV either in one or separate rooms. This model could be particularly efficient in settings 
with high HIV prevalence where most TB patients have HIV and in settings where 
availability of human resources is an issue, avoiding the need for referral and offering 
better coordinated care for patients.  
A concern with this model is the risk of nosocomial spread of TB. It should be noted 
however that the risk of TB transmission is not unique to this model, as it exists in 
general waiting areas of all health facilities in high burden settings (wherever coughing 
patients with undiagnosed pulmonary TB are regularly presenting). Thus, 
implementation of proper infection control measures is crucial throughout health 
facilities in high burden settings in order to minimise the risk of nosocomial spread of TB 
to immune-suppressed people living with HIV.  
However, integrated care supports early detection and treatment of undiagnosed 
infectious tuberculosis, and may result in a reduction of TB risk compared with separate 
services. Increase in notification of smear-negative pulmonary and extra-pulmonary TB 
and of treatment success rates in integrated TB/HIV was also observed in Lesotho and 
South Africa. This model also supports timely initiation of ART in TB patients living with 
HIV without the necessity to refer them as shown in South Africa. 
 
 
7.5.1.3.2 Resource mobilisation and capacity-building 
Collaborative TB/HIV activities, which build on well-resourced strategies, may not 
require much additional financial input. If either or both programmes are under-
resourced in funds or human capacity, additional resources should first be mobilised to 
strengthen them. 
Joint proposals to solicit resources for implementing collaborative activities should be 
prepared, within the framework of the joint coordinating body, building on the 
comparative strengths of both programmes and the specific needs of the country.  
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Alternatively, both HIV and TB funding proposals (for example to the Global Fund to 
fight AIDS, TB and Malaria, to the United States President’s Emergency Plan for AIDS 
Relief, or any other funding streams) should include resources to address collaborative 
TB/HIV activities in each proposal, with clear division of labour to avoid duplication of 
efforts. Joint capacity-building for collaborative activities should include training of TB, 
HIV and primary healthcare workers in TB/HIV issues. Also important is ensuring 
continued competency based education of healthcare workers through clinical 
mentoring, regular supportive supervision and the availability of standard operating 
procedures and job aids, reference materials and up-to-date national guidelines. 
Capacity should also be enhanced in the healthcare system, for example in the 
laboratory, supply management, health information, referral and integrated service 
delivery systems, to enable them to cope better with the increasing demands of 
collaborative TB/HIV activities. 
 
 
7.5.1.3.3 Involving nongovernmental and other civil society organisations and 
communities 
Expanding collaborative TB/HIV activities beyond the health sector through meaningful 
involvement with communities, nongovernmental and civil society organisations and 
individuals in the planning, implementation and monitoring of TB/HIV activities at all 
levels is crucially important.  
 
People at risk of or affected by TB and HIV as well as community-based organisations 
working on advocacy, treatment literacy and community mobilisation are key actors in 
generating the required demand for integrated services at all levels of care. Their 
recognition and support, including financial support, is therefore critical.  
Advocacy targeted at influencing policy and sustaining political commitment, 
programme implementation and resource mobilisation is very important to accelerate 
the implementation of collaborative TB/HIV activities.  
 
Services for TB prevention, diagnosis, treatment and care can be integrated with those 
for HIV, and vice versa, through community-based organisations such as TB care or 
HIV home-based care. Trained home-based care and community healthcare workers as 
well as nongovernmental organisations have been successful in providing TB and HIV 
services in various countries. Community-based TB and HIV care services are cost-
effective. While implementing collaborative TB/HIV activities, it is imperative that civil 
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society organisations, including nongovernmental and community-based organisations, 
advocate, promote and follow national TB and HIV guidelines, including monitoring and 
evaluation of TB/HIV activities using nationally recommended indicators. 
 
7.5.1.3.4 Engaging the private-for-profit sector 
The engagement of the private-for-profit sector in implementing collaborative TB/HIV 
activities requires coordination and collaboration among HIV programmes and TB 
control programmes as well as private service providers and their professional 
associations. This collaboration can be either at national, state, regional, provincial or 
district level, depending on the local context. Private-for-profit sector representation 
should be included in TB/HIV coordinating bodies at all levels and should be 
encouraged to initiate and implement collaborative activities in accordance with national 
norms and guidelines. 
 
 
7.5.1.3.5 Addressing the needs of key populations: women, children and people who 
use drugs 
Active TB has been diagnosed at rates up to 10 times higher in pregnant women living 
with HIV than in women without HIV infection; maternal TB is associated with a 2.5 fold 
increased risk of vertical transmission of HIV infection to the unborn child. Similarly, HIV 
infection is a risk factor for active TB disease in infants or children.  
 
More severe forms of TB disease and higher mortality rates are reported in children 
living with HIV. Bacille Calmette–Guérin (BCG) is a live vaccine and should not be given 
to infants and children with known HIV infection. However, HIV infection cannot reliably 
be determined at birth, and the majority of infants born to HIV-infected mothers will be 
HIV uninfected.  
BCG should therefore be administered to infants born to HIV-infected mothers in HIV 
prevalent settings unless the infant is confirmed as HIV-infected. National HIV 
programmes and TB control programmes should ensure that TB prevention, screening, 
diagnosis and treatment as well as HIV prevention, diagnosis, treatment and care 
services are integrated with those for maternal and child health (MCH) and prevention 
of HIV vertical transmission. People living with HIV in congregate settings, such as 
prisons and centres for refugees or internally displaced persons, and people who use 
drugs have a higher risk of and incidence of TB and HIV infection.  
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People who inject drugs and use alcohol hazardously have a higher risk of co-infection 
with HIV, TB and hepatitis. The joint plans, especially in settings where injecting drug 
use is fuelling the HIV epidemic, should therefore ensure that services for prevention, 
diagnosis, treatment and care of TB are combined with harm reduction measures, 
including the provision of testing for hepatitis B and C infection, and referral for 
treatment of people found to have infectious hepatitis. Prisons should ensure that 
integrated services are available to deliver effective prevention, including TB infection 
control measures, diagnosis and treatment of HIV, TB and hepatitis as well as harm-
reduction services. 
 
 
7.5.1.3.6 Advocacy and communication 
Advocacy targeted at influencing policy, programme implementation, and resource and 
community mobilization is important to accelerate the implementation of collaborative 
TB/HIV activities at all levels. Two-way communication between the programmes and 
the general public and with affected populations can inform and create awareness about 
both diseases and is crucial for ensuring that patients actively seek out and demand 
services.  
 
Effective communication measures focused on communities rather than individuals that 
combine a series of elements from the use of data, science, research, policy and 
advocacy can inform the public, shape perceptions and attitudes, mitigate stigma, 
enhance the protection of human rights, create demand for services, form stronger links 
with health services and systems, improve provider client relationships, and monitor and 
evaluate TB/HIV activities. Joint TB/HIV communication strategies should ensure the 
mainstreaming of HIV components in TB communication and of TB components in HIV 
communication. 
 
7.5.1.3.7 Operational research to scale up collaborative TB/HIV activities 
Cultural and system-wide differences between HIV and TB care providers and 
operational difficulties for providing effective and appropriate interventions have 
contributed to a lack of progress in expanding collaborative TB/HIV activities.  
Operational research is needed to define how best to provide high quality integrated TB 
and HIV interventions at facility and community levels in order to inform global and 
national policy and strategy development. Priority research questions for TB/HIV in HIV 
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prevalent and resource limited settings, including for operational research, have been 
identified and need to be urgently answered 
 
7.5.1.4 Conduct monitoring and evaluation 
 
HIV programme and TB control programmes should establish harmonised indicators 
and standard reporting and recording templates to collect data for monitoring and 
evaluation of collaborative TB/HIV activities. 
Organisations implementing collaborative TB/HIV activities should embrace harmonised 
indicators and establish a reporting mechanism to ensure that their data is captured by 
the national monitoring and evaluation system of the country. 
 
The WHO guide to monitoring and evaluation of collaborative TB/HIV activities and the 
three interlinked patient monitoring systems for HIV care/ART, MCH/PMTCT and 
TB/HIV should be used as a basis to standardise country-specific monitoring and 
evaluation activities. 
 
Monitoring and evaluation provides the means to assess the quality, effectiveness, 
coverage and delivery of collaborative TB/HIV activities. It promotes a learning culture 
within and across the programmes and ensures continuous improvement of individual 
and joint programme performance.  
 
Monitoring and evaluation involves collaboration between the programmes and the 
general health system, the development of referral linkages between different services 
and organisations, and joint supervision. These activities should be integrated with 
existing monitoring and evaluation systems.  
 
Establishing and identifying harmonised indicators that should be captured by each 
programme are essential to avoid duplication of effort, and national reporting and 
recording formats should be standardised. Using the three interlinked patient monitoring 
systems for HIV care/ART, MCH/PMTCT, and TB/HIV will facilitate the crosschecking 
and reconciliation of data between HIV programmes and TB control programmes at 
local and country levels and will strengthen country ownership of data.  
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Evidence from operational research has shown the importance of standardised 
monitoring and evaluation of collaborative TB/HIV activities to determine the impact of 
the activities and to ensure implementation and effective programme management. 
 
7.5.2 THEME 2: Reduce the burden of TB among people living with HIV and 
initiate early antiretroviral therapy: the Three I’s for TB/HIV  
(HIV Programme activities) 
 
In this theme, the HIV care providers need to integrate activities to decrease the burden 
of TB among PLHIV during HIV patients’ follow-up care. The three primary activities 
outlined in the pocket guide are described in the following sections. 
  
7.5.2.1 Intensify TB case-finding and ensure high-quality anti-tuberculosis 
treatment 
Adults and adolescents living with HIV should be screened for TB with a clinical 
algorithm; those who report any one of the symptoms of current cough, fever, weight 
loss or night sweats may have active TB and should be evaluated for TB and other 
diseases. 
Children living with HIV who have any of the following symptoms: poor weight gain, 
fever or current cough or contact history with a TB case, may have TB and should be 
evaluated for TB and other conditions. If the evaluation shows no TB, children should be 
offered IPT regardless of their age. 
TB patients with known positive HIV status and TB patients living in HIV prevalent 
settings should receive at least six months of rifampicine based treatment regimen. The 
optimal dosing frequency is daily during the intensive and continuation phases. 
All people living with HIV should be regularly screened for TB using a clinical symptom 
based algorithm consisting of current cough, fever, weight loss or night sweats at the 
time of initial presentation for HIV care and at every visit to a health facility or contact 
with a healthcare worker afterwards. Adults and adolescents living with HIV who report 
any one of the symptoms of current cough, fever, weight loss or night sweats may have 
active TB and should be evaluated for TB and other diseases.  
Screening for TB is important regardless of whether people have received or are 
receiving IPT or ART. Similarly, children living with HIV who have any one of the 
268 
following symptoms: poor weight gain, fever or current cough or contact history with a 
TB case, may have TB and should be evaluated for TB and other conditions. 
In people with a positive screen, the diagnostic workup for TB should be carried out in 
accordance with national guidelines and principles of sound clinical practice to identify 
either active TB or an alternative diagnosis.  
Smear negative pulmonary and extra-pulmonary TB is common among people living 
with HIV and associated with poor treatment outcomes and excessive early mortality. If 
smear negative pulmonary TB or extra-pulmonary TB is suspected, diagnostic 
processes should be expedited using all available and appropriate investigations, 
including mycobacterial culture.  
New TB patients living with HIV should receive a TB regimen containing six months of 
rifampicine (two months of Isoniazid, rifampicine, pyrazinamide and ethambutol followed 
by four months of rifampicine and Isoniazid, 2HRZE/4RH) on a daily schedule; and 
should be started on ART regardless of CD4 count as soon as possible within the first 
eight weeks of anti-tuberculosis treatment. 
 
7.5.2.2 Initiate TB prevention with Isoniazid preventive therapy and early 
antiretroviral therapy 
Adults and adolescents living with HIV should be screened with a clinical algorithm; 
those who do not report any one of the symptoms of current cough, fever, weight loss or 
night sweats are unlikely to have active TB and should be offered IPT. 
Adults and adolescents who are living with HIV have unknown or positive tuberculin skin 
test (TST) status and are unlikely to have active TB should receive at least six months 
of IPT as part of a comprehensive package of HIV care. IPT should be given to such 
individuals irrespective of the degree of immune-suppression, and also to those on 
ART, those who have previously been treated for TB, and pregnant women. 
TST is not a requirement for initiating IPT in people living with HIV. People living with 
HIV who have a positive TST benefit more from IPT; TST can be used where feasible to 
identify such individuals. In addition, providing IPT to people living with HIV does not 
increase the risk of developing Isoniazid-resistant TB. Therefore, concerns regarding 
the development of INH resistance should not be a barrier to providing IPT. 
Children living with HIV who do not have poor weight gain, fever or current cough are 
unlikely to have active TB. 
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Children living with HIV who are more than 12 months of age and who are unlikely to 
have active TB on symptom-based screening and have no contact with a TB case 
should receive six months of IPT (10mg/kg/day) as part of a comprehensive package of 
HIV prevention and care services. 
In children living with HIV who are less than 12 months of age, only those who have 
contact with a TB case and who are evaluated for TB (using investigations) should 
receive six months IPT if the evaluation shows no TB disease. 
All children living with HIV after successful completion of treatment for TB disease 
should receive Isoniazid for an additional six months. 
All people living with HIV with CD4 counts of ≤350 cells/mm3 irrespective of the WHO 
clinical stage should start ART. 
 
7.5.2.3 Infection control for TB in healthcare and congregate settings ensured 
 
HIV programmes and TB control programmes should provide managerial direction at 
national and sub-national levels for the implementation of TB infection control in 
healthcare facilities and congregate settings. 
Each healthcare and congregate setting should have a TB infection control plan of the 
facility, preferably included in a general infection control plan, supported by all 
stakeholders, which includes administrative, environmental and personal protection 
measures to reduce transmission of TB in healthcare and congregate settings, and 
surveillance of TB disease among workers. 
Healthcare workers, community health workers and care providers living with HIV 
should be provided with ART and IPT if eligible. Furthermore, they should be offered an 
opportunity for transfer to work in clinical sites that have the least risk of TB 
transmission. 
At facility level, measures to reduce TB transmission include administrative, 
environmental and personal protection controls, which are aimed at generally reducing 
exposure to M. tuberculosis of healthcare workers, prison staff, police and any other 
persons living or working in the congregate settings.  
Administrative controls consist of triage to identify people with TB symptoms, separation 
of infectious cases, control of the spread of pathogens (cough etiquette and respiratory 
270 
hygiene), rapid diagnosis and prompt initiation of TB treatment, and reduced 
hospitalisation.  
Environmental controls include maximising ventilation systems (natural or mechanical) 
and using upper room ultraviolet germicidal irradiation (if applicable).  
Personal protective interventions include use of respirators and prevention, treatment 
and care packages for healthcare workers including HIV prevention interventions, and 
ART and IPT for workers who are living with HIV.  
Healthcare workers should have access to acceptable, confidential and quality assured 
HIV testing. Healthcare workers living with HIV should be provided with ART, but even 
with adequate response to treatment they will remain at higher risk of TB. Transfer of 
their clinical responsibilities into sites that have the least risk of TB transmission and 
regular TB screening should be considered to mitigate this risk. Similarly, healthcare 
workers with active TB should be relocated from HIV care facilities.  
Patients and their communities should be trained on TB transmission, infection control 
and cough etiquette to reduce the risk of TB transmission in healthcare facilities and 
congregate settings. 
 
7.5.3 THEME 3: Decrease the burden of HIV in patients with presumptive and 
diagnosed TB (TB Programme activities) 
  
In this theme, the TB care providers need to integrate activities to decrease the burden 
of HIV among TB during TB patients’ follow-up cares. The five primary activities outlined 
in the pocket guide are described in the following sections. 
 
7.5.3.1 Provide HIV testing and counselling to patients with presumptive and 
diagnosed tuberculosis 
 
Routine HIV testing should be offered to all patients with presumptive and diagnosed for 
TB. Partners of known HIV-positive TB patients should be offered voluntary HIV testing 
and counselling with mutual disclosure. 
TB control programmes should mainstream provision of HIV testing and counselling in 
their operations and routine services. 
The vast majority of people living with HIV do not know their HIV status and seek 
healthcare from general service providers. HIV testing and counselling for people with 
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diagnosed or presumptive TB offers an entry point for a continuum of prevention, care, 
support and treatment for HIV and for TB. Evidence from observational studies shows 
that testing patients with presumptive and diagnosed TB and their contacts for HIV 
yields a high number of new diagnoses of HIV infection, as prevalence of HIV is higher 
than among the general adult population.  
 
The yield of HIV-positive testing in TB patients varies significantly (from 6.3% to 77%). 
Studies in sub-Saharan Africa have shown that HIV testing of presumptive TB cases 
who turn out not to have active TB disease also yields high HIV-positive results. One 
study in Thailand showed 74% acceptance rate of HIV testing among contacts of TB 
patients and a higher (13.8%) HIV prevalence rate among contacts of HIV-positive TB 
cases as compared with contacts of HIV negative TB cases (2.5%).  
Voluntary HIV testing and counselling for sexual or needle-sharing partners, with shared 
disclosure and mutual support, may also improve the uptake of and adherence to ART, 
benefiting both the index individual and their partners regardless of HIV status. 
 
Routine HIV testing and counselling to all patients with presumptive and diagnosed TB 
as benefits of testing accrue to the patient, their partner, the family and the community 
at large. The testing should be readily available and voluntary, informed consent should 
be obtained and confidentiality should be protected.  
Moreover, TB patients with a new potential HIV exposure or who are at higher risk of 
HIV exposure and with an HIV-negative test result should be re-tested after four weeks 
from the time of initial testing.  
Age-appropriate algorithms should be in place for undertaking HIV testing in young 
children, and HIV testing should be family and child focused. All people diagnosed with 
HIV infection should be offered HIV prevention, diagnosis, treatment and care services, 
including ART. These services should be offered by TB control programmes or through 
effective referral to HIV services. 
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7.5.3.2 Introduce HIV preventive methods for patients with presumptive and 
diagnosed tuberculosis 
TB control programmes should implement comprehensive HIV prevention strategies for 
their patients and their partners, targeting sexual, parenteral or vertical transmission or 
should establish a referral linkage with HIV programmes to do so. 
HIV programmes and TB control programmes should implement procedures for 
voluntary, acceptable and confidential HIV counselling and testing for healthcare 
providers and for reduction of occupational and nosocomial exposure to HIV infection in 
their services. 
All personnel working with presumptive and confirmed TB cases, people living with HIV 
and people who use drugs should be able to assess risk factors for HIV infection and 
transmission and should provide comprehensive information and services to their clients 
to minimise their risks. 
HIV programmes and TB control programmes should collaborate with harm reduction 
services to ensure universal access to comprehensive TB and HIV prevention, 
diagnosis, treatment and care as well as drug treatment services, including opioid 
substitution therapy, for people who use drugs in a holistic person-centred approach to 
maximise access and adherence within one setting as much as possible. 
 
TB control programmes should ensure that vertical transmission of HIV is prevented by 
referring all HIV-positive pregnant women attending TB services to providers of services 
for prevention of vertical transmission of HIV for antiretroviral therapy or prophylaxis as 
needed. 
 
Prevention of HIV includes interventions to: 
• prevent sexual transmission such as male and female condoms, male 
circumcision, HIV testing and counselling including couples counselling and 
testing, early ART as per WHO guidelines; 
• prevent transmission through sharing contaminated injecting equipment among 
injecting drug users; combined with  
• behavioural interventions and brief interventions to prevent hazardous alcohol 
use and use of other psycho-stimulants. 
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HIV prevention services also include prevention of vertical transmission of HIV, which 
comprises two key approaches:  
• HIV-infected women, including during pregnancy, with CD4 counts ≤350 
cells/mm3 irrespective of WHO clinical staging or in clinical stage 3 or 4 
irrespective of the CD4 cell count, should start lifelong ART for their own health, 
which is also safe and effective in reducing vertical transmission.  
• For HIV-infected pregnant women who do not need ART for their own health, 
prophylaxis with triple ARV medicines or with zidovudine plus lamivudine to 
prevent HIV transmission is needed and should be continued until one week after 
all infant exposure to breast milk has ended. 
In Ethiopia, with its  high HIV prevalence and low male circumcision rates in some parts 
of the country, medical male circumcision in HIV negative men is also recommended, 
combined with HIV testing and counselling and promotion of consistent condom use. 
 
In healthcare settings, transmission of HIV can be prevented through primary prevention 
measures such as standard precautions, injection safety, blood safety and safe waste 
disposal, as well as secondary prevention measures such as occupational post-
exposure prophylaxis. In addition, improved treatment of sexually transmitted infections 
has been shown to reduce HIV incidence in an environment characterised by an 
emerging HIV epidemic.  
 
 
7.5.3.3 Provide Cotrimoxazole preventive therapy for tuberculosis patients 
living with HIV 
Routine Cotrimoxazole preventive therapy should be administered in all HIV-infected 
patients with active TB disease regardless of CD4 counts. 
 
Cotrimoxazole preventive therapy is a broad spectrum antimicrobial agent that prevents 
a range of secondary bacterial and parasitic infections in eligible adults and children 
living with HIV. TB patients living with HIV should receive CPT and it should be 
implemented as an integral component of the HIV chronic care package. CPT is a 
simple, well tolerated and cost effective intervention for people living with HIV and can 
be administered concomitantly to ART. 
 
Therefore, routine CPT should be administered in all HIV-infected patients with active 
TB disease regardless of their CD4 cell count. Moreover, HIV programmes and TB 
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control programmes should establish a system to provide CPT to all eligible people 
living with HIV who have active TB. 
 
7.5.3.4 Ensure HIV prevention, treatment and care for all tuberculosis patients 
living with HIV 
All people living with HIV who are diagnosed with TB should receive integrated services 
for prevention, diagnosis, treatment and care of TB and HIV.  
HIV programmes and TB control programmes should ensure access to a continuum of 
comprehensive and integrated prevention, care and treatment for people living with HIV 
who are receiving or who have completed their anti-tuberculosis treatment. 
 
A comprehensive package of prevention, diagnosis, treatment and care interventions 
(continuum of care) should be provided to all people living with HIV, ideally starting well 
before the need for ART. Pre-ART care includes regular assessment of the clinical and 
immunological stages of infection, prevention of illness, care for opportunistic infections, 
preparation for adherence to ART, nutritional support, provision of safe water, sanitation 
and hygiene, psychosocial support, and prevention and management of mental health 
disorders, including alcohol and other substance use.  
 
It is also essential to provide HIV prevention methods for people already living with HIV 
to prevent inadvertent HIV transmission (“positive prevention” or “prevention for 
positives”). A continuum of care should also be provided to people living with HIV who 
are receiving or who have completed their anti-tuberculosis treatment through 
integrated services or strengthened referral systems. 
 
Particular attention should be paid to seriously ill patients (e.g., patients with multidrug-
resistant and extensively drug-resistant TB). Palliative care, both chronic and terminal 
as needed, should be offered to ensure that patients and their families live out their lives 
with minimal suffering and loss of dignity, even when all available curative treatments 
have been exhausted. 
 
 
7.5.3.5 Provide Antiretroviral therapy to TB patients living with HIV 
 
ART should be started in all TB patients living with HIV, irrespective of their CD4 counts. 
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Anti-tuberculosis treatment should be initiated first, followed by ART as soon as 
possible within the first eight weeks of treatment. Those HIV-positive TB patients with 
profound immune-suppression (e.g. CD4 counts less than 50 cells/mm3) should receive 
ART immediately within the first two weeks of initiating TB treatment. 
Efavirenz should be used as the preferred non-nucleoside reverse transcriptase 
inhibitor in patients starting ART while on anti-tuberculosis treatment. 
 
Antiretroviral therapy greatly improves the survival and the quality of life of TB patients 
living with HIV, prevents HIV transmission and should be considered part of HIV and TB 
treatment and prevention.  
 
The availability of ART can also encourage people to be tested for HIV. HIV 
programmes and TB control programmes should ensure that TB patients diagnosed 
with HIV infection are offered ART as early as possible, preferably within integrated 
services or within TB health facilities.  
 
Effective referral to HIV services remains an alternative but relies on sound referral 
systems and patients’ ability to afford other costs such as transport and lost wages.  
HIV programmes and TB control programmes should work together to guarantee ART 
to all TB patients living with HIV in a decentralised manner. 
 
Patients should be closely followed-up to assess the occurrence of side-effects related 
to co-treatment and of TB associated immune reconstitution inflammatory syndrome 
(IRIS), which is common in patients with TB started on ART but usually self-limited.  
 
HIV stakeholders and service providers should establish a mechanism to ensure that 
people living with HIV receive anti-tuberculosis treatment with ART, emphasising 
integrated and patient-centred care. Early use of ART is also recommended for TB 
patients living with HIV who also receive medication with second-line anti-tuberculosis 
regimens for drug-resistant TB.  
Evidences showed that, rifampicine reduce drug levels of both non-nucleoside reverse 
transcriptase inhibitors and protease inhibitors through induction of the cytochrome 
P450 liver enzyme system. In addition, comparing efavirenz and nevirapine based ART 
in HIV-infected TB patients receiving rifampicine showed that both standard doses of 
efavirenz and nevirapine are effective in achieving viral load suppression. However, 
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reports of efficacy, safety and tolerability of efavirenz and nevirapine administered with 
rifampicine varied across observational studies.  
When rifampicine is given with protease inhibitors, highly variable and mainly sub-
therapeutic plasma concentrations of the protease inhibitor are observed, even in the 
presence of boosted doses of ritonavir. Rifabutin, listed in the WHO Model List of 
Essential Medicines, is a less potent inducer of the cytochrome P450 system which can 
be used in patients on ART regimens that include a protease inhibitor. 
 
 
7.6 ANALYSIS AND VALIDATION OF THE POCKET GUIDE 
 
According to Macmillan Dictionary, a guide is ‘a book about a particular subject or type 
of activity’ (Macmillan Dictionary, 2012).  
Analysis is the purposeful breakdown of statements into components, according to 
Rogers (2002,(in Moleki 2008:175). This is done to identify relationships between 
statements and relative hierarchy of ideas contained in a guideline.  
 
Similarly, evaluation, as described by Moleki (2008:175), is judgment about the value 
and logical structure of a guideline. It also determines the extent to which the guidelines 
satisfy certain external criteria and/or standards. In addition, evaluation of a guideline 
allows the user or evaluator to draw judgment and conclusions about its validity (Moleki, 
2008:175).  
 
The above pocket guide for collaborative TB/HIV care service was validated by experts 
in the field of collaborative TB/HIV care service provision working for both governmental 
and nongovernmental organisations. The pocket guide was evaluated for clarity, 
simplicity, generality, rational structure and operational adequacy. Moleki (2008:175) 
has used the following criteria for evaluation of her guidelines for facilitation of clinical 
accompaniment of critical care nursing students in open and distance learning 
programme. 
 
7.6.1 Clarity and relational structure 
 
The guideline was validated for trustworthiness, semantic clarity and structural clarity. 
Five persons (including a PLHIV) working in the field of TB and HIV were selected to 
serve as reviewers for the pocket guide. The team of reviewers was composed of 
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technical expert, expert end users, a coordinator of collaborative TB/HIV care and a 
programme management expert working in the field of TB/HIV control programmes. 
Prospective reviewers were discretely contacted over face-to-face, in the workplace and 
requested to serve as reviewer for the pocketbook for collaborative TB/HIV care for 
health workers in Ethiopia. On the whole, all five persons agreed to participate in the 
review and validation process. Electronic copies of the pocket guide and a brief 
description of processes followed by the researcher to develop the pocket guide were e-
mailed to each of the reviewers. Reviewers were requested to review and validate the 
pocket guide for trustworthiness, semantic clarity and structural clarity. Reviewers were 
given options to provide written feedback or arrange to discuss their comments with the 
researcher. Each reviewer was given one month to respond the feedback. Reviewers 
were reminded prior to and on expiration of the one month timeline to revert with their 
comments. While four reviewers provided written feedback, one opted to discuss his 
comments with the researcher. The e-mailed comments were compiled and used to 
update the pocket guide. As described by Moleki (2008:177), the semantic clarity 
questioned the theoretical meaning of concepts, while structural clarity reflected on the 
interrelationship and connections between the conceptual framework and the theoretical 
framework used to develop the pocket guide.  
 
7.6.2 Simplicity and operational adequacy 
 
The pocket guide was evaluated to establish its suitability and applicability in the 
provision of collaborative TB/HIV care services in public health facilities in Ethiopia. For 
primary healthcare worker to be simple and operationally adequate, it has to first appear 
pocket sized and user friendly summary of all the specific activities for collaborative 
TB/HIV care services in a simple and clear language. 
 
7.6.3 Generality of the pocket guide/guideline 
 
Moleki (2008:177) identifies generality as the breadth of the scope and purpose of the 
guidelines. The pocket guide was developed to facilitate staff providing TB/HIV care to 
use proven, culturally and linguistically appropriate strategies and tools to enable end 
users understand all prevention, treatment and care options and to make decisions 
consistent with their values and preferences.  
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7.7 RECOMMENDATIONS FOR IMPLEMENTATION OF THE POCKET GUIDE 
 
The following themes of recommendations are outlined for the implementation of the 
pocket guide as an immediate output of this thesis work. 
 
 
7.7.1 Qualifying statements 
 
When formulating a pocket guide for a disease as complex as HIV and TB, it is 
impossible to anticipate every scenario. It is expected that, in specific situations, there 
will be valid exceptions to the approaches offered in this pocket guide and sound reason 
to deviate from the recommendations provided within. 
 
 
7.7.2 Implementation strategy 
 
The HIV programme and TB control programme teams of the Federal Ministry of Health 
(FMoH), Ethiopia, oversees the development, publication, dissemination and 
implementation of any clinical practice guidelines for TB/HIV care, in collaboration with 
other stakeholders, including PLHIV, development partners and implementation 
partners in Ethiopia. Therefore, the researcher will sensitise a development partner to 
take the lead in advocating for the adaptation of this pocket guide for promotion of 
collaborative TB/HIV care services in public health facilities in Ethiopia. This pocket 
guide addresses uniform and systematic management of TB/HIV patients at all levels of 
the healthcare delivery system. 
 
 
7.7.3 Pocket guide dissemination 
 
The pocket guide is disseminated to healthcare providers and end-users through 
presentation at conferences, seminars, workshops, and pre-service trainings. 
Distribution methods include institutional websites (if any), printed and distributed hard 
copies for those who have no access to the Internet.  
 
7.7.4 Pocket guide implementation 
 
The researcher will work with a development partner in Ethiopia to promote the adoption 
of the pocket guide by HIV chronic care division of the FMoH. It is envisaged that the 
FMoH will mobilise a stakeholders meeting to review, analyse and critique the pocket 
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guide, with a view to adapting for implementation in public health facilities in Ethiopia. 
Once adapted, the government of Ethiopia, development partners and implementing 
partners will integrate the pocket guide into their collaborative TB/HIV care training 
curriculum for all cadres of healthcare workers.  
The pocket guide will also be presented in continuing medical education sessions 
usually held in every health facility providing TB/HIV collaboration activities and through 
video and audio conferencing. Given the current drive by donors to address integrated 
TB/HIV care, indicators will be developed based on the impact of the pocket guide, on 
performances of TB/HIV care health workers to what extent the pocket guide has been 
implemented. 
Finally, this pocket guide will bring practical solutions to common problems related to 
access to technical guide, quality service delivery, or guidance for coordination of 
TB/HIV care services, in an effort to promote collaborative TB/HIV care services in the 
country. 
 
7.7.4.1 Collaborative TB/HIV pocket guide implementation tools 
 
Effective implementation of this pocket guide cannot be done in isolation. The following 
basic tools are necessary to support the implementation of this pocket guide: 
• National implementation guideline for TB/HIV collaboration activities 
• National ART guidelines 
• National TB and Leprosy treatment guidelines  
• National prevention of mother to child transmission of HIV (PMTCT) 
guidelines 
• National HIV testing and counselling guidelines 
• National Chronic HIV care manual 
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7.8 CONCLUSION 
 
This chapter has described the pocket guide for TB/HIV collaboration activities for 
health workers in Ethiopia. The pocket guide was developed to facilitate TB/HIV care 
providers in delivering improved collaborative TB/HIV care services and to make 
decisions consistent with their professional knowledge, ethics, and packages of 
comprehensive HIV care.  
The Federal Ministry of Health of Ethiopia, in collaboration with stakeholders, is 
encouraged to make use of the pocket guide as additional resource material to 
strengthen the implementation of collaborative TB/HIV care in the country. 
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SOUTH AFRICA HEALTH STUDIES RESEARCH AND ETHICS COMMITTEE 
 ANNEXURE B: LETTER OF ETHICAL CLEARANCE FROM THE ADDIS ABAB CITY 
ADMINISTRTION HEALTH BUREAU 
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ANNEXURE C: LETTER OF PERMISSION FROM ADDIS ABABA HEALTH BUREAU 
 
 ANNEXURE D: COVERING LETTER ACCOMPANYING INTERVIEWER 
ADMINISTERED QUESTIONNAIRE 
 
Dear Sir/Madam,  
 
SUBJECT: PROMOTING THE IMPLEMENTATION OF COLLABORATIVE TB/HIV 
ACTIVITIES IN ADDIS ABABA, ETHIOPIA  
 
Hello, my name is Amenu Wesen and I have been working with people living with 
HIV/AIDS. Currently, I am studying for Doctor of Literature and Philosophy on Health 
studies at University of South Africa, and this research is part of the study. I am 
interviewing clients attending TB clinics and HIV chronic care clinic at this health facility 
in order to find out how the services are being delivered to you concerning activities to 
decrease the burden of tuberculosis and HIV among patients of TB and HIV. The 
findings of our discussion might get published and contribute to the improvements of the 
services provided to you.  
 
I would like to have discussion with you about the service provision concerning activities 
to decrease the burden of TB/HIV among TB and HIV patients while attending at the TB 
or HIV chronic care clinics. Our discussion will not come to detail for private matters and 
the information that you provide will be used solely for the purpose of this study. 
 
Your name will not be asked and unique identification is not required. You do not have 
to discuss issues that you do not want to. If you want to withdraw from the study any 
time along the discussion process, you will not be obliged to continue or give reasons 
for doing so. 
 
Refusing to participate or withdrawing from the study along the process will not have 
any consequences on you and the services provided to you. However, the information 
that you provide during the discussion will help greatly to understand the status of 
service provision to HIV and TB patients that might help in improving the service 
provision. 
 
I would like to appreciate your help in responding to this interview. If you have any 
questions or anything that is not clear please feel free to ask. 
 
If you are clear with the information provided and agree to participate please sign on the 
consent form attached. 
 
Kind regards  
 
Amenu Wesen Denegetu (BSC, MPH), DLitt et Phil (Candidate)  
Tel: +251911647699 or e-mail: 45085609@mylife.unisa.ac.za or denegetu@gmail.com. 
 
 
2 
ANNEXURE E: THE CONSENT FORM 
 
STUDY TITLE: PROMOTING THE IMPLEMENTATION OF COLLABORATIVE TB/HIV 
CARE SERVICES IN ADDIS ABABA, ETHIOPIA. 
 
RESEARCHER: AMENU WESEN DENEGETU  
 
Amenu Wesen Denegetu, a public health professional currently pursuing a Doctoral 
degree from the University of South Africa conducting a study as titled above in the 
fulfilment of the requirements for the degree of Doctor of Literature and Philosophy 
degree in Health Studies (DLitt et Phil). This study will be conducted in all ten sub-cities 
of Addis Ababa City Administration at selected Public Health facilities.  
 
The purpose of this study is to identify gaps in the implementation of collaborative 
TB/HIV care services in Addis Ababa City Administration. The researcher intends to use 
the findings from this research to promote better implementation modalities for 
collaborative TB/HIV care services. 
 
The Addis Ababa City Administration Health Bureau ethical review committee has 
approved that the study can be conducted in the City Administration. Heads of the study 
health facilities have been notified to this effect. 
 
I the undersigned individual being oriented about the relevance of this study in 
improving the service provision of health facilities on collaborative TB/HIV care services 
was well informed. I have been also informed that, there will be no risk or harm to my 
participation in this study. My participation in this study is crucial and all my information is 
to be kept confidential and will be used solely for this study. In addition, I have been well 
informed that my name will not be asked and unique identification is not required. I have 
the right not to discuss issues that I do not want to. If I want to withdraw from the study 
any time along the discussion process, I will not be obliged to continue or give reasons 
for doing so. 
 
However, my agreement to participate in this study is with the assumption that, the 
information that I provide during the discussion will help greatly to understand the status 
of service provision to people living with HIV/AIDS that might help in improving the 
service provision. 
 
In case you need any clarification, you can ask the research assistants discussing with 
you. Or you can contact the researcher with the following address. Amenu Wesen: Tel: 
+251911647699; e-mail: 45085609@mylife.unisa.ac.za. 
 
I have read this form and voluntarily consent to participate in this study.  
Participant’s Signature:   Date:    
I have explained this to the above participant and have sought his/her understanding for 
informed consent.  
Researcher/ research assistant’s Signature:  Date:    
 ANNEXURE F: INTERVIEWER-ADMINISTERED QUESTIONNAIRE FOR TB 
PATIENTS 
 
Questionnaire for Tuberculosis Patient Participants 
Name of Health Facility          
Name of interviewer           
Part I: Socio-Demographic Characteristics                    Quest. No: 
Q.No Questions Responses Code 
101 Age (full years) 
 
_________ 
 
102 Sex 
1. Male             
2. Female       
 
103 Marital status 
1. Single  
2. Married  
3. Divorced  
4. Widowed  
5. Separated  
 
104 Religion 
1. Christian  
2. Muslim        
99. Other 
 
105 Ethnicity 
1. Amhara  
2. Oromo  
3. Gurage  
4. Tigre  
88.Did not mention 
99. Other _______________    
 
106 Educational status 
1. No formal education  
2. Primary (grades 1 - 6)  
3. Secondary (grade 7 - 12) 
4. Post secondary (12+)  
 
107 Occupation 
1. Housewife    
2. Government employee 
3. Nongovernmental 
employee 
4. Private employee   
5. Self employed/Merchant  
6. Unemployed  
99. Other)_______________ 
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Part II: Prevalence of HIV among TB Patients in the Health Facilities 
 
Q.No Questions Responses Code 
201 
How long have you been 
diagnosed for TB? 
1. Less than 2 months 
2. 2-5 months       
3. 6-8 months      
4. More than 8 months 
 
202 
How long have you been 
on TB treatment? 
1. Less than 2 months       
2. 2 -5 months  
3. 6-8 months       
4. More than 8 months     
 
203 
Have you ever been 
tested for HIV before you 
know your TB disease?  
1. Yes     
2. No 
3. I don’t remember/know 
 
204 
If yes to Q203, when have 
you been tested? 
1. Before 6 months  
2. Before 6-11 months   
3. Before 1-2 years  
4. Before >2 years 
 
205 
If yes to Q204, how was 
your result? 
1. Negative 
2. Positive 
3. Do not want to disclose 
 
206 
If positive to Q205, have 
you started of HIV care 
and treatment? 
1. Yes 
2. No 
 
207 
If No for Q203 or negative 
to Q205, have you been 
offered for HIV test now 
during your TB treatment? 
1. Yes 
2. No 
 
208 
If yes to Q207, have you 
been tested? 
1. Yes 
2. No 
 
209 
If yes to Q208, who 
offered the test? 
1. TB clinic health worker 
2. At HIV care/VCT clinic 
3. At ANC clinic 
4. At outpatient department 
5. Inpatient department 
99. Other ________________ 
 
210 
If yes to Q207, when have 
you been tested? 
1. During the same time of TB 
diagnosis 
2. Within 2 months of TB 
treatment 
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3. Within 3-5 months during 
TB treatment  
4. After 5 months during TB 
treatment 
5. I don’t remember 
211 
If yes to Q208, how was 
your result? 
1. Negative 
2. Positive 
3. Did not want to disclose 
 
212 
If positive to Q210, have 
you started of HIV care 
and treatment? 
1. Yes 
2. No 
 
213 
If yes to Q211 or Q206, 
have you already started 
HAART? 
1. Yes 
2. No 
 
 
Part III: Activities to decrease the burden of HIV among TB patients 
 
Q.No Questions Responses Code 
301 
Is HIV testing offered or 
encouraged at TB clinic?  
1. Yes       
2. No        
3. I don’t know             
 
302 
Do you know about 
Cotrimoxazole preventive 
therapy?  
1. Yes           
2. No              
 
303 
Do people living with 
HIV/AIDS who have also TB 
have access to CPT as part 
of the package of care in this 
health facility? 
1. Yes    
2. No 
3. I don’t know  
   
 
304 
If the response to Q 303 is 
no, why not? 
1. I don’t know   
2. No drug/expensive 
  
3. Care takers don’t order  
99.Other;specify:_______
___ 
 
305 
Have you ever been provided 
with CPT? 
1. Yes 
2. No 
 
306 
If you were taking or currently 
under CPT, from where 
did/do you collect the drug?  
 
1. HIV clinic    
2. TB clinic     
3. General pharmacy 
  
4. I did/do not take  
99. Other; 
specify:_______________ 
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Part IV: Qualitative Short answered interview for TB patients 
Q.No Questions Responses Code 
401 
How does the service 
provision of health facilities 
for both TB and HIV patients 
affect on your health?   
 
 
402 
How do you think health 
workers at TB clinic in this 
health facility assisted you in 
improving your health 
regarding your HIV risks and 
status? 
 
 
403 
Do you think provision of both 
HIV and TB care services at 
the same health facility be 
feasible or practical? How is 
that? 
 
 
404 
What do you feel of the 
service provision quality in 
general regarding TB and HIV 
in this health facility? 
 
 
405 
How do you evaluate the 
behaviour of health care 
providers towards their 
patients? 
 
 
406 
How do you evaluate the 
performance of health care 
providers in your opinion 
towards their patients?  
 
 
407 
What comments do you have 
to improve the service 
provision of HIV and TB care 
in this health facility? 
 
 
 
Thank you!!!
 ANNEXURE G: INTERVIEWER-ADMINISTERED QUESTIONNAIRE FOR HIV 
PATIENTS 
Questionnaire for HIV Patient Participants 
Name of Health Facility          
Name of interviewer           
 
Part I: Socio-Demographic Characteristics                    Quest. No: 
 
Q.No Questions Responses Code 
101 Age (full years) 
 
_________ 
 
102 Sex 
1. Male             
2. Female       
 
103 Marital status 
1. Single  
2. Married  
3. Divorced  
4. Widowed  
5. Separated  
 
104 Religion 
1. Christian  
2. Muslim        
99. Other 
 
105 Ethnicity 
1. Amhara  
2. Oromo  
3. Gurage  
4. Tigre  
88.Didn’t mention 
99. Other _______________   
 
106 Educational status 
1. No formal education  
2. Primary (grades 1 - 6)  
3. Secondary (grade 7 - 12) 
4. Post secondary (12+)  
 
107 Occupation 
1. Housewife    
2. Government employee 
3. Nongovernmental 
employee 
4. Private employee   
5. Self employed/Merchant  
6. Unemployed  
99. Other)_______________ 
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Part II: Prevalence of Tuberculosis among People Living With HIV in the 
health facilities 
Q.No Questions Responses Code 
201 
How long have you been 
diagnosed for HIV 
positive? 
1. Less than 6 months       
2. 6 -11 months      
3. One year – Three years 
4. More than 3 years       
 
202 
How long have you been 
on HAART? 
1. Less than 6 months       
2. 6 months – one year      
3. More than one year       
4. Not yet started       
 
203 
Have you ever been 
diagnosed for TB before 
you know your HIV 
positive status?  
1. Yes     
2. No 
3. I don’t remember/know 
 
204 
If yes to Q203, when have 
you been diagnosed? 
1. Before less than 6 months of 
knowing HIV positive status  
2. Before 6 months -1 year 
duration of knowing HIV 
positive status 
3. Before 1.1-2 year of knowing 
HIV positive status   
4. Before 2.1-3 years of knowing 
HIV positive status  
5. Before >3 years 
 
205 
If yes to Q204, which site 
of TB was that? 
1. Pulmonary 
2. Extra-pulmonary 
 
206 
If yes to Q204, have you 
completed your treatment 
for TB? 
1. Yes 
2. No 
3. Still on treatment 
 
207 
Have you been diagnosed 
for TB after you know your 
HIV positive status? 
1. Yes 
2. No 
 
208 
If yes to Q207, which site 
of TB was that? 
1. Pulmonary 
2. Extra-pulmonary 
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209 
If yes to Q207, when have 
you been diagnosed? 
1. During the same time up to 1 
month of HIV test 
2. After 2-6 months of HIV test 
3. After 7-11months  of HIV test  
4. After 1-2 years of HIV test 
5. After 2.1-3 years of HIV test 
6. After >3 years of HIV test 
 
210 
If you have been 
diagnosed for TB, did/do 
you take your treatment? 
1. Yes 
2. No 
 
211 
If the response is NO for 
Q210, why not? 
1. I don’t want to take 
2. They didn’t give me 
3. I don’t know 
4. Other ________________ 
 
212 
Have you already started 
ART during your diagnosis 
for TB? 
1. Yes 
2. No 
 
 
Part III: Activities to decrease the burden of TB in PLHIV 
Q.No Questions Responses Code 
301 
Is HIV testing offered or encouraged at TB 
clinic?  
1. Yes      
2. No       
3. I don’t know            
 
302 
Do you know about Cotrimoxazole 
preventive therapy?  
1. Yes          
2. No      
        
 
303 
Do people living with HIV/AIDS who have 
also TB have access to CPT as part of the 
package of care in this health facility? 
1. Yes   
2. No 
3. I don’t know
    
 
304 If the response to Q 303 is no, why not? 
1. I don’t kno  
2. No 
drug/expensive  
3. Care takers 
don’t order  
99.Other; 
specify:_________ 
 
305 Have you ever been provided with CPT? 
1. Yes 
2. No 
 
 
306 
If you were taking or currently under CPT, 
from where did/do you collect the drug?  
 
1. HIV clinic   
2. TB clinic   
3. General 
pharmacy  
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4. I did/do not 
take  
99. Other; 
specify:__ 
 
Part IV: Qualitative interview for HIV positive patients 
Q.No Questions Responses Code 
401 
How does the service provision of health 
facilities for both TB and HIV patients affect 
on your health?   
 
 
402 
How do you think health workers at HIV 
clinic in this health facility assisted you in 
improving your health regarding your TB 
risks and status? 
 
 
403 
Do you think provision of both HIV and TB 
care services at the same health facility be 
feasible or practical? How is that? 
 
 
404 
What do you feel of the service provision 
quality in general regarding TB and HIV in 
this health facility? 
 
 
405 
How do you evaluate the behaviour of 
health care providers towards their 
patients? 
 
 
406 
How do you evaluate the performance of 
health care providers in your opinion 
towards their patients?  
 
 
407 
What comments do you have to improve 
the service provision of HIV and TB care in 
this health facility? 
 
 
408 
How many episodes of diarrhoea have you 
encountered for the last one year? 
 
 
409 
How many episodes of URTIs have you 
encountered for the last one year? 
 
 
410 
How any episodes of LRTIs have you 
encountered for the last one year? 
 
 
 
Thank you!!!
 ANNEXURE H: INTERVIEW QUESTIONNAIRE FOR TB/HIV CARE FACILITY 
COORDINATORS AND/OR TB/HIV CARE PROVIDERS 
 
Name of Health Facility          
Name of interviewer           
Part I: Socio-Demographic Characteristics                    Quest. No: 
Q.No Questions Responses Code 
101 Age (full years) 
 
_________ 
 
102 Profession 
1. MD/HO 
2. Nurse BSc 
3. Nurse 
4. Other; 
______________ 
 
103 Sex 1. Male             
2. Female 
 
104 
Number of years of service in 
TB/HIV clinics 
 
____________ 
 
 
Part II:  Programme implementation of collaborative TB and HIV services 
Q.No Questions Responses Code 
201 
Is there a functional coordinating 
body for TB/HIV activities 
effective at each of the following 
levels? 
1. National level?   Yes      
No 
2. Regional level?  Yes      
No 
3. Sub-city level?   Yes      
No 
4. Health Facility level?  
Yes     No 
 
202 
If yes to Q201, at any one level 
for, which of the following 
representatives in attendance? 
1. Representative from TB 
control programme 
2. Representative from 
HIV programme 
3. Representative from 
partner organizations 
4. Other;______________
__    
 
203 Have surveillance of HIV 
prevalence among TB patients 
1. National level:   Yes      
No 
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been conduct ever? 2. Regional level:  Yes      
No 
204 
Does joint TB/HIV planning been 
carried out ever? 
1. National level:   Yes      
No 
2. Regional level:  Yes     
No 
3. Sub-city level:   Yes       
No 
4. Health facility level:  
Yes     No  
 
205 
Does joint monitoring and 
evaluation for TB/HIV activities 
been conducted ever? 
1. National level:   Yes        
No 
2. Regional level:  Yes       
No 
3. Sub-city level:   Yes        
No 
4. Health facility level:  
Yes       No 
 
206 
Does routine screening for cough 
of more than 2 weeks being done 
for each HIV positive patients at 
each of their follow-up visits? 
1. Yes 
2. No 
3. I don’t know  
 
207 
Does routine diagnosis of 
tuberculosis being done based 
on cardinal signs for each of HIV 
positive patients at their follow-up 
visits?  
1. Yes 
2. No 
 
208 
Does prompt treatment being 
given for all confirmed 
tuberculosis cases among HIV 
positive patients within the health 
facility?  
1. Yes 
2. No 
 
209 
Do health facilities provide IPT 
for all HIV positive patients 
having latent TB?  
1. Yes 
2. No 
 
210 
Are there a mechanism for 
ventilation of rooms and enough 
waiting area for HIV positive 
patients to prevent transmission 
of TB in health facilities? 
(Observe) 
1. Yes 
2. No 
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211 
Do health care providers use 
personal protective masks to 
prevent transmission of TB for 
themselves and to patients?  
1. Yes 
2. No 
 
212 
Is there regular health education 
given to all HIV positive and/or 
TB patients about TB 
transmission?  
1. Yes 
2. No 
 
213 
Do all TB patients being offered 
HIV counselling and testing 
services?  
1. Yes 
2. No 
 
214 
Do health workers at TB clinic in 
the health facilities promote safer 
and more responsible sexual 
behaviour to reduce transmission 
of HIV?  
1. Yes 
2. No 
 
215 
Do health workers at the health 
facilities practice measures to 
ensure the safety of the blood 
supply and medical equipments 
to reduce transmission of HIV?  
1. Yes 
2. No 
 
216 
Do health facilities provide ART 
treatment or prophylaxis for 
pregnant women living with HIV 
for TB suspects and patients? 
1. Yes 
2. No 
 
217 
Do health facilities established a 
system to provide CPT to eligible 
people living with HIV for those 
who have active TB?  
1. Yes 
2. No 
 
218 
Do TB and HIV programmes 
ensured a continuum of care and 
support for people living with 
HIV, during and after TB 
treatment?  
 
1. Yes 
2. No 
 
219 
Do health facilities created 
mechanisms to provide ART to 
eligible TB patients?  
1. Yes 
2. No 
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220 
Do health facilities ensure 
continuity of ART after 
completion of TB treatment?  
1. Yes 
2. No 
 
 
Part III:  Programme implementation impacts on staff performances 
Q.No Questions Responses Code 
301 
Do you have attended relevant 
trainings related to your duty?  
Which ones?  
 
_______________ 
 
302 
How do you think provision of 
integrated TB and HIV care 
services in the same health 
facility affect your 
performances? 
 
_______________ 
 
303 
Do you think the logistic supply 
for TB and HIV care are enough 
and supplied regularly? How?  
 
_______________  
 
304 
How do you evaluate the 
facility’s physical structure 
convenience for provision of 
integrate TB and HIV care in 
your work area? 
 
_______________ 
 
305 
How do the health facility’s 
administrative conditions affect 
your TB and HIV care provision? 
 
_______________ 
 
306 
What are some of the problems 
that you have encountered 
regarding TB and HIV care 
provision in your health facility?  
 
_______________ 
 
307 
What recommendations do you 
have to improve the care 
provision of TB and HIV patients 
in your health facility?  
 
_______________ 
 
308 
Anything you what to add or to 
say regarding TB/HIV 
collaborative activity provision in 
your health facility? 
 
 
_______________ 
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Part IV:   Impacts of programme implementation on infrastructure 
Q.No Questions Responses  
401 
How does the commencement 
of TB/HIV collaborative activities 
affected the infrastructure of the 
health facility; be it in renovation 
or rearrangement? 
 
 
402 
What other cross-cutting 
services have been started due 
to the change in infrastructure of 
the health centre as the result of 
the TB/HIV collaborative 
activities commencement? 
 
 
403 
Which health facility services 
have been restructured due to 
the change in infrastructure of 
the health centre as the result of 
the TB/HIV collaborative 
activities commencement? 
 
 
404 
How does the commencement 
of the TB/HIV collaborative 
activities in the health facility 
affected the provision of other 
services? 
 
 
405 
How did the commencement of 
the TB/HIV collaborative 
activities in the health centre 
resulted in the need for 
additional infrastructure? 
 
 
Part V: Impact of TB/HIV collaborative activities on human resource 
 
Q.No Questions Responses  
501 
How does the health facility 
affected in human resource due 
to the commencement of 
TB/HIV collaborative activities? 
 
 
502 
Do all health workers trained on 
at least one of the activities for 
TB/HIV collaborative activities? 
Which trainings? 
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503 
How does the performance of 
health workers in the health 
facility affected due to the 
commencement of TB/HIV 
collaborative activities? 
 
 
504 
In what scheme are health 
workers assigned in one of the 
TB/HIV collaborative activity 
departments in the health 
facility? 
 
 
505 
What are the opportunities 
created on human resource due 
to the commencement of 
TB/HIV collaborative activities in 
the health facility? 
 
 
506 
What are the challenges faced 
on human resource due to the 
commencement of TB/HIV 
collaborative activities? 
 
 
507 
Any recommendations regarding 
human resource towards the 
TB/HIV collaborative activities in 
the health facility? 
 
 
 
Thank you!!!
 ANNEXURE I: FOCUS GROUP DISCUSSION GUIDE FOR TB PATIENTS  
 
FGD Guide for TB patients  
Name of health facility:       
Name of moderator:        
Name of note taker:        
Date of discussion:        
Start time    Adjourned:     
1. Your ages            
2. Your sex             
3. What do you know about TB and HIV?  
4. What is the relationship between TB and HIV? 
5. How does the health care delivery system assist people of those diseases? 
6. What are the services provided by health care workers in your area to decrease the 
burden of TB and HIV? 
7. How does the service provision of health facilities for both TB and HIV patients affect 
on your health? 
8. How do you think health workers at TB clinic in this health facility assisted you in 
improving your health regarding your HIV risks and status? 
9. Do you think provision of both HIV and TB care services at the same health facility 
be feasible or practical? How is that? 
10. What do you feel of the service provision quality in general regarding TB and HIV in 
this health facility? 
11. How do you evaluate the behaviour of health care providers towards their patients? 
12. How do you evaluate the performance of health care providers in your opinion 
towards their patients? 
13. What comments do you have to improve the service provision of HIV and TB care in 
this health facility? 
 
Thank you very much for your time and participation! 
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ANNEXURE J: FOCUS GROUP DISCUSSION GUIDE FOR HIV PATIENTS  
 
FGD Guide for HIV patients  
Name of health facility:       
Name of moderator:        
Name of note taker:        
Date of discussion:        
Start time    Adjourned:     
1. Your ages            
2. Your sex             
3. What do you know about TB and HIV?  
4. What is the relationship between TB and HIV? 
5. How does the health care delivery system assist people of those diseases? 
6. What are the services provided by health care workers in your area to decrease the 
burden of TB and HIV? 
7. How does the service provision of health facilities for both TB and HIV patients affect 
on your health? 
8. How do you think health workers at HIV clinic in this health facility assisted you in 
improving your health regarding your TB risks and status? 
9. Do you think provision of both HIV and TB care services at the same health facility 
be feasible or practical? How is that? 
10. What do you feel of the service provision quality in general regarding TB and HIV in 
this health facility? 
11. How do you evaluate the behaviour of health care providers towards their patients? 
12. How do you evaluate the performance of health care providers in your opinion 
towards their patients? 
13. What comments do you have to improve the service provision of HIV and TB care in 
this health facility? 
 
Thank you very much for your time and participation!
 ANNEXURE K: INTERVIEW QUESTIONNAIRE FOR REGIONAL COORDINATOR 
FOR COLLABORATIVE TB/HIV CARE 
 
1. MECHANISMS FOR COLLABORATION  
The TB/HIV Policy recommends the establishment of a coordinating body; surveillance 
of HIV prevalence among TB patients; joint TB/HIV planning; and monitoring and 
evaluation.  
1.1 Set up a coordinating body for TB/HIV activities at all levels  
 
Is there a joint coordinating body (JCB) for TB/HIV activities in your country?  
Yes � No �  
Does it work at the:  
• National level? Yes � No �  
• Regional level? Yes � No �  
• District level? Yes � No �  
• Local or community level? Yes � No �  
 
Please check all that apply. 
  
If no to any of the above, what are the reasons why the JCB doesn’t exist? What needs to 
happen for a JCB to be established? Are there similar bodies that can take up the task of 
TB/HIV joint planning?  
After answering these questions, please skip to question 1.2.  
____________________________________________________________________________________
______________________________________________________________________________  
If yes to any of the above, what is the structure of the JCB, how frequently does it meet and 
how open is it to community input and participation? Briefly outline the JCB’s main functions 
and responsibilities. What are the strengths of the JCB? What are the limitations of the 
JCB? 
____________________________________________________________________________________
______________________________________________________________________________  
Does the JCB include members from the national HIV/AIDS programme and the 
national TB programme?  
Yes � No �  
Are there representatives of TB/HIV co-infected communities, or from people living with 
HIV/AIDS organizations or TB patient support groups on the JCB?  
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Yes � No �  
(Sources: NACP, NTP, Ministry of Health, community-based organizations, people living 
with HIV/AIDS and/or TB)  
1.2 Conduct surveillance of HIV prevalence among tuberculosis patients  
Is information about HIV prevalence among TB patients collected at the:  
• national level? Yes � No �  
• regional level? Yes � No �  
• local level? Yes � No �  
 
Please check all that apply.  
If yes to any of the above, what are the mechanisms (sentinel, cross sectional, periodic) 
to collect this data? 
____________________________________________________________________________________
______________________________________________________________________________  
Is this information available to the public?  
Yes � No �  
If you were able to find this information, please note where you found it and what the 
information contains. Based on your knowledge, does the information accurately reflect 
the situation on the ground? If you were unable to find it, please note who you asked 
and what they said. 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, Ministry of Health, health care workers, people living with 
HIV/AIDS and/or TB)  
1.3 Carry out joint TB/HIV planning  
1.3.1 Joint strategic plan  
Does the JCB have a strategic plan for TB/HIV at the:  
• National level? Yes � No �  
• Regional level? Yes � No �  
• Local level? Yes � No �  
Please check all that apply.  
4 
If no, is TB/HIV addressed in other strategic plans? Which ones? After answering these 
questions, please skip to question 1.2.2. 
____________________________________________________________________________________
______________________________________________________________________________  
If yes, are you and other community activists able to get a copy of the plan(s)?  
Yes � No �  
Do community activists know the objectives and activities in the plan(s)? If not, why not? 
____________________________________________________________________________________
______________________________________________________________________________  
Did community activists participate in the formulation of the plan(s)?  
Yes � No �  
Does the strategic plan(s) reflect the community’s priorities?  
Yes � No �  
If not, what is missing? 
____________________________________________________________________________________
______________________________________________________________________________  
Is there a role outlined for community advocates to play in the implementation of the 
plan(s)?  
Yes � No �  
Comments: 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, Ministry of Health, community-based and non-governmental 
organizations)  
1.3.2 Funding  
What is the level of government funding available for TB/HIV activities? 
____________________________________________________________________________________
______________________________________________________________________________  
Is information publicly available on how international funds are being used to support 
TB/HIV activities?  
Yes � No � 
____________________________________________________________________________________
_____________________________________________________________________________  
Is the government able to implement the TB/HIV activities outlined in the Policy with the 
current available funding?  
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Yes � No �  
If there is not enough funding for TB/HIV activities, please ask about which activities are 
not supported and some of the reasons why. If possible, what is an estimate of the 
funding gap? Is there any international funding for TB/HIV activities? 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, Ministry of Health, donors)  
1.3.3 Training and capacity building  
Is there a training manual for health care workers, which clearly outlines how to manage 
co-infected patients?  
Yes � No �  
If no, what kinds of training do health care workers need? Please include specific 
examples. 
____________________________________________________________________________________
______________________________________________________________________________  
If yes, do the TB/HIV plans include training for community organizations and 
advocates?  
Yes � No �  
Are PLWHA networks involved in training and capacity building preparations?  
Yes � No �  
Please comment on how these trainings could be effectively organized and who should 
be involved in developing and implementing them? 
____________________________________________________________________________________
______________________________________________________________________________ 
Are TB and HIV testing services available at local clinics?  
Yes � No �  
Is there a system for health care workers and service providers to refer co-infected 
patients between TB and HIV/AIDS clinics?  
Yes � No �  
Please comment on how this system works, highlighting any difficulties or problems 
faced by health care workers and any obstacles to access services for TB/HIV co-
infected patients: 
____________________________________________________________________________________
______________________________________________________________________________  
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(Sources: NACP, NTP, PLWHA networks, health care workers at both HIV/AIDS and TB 
clinics, people living with HIV/AIDS and/or TB)  
1.3.4 TB/HIV communication: advocacy, programme communication and social 
mobilization  
Is the government providing information to the public about the elevated risk of TB 
among people living with HIV/AIDS (i.e. dangers of TB/HIV co-infection; prevention 
methods; symptoms; availability of services; treatment options)?  
Yes � No �  
Does the government or JCB have a plan to make sure this information reaches 
affected communities? (i.e. leaflets, radio broadcasts, television ads, print ads)?  
Yes � No � 
Please comment on the effectiveness of these materials and on their availability to 
affected communities and individuals. 
____________________________________________________________________________________
______________________________________________________________________________  
Do community organizations and people at risk for TB or TB/HIV know about and have 
access to this information?  
Yes � No �  
Are community organizations and people at risk for TB or TB/HIV involved in education 
plans or outreach activities to inform others in the community about TB/HIV?  
Yes � No �  
If yes, how are they involved? 
____________________________________________________________________________________
______________________________________________________________________________  
What other kinds of communication and information-sharing activities do you think are 
needed in your country/region/district/community? What are the gaps and what can be 
done to make a difference? 
____________________________________________________________________________________
______________________________________________________________________________ 
Are community groups carrying out advocacy activities with decision-makers to ask for 
improved TB/HIV services?  
Yes � No �  
If yes, what kind of activities are they performing? How are they doing this? Have they 
been successful? If there is no community advocacy, please explain the reasons why. 
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____________________________________________________________________________________
______________________________________________________________________________  
What kind of training and support do you think community groups need to help them 
become more involved in TB/HIV social mobilization and advocacy activities? 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, health care workers, PLWHA networks, community-based and 
non-governmental organizations)  
1.3.5 Community involvement in collaborative TB/HIV activities  
Do community-based or non-governmental organizations integrate TB prevention, 
diagnostic and care services into the HIV/AIDS prevention, care and support services?  
Yes � No �  
If yes, how? If not, why not and are there plans to integrate these services in the future? 
____________________________________________________________________________________
______________________________________________________________________________  
Are TB and HIV/AIDS patient support groups involved in planning, implementation and 
advocacy around collaborative TB/HIV activities?  
Yes � No �  
If yes, how? Please provide specific examples. 
____________________________________________________________________________________
______________________________________________________________________________  
If not, why not and are there plans to involve HIV/AIDS and/or TB patient support 
groups in TB/HIV collaborative activities in the future? 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, health care workers, PLWHA networks, community-based and 
non-governmental organizations)  
1.4 Conduct monitoring and evaluation  
Are there any official efforts to monitor and evaluate TB/HIV collaborative activities?  
Yes � No �  
If no, are there plans to monitor and evaluate TB/HIV activities in the future? 
____________________________________________________________________________________
______________________________________________________________________________  
If yes, how is it being done? Are they monitored through the TB programme, HIV 
programme or both? 
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____________________________________________________________________________________
_________________________________________________________________  
Is the monitoring data available to community organizations?  
Yes � No �  
Are the people who use TB and HIV services consulted in evaluations activities?  
Yes � No �  
Are these evaluations being used to improve the quality of TB and HIV services?  
Yes � No �  
Is the government producing a report on the core TB/HIV indicators as recommended 
by WHO2?  
Yes � No �  
Are community groups involved in monitoring and evaluating TB/HIV activities and 
services?  
Yes � No �  
If yes, how are they involved? If not, why not? 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, Ministry of Health, health care workers, community-based and 
non-governmental organizations)  
 
2. ACTIVITIES TO DECREASE THE BURDEN OF TB IN PLWHA  
2.1 Establish intensified TB case-finding  
Is TB testing offered or encouraged at HIV testing and counselling centres?  
Yes � No �  
Please comment: 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, health care workers, people living with HIV/AIDS and/or TB)  
2.2 Introduce Isoniazid preventive therapy  
Is Isoniazid preventive therapy (IPT) offered to people living with HIV/AIDS?  
Yes � No �  
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Do people living with HIV/AIDS have access to information about IPT?  
Yes � No �  
If yes, what kind of information is available and is it effective? 
____________________________________________________________________________________
______________________________________________________________________________  
Do people living with HIV/AIDS who do not have active TB have access to IPT as part 
of their package of care?  
Yes � No �  
If not, why not? Please comment on what the obstacles are for making IPT available 
and how you think these obstacles can be overcome? 
____________________________________________________________________________________
______________________________________________________________________________  
Where is IPT available?  
HIV clinic �  
TB clinic �  
Public Hospital �  
Other � Please specify: _______________  
Please check all that apply.  
(Sources: NACP, NTP, health care workers, donors, people living with HIV/AIDS and/or 
TB)  
Ensure control of TB infection in health care and congregate settings 
Are there any guidelines on how to separate people presenting TB symptoms from 
people living with HIV/AIDS and others at high risk of TB?  
Yes � No �  
If yes, who developed these guidelines? Are these guidelines being followed in HIV 
testing, counselling and care centres? 
____________________________________________________________________________________
______________________________________________________________________________  
Do the guidelines address issues of patient confidentiality? Please comment. 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, and health care workers)  
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3. ACTIVITIES TO DECREASE THE BURDEN OF HIV IN TB PATIENTS  
3.1 Provide HIV testing and counselling  
Is HIV testing and counselling offered to all TB patients?  
Yes � No �  
If HIV testing and counselling is available, is it available for free or is there a fee? 
____________________________________________________________________________________
______________________________________________________________________________  
If HIV testing and counselling is not available to all TB patients, please specify when 
and where some TB patients do have access. 
____________________________________________________________________________________
______________________________________________________________________________  
Does the TB control programme provide HIV testing and counselling in TB centres?  
Yes � No �  
If not, have they established a referral linkage with the HIV/AIDS programme to do so? 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, health care workers, people living with HIV/AIDS and/or TB)  
3.2 Introduce HIV prevention methods  
Does the TB control programme have an HIV prevention strategy?  
Yes � No �  
If yes, does the strategy target people most at risk of HIV infection? (Including 
transmission through sexual activity, mother-to-child, and injection drug use), if not, is 
there a referral linkage with the HIV/AIDS programme to do so? 
____________________________________________________________________________________
______________________________________________________________________________ 
Are clients attending TB clinics screened for sexually transmitted infections?  
Yes � No �  
If yes, are those patients with symptoms of sexually transmitted infections treated or 
referred to the relevant treatment providers? Is there any data on referrals?  
____________________________________________________________________________________
______________________________________________________________________________ 
Are HIV prevention services available through the TB control programme?  
Yes � No �  
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Please comment on the extent to which TB centres offer HIV prevention services and 
information (on mother-to-child transmission; harm reduction; reduction of work place 
and hospital acquired exposure to HIV infection). 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, health care workers, people living with HIV/AIDS and/or TB)  
3.3 Introduce Cotrimoxazole preventive therapy  
Is Cotrimoxazole preventive therapy available to eligible people living with HIV/AIDS 
who have active tuberculosis?  
Yes � No �  
If not, why not. Please comment. 
____________________________________________________________________________________
______________________________________________________________________________ 
If yes, is there ongoing patient monitoring of drug side effects? 
____________________________________________________________________________________
______________________________________________________________________________ 
(Sources: NACP, NTP, health care workers, people living with HIV/AIDS and/or TB)  
3.4 Ensure HIV/AIDS care and support  
Are people living with HIV/AIDS who are diagnosed with TB provided with any of the 
following HIV/AIDS care and support services?  
Nutrition �  
Palliative Care �  
Home Based Care �  
Prevention �  
PMTC �  
Other � Please specify: _______________  
None �  
Please check all that apply. 
Has the TB programme established a referral linkage with the HIV/AIDS programme to 
provide the continuum of care and support for people living with HIV/AIDS who are 
receiving or have completed TB treatment?  
Yes � No �  
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Please comment. 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, health care workers, people living with HIV/AIDS and/or TB)  
3.5 Introduce antiretroviral therapy (ART)  
Are all HIV positive TB patients assessed for eligibility of ART?  
Yes � No �  
If no, what are the criteria for eligibility and who determines which patient receives 
ART? 
____________________________________________________________________________________
______________________________________________________________________________  
What drugs are available for someone who is co-infected with TB and HIV? Is proper 
care taken to monitor drug interactions? How is this issue addressed by the TB control 
Programme? 
____________________________________________________________________________________
______________________________________________________________________________  
Is ART available for HIV-positive TB patients?  
Yes � No �  
If no, has the HIV/AIDS programme and TB programme created a mechanism to 
provide ART to eligible HIV-positive tuberculosis patients?  
Yes � No �  
Please comment. 
____________________________________________________________________________________
______________________________________________________________________________  
(Sources: NACP, NTP, Ministry of Health, health care workers, people living with 
HIV/AIDS and/or TB)  
Other comments or observations: 
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
________________________________________________________________________ 
 
 
Thank you very much for your time and participation! 
 
